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Abstract
Through exposure to melphalan or taxol, four novel multidrug resistant variants o f the human nasal 
carcinoma cell line, RPMI-2650 and human lung carcinoma cell line, DLKP, were established In vitro 
toxicity tests revealed that the RPMI-2650 taxol-resistant variant exhibited significant resistance to taxol, 
vincristine, adriamycin and vinblastine The RPMI-2650 melphalan-resistant variant exhibited significant 
resistance to melphalan, cadmium chlonde, adriamycin, vinblastine and VP-16 The DLKP long term 
melphalan-selected variant exhibited significant resistance to melphalan, cadmium chlonde, cisplatin, 
adnamycm and vinblastine A similar cross resistance profile was observed in the DLKP pulse selection 
variant with the exception that this variant displayed no obvious cross resistance to vinblastine Adnamycm 
distnbution studies revealed decreased intracellular adnamycm accumulation in the RPMI-2650 taxol- and 
melphalan-resistant variants However, intense nuclear fluorescence was observed following treatment with 
verapamil and cyclosporin A Charactensation studies demonstrated that the resistant phenotype in the 
RPMI-2650 taxol-resistant variant appeared to be mainly P-glycoprotem mediated Protein and mRNA 
analysis by Western blotting, immunocytochemistry and RT-PCR demonstrated an overexpression of MRP1, 
cMOAT (MRP2) and MRP3 m the RPMI-2650 melphalan-resistant vanant compared to its parental cell line 
Sulindac or indomethacin could reverse melphalan toxicity m this vanant Western blotting analysis also 
showed the overexpression of MRP1 in the DLKP melphalan long term and pulse selection cells, suggesting 
the involvement o f MRP family members in mediating melphalan resistance m these variants Significant 
iterations in GST activity and metallothionem expression m these vanants were not observed
Results obtained from invasion assays demonstrated that the RPMI-2650 and DLKP melphalan-resistant 
/ariants were more invasive than their respective parental cells and the RPMI-2650 taxol-resistant vanant It 
ippears that increased expression o f a 2Pi, CX5P1, a 6P) and a,6^ 4 integrins, decreased expression o f a 4p1; 
itronger adhesion to collagen type IV, lamirun, fibronectin and matngel and expression of MMP-2, MMP-9 
md c-myc may all contribute to the high mvasiveness of the RPMI-2650 melphalan-resistant vanant 
ncreased expression o f a 2 and Pi integnn subunits and overexpression of MMP-2 and MMP-9 may be 
esponsible for the invasiveness o f the DLKP melphalan-selected variants Decreased expression of a 2 
ntegrin which may result in decreased attachment to collagen type IV, lack of cytokeratin 18 and no 
letectable expression of any proteases may be responsible for the non-invasiveness o f the RPMI-2650 taxol- 
ssistant vanant
hese results suggest that exposure to melphalan can result in not only a multidrug resistance phenotype but 
ould also make cancer cells more invasive and metastatic
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1. Introduction
1.1 General introduction
Chemotherapy constitutes the principal therapeutic tool to treat unresectable or disseminated 
tumours Although there has been significant impact on survival m some malignancies, the 
majority o f  human cancers are resistant to chemotherapy at presentation or become resistant 
after an initial response This suggests that resistance is inherent in a tumour cell or evolves  
under the selection pressure o f  drug administration In some cases, tumour cells are not only 
resistant to a specific drug or group o f  drugs with structural or functional similarities, but also 
resistant to a group o f  functionally and structurally dissimilar drugs This type o f  resistance is 
called multidrug resistance (M DR) M echanisms o f  M DR include exclusion o f  drug from the 
cell, increased detoxification o f  the drug, alteration in drug targets, failure to activate the drug 
to its active form, enhanced repair capability o f  the cell after injury or failure to engage an 
appropriate response leading to apoptosis in the damaged cells Many o f  these factors may 
co-exist in human tumours Thus, a major goal in experimental as w ell as clinical 
investigation o f  M DR is to discover unique methods by which to reverse or circumvent it
Apart from MDR, invasion and metastasis is another major cause o f  death for cancer patients 
The complexity o f  the metastatic process has forced mvestigators to focus on one step at a 
time m order to reduce the number o f  variables Invasion is one o f  the most critical steps in 
metastasis Dynam ic interactions among cell adhesion m olecules, extracellular matrix, 
proteases, cytoskeletal proteins and signalling m olecules contribute to the invasive behaviour 
o f  the tumour cells M DR and invasion/metastasis are correlated phenomena Highly  
multidrug resistant tumour cells can survive chemotherapy and escape to distant sites o f  the 
body or highly metastatic cells can escape from the effect o f  chemotherapy A  relationship 
between these two phenotypes has been demonstrated by two types o f  experiments firstly, in 
some cases, invasive/metastatic cells develop drug resistance more readily than non- 
mvasive/metastatic cells (Cillo et a l , 1987), secondly, some tumour cells selected for the 
resistance to chemotherapeutic drugs are more invasive/metastatic relative to non-resistant 
cells (Lucke-Huhle et a l , 1994) M echanisms underlying this relationship are not clear It is 
supposed that malignant tumours arise as the end result o f  an accumulation o f  genetic 
mutations involving a number o f  oncogenes and tumour suppressor genes Many o f  these 
genes could affect the expression o f  cell growth, differentiation, drug resistance, invasion and 
metastasis Hence, an important goal o f  future research would be to determine whether a
1
com m on transcription factor exists that turns on tw o  sets o f  genes, those responsible for drug 
resistance, and those responsible for increased cell invasion  and m etastasis
1.2 Pharmacology of MDR drugs
1.2.1 Taxol ( Paclitaxel)
The major source o f  taxol (paclitaxel) is the bark o f  a slow -grow ing yew  tree, taxus 
brevifolia D esp ite  the elucidation o f  its broad activity and its unique structure by M onroe  
W all and co-w orkers in the late 1960s (Warn et a l , 1971), it is still m  a relatively early stage  
o f  clin ical developm ent In 1979, H orw itz and co-w orkers discovered that this agent could  
induce n ovel b io log ic  effects and had a unique m echanism  o f  action (S ch iff  et a l , 1979, 
1980) Taxol, sim ilar to etoposide (V P -16), vinblastine and vincristine, is thought to o w e  its 
antitumour effects to disruption o f  m itosis It interferes w ith  chrom osom e changes during the 
cell cy c le  and thus is tox ic  to proliferating cells Taxol induces a shift in the p hysio logica l 
equilibrium  betw een  m icrotubules and tubulin toward polym erisation and form ation o f  
dysfunctional m icrotubules
Fig. 1.2.1 A side view of a microtubule with the tubulin molecules aligned into long parallel rows 
Each of the 13 protofilaments is composed o f a series o f tubulin molecules (a/p heterodimers) (A) 
Electron micrograph o f a microtubule seen m cross-section (B) Electron micrograph o f a side view of  
a microtubule (C and D) Schematic diagrams of a microtubule
tjbuVm u
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The major component o f  microtubules is tubulin, a protein containing two non-identical (a  
and P) 50kD subunits, arranged head-to-tail in linear protofilaments A  single microtubule is 
composed o f  13 parallel protofilaments, forming a hollow structure with a “minus” end, 
which is usually stabilised by attachment to an organising centre, and a “plus” end, at which  
growth or shrinkage takes place (figure 1 2  1) Individual microtubules can oscillate between  
polymerisation and depolymerisation and the net status o f  the microtubule population is very 
sensitive to factors affecting the equilibrium between free tubulin dimers and assembled 
polymers In contrast to other known microtubule antagonists, taxol disrupts the equilibrium  
between free tubulin and microtubules by shifting it in the direction o f  assembly rather than 
disassembly A s a result, taxol treatment causes both the stabilisation o f  ordinary cytoplasmic 
microtubules and the formation o f  abnormal bundles o f  microtubules (Schiff et a l , 1979 and 
1980) Competitive binding experiments demonstrated that the taxol binding site is distinct 
from those used by other agents including colchicine, vincristine, etc (Kumar et a l , 1981, 
Schiff et a l , 1981)
Studies have shown that phosphorylation o f  bcl-2 at serine residues leads to loss o f  bcl-2 
antiapoptotic function (Haidar et a l , 1995) It was also found that taxol ( l-1 0 |iM ) induces 
bcl-2 phosphorylation followed by apoptosis (Haidar et a l , 1995, 1996) Since taxol inhibits 
microtubule depolymerisation, it was suggested that microtubule damage may lead to cancer 
cell apoptosis through a mechanism involving bcl-2 phosphorylation and that this pathway 
may be important in normal physiological elimination o f  cells w ith damaged mitotic 
apparatus
Resistance to taxol arises through two major mechanisms, i e overexpression o f  P- 
glycoprotein (Roy et a l , 1985, Greenberger et a l , 1987) and mutation o f  the gene coding for 
one o f  the tubulin subunits (Schibler et a l , 1986) In the latter case it has been hypothesised 
that, in the absence o f  drugs, the equilibrium between free tubulin and microtubules is shifted 
toward disaggregation (Cabral et a l , 1986), therefore the mutant cells have slightly greater 
tolerance for taxol-induced stabilisation than that o f  the parent cells Som e mutants were not 
only resistant to taxol but they also required it for growth, presumably as a result o f  an 
extreme shift toward disaggregation
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Although taxol is still in a relatively early stage o f  chnical development, it has been shown to 
be very active in the treatment o f  refractory ovarian cancer (Rowinsky e t a l , 1990, McGuire 
e t a l , 1989) Encouraging results have also been obtained m patients with metastatic breast 
cancer (Holm es el a l , 1991, Marty et a l , 1999) It is hoped that taxol treatment w ill also be 
effective in other tumours, including non-small-cell lung cancer and colon cancer
Apart from hypersensitivity, neutropenia is the most common dose-limiting toxicity for taxol 
Severe mucositis, manifested as ulcerations o f  the mouth and throat, appears to be a 
cumulative effect o f  taxol administration (Rowinsky et a l , 1990) Taxol causes some 
reversible neurotoxicities, most often numbness and paresthesia in the hands and feet 
(Rowinsky et a l , 1990) A  variety o f  cardiac abnormalities have also been associated with  
taxol treatment (Rowinsky e t a l , 1991)
Taxol (paclitaxel) and taxotere (docetaxel) are called taxoids Taxotere is a semisynthetic 
taxoid using a precusor extracted from the European yew  tree, taxus baccata  Taxotere and 
taxol have similar mechanisms o f  action while taxotere is about twice as potent as an 
inhibitor o f  microtubule depolymerisation (Gelmon et a l , 1994)
1.2.2 Melphalan
HOOCCHCH2— 1
I
Fig. 1.2.2 The chemical structure of melphalan
Melphalan (L-phenylalamne mustard) is a member o f  a group o f  drugs called alkylating 
agents It was first synthesised m 1954 in an attempt to obtain an anticancer drug that would 
preferentially localise in a particular tissue Since phenylalanine is a precursor o f  melanin, it 
was postulated that phenylalanine mustards might preferentially accumulate in melanomas 
and thereby produce a selective effect, however the goal o f  a “site-directed” effect has not yet 
been achieved (Pratt et a l , 1994) The alkylating agents are highly reactive compound that 
can form covalent bonds with a number o f  nucleophilic groups such as ammo, carboxyl,
4
sulfhydryl or im idazole m oieties in proteins and nucleic acids (Price et a l , 1975) At neutral 
or alkaline pH, one o f  the chlorethyl side chains o f  melphalan undergoes a cyclisation, 
releasing chloride ions and forming a highly reactive intermediate which can attack 
nucleophilic groups One important reaction in the cytotoxic effect o f  melphalan is the 
formation o f  a covalent bond between the drug and the 7-nitrogen group o f  guanine Since 
melphalan is a bifunctional alkylating agent (containing two reactive chlorethyl side chains), 
it can then undergo a similar cyclisation o f  the second side chain and form a covalent bond 
with another nucleophilic group
These reactions may result in cross-linking between D N A  strands or linkages between bases 
within the same strand o f  D N A  Strand scission also occurs as a result o f  endonuclease attack 
when the cell attempts to repair the segment o f  D N A  contaming the drug adduct There is 
evidence that the cytotoxicity o f  melphalan at therapeutic levels is mamly due to an inhibition 
o f  D N A  replication since alkylation o f  D N A  decreases its ability to act as a template for 
D N A  synthesis (Brewer et a l , 1961, Ruddon et a l , 1968, Roberts et a l , 1971)
Although some tumour cells selected for resistance to melphalan have increased excision
repair activity (Ewig e t a l , 1977), this mechanism may not be a major factor in the
development o f  clinical resistance to these drugs (Fox, 1984) Two important mechanisms o f
resistance are increased drug inactivation due to the reaction with cellular thiols and
decreased drug uptake Increased drug inactivation is based on elevated cellular levels o f  
I
glutathione (GSH), a compound that reacts with the cytotoxic electrophilic derivatives o f  
melphalan and detoxifies them The enzyme that catalyses this conjugation is glutathione S- 
transferase, and increased levels o f  this enzyme have been observed in model tumour systems 
(Tew e t a l , 1988) Depletion o f  GSH with butathionine sulfoximine (BSO ), an inhibitor o f  
y-glutamlycysteine synthetase which catalyses the first step o f  GSH formation can increase 
the in vitro  cytotoxicity o f  melphalan (Richardson and Sieman, 1992)
It has been shown that tumour cell lines resistant to melphalan take up the drug at a slower 
rate than that o f  the drug sensitive parental cells (Goldenberg et a l , 1984) MRP-mediated 
ATP-dependent transport was observed for the conjugates monochloro-mono[3H]glutathionyl 
melphalan (Jedlitschky et a l , 1996) Resistance mechanisms such as increased excision  
repair and increased cellular glutathione would be expected to yield cross-resistance among a
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variety of DNA cross-linking drugs Resistance due to decreased drug uptake would yield 
cross resistance only if the same uptake mechanism was shared by different drug classes 
Tumour cells selected for resistance to one alkylating agent can show cross resistance to 
another agent and simultaneously respond like the drug-sensitive parent cell line to many 
other alkylating drugs (Schabel et a l , 1978) Generally, however, the level of cross­
resistance among alkylating agents is low in human tumor cells (Frei et a l , 1985, 1988) 
Consequently, high dose alkylating agent combination regimens have been administered to 
patients with advanced cancers (Antman et a l , 1987)
High levels of metallothioneins are also associated with resistance to alkylating agents 
(Kelley, 1988) Metallothioneins are small 6-7kD cysteine-rich proteins that appear to protect 
cells from the toxicity of heavy metals such as copper, zinc and cadmium The functional 
significance of metallothioneins may extend beyond their ability to protect cells by binding 
electrophilic heavy metal ions, since they can be induced by steroids, stress, X-rays, high O2 
tension and alkylating agents Pretreatment of CHO cells with Zn for several hours prior to 
exposure to melphalan resulted in the induction of considerable resistance to melphalan 
(Tobey, 1982)
In addition, cells that have an impaired ability to undergo apoptosis would be expected to be 
resistant to chemotherapeutic agents The overexpression of the bcl-2 oncogene has been 
shown to inhibit apoptosis in several cell types, and also to produce cells that are less 
sensitive to alkylating and other cytotoxic agents (Collin, 1992)
Melphalan is generally considered to be cell cycle phase nonspecific It is most cytotoxic to 
rapidly growing cells (Van Putten et a l , 1971) Melphalan is used in the treatment of 
melanoma, multiple myeloma, Ewring’s sarcoma, acute leukaemia, malignant lymphoma, 
colon carcinoma, breast cancer and ovarian cancer (Samuels and Bitran, 1995) The major 
toxicity of melphalan is bone marrow depression, sterility, amenorrhea and acute 
nonlymphocytic leukaemia (Greene et a l , 1986)
1.2.3. Adriamycin
Adnamycin, or doxorubicin, is an anthracycline antibiotic isolated from species of 
streptomyces It has a characteristic four-ring structure that is linked via a glycosidic bond to
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the amino sugar, daunosamine The anthracycline drugs, which are members of noncovalent 
DNA-bmding drugs, all have regions that stack between the paired bases in DNA, forming a 
tight drug-DNA interaction that is critical for their cytotoxic, mutagenic and carcinogenic 
effects Adnamycin has also been shown to induce double strand DNA breaks in cultured 
mammalian cells (Nelson et a l , 1984) The DNA breaks are caused by the enzyme 
topoisomerase II This enzyme controls the degree of DNA supercoiling by cleaving and 
reannealing DNA such that the coil is relaxed by one turn Adriamycin somehow interferes 
with the DNA strand breakage-reunion reaction of topoisomerase II (Tewey et a l , 1984) The 
observation that a direct correlation between topoisomerase II activity and adriamycin 
resistance exists m several cell lines strongly supports the involvement of topoisomerase II in 
the cytotoxicity pathway (Glisson et a l , 1986, Pommier et a l , 1986, Deffie et a l , 1989)
The topoisomerase II mechanism is not the only way in which adriamycin cleaves DNA 
Adriamycin can also precipitate the formation of active oxygen species which cause single- 
strand breakage Adriamycin contains a hydroxyquinone, which is an iron-chelating structure 
(Myers et a l , 1986) The adnamycin-Fe complex forms a complex with DNA that differs 
from the intercalated drug-DNA complex (Eliot et a l , 1984) The drug-Fe-DNA complex, 
like the free drug-Fe complex, catalyses the transfer of electrons from glutathione to oxygen, 
resulting in the formation of active oxygen species The drug-Fe-DNA complex also 
generates hydroxyl radicals from hydrogen peroxide, which results in DNA cleavage (Muindi 
et a l , 1985) Free radical generation by the drug-Fe-DNA complex is critical for adriamycin- 
mduced cardiotoxicity
The most common resistance mechanism m cells selected for adriamycin resistance in vitro is 
increased drug efflux This is due to the overexpression of a number of proteins including P- 
glycoprotein, MRP family members and LRP, the multidrug transporters discussed in detail 
in 1 4, 1 5 and 1 6 respectively Two other mechanisms of resistance to adriamycin have also 
been reported In a number of cell lines, decreased topoisomerase II activity has been found 
to correlate with adriamycin resistance (Glisson et a l , 1986, Pommier et a l , 1986, Deffie et 
a l , 1989), while in other cell lines increased glutathione peroxidase activity has been 
observed (Sinha et a l , 1989) Reduced glutathione reacts with drug-generated reactive 
oxygen compounds such as peroxides (Tew et a l , 1988) and increased levels of glutathione 
or glutathione S-transferase have been found in some adnamycin-resistant cell lines (Batist 
et a l , 1986) In such cell lines, butathione sulfoximine (BSO), the inhibitor of y -glutamyl
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synthetase, reduces glutathione levels and partially reverses adnamycin resistance (Kramer et 
al,  1987)
Adnamycin has a very broad range of clinical usefulness It is active against carcinomas of 
the breast, lung (small cell), thyroid, ovary, as well as sarcomas of the bone and soft tissue, 
pediatric solid tumours and acute leukaemias, lymphomas and myeloma (Hortobagyi, 1997) 
Adnamycin treatment frequently causes nausea and vomiting, and patients may experience 
anorexia and diarrhoea Myelosuppression is dose related and occurs in 60% to 80% of 
patients (O’Bryan et a l , 1977) Adnamycin also produces unique cardiotoxic reactions in 
both adults and children (Lenaz et a l , 1976, Gilladoga et a l , 1976) Two types of reactions 
are observed early, transient electrocardiographic changes and a delayed progressive 
cardiomyopathy (Lenaz et al ,  1976) which presents as a severe congestive heart failure 
Efforts to reduce cardiotoxicity focused on iron chelators The EDTA analogue, ICRF-187, 
appears to be able to decrease adnamycin-induced cardiac toxicity (Doroshow, 1991)
1.2.4. Vinca alkaloids
While working with extracts of the periwinkle plant ( Vinca rose Linn), Noble and coworkers 
(1958) observed granulocytopenia and bone-marrow suppression in rats These observations 
led to the purification of an active alkaloid Johnson et al (1963) demonstrated activity of 
certain alkaloidal fractions against acute lymphocytic neoplasm in mice Fractionation of 
these extracts yielded two active alkaloids vinblastine and vincristine
The vmca alkaloids are cell-cycle specific agents, and similar to other drugs such as 
colchicine and podophyllotoxin, they bind specifically to free tubulin dimers Although these 
agents do not share the same binding site, their interactions with tubulin have the common 
effect of disrupting the balance between microtubule polymerisation and depolymerisation 
This results in the net dissolution of microtubules, destruction of the mitotic spindle, and 
arrest of cells in metaphase (Margulis, 1973, Wilson et a l , 1975, Mandelbaum-Shavit et a l , 
1976) In the absence of an intact mitotic spindle, the chromosomes may disperse throughout 
the cytoplasm or may occur in unusual groupings, such as balls or stars The inability to 
segregate chromosomes correctly during mitosis ultimately leads to cell death The bmding 
of vmca alkaloids to tubulin is kinetically complex (Na et a l , 1986) and depends on many 
factors, including ionic strength (Singer et a l , 1988), magnesium-ion concentration (Na et 
al,  1986), interaction with nontubulin proteins (Donoso et al,  1979) and nucleotide
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concentration (Bowman et a l , 1988)
Acquired resistance to vinca alkaloids usually results from overexpression of P-glycoprotem, 
MRP1 or cMOAT It can be overcome in vitro by incubating the cells with compounds that 
compete with vinca alkaloids for binding to P-glycoprotem or MRP and studies with one 
such agent, verapamil, indicate that this strategy may also be practical in vivo (Tsuruo et a l , 
1983, Akiyama et a l , 1988, Dalton et a l , 1989) Resistance can also be due to alterations in 
tubulin structure In some instances these mutations affect binding of the drug to tubulin 
(Ling et a l , 1979) Many other mutants have been isolated, in which tubulin has been altered 
so as to affect its intrinsic ability to form microtubules (Cabral et a l , 1986) These mutants 
have several common characteristics, including relatively low levels of resistance (two- to 
three-fold), cross-resistance to other microtubule-assembly inhibitors, and collateral 
sensitivity to microtubule-stabilising agents (e g taxol)
The minor differences in the structure of vinca alkaloid molecules result in notable 
differences in both the toxicity and antitumour spectra of vincristine and vinblastine 
Vincristine, in combination with prednisone, is widely used in combination chemotherapy for 
induction of remission of acute leukaemias m adults and children due to its rapidity of action 
and its lesser tendency for myelosuppressive action Complete remissions are obtained in 80- 
90% of such patients (Rowinsky et a l , 1991, Willemze et a l , 1980, Ortega et a l , 1977) 
Similar success is achieved in treating Hodgkin’s lymphoma (Bonadonna et a l , 1986) and 
aggressive non-Hodgkin’s lymphoma (Longo et a l , 1991) with vincristine-containing 
combinations Vincristine is also included in combinations for treating various solid tumours, 
such as small-cell lung carcinoma and breast carcinoma in adults and Wilm’s tumor, 
neuroblastoma, rhabdomyosarcoma and Ewing’s sarcoma in children (Rowinsky et a l , 1991, 
Johnson et al, 1987) The most important clinical use of vinblastine is with bleomycin and 
cisplatin in the treatment of metastatic testicular tumours Vinblastine is also an important 
drug in the treatment of Hodgkin’s lymphoma, where it has been used instead of vincristine, 
providing similar antitumour activity with less neurotoxicity (Sutcliffe et a l , 1978, Diggs et 
a l , 1977) Vinblastine is effective against non-Hodgkin’s lymphoma (Palmier et a l , 1990) 
and has produced responses in patients who had developed resistance to vincristine, 
indicating that cross-resistance does not always occur between these two drugs (Jackson et 
al,  1987)
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The clinical toxicity of vincristine is mostly neurological, the most common symptom of 
which is a depressed Achilles tendon reflex (Sandler et a l , 1969) Other toxicities include 
cranial nerve palsies, transient cortical blindness, confusion, delirium and depression (Byrd et 
a l , 1981) Unlike the great majority of antineoplastic agents, vincristine does not cause 
significant myelosuppression Myelosuppression (primarily neutropenia) is the major toxicity 
caused by vinblastine (Rowinsky et a l , 1991) The neurotoxic symptoms caused by 
vinblastine are similar to (although less common and less severe than) those resulting from 
vincristine administration
1.2.5. Etoposide (VP-16)
Etoposide is a semisynthetic derivative of podophyllotoxin, a microtubule inhibitor found m 
extracts of the mandrake plant Although it was initially thought that etoposide might also 
inhibit microtubule function, further investigation indicated that the enzyme topoisomerase II 
(Topo II) (discussed in detail in 1 5 2) was the major target of this drug in eukaryotic cells 
(Topo II can temporarily break DNA strands and reseal these breaks, resulting m the DNA 
been sufficiently untangled and relaxed to allow transcription and replication) (Ross et a l , 
1984)
Topoisomerase II first interacts with DNA by reversibly forming a noncovalent complex At 
this stage no DNA strand breaks have been made and this initial complex is termed 
“noncleavable” The enzyme then cut both DNA strands, forming a covalent bond between 
its protein and one of the newly formed 5’- phosphate ends of the DNA This complex is 
called “cleavable” The cleavable complex is either rapidly converted back to the 
noncleavable complex or the breaks are resealed and the enzyme dissociates from the DNA 
Inhibitors such as etoposide stabilise the cleavable complex, preventing it from going back to 
the non-cleavable complex Although stabilisation of the cleavable complex persists while 
the etoposide is present, removal of the drug results in a rapid return of apparently normal 
topoisomerase function (Long et a l , 1985)
A phenotype has been identified in which cells that are resistant to etoposide retain normal 
sensitivity to vmca alkaloids and normal drug-transport characteristics (Danks et a l , 1987) 
This phenotype appears to arise from the expression of forms of topoisomerase II with altered 
catalytic activities (Sullivan et a l , 1989, Glisson et a l , 1986) Another form of resistance has 
been traced to a mutation that resulted in underexpression of topoisomerase II protein with
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otherwise normal catalytic properties (Deffie et a l , 1989)
Overexpression of P-glycoprotein or MRP is another mechanism of resistance to etoposide 
which results in decreased intracellular drug accumulation (Sinha et a l , 1988) due to reduced 
influx of drugs (Politi et a l , 1989) It has also been observed that etoposide treatment 
prevents activation of protein kinase, p34cdc2 (Lock et a l , 1990) This kmase, which 
ordinarily becomes activated at the end of the G2 phase of the cell cycle, is thought to have a 
critical role in allowing cells to begin mitosis It is therefore possible that the arrest of cells in 
the G2 phase of the cell cycle observed after treatment with etoposide is due to interference 
with p34cdc2 function
Etoposide has the most significant impact in the treatment of testicular cancers in which it 
was found to be effective in patients whose tumours were resistant to prior treatment 
(Loehrer et a l , 1991, Newlands et a l , 1977) Small-cell lung cancer is another disease m 
which etoposide plays an important therapeutic role (Johnson et a l , 1991) The major 
toxicity attributable to etoposide is myelosuppression Mucositis can be dose-limiting at 
higher doses in which marrow is rescued by transplantation (Herzig, 1991) Rapid drug 
infusions occasionally cause hypotension (Cohen et a l , 1977)
1.2.6. Cisplatin (cis-diainminedichloroplatimim II)
The potential of cisplatin as an antitumour agent was recognised through the observation 
made by Rosenberg et al (1965) that certain metal compounds inhibited bacterial division 
Their study had been designed to explore the possible effects of an electric field on the 
growth of E Coli, but they noted that the bacteria ceased dividing and grew in the form of 
long filaments
It became clear that cell division was being inhibited by an electrolysis product of the 
platinum electrode Rosenberg and his colleagues tested the antitumour activity of several 
platinum compounds and demonstrated that cisplatin was effective against leukaemia in mice 
(Rosenberg et a l , 1969) Since all the trans-compounds tested have been ineffective, the cis- 
configuration appears to be required When cisplatin is dissolved m water, chloride 10ns are 
displaced, allowing the formation of the reactive forms of the compound Both cis- and trans- 
lsomers exchange chloride 10ns for such nucleophilic group as RS', R-S-CH3, R-NH2 etc to
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form links that can be very stable There is considerable evidence that DNA is the principal 
target for the cytotoxic action of cisplatin (Pinto et a l , 1985) Regardless of whether it is 
purified DNA, intact cells, or tumour-bearing patients that are exposed to cisplatin, the 
principal coordinate is an mtrastrand cross-link formed by binding of the drug to two 
neighbouring guanines Intrastrand cross-linkage accounts for inhibition of DNA replication 
which leads to cell death In addition to DNA-DNA cross-links, DNA-protein cross-linking 
also occurs
No dominant mechanism of resistance to cisplatin has been identified Often resistant cells 
have an increased capacity to repair mtrastrand adducts (Fox, 1984), but in many studies the 
increase in repair capacity has not been sufficient to explain the extent of resistance (Eastman 
et a l , 1988) Cisplatin reacts readily with compounds containmg SH groups Thus, resistance 
in some cell lines has been found to correlate with increased glutathione content (Behrens et 
a l , 1987) Another thiol-containing modifier of drug response is the metal-binding protem 
metallothionein It has been found that tumours from cells with a high level of 
metallothionein have a decreased therapeutic response to cisplatin in comparison to tumours 
from the parent cells which have a low metallothionein levels (Endresen et a l , 1984) 
Resistance to cisplatin has also been shown to be associated with decreased intracellular 
accumulation which might be caused by MRP family members (see section 1 4)
Cisplatin is an effective component of combination drug protocols used to treat a variety of 
human malignancies, most notably tumours of the testis, ovary, head and neck, lung and 
bladder (Einhorn, 1986, Ozols et a l , 1991) The major delayed toxic effects of cisplatin are 
nephrotoxicity, peripheral neuropathy, with nephrotoxicity and ototoxicity often being dose- 
limiting Cisplatin produces a dose-dependent ototoxicity that may be manifested by tinnitus 
or hearing loss (Piel et a l , 1974) Patients receiving cisplatin should have audiometric 
testing, particularly if they are being treated with other potentially ototoxic drugs
1.2.7. 5-FIuorouracil
5-Fluorouracil (5-FU) was first synthesised in 1957 and is a member of the antimetabolite 
group of drugs Its major action is through inhibition of nucleotide synthesis and through 
incorporation into nucleic acids (Pratt et a l , 1994)
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5-FU is structurally similar to thymine and is the most important pyrimidine antagonist 5-FU 
can be metabolised to FdUMP (5-fluorodeoxyuridine monophosphate) which inhibits 
thymidylate synthetase and consequently DNA synthesis 5-FU can also be metabolised to 
FUTP (fluoroundine triphosphate) which can incorporate into various types of RNA
As is the case with all antimetabolites, alterations in the enzymatic pathways by which the 
administered drug is converted to active metabolites can influence its actions The quantity 
(Washtien et a l , 1982, Berger et al, 1988) and quality (Berger et a l , 1988) of the target 
enzyme are critical determinants of the extent of inhibition of thymidylate synthesis It has 
also been recognised that the availability of the reduced folate cofactor has a profound impact 
on the effectiveness of thymidylate synthetase inhibition by 5-FU (Ullman et a l , 1978) This 
knowledge has been applied to the design of clinical treatment protocols and the increased 
efficacy of 5-FU treatment by concurrent administration of a reduced folate represents a 
significant advance m the use of this drug (Germ et a l , 1987)
However, if thymidylate synthetase inhibition was the only important mechanism in 5-FU- 
mduced cytotoxicity, then exogenously supplied thymidine would always protect cells from 
5-FU However this has failed to act as a universal antidote to 5-FU It is therefore probable 
that 5-FU’s primary cytotoxic mechanism is not the same in all cell lines, and that this 
heterogeneity is the basis for the wide variability of response to 5-FU treatment observed in 
vivo
Table 12 7 represents the mechanisms of resistance to 5-FU
1 increased level of expression of thymidylate synthetase
2 altered bindmg affinity of thymidylate synthetase for FdUMP
3 decreased incorporation of 5-FU into RNA
4 decreased incorporation of 5-FU into DNA
5 decreased pools of the reduced folate
6 increased level of expression of dUTPas
Table 1.2.7 Mechanisms of resistance to 5-FU (Chu et a l , 1994)
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5-FU is used to treat several types of solid tumours, including colorectal, breast, head and 
neck, gastric and pancreatic cancers (Germ, 1990) In addition to havmg antitumour activity 
on its own, 5-FU interacts with radiotherapy to produce radiosensitisation Nausea, vomiting, 
anorexia, stomatitis and diarrhoea can occur during systemic therapy with 5-FU with the 
frequency of side effects varying with the treatment schedule employed Stomatitis and 
diarrhoea are the most common dose-limiting toxicities when 5-FU is admimstered by 
continuous infusion
1.3 P-glycoprotein (Pgp)
Fig. 1.3 Predicated structure o f  P -g lycopro te in  w ith  cluster o f  g lycosy la tion  sites m  the f irs t external 
dom ain and nucleotide b ind ing  fo lds (Croop, 1993)
P-glycoprotein is the best characterised MDR marker Juliano and Ling (1976) first identified 
a 170kD membrane glycoprotein overexpressed in multidrug resistant cell lines The length 
of Pgp varies from 1276 to 1281 ammo acids predicting a molecular weight of approximately 
140kD Approximately 10-15kD of the molecular weight is accounted for by N-linked 
glycosylation (Greenberger et a l , 1988) Examination of the ammo acid sequence identifies a 
peptide which traverses the plasma membrane 12 times A short, highly charged cytoplasmic 
domain precedes three membrane loops which are followed by a large cytoplasmic domain 
which binds to ATPase A cluster of potential N-linked glycosylation sites are located in the 
first external loop The large cytoplasmic domain is followed by three additional membrane 
loops and another large cytoplasmic domain which can also bind to ATPase Experimental 
evidence indicates that Pgp binds and hydrolyses ATP (Ambudkar et a l , 1992) which is 
required for the energy supply for drug transport Posttranslational modification of Pgp
Outside
Membrai
Inside
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through phosphorylation has been demonstrated for many years (Carlsen et a l , 1977, Center, 
1983, Fine et a l , 1988, Ma et a l , 1991) Exposure of cells to substrates for Pgp including 
chemotherapeutic drugs and chemosensitisers produces hyper-phosphorylation of the 
molecule (Hamada et a l , 1987) Pgp can be phosphorylated by a variety of serine/threonine 
kinases such as protein kinase C (PKC), cAMP-dependent protein kinase (PKA) and 
calmodulin-dependent protein kinase II PKC has received most attention It has been found 
that PKC is often increased in MDR cells compared to the parental cells (Aquino et a l , 1988, 
Posada et a l , 1989, Anderson et a l , 1991), but not in all MDR cell lines (Palyyoor et al,
1987) Some data suggested that the effect of phosphorylation of Pgp was to increase the 
velocity of transport and not the affinity of the transporter for its substrates (Halt et a l , 
1993)
Two distinct human genomic clones were isolated by cross hybridisation with probes from 
the amplified hamster domain (Romnson et a l , 1986) One of these clones, human mdrl, 
identified amplified DNA sequences and a 4 5Kb mRNA overexpressed in MDR cell lines 
Similarly, using an independently derived hamster mdr probe, a novel set of cDNAs with 
high homology to human mdrl were isolated from a human liver cDNA library and 
designated mdr3 (Van der Bliek et a l , 1987, 1988) Cross hybridisation and sequence 
comparisons indicate that the cDNAs isolated from human, murine and hamster libraries are 
members of a multigene family which encodes the P-glycoprotein (Gros et al, 1986, Ueda et 
al,  1986) Comparisons of mtron sequences (Ng et al, 1989), untranslated sequences 
(Endicott et a l , 1987, Hsu et a l , 1989) and coding regions (Hsu et a l , 1989, Endicott et a l ,
1991) have identified three classes of mammalian P-glycoprotein as indicated in table 13 P- 
glycoprotein multigene families are clustered in tandem on chromosome 7 m humans (Lmcke 
et a l , 1991)
Class I II m
Human mdrl mdr3
Mouse mdr3 mdrl mdr2
Hamster pgpl pgp2 pgp3
Table 1.3 Classification and nomenclature of mammalian P-glycoprotems
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Substrates for Pgp include adnamycin, daunorubicin, mitoxantrone, colchicine, vinblastine, 
vincristine, taxol, etoposide, temposide, actinomycin D, verapamil and rhodamine 123 
Resistance patterns associated with Pgp overexpression have been described in a vast number 
of MDR cell lines The typical pattern includes cross-resistance to anthracyclines, 
epipodophyllotoxins, vinca alkaloids, colchicine, taxol and actinomycin D
The compounds which interact with Pgp are usually small lipophilic cations (Beck, 1990) and 
are likely to enter the cell by diffusion Pgp may recognise its substrates while they are still 
present within the lipid bilayer and remove them directly from the plasma membrane Thus, 
Pgp which acts as an energy-dependent drug efflux pump might itself be responsible for both 
a decreased influx and increased efflux of drugs
The cellular and tissue distribution of Pgp has been widely studied Immunohistochemical 
stainmgs have shown high levels of Pgp in human adrenal cortex, kidney and placenta 
(Sugawara et a l , 1988a, 1988b) Pgp has also been localised to the apical biliary surface of 
hepatocytes, the columnar epithelial cells of colon and jejunum (Thiebaut et a l , 1987) and 
the apical brush border membrane surface of epithelial cells from renal proximal tubule cells 
(Lieberman et a l , 1989) The endothelial cells of human capillary blood vessels at the blood- 
brain barrier and blood-testis barrier also express Pgp (Cordon-Cardo et al,  1989, Thiebaut 
et a l , 1989) The expression of Pgp in these tissues suggests either a physiological role in 
secreting substances from these tissues, such as bilirubin (Gosland et a l , 1993) or steroid 
hormones (Ueda et a l , 1992), or a protective role by excluding potentially toxic xenobiotics 
or mutagenic chemicals (Ferguson and Baguley, 1993)
A major study by Goldstein et al (1989) analysing clinical samples demonstrated elevated 
Pgp expression in untreated tumours derived from tissues known to normally express Pgp, 
such as colon cancer, renal cell carcinoma, hepatoma and adrenocortical carcinoma Many 
other untreated tumours from tissues which do not normally express Pgp had low or 
undetectable levels of mdrl mRNA, such as breast cancer, non-small cell lung cancer, gastric 
cancer, carcinoma of prostate and chronic myelogenous leukaemia
Chan et al (1991) conducted a retrospective analysis of tumour biopsies from 67 children 
with neuroblastoma using immunohistochemical staining for Pgp This study showed a strong 
association between Pgp expression and lack of chemotherapeutic response and poor
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survival Analysis of samples from 30 children with rhabdomyosarcoma showed that while 
the presence or absence of Pgp expression did not predict for clinical responsiveness since 
nearly all patients responded, it proved a significant predictor of relapse and overall survival 
(Chan et a l , 1990) Therefore, the expression of Pgp was prognostic of the success or failure 
of therapy for these two types of childhood malignancies Ronmson and co-workers used 
PCR technique to retrospectively analyze the correlation between low levels of mdrl mRNA 
and response to chemotherapy in 100 ovarian and small cell lung cancer patients (Holzmayer 
et a l , 1992) A highly significant correlation was found between the absence of PCR 
detectable gene expression and responsiveness to chemotherapy
Bradley et al (1994) studied the expression of Pgp during stepwise progression to rat liver 
cancer Their results showed that Pgp expression was higher in the large hyperplastic nodules 
and in hepatocellular carcinoma than in the normal liver These findings suggested that Pgp 
might be associated with a more progressed malignant phenotype m liver carcinogenesis
1.4 MRP fam ily members
In humans, six members of the multidrug resistance protein (MRP) family, designated 
MRP1-MRP6, have been identified They are membrane proteins mediatmg the adenosme 
triphosphate (ATP)-dependent transport of anionic conjugates and amphiphilic anions, such 
as the bilirubin glucuronosides
1.4.1 MRP1
MRP1 is a 1531-ammo acid integral membrane phosphoprotein with a molecular weight of 
190kD that is encoded by a 6 5-kilobase mRNA (Cole et a l , 1992) MRP1 was cloned 
originally from a multidrug resistant small cell lung cancer cell line H69AR (Cole et a l ,
1992) and has subsequently been found to be overexpressed in a number of drug-selected cell 
lines derived from a variety of different tumour types (Slovak et a l , 1995, Zaman et a l , 
1994, Barrand et a l , 1993, Schneider et a l , 1995) Computer-assisted analysis of MRP 
mRNA suggested that it encodes a member of the ABC superfamily of transmembrane 
transporters The amino acid sequence identity between Pgp and MRP1 is very low 
(approximately 15%) and restricted to the generally conserved nucleotide binding domains 
(NBDs) (Cole et a l , 1992) MRP1 contains two NBDs, each preceded by a multi-spanmng
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transmembrane region The protein has also been shown to be glycosylated and 
phosphorylated, primarily on serine residues (Almquist el a l , 1995, Ma et a l , 1995) 
Unmodified MRP1 polypeptide has a molecular weight of 170kD and is processed into a 
mature 190kD form by the addition of N-linked complex oligosaccharides (Almquist et a l , 
1995) The protein kinases responsible for the phosphorylation of MRP1 have not been 
identified, although preliminary inhibitor studies have suggested that PKC may be involved 
(Ma et a l , 1995) Chromosomal localisation of mrpl gene is at 16pl3 l(Cole et a l , 1992)
Fig. 1.4.1 A predicted structure of MRP1 Each half of MRP1 consists of several membrane- 
spanning segments, followed by a NBD (nucleotide binding domain) (Lautier et a l , 1996)
The pattern of resistance in MRP1 overexpressing cell lines typically includes cross­
resistance to anthracyclines, epipodophyllotoxins, vinca alkaloids but not anti-metabolites In 
contrast to Pgp overexpressing cells, MRP 1-transfected HeLa cells are resistant to arsemte, 
but not to mitoxantrone (Cole et a l , 1994) The resistance profile of murine NIH 3T3 cells 
transfected with human MRP1 is similar to that of transfected HeLa cells (Breunmger et a l ,
1995) MRP 1-transfected human SW1573 lung cancer cells also have a similar profile except 
that they are relatively more resistant to colchicine than the anthracycline and are not 
resistant to arsemte (Zaman et a l , 1994, 1995) Although it is possible that these differences 
may be attributed to the cell type used for transfection, they may also be explained by 
differences in the levels of MRP 1 in the various transfectants
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Table 1.4.1.1 C h e m o th e rap e u tic  agents k n o w n  to  be the  substrates o f  Pgp o r  M R P  fa m ily  
m em bers
M R P 1  o ve rexp re ss ing  ce lls  se lected in  V P - 16, v in c r is t in e , e p iru b ic in , and n o v o b io c in  have 
been described  (L o e  et al., 1996b), as w e ll as c e ll lin e s  exp ress ing  b o th  Pgp and M R P 1  
(S lap ak  et al., 1994; B ro c k  et al., 1995; H asegaw a et al., 1995). W h a t de te rm ines w h e th e r 
M R P 1  o r  P gp  w i l l  be overexpressed  is n o t kn o w n . I t  has been suggested th a t o ve rexp re ss ion  
o f  M R P  1 m ay c o n fe r in it ia l  lo w  leve ls  o f  resistance, w h ile  o ve re xp re ss io n  o f  Pgp m ay appear 
la te r, in  response to  h ig h e r d ru g  concen tra tions . D u r in g  subsequent se le c tion  in  h ig h e r d ru g  
co nce n tra tion s , express ion  o f  M R P  1 m ay decrease o r rem a in  constan t and o ve re xp re ss io n  o f  
Pgp m ay em erge. H o w e v e r, th is  does n o t o c c u r in  a ll cases (L a u tie r  et al., 1996).
M R P 1  tran s fe c tan ts  have been u n ifo rm ly  fo u n d  to  d isp la y  a decrease in  d ru g  a c c u m u la tio n  
(C o le  et al., 1994; B re u n in g e r et al., 1995; Z am an  et al., 1994). M R P 1  has been re p o rte d  to  
be loca te d  p re d o m in a n tly  in  the  p lasm a m em brane  o f  severa l c e ll line s  in c lu d in g  M R P  
tran s fe c ted  H e L a  and S W 1573  ce lls , as w e ll as the  d ru g  se lected ce ll line s  H 6 9 A R , C O R - 
L 2 3 R  and G L C 4 /A D R  (A lm q u is t  et al., 1995; F lens et al., 1994; B a rra n d  et al., 1995). T he  
lo c a lis a tio n  o f  M R P  1 in  the  p lasm a m em brane  supports  a ro le  fo r  th is  p ro te in  as an e f f lu x  
pum p. H o w e v e r, in  H L 6 0 /A D R  ce lls  and ce rta in  o th e r ce lls , M R P 1  has been re p o rte d  to  be 
loca te d  m a in ly  in  the  e n d o p la sm ic  re tic u lu m  o r  associated w ith  c y to p la s m ic  s truc tu res ,
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p o s s ib ly  th e  G o lg i apparatus (F lens  et al, 1994, 1996, M a rq u a rd t et al, 1992, 
K r is h n a m a c h a ry  et al, 1993) W h e th e r the  lo c a lis a tio n  o f  M R P  1 in  a ll o f  these in tra c e llu la r  
co m p a rtm e n ts  co n tr ib u te s  to  the  d ru g  res is tance phe no typ e  is  u n k n o w n
T he re  is  n o w  co ns ide rab le  ev idence  th a t M R P 1  can fu n c t io n  as a h ig h  a f f in i ty  tra n s p o rte r  o f  
c y s te in y l le u ko trie n e s , m o s t n o ta b ly  th e  G S H -co n ju g a te  L T C 4 (L e ie r  et al, 1994, M u l le r  et 
al, 1994, L o e  et al, 1996a) T h is  a ra ch id om c  a c id  d e r iv a tiv e  and its  m e ta bo lites , L T D 4 and 
L T E 4, are a c tive  co m p on en ts  o f  the  "s lo w  re a c tin g  substance o f  a n a p h y la x is " T h e y  are 
in v o lv e d  in  the  c o n tro l o f  va scu la r p e rm e a b ility  and sm o o th  m usc le  c o n tra c tio n  and have  
been im p lic a te d  in  the  pa thogenesis  o f  asthm a (H a y  et al, 1995) S evera l o th e r p o te n tia l 
substra tes fo r  M R P 1  have  a lso been id e n t if ie d  b y  d ire c t tra n s p o rt studies, am ong  th e m  are 
g lu ta th io n e  d is u lf id e  (o x id is e d  g lu ta th io n e ) and s te ro id  g lu cu ro m d e s  such as 1 7P -e s tra d io l 
1 7 -(P -D  g lu c u ro m d e ) (L e ie r  et al, 1996, Je dh tschky  et al, 1996) M a n y  o rg a n ic  an ions have  
been  s h o w n  to  act as c o m p e tit iv e  in h ib ito rs  o f  e ith e r L T C 4 o r  1 7P -es trad io l 1 7 - (p -D  
g lu c u ro m d e ) tra n s p o rt These in c lu d e  a w id e  range  o f  a n io n ic  con juga tes  o f  b ile  sa lts and 
s te ro id  ho rm o ne s  (L e ie r  et al, 1996, Je dh tschky  et al, 1996, L o e  et al, 1996) T h e  b ro ad  
substra te  s p e c if ic ity  o f  M R P  1 fo r  o rg a n ic  an ions  p ro m p te d  th e  su gg es tio n  th a t M R P 1  m ay be 
the  m u lt is p e c if ic  o rg a n ic  a n io n  tra n s p o rte r ( M O A T )  In  ro d e n t l iv e r ,  c M O A T  (c a n a lic u la r  
m u lt is p e c if ic  o rg a n ic  a n io n  tra n s p o rte r)  m ed ia tes the  b il ia r y  e x c re tio n  o f  endogenous and 
exogenous co m p ou nd s  fo l lo w in g  th e ir  m o d if ic a t io n  b y  phase I I  c o n ju g a tin g  enzym es to  fo rm  
a m p h ip h il ic  an ions  D e sp ite  c e rta in  co m m o n  p h a rm a c o lo g ic  fea tu res  o f  M R P  1- and M O A T -  
m e d ia te d  tra n sp o rt, ev idence  in d ic a te d  th a t th e y  are d if fe re n t p ro te in s  due to  the  c lo n in g  o f  a 
n o v e l c M O A T  fro m  ra t l iv e r  (P au lusm a et al, 1996)
A lth o u g h  M R P  1 has been  s h o w n  to  reduce  c e llu la r  a c c u m u la tio n  o f  som e d rugs  to  w h ic h  i t  
co n fe rs  res is tance, such as d a u n o ru b ic in , V P - 16 and v in c r is t in e , i t  has n o t been  p o ss ib le  to  
d em onstra te  d ire c t tra n s p o rt o f  these com pounds  o r  o th e r u n m o d if ie d  ch e m o th e ra pe u tic  d rugs  
b y  M R P l-e n r ic h e d  m em brane  ves ic les  (M u lle r  et al, 1994, L o e  et al, 1996a, Je d h tsch ky  et 
al, 1996) These ch e m o th e ra pe u tic  agents have also been fo u n d  to  be v e ry  p o o r  in h ib ito rs  o f  
L T C 4  tra n s p o rt (M u lle r  et al, 1994, L o e  et al, 1996a) These o bse rva tions , c o m b in e d  w i th  
the  dem on s tra te d  a b i l it y  o f  M R P  1 to  tra n s p o rt G S H -co n ju g a te  L T C 4, led  to  th e  sugges tion  
th a t M R P  1 reduced  d ru g  a ccu m u la tio n , n o t b y  tra n s p o rtin g  u n m o d if ie d  d rugs  d ire c t ly , b u t b y  
e f f lu x in g  d ru gs  a fte r th e ir  c o n ju g a tio n  to  G S H  H o w e v e r, G S -con juga tes  o f  d a u n o ru b ic in  o r
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v in c r is t in e  are n o t de tectab le  in  th e  c u ltu re  m e d iu m  o f  M R P l-o v e re x p re s s in g  ce lls  exposed  to  
e ith e r o f  these tw o  d rugs  (Z a m a n  et al, 1995) A lte rn a t iv e  p o s s ib ilit ie s  c u rre n tly  u n d e r 
in v e s tig a tio n  are th a t M R P 1  can co -tra n sp o rt G S H  and d ru g  w ith o u t  co n ju g a te  fo rm a tio n  o r  
th a t G S H  fa c ilita te s  d ru g  tra n s p o rt b y  an as y e t u n d e fin e d  m echan ism
M R P 1  e xp ress io n  has been de tected  in  a w id e  range o f  non -se lec ted  h u m a n  tu m o u r  c e ll line s , 
in c lu d in g  those  d e rive d  fro m  s m a ll c e ll and n o n -s m a ll c e ll lu n g , co lo n , gas tric , breast, 
o v a r ia n  ca rc inom as, neu rob las tom a , th y ro id  and g lio m a  (L o e  et al, 1996, N o o te r  et al, 1995, 
K ru h  et al, 1995) E x p re s s io n  o f  M R P  1 has a lso been de tected  in  tu m o u r  sam ples f ro m  
p a tie n ts  w i th  c h ro n ic  and acute  leukaem ias
V e ra p a m il and c y c lo s p o rm  A , w h ic h  are w e l l  characte rised  in h ib ito rs  o f  P gp, u s u a lly  sh o w  
e ffe c t o n  d ru g  s e n s it iv ity  and tra n s p o rt in  d ru g  se lected o r M R P  1- tra n s fec ted  ce lls  (see 
se c tion  4  4 )  C om po u nd s  re p o rte d  to  reverse  M R P  1-assoc ia ted  res is tance  to  a s ig n if ic a n t 
degree in  a t least one m o d e l system  in c lu d e  d ih y d ro p y n d in e  n ic a rd ip in e  and N I K  2 50  (C o le  
et al, 1989, A b e  et al, 1995), d if lo x a c m  (G o lla p u d i et al, 1995), the  b is in d o ly m a le im id e  
G F 1 0 9 2 0 3 X  (G e k e le r et al, 1995a), M K 5 7 1  (G e ke le r et al, 1995b) and th e  c y c lo s p o rm  
ana logue  P S C  833 (B a rra n d  et al, 1993) S ens itisa tion  b y  these co m p ou nd s  is  o fte n  
dependen t o n  th e  d ru g  and ty p e  o f  ce lls  tested
T he  o b s e rv a tio n  th a t m em brane  ve s ic le s  fro m  M R P  ove rexp re ss ing  ce lls  c o u ld  tra n s p o rt the  
g lu ta th io n e  c o n ju g a te  L T C 4  suggested th a t in tra c e llu la r  G S H  le ve ls  m ig h t be in v o lv e d  in  
M R P  1-assoc ia ted  d ru g  resis tance T he  le ve ls  o f  G S H  in  tran s fe c ted  and d ru g -se le c ted  M R P 1  
ce lls  re la t iv e  to  th e ir  sens itive  p a ren ta l ce lls  v a ry  co n s id e ra b ly  (Z a m a n  et al, 1995, 
V e rs a n tv o o tt et al, 1995a, C o le  et al, 1990) T he  a b il ity  o f  the  y -g lu ta m y lc y s te m e  synthe tase  
in h ib ito r  B S O  (w h ic h  resu lts  in  d e p le tio n  o f  G S H ) to  c irc u m v e n t M R P l-m e d ia te d  M D R  
va rie s  g re a tly  as w e l l  (Z a m a n  et al, 1995, G e ke le r et al, 1995b, C o le  et al, 1990, S chne ide r 
etal, 1995, D a v e y  etal, 1995) T he  basis o f  th is  v a r ia b i l i t y  is  n o t u n d e rs to od
1.4.2 cMOAT (MRP2)
A n  is o fo rm  o f  M R P  1, w i th  a s im ila r  substrate  s p e c if ic ity  and a d is t in c t sequence, has been 
c lon ed  and lo c a lis e d  p re d o m in a n tly  to  the  hepa tocy te  c a n a lic u la r m em brane  (B u c h le r  et al, 
1996, P a u lu sm a  et al, 1996, K e p p le r  and K a rte n b e ck , 1996, K e p p le r  and K o m g , 1997) T h is
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is o fo rm  has been  te rm e d  c M O A T  (c a n a lic u la r  m u lt is p e c if ic  o rg a n ic  a n io n  tra n s p o rte r) o r  
M R P 2  c M O A T  m ed ia tes  th e  A T P -d e p e n d e n t tra n s p o rt o f  g lu ta th io n e  S -con juga tes  and 
g lu c u ro n id e s  f ro m  the  l iv e r  in to  b ile  (K e p p le r  and K o m g , 1997, Je d h tsch ky  et a l , 1997) and 
across th e  ap ica l m em brane  o f  k id n e y  p ro x im a l tu bu les  (S chaub  et a l , 1997)
H u m a n  c M O A T  is  com posed  o f  1545 am m o acids C o m p a ris o n  b e tw e en  h u m a n  M R P 1  and 
c M O A T  in d ica te s  an o v e ra ll a m m o ac id  id e n t ity  o f  4 9 % , w he re  th e  h ig h e s t degree o f  id e n t ity  
is  in  th e  c a rb o x y l- te rm in a l d o m a in  and in  n u c le o tid e -b in d m g  d om a ins  (B u c h le r  et a l , 1996) 
T he  m o le c u la r  w e ig h t o f  u n g ly c o s y la te d  c M O A T  is 1 74 kD  (T a m g u c h i et a l , 1996) I t  is  N -  
g ly c o s y la te d  in  its  m a tu re  fo rm  and has 1 90 kD  m o le c u la r  w e ig h t C h ro m o so m a l lo c a lis a tio n  
o f  cm o a t gene is  at 10q24 In  p o la rised  e p ith e lia l ce lls , such  as hepa tocy tes , c M O A T  is  
s tr ic t ly  lo ca hse d  to  th e  ap ica l d om a ins  o f  hepa tocy tes  (B u c h le r  et a l , 1996) and p ro x im a l 
tu b u le  e p ith e lia l ce lls  o f  the  k id n e y  (S chaub  et a l , 1997)
T he  substra te  s p e c if ic ity  o f  c M O A T  has been  s tud ied  m o s t e x te n s ive ly  in  in s id e -o u t 
h e p a to cy te  c a n a lic u la r  m em brane  ve s ic le s  f ro m  n o rm a l ra t l iv e r  in  c o m p a ris o n  w i th  
m em brane  ve s ic le s  f ro m  m u ta n t rats la c k in g  c M O A T  ( Is h ik a w a  et a l, 1990, B u c h le r  et a l ,
1996) c M O A T  has a s im ila r  sp ec trum  o f  substrates as M R P 1  in c lu d in g  LTC4, LTD4, 1 70 - 
g lu c u ro n o s y l e s tra d io l, o x id iz e d  g lu ta th io n e  (G S S G ) and m o n o g lu c u ro n o s y l b i l i r u b in  
Substra te  s p e c if ic ity  d iffe re n ce s  be tw een  M R P 1  and c M O A T  are in d ic a te d  b y  a h ig h e r 
a f f in i ty  and tra n s p o rt ra te  o f  M R P 1  fo r  LTC4 and b y  th e  p re fe re n tia l tra n s p o r t o f  
m o n o g lu c u ro n o s y l b i l i r u b in  and b is g lu c u ro n o s y l b i l i ru b in  b y  c M O A T  (Je d h tsch ky  et a l ,
1997)
T he  h u m a n  D u b in -J o h n s o n  syn d rom e  is  a ra re  au tosom a l recessive  l iv e r  d is o rd e r P a tien ts  
have  im p a ire d  h e p a to b ilia ry  tra n s p o rt o f  b ile  sa lt o rg a n ic  an ions  (re v ie w e d  b y  R o y  
C h o w d h u ry  et a l , 1994) T he  absence o f  c M O A T  is  the  m o le c u la r  basis o f  th is  h e re d ita ry  
disease (B u c h le r  et a l , 1996, K a rte n b e c k  et a l , 1996) A  h ig h ly  s im ila r  p h e n o typ e  has been 
described  fo r  a m u ta n t W is ta r  ra t stra in , the  tra n s p o rt d e fic ie n t (T R ')  ra t, w h ic h  is  d e fe c tiv e  in  
c M O A T  These m u ta n t a n im a ls  la c k  the  h e p a to b ilia ry  e x c re tio n  o f  m a n y  o rg a n ic  an ions 
in c lu d in g  b il iru b m -g lu c u ro n id e , c y s te m y l- le u k o tn e n e s  and som e d iv a le n t b ile  sa lt co n jug a tes  
(P a u lusm a  et a l , 1996)
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O ve re xp re ss io n  o f  c M O A T  has been lin k e d  w ith  res is tance to  v in b la s tin e  (E ve rs  et al, 1998), 
c is p la tin , v in c r is t in e , a d n a m y c in  and ca m p to th e c in  d e riva tive s , b u t n o t to  e toposide, 5 -F U  
and m ito m y c in  C  (K o ik e  et al, 1997, T a n ig u c h i et al, 1996)
1.4.3 MRP3
In  a d d it io n  to  M R P 1  and c M O A T  (M R P 2 ), o th e r M R P  h om o lo gu es  e n co d in g  G S -X  pum ps 
m ig h t be p resen t in  the  h um an  genom e, c o n s id e r in g  th a t th e re  are at leas t fo u r  M R P  
h o m o lo g u e s  expressed in  the  s o il nem atode  caenorhabditis elegans (B ro e k s  et al, 1996) 
B o g u s k i et al (1 9 9 6 ) th e re fo re  searched the  expressed sequence ta g  (E S T ) l ib ra ry  fo r  
p u ta tiv e  h u m a n  M R P  h o m o lo g u e s  and fo u n d  th ree  M R P  h o m o lo g u e s  w h ic h  w e re  des ignated  
M R P 3 , M R P 4  and M R P  5 m  hum ans
L ik e  th e  G S -X  pum ps M R P 1  and c M O A T , M R P 3  is  a lso  an o rg a n ic  a n io n  and m u lt id ru g  
tra n s p o rte r  O f  a ll the  M R P  fa m ily  m em bers, M R P 3  is  c losest to  M R P 1  (5 8 %  am m o a c id  
id e n t ity )  ( K o o l et al, 1999) In  M a d in -D a rb y  can ine  k id n e y  I I  ce lls , M R P 3  is  lo ca te d  o n  the  
b aso la te ra l m em brane  and m ed ia tes  o rg a n ic  a n io n  S -(2 ,4 -d im tro p h e n y l-)g lu ta th io n e  tra n s p o rt 
(K o o l et al, 1999) M R P 3  is  a lso  lo ca lise d  to  the  b aso la te ra l m em brane  o f  h u m a n  
h epa tocy tes  (K o m g  et al, 1999) I t  is  com posed  o f  1527 am m o ac ids and encoded  b y  4581 
base p a irs  o f  c D N A  T h e  M R P 3  gene is  loca te d  on  ch ro m o som e  17 (K o o l et al, 1997) T o  
date, M R P 3  has been  fo u n d  to  be expressed in  the  l iv e r ,  co lo n , pancreas, k id n e y  (K o m g  et 
al, 1999), in te s tin e  and adrena l g la n d  (K o o l et al, 1999)
O ve re xp re ss io n  o f  M R P 3  has been dem onstra ted  in  severa l a d n a m y c in -re s is ta n t sub lines  o f  
th e  S W 15 73 /S 1  h u m a n  n o n -s m a ll-c e ll lu n g  cancer c e ll l in e  and a lso m  th e  c is p la tm -re s is ta n t 
H C T 8/D D P  c o lo n  ca rc in o m a  c e ll l in e  (K o o l et al, 1997) In  o v a ria n  c a rc in o m a  ce lls  (2 0 0 8 ), 
M R P 3  o ve re xp re ss io n  resu lts  in  lo w - le v e l res is tance  to  the  e p ip o d o p h y llo to x in s  e topos ide  
and te m p o s id e  and h ig h - le v e l res is tance  to  m e th o tre xa te  (K o o l et al, 1999) S tud ies have  
s h o w n  th a t the  M R P 3 -o v e re x p re s s in g  c e ll l in e  2008  and M a d in -D a rb y  can ine  k id n e y  I I  c e ll 
l in e  do  n o t sh ow  increased g lu ta th io n e  e x p o rt o r  decreased leve ls  o f  in tra c e llu la r  g lu ta th io n e , 
in  c o n tra s t to  ce lls  o ve rexp re ss ing  M R P  1 o r c M O A T  (K o o l et al, 1999)
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1.4.4 MRP4-6
N o t m u c h  is  k n o w n  a b o u t th e  substrate  s p e c if ic ity  o f  M R P 4 , M R P 5  o r  M R P 6 M R P 4  and 
M R P 5  genes are loca te d  o n  ch ro m o som e  13 and 3 re s p e c tiv e ly  (K o o l et al, 1997) In  a pane l 
o f  h u m a n  c e ll lin e s  d e riv e d  f ro m  v a rio u s  tissues and th e ir  res is ta n t sub lm es (se lec ted  w i th  
e ith e r a d r ia m y c in , c is p la tin , te tra p la tin  o r  ca d m iu m  c h lo rid e ), M R P 4  w as expressed a t v e ry  
lo w  le v e ls  in  th e  p a re n ta l ce lls  and no  ove rexp re ss ion  o f  M R P 4  w as de tected  in  res is ta n t 
sub lm es In  con tras t, M R P 5  w as  fo u n d  to  be h ig h ly  expressed in  a ll th e  p a ren ta l c e ll lin e s , 
w i th  the  m o s t s ig n if ic a n t m crease observed  in  the  lu n g  a de no ca rc ino m a  c e ll lm e  M O R /P  and 
o v a r ia n  ca rcm o m a  c e ll lm e  2008  H o w e v e r, s im ila r  to  the  resu lts  ob ta ined  w i th  M R P 4 , no  
s ig n if ic a n t M R P 5  o ve rexp re ss ion  w as  n o te d  m  th e  res is ta n t ce lls  A  s lig h t m crease o f  M R P 5  
R N A  w as  de tec ted  in  th ree  c is p la tin -re s is ta n t c e ll lines , T 2 4  D D P 1 0  (b la d d e r ca rcm om a  c e ll 
lm e ), H C T 8/D D P  (c o lo n  ca rcm om a  c e ll l in e )  and K C P -4  (e p id e rm o id  ca rcm om a  c e ll lm e )  
(K o o l et al, 1997) M R P 4  is  a lso  rep o rte d  to  be expressed a t a lo w  le v e l in  a n u m b e r o f  tissue  
types  w he reas M R P 5  w as de tected  in  substan tia l am oun ts  in  e ve ry  tissue  tested, w ith  
re la t iv e ly  h ig h  e xp ress io n  in  ske le ta l m usc le  and b ra m  (K o o l et al, 1997) T h e  fu n c t io n  o f  
M R P 4  and M R P 5  rem a ins  u n k n o w n  I t  seems th a t M R P 4  m ay n o t be co rre la ted  to  m u lt id ru g  
res is tance
O ve re xp re ss io n  o f  the  M R P 6 gene in  M D R  ce lls  is  in v a r ia b ly  associa ted  w i th  the  
a m p lif ic a t io n  o f  th e  ad jacen t M R P 1  gene and M R P 6 p ro b a b ly  does n o t c o n tr ib u te  to  
res is tance  ( K o o l et al, 1999)
1.5 Alternative mechanisms of MDR
1.5.1 Lung resistance-related protein (LRP)
L u n g  res is ta nce -re la te d  p ro te in  (L R P ) is  a l lO k D  p ro te in  w h ic h  w as id e n t if ie d  in  the  
a d n a m y c in -re s is ta n t n o n -s m a ll c e ll lu n g  cancer ce ll lm e  S W 1 5 7 3 /2 R 1 2 0  m  1993 (S cheper et 
al, 1993) S ince  its  id e n t if ic a t io n , L R P  has been  fo u n d  to  be overexpressed  in  a la rg e  n u m b e r 
o f  M D R  c e ll lin e s  in d ic a tin g  th a t L R P  ove rexp re ss ion  is  a fre q u e n t fe a tu re  in  n on -P g p  
m e d ia te d  M D R  L R P  o ve rexp re ss ing  M D R  c e ll lin e s  in c lu d e  th e  sm a ll c e ll lu n g  cance r c e ll 
lm e  G L C 4 /A D R , th e  f ib ro s a rc o m a  c e ll lm e  H T 1 0 8 0 /D R 4 , the  b reast cancer c e ll lin e s  
M C F 7 /M ito x  and M C F 7 /M R  and the  m y e lo m a  c e ll lm e  8 2 2 6 /M R 4 0  (S cheper et al, 1993) 
U p -re g u la t io n  o f  L R P  has been  observed e a rly  d u r in g  the  process o f  d ru g  se le c tio n  in  v a r io u s
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c e ll lin e s  T h is  o b s e rv a tio n  suggests th a t the  LR P -a ssoc ia ted  m ech an ism  m ig h t be in v o lv e d  in  
lo w  o r  m od era te  le ve ls  o f  d ru g  res is tance ( Iz q u ie rd o  et al, 1995)
C o m p a ra tiv e  sequence ana lys is  in d ic a te d  th a t L R P  shares 5 7%  and 87 7 %  am m o ac id  
id e n t ity  w i th  th e  m a jo r  v a u lt  p ro te in s  fro m  Dictyostelium Discoideum (K e de rsh a  et al, 1993) 
and Rattus Norvigecus (K ic k h o e fe r  et al, 1994) re s p e c tiv e ly  T hus, L R P  w as id e n t if ie d  as 
the  h u m a n  m a jo r  v a u lt  p ro te in  (S c h e ffe r  et al, 1995) w h ic h  is  the  c o m p o n e n t o f  c e llu la r  
o rgan e lles  te rm e d  v a u lts  (R o m e  et al, 1991, K ede rsha  et al, 1986)
V a u lts  w e re  f ir s t  id e n t if ie d  b y  n e g a tive  s ta inm g  and tra n sm iss io n  e le c tro n  m ic ro s c o p y  in  
1986 (K e de rsh a  et al, 1986) T he  te rm  "v a u lts "  w as chosen b y  R o m e  et al (1 9 9 1 ) to  describe  
th e  m o rp h o lo g y  o f  th e  p a rtic le s  w h ic h  cons is t o f  m u lt ip le  arches s im ila r  to  those  fro m  
ca thed ra l v a u lts  V a u lts  are c o m p le x  r ib o n u c le o p ro te in  p a rtic le s  w h ic h , in  th e  ra t, are 
com posed  o f  a m a jo r  v a u lt  p ro te in  o f  1 04 kD  (a c c o u n tin g  fo r  >  7 0%  o f  the  mass o f  th e  
p a rtic le ) , th re e  m in o r  p ro te in s  o f  210 , 192 and 54 k D  and a sm a ll R N A  m o le c u le  (R o m e  et 
al, 1991, K e de rsha  et al, 1986, 1991) T he  v a u lt  p a rtic le  has 2 - fo ld  s y m m e try  and each h a l f  
can be opened in to  a f lo w e r - l ik e  s tru c tu re  w h ic h  con ta ins  e ig h t peta ls  su rro u n d in g  a ce n tra l 
r in g  (K e de rsh a  et al, 1991) T o  date, the  fu n c t io n  o f  v a u lts  is  u n k n o w n  M o s t  v a u lts  are 
p resen t m  th e  c y to p la s m  b u t a sm a ll fra c t io n  o f  v a u lts  are lo ca lise d  to  th e  n u c le a r m em brane  
and n u c le a r p o re  com p lexes (C h u g a m  et al, 1993) w h e re  th e  v a u lts  w e re  hypo the s ised  to  
c o n s titu te  th e  ce n tra l p lu g s  o f  the  n u c le a r po re  c o m p le x  so th a t th e y  m ig h t p ro te c t the  nuc leus  
f ro m  n u c le a r to x in s  T ra n s fe c tio n  o f  o n ly  the  L R P  gene its e lf , c o d in g  fo r  one h u m a n  m a jo r  
v a u lt  p ro te in , has fa ile d  to  co n fe r M D R  (S c h e ffe r et al, 1995) T h is  f in d in g  in d ica te s  th a t the  
co m p le te  v a u lt  p a r t ic le  is  re q u ire d  to  ca rry  o u t fu n c t io n a l a c t iv ity
T he  c o n c o m ita n t o ve rexp re ss ion  o f  L R P  and M R P  appears to  be a fre q u e n t even t in  n on -P g p  
M D R  c e ll lin e s  such  as the  S W 1 5 7 3 /2 R 1 2 0  and G L C 4 /A D R  c e ll lin e s  T h e  L R P  gene has 
been  lo c a lis e d  to  th e  sh o rt a rm  o f  ch ro m o som e  16 (1 6 p l 1 2 ), w h ic h  is  p ro x im a l to  th e  M R P 1  
gene (1 6 p l3  1) T h is  ra ised  the  p o s s ib il ity  th a t th e  L R P  gene w as  s im p ly  c o -a m p lif ie d  w i th  
th e  M R P 1  gene H o w e v e r, th is  th e o ry  w as e lim in a te d  w h e n  a m p lif ic a t io n  o f  th e  M R P  gene, 
b u t n o t o f  th e  L R P  gene, w as fo u n d  in  S W 1 5 7 3 /2 R 1 2 0  and G L C 4 /A D R  ce lls  (S lo v a k  et al,
1995) F u rth e rm o re , in  H T 1 0 8 0 /D R 4  ce lls , b o th  L R P  and M R P 1  genes w e re  a m p lif ie d  m  the  
h o m o g e n e o u s ly  s ta ined re g io n  (hsr), b u t o n ly  the  M R P 1  genes w e re  con tam ed  w i th in  h s r 
(S lo v a k  et al, 1995) These resu lts  in d ic a te d  th a t a lth o u g h  b o th  th e  M R P 1  and L R P  genes
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m ap to  the  sh o rt a rm  o f  ch ro m o som e  16, th e y  are ra re ly  c o -a m p lif ie d  and are n o t n o rm a lly  
loca te d  w ith m  the  same a m p lic o n
L R P  and P gp  are ra re ly  s im u lta n e o u s ly  overexpressed  in  d ru g -se le c ted  M D R  ce lls  such  as 
n o n -s m a ll lu n g  cance r S W 1 5 7 3 /2 R 1 6 0 , th e  o va ria n  c a rc in o m a  A 2 7 8 0 A D  and th e  m y e lo m a  
8 2 2 6 /D o x 6  and 8 2 2 6 /D o x 4 0  c e ll lin e s  w h ic h  are P g p -p o s itiv e  b u t L R P -n e g a tiv e  (S cheper et 
al, 1993) L R P  o ve rexp re ss ion  has a lso been re p o rte d  in  P g p /M R P -n e g a tiv e  M D R  c e ll hnes 
such as th e  m ito x a n tro n e  se lected M C F 7 /M R  c e ll l in e  (F u tsch e r et al, 1994)
H ig h  L R P  e xp ress io n  has been sh ow n  in  e p ith eh a  o f  th e  b ronchus, d ig e s tiv e  tra c t, 
ke ra tin o cy te s , adrena l c o rte x  and m acrophages ( Iz q u ie rd o  et al, 1995) R e la t iv e ly  h ig h  
exp ress io n  has a lso  been fo u n d  m  p ro x im a l tu b u le s  o f  th e  k id n e y , tra n s it io n a l u ro th e liu m  and 
d u c ta l p an c re a tic  ce lls  ( Iz q u ie rd o  et al, 1995) S tudies have a lso  sh ow n  th a t co lo n , rena l, 
p an c re a tic  and e n d o m e tria l cancers express h ig h  le ve ls  o f  L R P  w hereas lo w  le ve ls  o f  L R P  
w e re  n o te d  in  g e rm  c e ll tu m o u rs , W ilm 's  tu m o u rs , rha bd om yosa rcom a, E w in g 's  sa rcom a and 
acute  m y e lo id  le u ka e m ia  ( Iz q u ie rd o  et al, 1995) A  re p o r t on  the  exp ress ion  o f  L R P  in  42  
lu n g  cancer spec im ens show ed  L R P  p o s it iv i ty  in  83%  o f  the  squam ous c e ll ca rc inom as, 59%  
o f  adenocarc inom as and in  3 6 %  o f  la rge  c e ll u n d if fe re n tia te d  ca rc inom as In  con tras t, o n ly  
5%  o f  th e  s m a ll c e ll lu n g  cancers expressed L R P  (D in g e m a n s  et al, 1995)
1.5.2 Topoisomerase II
A m o n g  th e  c y to to x ic  d rugs  c u rre n tly  used, a n u m b e r are a c tive  o n  s p e c ific  n u c le a r enzym es 
ca lle d  topo isom erases T he  fu n c t io n  o f  topo isom erase  is  to  reg u la te  the  D N A  to p o lo g y , 
tra n s p o s itio n , re p a r t it io n , re c o m b in a tio n , re p lic a tio n , tra n s c r ip tio n  and o th e r D N A  processes 
(L iu ,  1983, K a f ia m  et al, 1986, Z y ls tra  et al, 1990) T w o  types  o f  topo isom erases e x is t one 
capable  o f  m tro d u c m g  sm g le -s tranded  b reaks (T o p o  I ) ,  the  o th e r capable  o f  p ro d u c in g  
dou b le -s tran d ed  b reaks (T o p o  I I )  in  th e  D N A  m o le cu le s  (W a n g , 1985, D ’ arpa, 1989)
T w o  d is t in c t is o fo rm s  o f  T o p o  I I  designated  topo isom erase  a  and P w ith  m o le c u la r  w e ig h ts  
o f  170 and 180 k D  re s p e c tiv e ly  have  been iso la te d  (D ra k e  et al, 1987, C hu ng  et al, 1989, 
T s u ts u i et al, 1993) T h e  is o fo rm s  have been sh ow n  to  have  d if fe re n t in tra n u c le a r 
lo c a lis a tio n  and tissu e  d is t r ib u t io n  (C a p ra m co  et al, 1992, Z im  et al, 1992, T s u ts u i et al,
1993), suggesting  th e ir  d if fe re n t ia l ro les  in  c e ll fu n c t io n  w ith  reg a rd  to  c e ll p ro life ra t io n  T he
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le v e l o f  to po isom erase  I I  a  increases a t the  onset o f  D N A  re p lic a t io n  and co n tin ue s  to  
increase  th ro u g h o u t th e  S and G 2 phases T he  le v e l reaches a p la teau  in  the  la te  G 2 to  M  phase 
o f  th e  c e ll c y c le  and th en  decreases a fte r m ito s is  (H e c k  et al, 1988) In  con tras t, th e  le v e l o f  
to po isom erase  I I  P does n o t appear to  v a ry  g re a tly  th ro u g h o u t th e  c e ll c y c le  (W oessne r et al, 
1991) T op o iso m e rase  I I  a  is  the  b e tte r ta rg e t fo r  the  topo isom erase  I I  in h ib ito rs  and th is  m ay  
e x p la in  w h y  som e o f  th e  in h ib ito rs  are p ro life ra t io n  s p e c ific  w i th  reg a rd  to  th e ir  to x ic it y  
(D ra k e  et al, 1987)
T h e  m ech an ism  o f  a c tio n  o f  topo isom erase  I I  is  as fo l lo w s  th e  re c o g n it io n  and b in d m g  o f  th e  
to po isom erase  enzym e  to  D N A , the  c leavage o f  the  f ir s t  d ou b le  strand o f  the  D N A , the  
passage o f  a second d ou b le  s trand  o f  D N A  th ro u g h  the  b reak, the  re lig a t io n  o f  th e  s trand - 
c leaved  D N A , and the  A T P -d e p e n d e n t tu rn o v e r  o f  the  topo isom erase  I I  (O s h e ro ff  et al,
1986) T op o iso m e rase  I I  is  the  ta rg e t fo r  a n th ra cyc line s , e p ip o d o p h y llo to x m s , q u ino lon es , 
co u m a rm s  and a c rid in es , a ll exam p les  o f  to po isom erase  I I  in h ib ito rs  T op o iso m e rase  I I  
in h ib ito rs  are th o u g h t to  k i l l  ce lls  b y  b in d in g  to  the  topo isom erase  I I  enzym e w h ic h  th e n  
b in d s  to  D N A  fo rm in g  a c o m p le x  w h ic h  ha lts  the  c a ta ly tic  a c t iv ity  o f  to po isom erase  I I  p r io r  
to  the  re lig a t io n  o f  the  c leaved  D N A  in te rm e d ia te  (R o b in s o n  and O s h e ro ff, 1990) T he  
s ta b ilise d  in te rm e d ia te  com p lexes fo rm  ba rrie rs  to  D N A  fo rk  p ro g ress io n  and thus  p re ve n t 
D N A  re p lic a t io n  (L iu ,  1989)
T w o  m ech an ism s o f  m u lt ip le  d ru g  res is tance are associated w ith  topo isom erase  I I  In  
c lass ica l m u lt id ru g  res is tance, in h ib ito rs  are a c tiv e ly  e ff lu x e d  fro m  ce lls  b y  P -g ly c o p ro te in  
In  a ty p ic a l m u lt id ru g  res is tance, topo isom erase  I I  is e ith e r reduced  o r m u ta te d  to  a fo rm  th a t 
does n o t in te ra c t w ith  th e  in h ib ito r  T h e re fo re  any tre a tm e n t th a t increases the  n u m b e r o f  
a c tive  to po isom erase  I I  m o le cu le s  p e r c e ll c o u ld  p a r t ia lly  c irc u m v e n t th is  ty p e  o f  res is tance  
Severa l typ e s  o f  a g o n is t in te ra c tio n s  a t c e ll surfaces have  been re p o rte d  to  in d u ce  tra n s ie n t 
increases in  th e  c e llu la r  a c tiv it ie s  o f  topo isom erase  I I  These in c lu d e  a rg in ine , vasop ress in , 
th ro m b in , le u k o tn e n e  D 4 and tu m o u r  necros is  fa c to r  (N a m b i et al, 1989, M a tte rn  et al, 1990 
and 1991, U ts u g i et al, 1990) These a c tiv a tio n s  are l ik e ly  to  be re la ted  to  s ig n a l tra n s d u c tio n  
p a th w a ys  th a t re s u lt in  p h o s p h o ry la tio n  and a c tiv a tio n  o f  topo isom erases e g  b y  a c tiva te d  
p ro te in  k ina se  C  o r  c y c lic  n u c le o tid e -d e p e n d e n t kinases
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M o d u la t io n  o f  to po isom erase  I I  m ay  in v o lv e  p h o s p h o ry la tio n  o f  the  enzym e I t  has been 
s h o w n  th a t topo isom erase  I I  is  p h o sp h o ry la te d  a t sp e c ific  serine  res idues, re s u lt in g  in  an 
increase  in  enzym e  a c t iv ity  (F ry  and H ic k s o n , 1993) T opo isom erase  I I  is  a n u c le a r m a tr ix  
p ro te in  and th us  changes in  th e  com ponen ts  o f  the  n u c le a r m a tr ix  d u r in g  the  c e ll c y c le  m ay  
re s u lt in  a lte ra tio n  in  th e  a c c e s s ib ility  o f  the  enzym e to  D N A  (B e c k  and D anks , 1991) O n  the  
o th e r hand, th e  a c t iv ity  o f  to po isom erase  I  and topo isom erase  I I  is  reg u la ted  in  a w a y  th a t 
m a in ta in s  c e llu la r  hom eostas is  w ith  respect to  h ig h e r o rd e r D N A  s tru c tu re  i e the  a m o u n t o f  
change in  D N A  te r t ia ry  s tru c tu re  th a t is ca ta lysed  b y  to po isom erase  I  in  a g iv e n  c e ll is  
ba lanced  b y  the  a m o u n t o f  change m  D N A  te r t ia ry  s tru c tu re  ca ta lysed b y  to po isom erase  I I  
(G e lle r t  et al, 1982) C onsequen tly  a d e f ic it  in  topo isom erase  I I  a c t iv ity  m ig h t be p a r t ia l ly  
o ffs e t b y  an increase  in  topo isom erase  I  a c t iv ity  T h is  suggests th a t c o m b in a tio n  tre a tm e n t 
w i th  to po isom erase  I  and topo isom erase  I I  in h ib ito rs  m ay  have  the  p o te n tia l to  p re v e n t 
to p o iso m e ra se -m e d ia te d  m u lt id ru g  resistance
1.5.3 Glutathione and Glutathione S-transferase
G lu ta th io n e  is  the  p r in c ip a l n o n -p ro te in  th io l in  m a m m a lia n  ce lls  and fu n c t io n s  as a 
scavenger o f  e le c tro p h ilic  to x in s  I t  is a tr ip e p tid e , syn thes ised  in  tw o  successive A T P -  
re q u irm g  steps T he  f ir s t  step in v o lv e s  the  fo rm a tio n  o f  an a m ide  lin k a g e  b e tw e en  cys te ine  
and g lu ta m a te , ca ta lysed  b y  th e  enzym e  g lu ta th io n e  synthetase and in  th e  second step th e  
enzym e  m ed ia tes  the  re a c tio n  o f  g ly c in e  to  the  c a rb o x y l te rm in a l o f  cys te ine  to  fo rm  
g lu ta th io n e
T he  g lu ta th io n e  S-transfe rases (G S T ) are a fa m ily  o f  m u lt ifu n c t io n a l c e llu la r  enzym es f ir s t  
d isco ve re d  in  the  e a rly  1960s (B o o th  et al, 1961) I t  has lo n g  been k n o w n  th a t G S T  enzym es 
are an in te g ra l p a r t o f  the  phase I  (o x id a t io n ) / phase I I  (c o n ju g a tio n ) system s th a t m e ta bo lise  
m an y  l ip o p h il ic  d rugs  and o th e r fo re ig n  com pounds  T h e  o v e ra ll re s u lt o f  m e ta b o lis m  b y  th is  
sys tem  is  th e  co n ve rs io n  o f  these l ip o p h il ic  co m p ou nd s  to  m o re  p o la r  d e r iv a tiv e s  in  a m an ne r 
th a t can fa c ilita te  th e ir  in a c t iv a t io n  and e lim in a t io n
G S T s  ca ta lyse  the  c o n ju g a tio n  o f  g lu ta th io n e , th ro u g h  the  s u lp h u r a to m  o f  its  cys te ine  
res idue , to  v a r io u s  e le c tro p h ile s , fo rm in g  stable  secre to ry  m e ta b o lite s  (Jakoby , 1978) G S T s 
have  been  lo c a lis e d  in  h um an  k id n e y , lu n g , b ra in , in tes tin e , ske le ta l m usc le  and adrena l 
g lands  (T s u c h id a  and Sata, 1992) The re  are th ree  m a in  classes o f  c y to s o lic  G S T  tc, a  and j i ,
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th e ir  c la s s if ic a tio n  b e in g  based o n  the  enzym es N -te rm in a l am m o ac id  sequence, substrate  
s p e c if ic ity , s e n s it iv ity  to  in h ib ito rs  and im m u n o lo g ic a l techn iques E a ch  o f  the  G S T  enzym es 
is  com posed  o f  su bu n its  a rranged as h e te ro - o r  h o m o - d im ers  o f  2 5 -2 9  k ilo d a lto n s
M C F -7  h u m a n  b reast cancer ce lls  have  been fo u n d  to  be a g o o d  m o d e l to  exam ine  the  e ffe c ts  
o f  G S T  o n  d ru g  res is tance since  th e  p a ren ta l c e ll l in e  has re m a rk a b ly  lo w  le ve ls  o f  G S T  
a c t iv ity  (M o s c o w  et al, 1989) In  a n u m b e r o f  c lones o f  M C F -7  tran s fe c ted  w ith  in d iv id u a l 
G S T  c D N A s , th e  increased  le ve ls  o f  G S T  isozym e  fa ile d  to  co n fe r s ig n if ic a n t le v e ls  o f  
res is tance  to  any o f  the  an tica nce r d rugs  tested Thus, i t  seem ed th a t increased a c t iv ity  o f  
G S T  i t s e lf  is  n o t s u ff ic ie n t fo r  c o n fe rr in g  M D R
A  n u m b e r o f  o th e r stud ies have s h o w n  th a t G S T  is  o fte n  expressed a t re m a rk a b ly  h ig h  le ve ls  
in  m a n y  typ es  o f  tu m o u rs  w h e n  com pared  to  G S T  leve ls  in  n o rm a l tissues o f  o r ig in  (Shea et 
al, 1988, M o s c o w  et al, 1989, P e te r et al, 1990 and 1992, M o o rg h e n  et al, 1991) T h is  is  
p a r t ic u la r ly  tru e  o f  g a s tro in te s tin a l m a lig n a n c ie s  (Peters et al, 1990 and 1992, H o w ie  et al, 
1 989) S tud ies re la t in g  G S T  exp ress ion  to  c lin ic a l o u tco m e  m  le u ka e m ia  have suggested th a t 
G S T  iso zym e  exp ress io n  m ay  be a p ro g n o s tic  m a rk e r in  le u ka e m ia  (T id e fe lt  et al, 1992) In  
b reast cancer, th e  idea  th a t G S T  express ion  m ig h t be a u s e fu l p ro g n o s tic  m a rk e r arose fro m  
the  o b s e rv a tio n  th a t G S T  express ion  is in v e rs e ly  co rre la ted  w ith  estrogen  re c e p to r status 
(M o s c o w  et al, 1988, H o w ie  et al, 1989)
O v e ra ll, th e re  is  no  co ns is te n t o r  c o m p e llin g  ev idence  th a t G S H  and G S T  augm en t resis tance 
in  m u lt id ru g  re s is ta n t c e ll lin e s
1.5.4 Metallothionein (MT)
T he  d is c o v e ry  o f  M T  (M a rg osh e s  and V a lle e , 1957) resu lted  fro m  the  search fo r  a b io lo g ic a l 
ro le  fo r  ca d m iu m  (C d ) M e ta llo th io n e in s  are a fa m ily  o f  u b iq u ito u s  m e ta l b in d in g  p ro te in s  
T h e  m a m m a lia n  M T s  have a m o le c u la r  w e ig h t o f  6 0 0 0 -7 0 0 0  da ltons, u s u a lly  c o n ta in in g  61 
o r  62  am m o ac ids in c lu d in g  20  cyste ines T he  c y s te in y l th io la te  s ide cha ins p e rm it M T s  to  
b in d  a w id e  sp ec trum  o f  h eavy  m eta ls , m o s t n o ta b ly  Z n , C d, C u, P t and H g  In  m am m a ls , 
M T s  b in d  z in c  p re d o m in a n tly , b u t z in c  can be re a d ily  d isp laced  b y  co p p e r and c a d m iu m  
H u m a n s  have  a t leas t 16 M T  genes c lus te red  on  ch ro m o som e  16 (W e s t et al, 1990) F o u r  
classes o f  M T s  have  been  fo u n d  M T I  and I I  are expressed a t a ll stages o f  d e v e lo p m e n t in  
m a n y  c e ll ty p e s  o f  m o s t o rgans, M T  H I is  expressed p re d o m in a n tly  in  neu rons  b u t a lso  in  g lia
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and m a le  re p ro d u c tiv e  o rgans (M a s te rs  et al, 1994, U c h id a  etal, 1991, M o f fa t t  et al, 1998) 
and M T  I V  is  expressed in  d if fe re n tia t in g  s tra tif ie d  squam ous e p ith e lia l ce lls  (Q u a ife  et al,
1994)
T he  p h y s io lo g ic a l fu n c t io n s  o f  m e ta llo th io n e in s  in c lu d e  h ea vy  m e ta l d e to x if ic a tio n , 
re g u la tio n  o f  in tra c e llu la r  Z n , C u  and C d  leve ls , free  ra d ic a l scaveng ing , p ro te c t io n  fro m  
io n iz in g  ra d ia tio n  and c o n tro l o f  g ro w th  and d if fe re n tia t io n  In d u c tio n  o f  M T s  has been  
w id e ly  s tu d ie d  b o th  in vivo and in  c e ll c u ltu re  In tra c e llu la r  M T s  co n te n t can  be increased  b y  
h ea vy  m eta ls , a lk y la t in g  agents, stress, in fe c tio n , in te r le u k in - 1, in te r fe ro n , estrogens, 
p rogeste rone , g lu c o c o rtic o id s , g lu cag on , e tc (L a z o  and Basu, 1991)
M T s  serve as re se rvo irs  fo r  essentia l m e ta ls  w h ile  p re v e n tin g  m e ta l to x ic ity  M T  can donate  
m e ta l to  m e ta l-fre e  m e ta llo p ro te in  (apo  M T  o r th io n e in )  Thus the  fu l ly  m e ta l-c o m p le x e d  M T  
serves as a m e ta l d o n o r, and th io n e in  acts as a ch e la tin g  agent, m o s t n o ta b ly  is  in  th e  case o f  
Z n  M ic ro - in je c t io n  o f  a p o M T  in to  l iv in g  ce lls  has been sh ow n  to  be capable  o f  re m o v in g  
z in c  fro m  z in c  f in g e r  D N A  b in d in g  p ro te in s , such as S P -1 and tra n s c ip tio n  fa c to r  I I I A  (Z e n g  
et al, 1991a, 1991b) A p o  M T  also has the  p o te n tia l to  re m o ve  z in c  fro m  p53 and in a c tiv a te  
i t  s im ila r ly  to  o the r zm c ch e la to rs  (H a in a u t et al, 1993, 1996, O ren  et al, 1996) T h is  
suggests th a t p e rs is ten t apo M T  ove rexp re ss ion  in  tu m o u r  ce lls, i f  p resent, m ay  p ro m o te  th e ir  
acce le ra ted  g ro w th  and increased  s u rv iv a l th ro u g h  in d u c t io n  o f  a p 5 3 -n u ll state T h e  re c e n tly  
observed  c a p a c ity  o f  M T -s p e c if ic  anti-sense o lig o n u c le o tid e s  to  cause b o th  c e ll g ro w th  a rrest 
and in d u c e  a pop tos is  in  d u c ta l b reast ca rc ino m a  ce lls  supports  th is  h yp o th e s is  (M a g e e d  et al,
1996)
H e a v y  m e ta l d e to x if ic a t io n  and re n d e rin g  res is tance to  som e e le c tro p h ilic  d rugs  are the  m o s t 
c o n c lu s iv e ly  supported  ro les  fo r  M T s  T he  f ir s t  hne  o f  de fence  aga ins t in f lu x  o f  h ea vy  m e ta ls  
appears to  be ra p id  m e ta l e f f lu x  In d u c tio n  o f  M T  and sequestra tion  o f  these m e ta ls  b y  M T  
p ro v id e s  a secondary lm e  o f  de fence V a r io u s  c e ll lin e s  th a t ca nn o t syn thesise  any M T  are 
se ns itive  to  ca d m iu m  to x ic ity ,  w he reas ce lls  th a t express excess am oun ts  o f  M T  are res is ta n t 
to  th is  m e ta l S e le c tio n  fo r  ca d m iu m  resis tance w ith  m a m m a lia n  c e lls  resu lted  in  u p  to  80- 
fo ld  a m p lif ic a t io n  o f  the  e n tire  M T  locu s  (D u rn a m  and P a lm ite r, 1987)
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T he re  is  n o w  co ns ide rab le  ev idence  th a t M T  has som e ro le  in  d e te rm in m g  the  respons iveness 
o f  ce lls  to  e le c tro p h ih c  d rugs  w h ic h  can reac t w ith  the  cyste ines o f  M T  S tud ies in d ic a te  th a t 
ce lls  w i th  an m crease in  m e ta llo th io n e in  le ve ls  are m o re  res is ta n t to  som e a n tica nce r d rugs  
(See T ab le  1 4  6)
Agent Reference
C isplatin Andrews et al, 1987
M elphalan Y u  et al, 1995
C hloram bucil Endresen et al, 1983
A d na m yc in W ebber et a l , 1988
B leom ycin Kondo et al, 1995
Cytarabine Kondo et al, 1995
Cyclophosphamide Satoh et al, 1994
Predmmustme Endresen et al, 1984
M ito m y c in  C Lohre r et al, 1989
Table 1 4  6 Anticancer drug resistance and m eta llo th ione in  overexpression
D ire c t  ev idence  th a t M T  is  im p o r ta n t in  res is tance to  e le c tro p h ih c  d rugs w as  o b ta in e d  b y  
D N A  tra n s fe c tio n  stud ies in  w h ic h  the  h um an  M T  I I  gene w as  in tro d u c e d  in to  m ouse  ce lls  on  
a b o v in e  p a p illo m a  v iru s  v e c to r  T he  re s u lt in g  trans fec tan ts  w e re  res is ta n t to  c is p la tin , 
c h lo ra m b u c il and m e lp h a la n  b u t n o t to  5 -F U  o r v in c r is t in e  (K e lle y  et al, 1988) T he  e ffe c t o f  
the  loss o f  M T  e xp ress io n  o n  th e  c y to to x ic ity  o f  a n ticance r agents u s in g  tra n sg e n ic  m ic e  w i th  
ta rge ted  d is ru p tio n s  o f  M T  I  and I I  genes ( M T  - / - )  has been e xam in e d  M T  - /-  ce lls  expressed 
n o  de tectab le  M T  com pared  to  w i ld  typ e  ce lls , and show ed  enhanced s e n s it iv ity  to  c is p la tin , 
m e lp h a la n , b le o m y c in  and cy ta ra b in e  (K o n d o  et al, 1995)
1.6 MDR modulators
A  m a jo r  g o a l in  e x p e rim e n ta l as w e ll  as c l in ic a l in v e s tig a tio n  o f  d ru g  res is tance  is  to  d isco ve r 
u n iq u e  m e th od s  b y  w h ic h  to  reserve  o r c irc u m v e n t i t  T he  f ir s t  re p o rt o f  th e  p h a rm a c o lo g ic a l 
reve rsa l o f  M D R  w as fro m  T s u ru o  and h is  co lleagues (1 9 8 1 ) I t  w as dem onstra ted  th a t the  
c a lc iu m  ch an ne l b lo c k e r, v e ra p a m il, and th e  c a lm o d u lin  an tagon is t, tr if lu o p e ra z in e , g re a tly
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p o te n tia te d  the  a n tip ro life ra t iv e  a c t iv ity  o f  v in c r is t in e  and p ro du ced  an increased c e llu la r  
a c c u m u la tio n  o f  v in c r is t in e  in  an M D R  m u rin e  leu kae m ia  c e ll lin e  in vitro and in vivo. S ince  
th is  o r ig in a l obse rva tion , m any com pounds have been sh ow n  to  an tagon ize  M D R  and are 
te rm e d  "ch em o sen s itise rs " o r  "res is tance  m o d if ie rs " . These co m p ou nd s  a lte r th e  d ru g  
a c c u m u la tio n  d e fe c t in  M D R  ce lls , u s u a lly  w ith o u t  c o m p le te ly  re ve rs in g  it, and cause l i t t le  o r  
no  p o te n t ia tio n  o f  d ru g  c y to to x ic ity  in  se ns itive  cells.
T h e  chem osens itise rs  described  to  date are g rouped  in to  s ix  b road  ca tegories: (1 )  c a lc iu m  
channe l b lo cke rs , (2 )  cyc lo sp o rin s , (3 )  c a lm o d u lin  an tagon is ts , (4 )  n o n c y to to x ic  
a n th ra c y c lin e  and v in c a  a lk a lo id  ana logues, (5 )  s te ro ids and h o rm o n a l ana logues, ( 6 ) 
m isce lla n e o u s  h y d ro p h o b ic , c a tio n ic  com pounds. A lth o u g h  these co m p ou nd s  share o n ly  
b ro ad  s tru c tu ra l s im ila r it ie s , a ll are e x tre m e ly  l ip o p h il ic ,  and m any are h e te ro c y c lic , 
p o s it iv e ly  charged  substances.
1.6.1 Verapamil
T su ru o 's  g ro u p  in i t ia l ly  ana lysed  the  e ffe c ts  o f  the  c a lc iu m  channe l b lo c k e r v e ra p a m il in  a 
v in c r is t in e  res is tan t m u rin e  le u ka e m ia  c e ll lin e  P388 (T s u ru o  et al., 1981). I t  w as sh ow n  th a t 
v e ra p a m il reve rsed  a p p ro x im a te ly  3 0 - fo ld  resis tance to  v in c r is t in e  and 7 - fo ld  res is tance  to  
v in b la s tin e  in  these P 3 8 8 /V C R  ce lls . In c u b a tio n  o f  P 3 8 8 /V C R  ce lls  w ith  v e ra p a m il fo r  5 
h ou rs  a lso caused a 1 0 -fo ld  increase in  the  a cc u m u la tio n  o f  [3H ]-v in c r is t in e . S ince  v e ra p a m il 
w as s h o w n  n o t to  a lte r v in c r is t in e  b in d in g  to  tu b u lin , the  ta rg e t o f  v in c a  a lk a lo id s , i t  w as 
co nc lud ed  th a t the  ch em ose ns itis ing  e ffe c t o f  ve ra p a m il w as  due to  a lte ra tio ns  in  d ru g  
a ccu m u la tio n . These stud ies also dem onstra ted  the  e ffe c t o f  v e ra p a m il in  a M D R  h um an  
acute  m ye lo g e n o u s  leu kae m ia  ( A M L )  ce ll l in e  K 5 6 2 /V C R  and a d r ia m y c in  res is ta n t 
P 3 8 8 /A D M  c e ll l in e  (T s u ru o  et al., 1981).
S ince these e a rly  o bse rva tion s , m any in v e s tig a to rs  have dem onstra ted  the  ch e m o se n s itis in g  
a c t iv ity  o f  v e ra p a m il in  v a rio u s  M D R  c e ll lines. T he  s e n s it iv ity  to  c y to to x ic  d rugs  o f  m o s t 
sens itive  ce lls  f ro m  w h ic h  these M D R  c e ll lin e s  w e re  d e rive d  w as n o t s ig n if ic a n tly  a ffe c te d  
b y  ve ra p a m il.
T h e  e ffe c t o f  v e ra p a m il on  cross-res is tance  to  ch em othe rapeu tic  d rugs  o th e r th a n  those  used 
fo r  in i t ia l  se le c tio n  has a lso been inve s tiga te d . In  some studies, v e ra p a m il p ro d u ce d  as g rea t 
an e ffe c t on  c ross-res is tance  to  d rugs as on p r im a ry  res is tance to  the  se le c ting  agent. In  a
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h um an  u te r in e  sa rcom a c e ll line , M E S -S A  se lected fo r  1 0 0 -fo ld  res is tance to  a d ria m y c in , 
6 ( iM  v e ra p a m il caused a 7 - fo ld  se ns itisa tio n  to  a d r ia m y c in  and a s im ila r  m ag n itu de  o f  
reve rsa l o f  c ross-res is tance  to  d au no m yc in , a c tin o m y c in  D  and m ito x a n tro n e  (H a rk e r  et al., 
1986; S ik ic  et al., 1989). In  o the r studies, ve ra p a m il has been fo u n d  to  be m ore  e ffe c tiv e  in  
re ve rs in g  res is tance  to  the  se le c ting  agents th an  to  the  o the r cross res is tan t drugs. F o r 
e xam p le , 5 ( iM  v e ra p a m il caused a 1 3 -fo ld  reve rsa l o f  2 0 0 -fo ld  a d r ia m y c in  res is tance in  the  
M C F -7  A d rR ce lls , b u t resu lted  in  o n ly  a 4 - fo ld  change in  the  4 0 0 -fo ld  c ross-res is tance  to  
c o lc h ic in e  (F o rd  et al., 1990). In  contrast, ve ra p a m il has a lso been sh ow n  to  have a g rea te r 
e ffe c t on  cross-res is tance  th an  on  p r im a ry  resistance to  se lec ting  d rugs in  som e c e ll lines . 
F o jo  et al. (1 9 8 5 ) dem onstra ted  th a t 20p .M  ve ra p a m il c o m p le te ly  reversed  the  2 0 - to  7 0 - fo ld  
c ross-res is tance  to  a d ria m y c in , v in b la s tin e  and v in c r is t in e  in  c o lc h ic in e  se lected K B  h um an  
e p id e rm a l c a rc in o m a  ce lls , w h ile  caus ing  o n ly  a 6 0 - fo ld  re d u c tio n  in  the  2 2 0 - fo ld  res is tance  
to  c o lc h ic in e .
These f in d in g s  are o f  in te res t w ith  respect to  b o th  the  m echan ism  and p h a rm a c o lo g y  o f  the  
ch e m o se n s itis in g  a c t iv ity  o f  v e ra p a m il and in  d e fin in g  the  m echan ism s b y  w h ic h  Pgp 
tra n sp o rts  s tru c tu ra lly  d is t in c t m o lecu les . I t  is  u n c le a r w h y  som e cross-res is tance  is  re fra c to ry  
to  m o d u la tio n  b y  v e ra p a m il. O ne p o s s ib il ity  is  th a t m u ta tio n s  in  the  m d r l gene (C h o i et al.,
1988) o r  p o s ttra n s la tio n a l m o d if ic a tio n s  o f  Pgp (H a it  and A fta b , 1992) m ay  cause 
chem osens itise rs  fo r  the  p u ta tiv e  d ru g  b in d in g  sites. A lte rn a t iv e ly , m u lt ip le  d ru g  b in d in g  
sites w ith in  P gp  co u ld  e x p la in  these phenom ena. O th e r studies p e rfo rm e d  in  severa l d if fe re n t 
M R P  1-o ve re xp re ss in g  ce ll line s  in c lu d in g  sm a ll ce ll lu n g  cancer c e ll lin e  H 6 9 A R , 
fib ro s a rc o m a  c e ll l in e  H T -1 0 8 0 /D R 4  and la rge  c e ll lu n g  cancer ce lls  C O R -L 2 3 R  show ed  th a t 
v e ra p a m il w as  e ffe c tiv e  as a chem osens itise r (G e rm an n  et al., 1997; B a rra n d  et al., 1993; 
C o le  et al., 1989), suggesting  th a t the  m echan ism s b y  w h ic h  v e ra p a m il c irc u m v e n ts  M R P 1 -  
m ed ia ted  d ru g  resis tance m ay be d is t in c t f ro m  those in  P gp -m ed ia te d  d ru g  resistance.
K esse l and W ilb e rd in g  (1 9 8 5 ) s tud ied  the  e ffe c t o f  ve ra p a m il on  the  c e llu la r  k in e tic s  o f  
a n th ra c y c lin e  in  P 3 8 8 /A D R  ce lls . D ru g  in f lu x  w as n o t a lte red  b y  v e ra p a m il, co ns is te n t w i th  a 
d if fu s io n a l m o d e l o f  a n th ra c y c lin e  in w a rd  tra n s p o rt w h ile  d a u n o m y c in  e f f lu x  f ro m  
P 3 8 8 /A D R  ce lls  w as in h ib ite d  b y  v a ry in g  degrees b y  2 to  2 0 | iM  v e ra p a m il. I t  has been 
c le a r ly  sh ow n  th a t ve ra p a m il in h ib its  the  Pgp associated, ene rgy-dependen t d ru g  e f f lu x  in  the  
M D R  ce lls . A  n u m b e r o f  in v e s tig a to rs  have show n  th a t p h o to a c tiva te d  v e ra p a m il ana logues
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b in d  to  P g p  and th a t v e ra p a m il in h ib its  th e  b in d in g  o f  m an y  ch e m o th e ra p e u tic  d rugs  as w e l l  
as o th e r chem osens itise rs  to  Pgp  (A k iy a m a  et al, 1988, B e c k  et al, 1988, C o rn w e ll et al, 
1987, Safa, 1988a, 1988b , 1987)
1.6.2 Cyclosporin A
T h e  im m u n o su p p re ss ive  d rug , c y c lo s p o r in  A , a h y d ro p h o b ic  c y c lic  p e p tid e  o f  11 a m m o  
acids, w as f ir s t  in ve s tig a te d  fo r  p o te n tia l a n t i-M D R  a c t iv ity  in  p a rt due to  re p o rts  o f  its  
c a lm o d u lin  b in d in g  p ro p e rtie s  (C o lo m b a m  et al, 1985), th o u g h  i t  w as  la te r  sh ow n  th a t 
c y c lo s p o r in  A  does n o t s p e c if ic a lly  in h ib it  c a lm o d u lin -m e d ia te d  processes (H a it  et al, 1987)
S la te r et al (1 9 8 6 ) f ir s t  s tud ied  the  e ffe c t o f  c y c lo s p o r in  A  in  M D R  ce lls  and fo u n d  th a t i t  
caused a 3 -  to  4 - fo ld  p o te n t ia tio n  o f  d a u n o m y c in  to x ic it y  in  E h rh c h  ascites ce lls  th a t had a 
v e ry  lo w  le v e l o f  res is tance  (2 - fo ld )  to  d au no m yc in , as w e l l  as caus ing  a 2 - fo ld  p o te n t ia t io n  
o f  d a u n o m y c m  c y to to x ic ity  in  sens itive  E h rh c h  ascites ce lls  S ince  then , severa l g ro u p s  have 
s h o w n  th a t c y c lo s p o r in  A  reverses resis tance and cross-res is tance  in  M D R  c e ll lin e s  (H a it  et 
al, 1989, T w e n ty m a n , 1988, 1987) C y c lo s p o r in  A  enhanced the  s e n s it iv ity  to  a d n a m y c in  in  
M D R  P 3 8 8 /D O X  ce lls , b u t had no  e ffe c t in  the  P 388  ce lls , a lth o u g h  a s m a ll increase  m  
a d r ia m y c in  a c c u m u la tio n  w as  seen in  b o th  c e ll lin e s  (H a it  et al, 1989) C ham bers et al 
(1 9 8 9 ) d em ons tra ted  an 11- fo ld  enhancem en t o f  a d n a m y c in  to x ic it y  in  sens itive  C h inese  
h am ste r o v a ry  A u x B l  ce lls  and a 6 2 - fo ld  enhancem ent in  c o lc h ic in e -re s is ta n t M D R  C H RC5 
ce lls  caused b y  c y c lo s p o r in  A  H o w e v e r, w h e n  the  e ffe c t o f  c y c lo s p o r in  A  o n  d ru g  
a c c u m u la tio n  w a s  s tud ied , i t  w as  fo u n d  th a t c y c lo s p o r in  A  increased  a d r ia m y c in  
a c c u m u la tio n  in  the  sens itive  ce lls , b u t had no  e ffe c t on  d ru g  a c c u m u la tio n  in  the  M D R  c e ll 
l in e  I t  has a lso  been fo u n d  th a t 0 5 -3 (j,M  c y c lo s p o r in  A  p a r t ia lly  reversed  the  a c c u m u la tio n  
d e fe c t o f  d a u n o m y c m  in  ano the r C h inese  ham ster o va ry  M D R  c e ll lin e , C H RB 3 , b u t d id  n o t 
a ffe c t d a u n o m ycm  a c c u m u la tio n  in  sens itive  A u x B l  ce lls  (S ilb e rm a n n  et al, 1989) These 
f in d in g s  suggest th a t th e  m ech an ism  o f  a c tio n  o f  c y c lo s p o r in  A  as a chem ose ns itise r m a y  be 
m o re  c o m p le x  th a n  v e ra p a m il I t  m ay  n o t be due o n ly  to  m o d if ic a t io n  o f  P gp  m e d ia te d  d ru g  
tra n sp o rt, in  a cco rd  w ith  its  k n o w n  a c t iv ity  as an in h ib ito r  o f  m a n y  im p o r ta n t c e llu la r  
enzym es In  fa c t, c y c lo s p o r in  A  is  the  in h ib ito r  o f  p ro te in  k ina se  C  (P K C ) w h ic h  can 
p h o s p h o ry la te  P gp  and th us  increase the  v e lo c ity  o f  d ru g  tra n s p o rt o f  P gp  (A fta b  et al, 
1991)
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T a m a i and Safa  (1 9 9 1 ) rep o rte d  k in e tic  ana lyses o f  the  e ffe c t o f  c y c lo s p o r in  A  o n  d ru g  
a c c u m u la tio n  0 5 | iM  c y c lo s p o r in  A  in h ib ite d  the  p h o to a ffm ity  la b e ll in g  o f  P gp  b y  a 
d e r iv a tiv e  o f  v in b la s tin e  b y  a p p ro x im a te ly  50%  T h is  s tu dy  suggests th a t c y c lo s p o r in  A  
reverses M D R  a t least in  p a r t b y  in te ra c tin g  w ith  Pgp  and in h ib it in g  o u tw a rd  tra n s p o rt o f  
c y to to x ic  d rugs  H o w e v e r, excess v e ra p a m il w as  inca pa b le  o f  in h ib it in g  c y c lo s p o r in  A  
tra n sp o rt, in d ic a tin g  e ith e r th a t c y c lo s p o r in  A  does n o t d ire c t ly  in te ra c t w ith  Pgp  o r  th a t these 
ch em osens itise rs  b in d  a t d if fe re n t sites to  Pgp
1.7 The cytoskeleton
T he  c y to s k e le to n  is  a c o m p le x  n e tw o rk  o f  p ro te in  f ila m e n ts  th a t extends th ro u g h o u t the  
c y to p la s m  o f  e u c a ryo tic  ce lls  U n lik e  a ske le to n  m ade o f  bone, the  c y to s k e le to n  is  a h ig h ly  
d y n a m ic  s tru c tu re  th a t reo rgan ises c o n tin u o u s ly  T he  c y to s k e le to n  a llo w s  ce lls  to  adop t a 
v a r ie ty  o f  shapes and to  ca rry  o u t co o rd in a te d  and d irec ted  m ove m e n ts  I t  a lso p ro v id e s  the  
m a c h in e ry  fo r  in tra c e llu la r  m ovem ents , such as the  tra n s p o rt o f  o rgane lles  and the  
se g rega tion  o f  ch rom osom es a t m ito s is  T h e  cy to s k e le to n  is  absent f r o m  b ac te ria , and i t  m ay  
have  been a c ru c ia l fa c to r  in  the  e v o lu t io n  o f  e u ca ryo tic  ce lls
T h e  d ive rse  a c tiv it ie s  o f  the  cy to s k e le to n  depend o n  th ree  types o f  p ro te in  f ila m e n ts , m ic ro  
fila m e n ts , m ic ro tu b u le s , and in te rm e d ia te  fila m e n ts  E a ch  ty p e  o f  f i la m e n t is  fo rm e d  f ro m  a 
d if fe re n t p ro te in  su b u n it a c tin  fo r  m ic ro fila m e n t, tu b u lin  fo r  m ic ro tu b u le s , and a fa m ily  o f  
re la ted  f ib ro u s  p ro te in s , such as c y to k e ra tin  o r  v im e n tin , fo r  in te rm e d ia te  fila m e n ts
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1.7.1 Microtubules
Fig. 1.7.1 A  side v ie w  o f  a m icro tubule  w ith  the tubu lm  molecules a ligned in to  long  para lle l rows 
Each o f  the 13 pro tofilam ents is composed o f  a series o f  tu bu lin  molecules (a /p  heterodimers)
M ic ro tu b u le s  are fo rm e d  fro m  m o lecu les  o f  tu b u lin , each o f  w h ic h  is  a h e te ro d im e r 
c o n s is tin g  o f  tw o  c lo se ly  re la ted  and t ig h t ly  lin k e d  g lo b u la r  p o ly p e p tid e s  ca lle d  a - tu b u h n  
and P -tu b u h n  (A m o s  et al, 1979) A lth o u g h  tu b u lin  is  p resen t m  v ir tu a lly  a ll e u c a ry o tic  ce lls , 
th e  m o s t abundan t source fo r  b io c h e m ic a l studies is  the  ve rte b ra te  b ra in  E x tra c t io n  
p ro ced ures  y ie ld  10 to  2 0 %  o f  the  to ta l so lu b le  p ro te in  as tu b u lm  in  b ra in , re f le c t in g  the  
u n u s u a lly  h ig h  d e n s ity  o f  m ic ro tu b u le s  m  th e  e longa ted  processes o f  ne rve  ce lls  (W a d e  et al, 
1993) A  m ic ro tu b u le  is  a c y lin d r ic a l s tru c tu re  in  w h ic h  the  tu b u lin  h e te ro d im e rs  are packed  
a ro un d  a ce n tra l co re  T he  s truc tu re  is b u i l t  f ro m  13 lin e a r p ro to f ila m e n ts , each com posed  o f  
a lte rn a tin g  a - a n d  P -tu b u h n  subun its  and b u n d le d  in  p a ra lle l to  fo rm  a c y lin d e r  (A m o s  et al, 
1979) T u b u lin  m o le cu le s  are d ive rse  In  m am m a ls  there  are a t least s ix  fo rm s  o f  a - tu b u l in  
and a s im ila r  n u m b e r fo r  P -tu bu hn , each encoded b y  a d if fe re n t gene (S u lliv a n , 1988) T he  
d if fe re n t fo rm s  o f  tu b u lin  are v e ry  s im ila r , and w i l l  g e n e ra lly  c o p o ly m e n s e  in to  m ix e d  
m ic ro tu b u le s  in  te s t tubes T h e  m ic ro tu b u le  is  a p o la r  s tru c tu re  I f  p u r if ie d  tu b u lin  m o le c u le s  
are a llo w e d  to  p o ly m e r is e  fo r  a sho rt t im e  at the  ends o f  frag m en ts  o f  s tab le  m ic ro tu b u le s , 
one end can be seen to  e longate  at th ree  tim e s  the  ra te  o f  the  o th e r T he  fas t g ro w in g  end is  
th e re b y  d e fin e d  as th e  p lu s  end and th e  o the r as the  m in us  end (B e rg e n  et al, 1980)
T h e  m ito t ic  sp in d le , w h ic h  fo rm s  a fte r  the  cy to p la s m ic  m ic ro tu b u le s  d isassem b le  a t th e  onset 
o f  m ito s is , is  the  ta rg e t fo r  a v a r ie ty  o f  sp e c ific  a n t im ito t ic  d rugs  th a t act b y  in te r fe r in g  w ith
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th e  exchange  o f  tu b u lin  subun its  b e tw e en  the  m ic ro tu b u le s  and the  free  tu b u lin  p o o l (In o u e , 
1981) O ne such a n t im ito t ic  d ru g  is c o lc h ic in e  (S a lm o n  et al, 1984) E a ch  m o le c u le  o f  
c o lc h ic in e  b in d s  t ig h t ly  to  one tu b u lin  m o le c u le  and p reven ts  its  p o ly m e r is a tio n  H o w e v e r, i t  
ca n n o t b in d  to  tu b u lin  once the  tu b u lin  has p o ly m e ris e d  in to  a m ic ro tu b u le  E x p o s u re  o f  a 
d iv id in g  c e ll to  c o lc h ic in e  causes the  ra p id  d isappearance o f  the  m ito t ic  sp in d le  w h ic h  k i l ls  
m a n y  d iv id in g  ce lls  T he  e ffe c ts  o f  v in b la s tin e  and v in c r is t in e  are s im ila r  to  those  o f  
c o lc h ic in e  T a x o l, h ow eve r, has the  o ppos ite  e ffe c t b y  caus ing  m u c h  o f  the  free  tu b u lin  to  
assem ble in to  m ic ro tu b u le s  and th en  s tab ilises  th e m  T he  s ta b ilis a tio n  o f  m ic ro tu b u le s  b y  
ta x o l arrests d iv id in g  ce lls  in  m ito s is
T h e  m ic ro tu b u le s  in  th e  c y to p la s m  o f  m terphase  ce lls  in  c u ltu re  can be v is u a lis e d  b y  s ta in in g  
the  ce lls  w i th  flu o re s c e n t a n t i- tu b u lin  a n tib od ie s  fo l lo w in g  f ix a t io n  T he  m ic ro tu b u le s  are 
seen in  g rea tes t d e n s ity  a round  th e  nuc leus  and rad ia te  o u t in to  the  c e ll p e r ip h e ry  in  f in e  lace - 
l ik e  th reads T he  cen trosom e  is  the  m a jo r m ic ro tu b u le -o rg a m s in g  ce n te r in  a lm o s t a ll a n im a l 
ce lls  (G lo v e r  et al, 1993) In  m terphase, i t  is  ty p ic a lly  lo ca te d  to  one side o f  the  nuc leus , 
c lose  to  the  o u te r su rface  o f  the  n uc lea r enve lope  E m bedded  in  the  cen trosom e  is  a p a ir  o f  
c y lm d n c a l s truc tu res  ca lled  ce n tn o le s  a rranged at r ig h t angles to  each o th e r in  an L -sh ap ed  
c o n fig u ra t io n  T he  cen trosom e d u p lica te s  and sp lits  in to  tw o  equal p a rts  d u r in g  m terphase, 
each h a l f  c o n ta in in g  a d u p lic a te d  c e n tn o le  p a ir  These tw o  dau gh te r cen trosom es m o v e  to  
o p p o s ite  sides o f  the  n uc leu s  w h e n  m ito s is  beg ins, and fo rm  the  tw o  po les o f  th e  m ito t ic  
sp in d le  (M a z ia , 1984) T he  centrosom e con ta ins  a n u m b e r o f  ce n tro s o m e -s p e c ific  p ro te in s , 
in c lu d in g  a spec ia l m in o r  fo rm  o f  tu b u lin , y - tu b u lm , w h ic h  m ay  in te ra c t w ith  the  n o rm a l 
a /p  tu b u lin  d im e r to  he lp  n uc lea te  m ic ro tu b u le s  (Josh i et al, 1992)
In d iv id u a l m ic ro tu b u le s  g ro w  to w a rd  the  c e ll p e r ip h e ry  at a constan t ra te  fo r  some p e r io d  
a fte r w h ic h  th e y  su dd en ly  s h r in k  ra p id ly  b ack  to w a rd  th e  cen trosom e T h e y  m ay  s h r in k  
p a r t ia l ly  and th e n  reco m m en ce  g ro w in g , o r  th e y  m a y  d isappea r c o m p le te ly , to  be rep la ce d  b y  
a d if fe re n t m ic ro tu b u le  (S a m m a k  et al, 1988) T h is  b e h a v io u r, ca lle d  d y n a m ic  in s ta b il ity ,  
p la ys  a m a jo r  ro le  in  p o s it io n in g  m ic ro tu b u le s  in  th e  c e ll and p ro v id e s  an o rg a n is in g  p r in c ip le  
fo r  c e ll m o rph og en e s is  (M itc h is o n  et al, 1991) T he  d y n a m ic  in s ta b il i ty  o f  m ic ro tu b u le s  
re q u ire s  an m p u t o f  ene rgy  w h ic h  is  generated  fro m  the  h y d ro ly s is  o f  G T P  G T P  b in d s  to  th e  
P -tu b u h n  s u b u n it o f  th e  h e te ro d im e ric  tu b u lin  m o le cu le , and w h e n  a tu b u lin  m o le c u le  adds to  
th e  end o f  a m ic ro tu b u le , th is  G T P  m o le cu le  is  h y d ro ly s e d  to  G D P  (E r ic k s o n  et al, 1992)
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T u b u lin  subun its  can be c o v a le n tly  m o d if ie d  a fte r th e y  p o lym e rise . These m o d if ic a tio n s  are 
the  a c é ty la tio n  o f  a - tu b u l in  on  a p a rtic u la r  ly s in e  and the  re m o v a l o f  the  ty ro s in e  res idue  
fro m  the  c a rb o x y l te rm in u s  o f  a - tu b u l in  (G re e r et al., 1989). A c é ty la t io n  and d e ty ro s in a tio n  
o c c u r o n ly  on  m ic ro tu b u le s  and n o t on  free  tu b u lin  m o lecu les . T hus  the  lo n g e r th e  t im e  th a t 
has e lapsed since  a p a r t ic u la r  m ic ro tu b u le  has p o lym e rise d , the  h ig h e r w i l l  be the  fra c t io n  o f  
its  su bu n its  th a t are ace ty la ted  and de ty ros ina ted . A c é ty la t io n  and d e ty ro s in a tio n  can be 
detected  b y  s p e c ific  a n tibod ies , and th e y  p ro v id e  a u se fu l in d ic a tio n  o f  the  s ta b il ity  o f  
m ic ro tu b u le s  in  ce lls .
1.7.2 The intermediate filaments
T he  in te rm e d ia te  fila m e n ts  are c le a r ly  d is t in g u is h a b le  f ro m  m ic ro fila m e n ts  and 
m o c ro tu b u le s  b y  th e ir  d ia m e te r size. T he  d iam e te rs  o f  in te rm e d ia te  fila m e n ts , m ic ro fila m e n ts  
and m ic ro tu b u le s  are 7 -1 4n m , 5nm  and 2 0 -2 5 n m  re sp e c tive ly . In te rm e d ia te  f ila m e n ts  are 
“ in s o lu b le ”  in  h ig h  sa lt b u ffe rs , and re fo ld  spon taneous ly  and ra p id ly  in vitro and in  near- 
p h y s io lo g ic a l b u ffe rs  f ro m  the  denatu red  state to  a -h e l ic a l  c o ile d -c o ils . These c o ile d -c o ils  
th en  se lf-assem b le  to  2 -3 n m  d ou b le  c o ile d -c o ils , to  lo n g  p ro to fila m e n ts  o f  2 -3 n m  d ia m e te r 
and f in a l ly  in to  in te rm e d ia te  f ila m e n ts  th a t are e ssen tia lly  in d is tin g u is h a b le  fro m  those  
fo rm e d  in  the  l iv in g  c e ll (T ra u b , 1985; S te ine rt et al., 1988).
O f  the  th ree  m a jo r  types  o f  cy to ske le ta l p ro te in s  in  e u k a ry o tic  ce lls  - a c tin  fila m e n ts , 
in te rm e d ia te  f ila m e n ts  and m ic ro tu b u le s , in te rm e d ia te  fila m e n ts  are the  m os t co m p le x . The re  
are a p p ro x im a te ly  50 d if fe re n t in te rm e d ia te  f ila m e n t p ro te in s  w h ic h  can be fu r th e r  
su b d iv id e d  in to  s ix  g ro u p s  (see ta b le  1.7.2).
T y p e  I A c id ic  ke ra tins
T y p e  I I N e u tra l and bas ic  ke ra tins
T y p e  I I I V im e n tin , desm in , p e r ip h e rin  and g lia l f ib r i l la r y  a c id ic  p ro te in
(G F A P )
T y p e  I V n e u ro fila m e n ts
T y p e  V N u c le a r la m in s
T y p e  V I N e s tin  (w h ic h  is fo u n d  in  m e lan o m a  and m e la n o cy te )
Table 1.7.2 C la s s ific a tio n  o f  in te rm e d ia te  f i la m e n t p ro te ins
38
T he  in te rm e d ia te  f i la m e n t s truc tu res  in  d if fe re n t c e ll typ es  are n o t fo rm e d  b y  the  sam e p ro te in  
b u t b y  d if fe re n t m em bers  o f  a la rge  m u ltig e n e  fa m ily ,  the  “ in te rm e d ia te  f i la m e n t p ro te in s ”  
M e m b e rs  o f  th is  fa m ily  are d if fe re n t ia lly  expressed in  pa tte rns  s p e c ific  fo r  a g iv e n  c e ll ty p e  
o r  p a th w a y  o f  d if fe re n tia t io n  ( M o l l  et al, 1982, O sb o rn  et al, 1983, Fuchs et al, 1987) 
C on seq ue n tly , th e  s p e c ific  c e llu la r  in te rm e d ia te  f i la m e n t p ro te in  c o m p le m e n t is c h a ra c te r is tic  
o f  th a t c e ll typ e
In  h u m a n  ce lls  and tissues, fo r  exam ple , the  p ro du c ts  o f  a p p ro x im a te ly  50 d if fe re n t 
m te rm e d ia te  f i la m e n t p ro te in  genes have been id e n t if ie d  T he  la rg e s t and m o s t c o m p le x  class 
o f  m te rm e d ia te  f i la m e n t p ro te in s  are th e  cy to ke ra tin s , th e  h a llm a rk s  o f  e p ith e lia l 
d if fe re n tia t io n  T he  v a rio u s  m te rm e d ia te  f i la m e n t p ro tem s d if fe r  co n s id e ra b ly  m  m o le c u la r  
s ize and e le c tr ic  charge, b u t have  a c o m m o n  bas ic  m o le c u la r  a rrangem en t T h e  ce n tra l 
e le m e n t is  a co re  segm ent, a “ ro d ”  o f  309 -331  a m ino  acids T h is  is  charac te rised  b y  a 
p re d o m in a n ce  o f  a m in o  acids fa v o u r in g  a -h e h c a l c o n fo rm a tio n  and a lso a ce rta in  
a rrangem en t o f  u n its  o f  h y d ro p h o b ic  am m o ac ids th a t is  k n o w n  fo r  its  te nd en cy  to  assum e a 
tw o -c h a m  c o ile d  a -h e lic a l c o n fig u ra t io n  (C re w th e r et al, 1983, C o n w a y  et al, 1990) In  
con tras t, th e  d om a ins  f la n k in g  th e  rod , i e th e  N - te rm in a l “ head”  and the  C -te rm in a l “ ta i l ” , 
do  n o t e x h ib it  a c o n s titu tiv e  a -h e lic a l c o ile d -c o il fo rm m g  cha rac te r and v a ry  g re a tly  in  size 
and a m m o  ac id  sequence (B a d e r et al, 1988, S tasiak et al, 1989)
T he  ro d  d o m a in  has been re la t iv e ly  w e l l  conserved  in  the  d ive rse  m te rm e d ia te  f i la m e n t 
p ro te in s  d u r in g  e v o lu t io n , n o t o n ly  in  size and s tru c tu ra l characte r, b u t a lso  m  te rm s  o f  am m o 
ac id  sequence h o m o lo g y  S tud ies have in d ica te d  th a t an in ta c t ro d  d o m a in  is  essen tia l fo r  
in te rm e d ia te  f i la m e n t fo rm a tio n  (L u  et al, 1990, R aats et al, 1990) D e le tio n s  o f  ro d  
segm ents o r  even c e rta in  p o in t m u ta tio n s  in  the  ro d  re s u lt in  th e  appearance o f  abe rran t 
s truc tu res  R o d  p o rtio n s  a lone, h ow eve r, are n o t capable  o f  assem bly  in to  in te rm e d ia te  
f ila m e n ts  (G e is le r  et al, 1982) In  con tras t, the  ta i l  d o m a in  has been s h o w n  to  be d ispensab le  
fo r  m te rm e d ia te  f i la m e n t assem bly  u n d e r a w id e  range o f  c o n d it io n s  (B a d e r et al, 1988, 
S tas iak et al, 1989)
T h e  g en e ra l p a tte rns  o f  d if fe re n t ia l exp ress ion  o f  the  genes e nco dm g  the  v a r io u s  m te rm e d ia te  
f i la m e n t p ro te in s  d u r in g  em bryogenes is  as w e ll  as in  a d u lt ve rteb ra tes , and in  c e rta in  
p a th o g e n ic  processes, in c lu d in g  tu m o u r fo rm a tio n  and m etastasis, have  been es tab lished
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(T ra u b , 1985, S tem ert et al, 1988, Fuchs et al, 1987) A s  a re s u lt o f  th e  re la t iv e ly  h ig h  
degree o f  m a in tenance  o f  the  express ion  pa tte rns  sp e c ific  fo r  ce rta in  c e ll types  d u r in g  
m a lig n a n t tra n s fo rm a tio n , an tib od ie s  to  the  v a rio u s  in te rm e d ia te  f i la m e n t p ro te in s  have  
becom e v a lu a b le  to o ls  fo r  im m u n o h is to c h e m ic a l “ c e ll ty p in g ”  in  tu m o r  d iagnos is , in c lu d in g  
cases o f  m e ta s ta tic  tu m o u rs  in  w h ic h  the  s ite  o f  o r ig in  o f  the  p r im a ry  tu m o u r is  u n k n o w n  
(O s b o rn  et al, 1989) In  ce rta in  c e ll types , p a r t ic u la r ly  d u r in g  em bryogenes is  and in  tu m o u rs , 
a d d it io n a l in te rm e d ia te  f i la m e n t p ro te in  genes can  be expressed, o fte n  spon taneous ly  w h ic h  
are n o t p a rt o f  th e  “ n o rm a l”  co m p le m e n t o f  the  sp e c ific  c e ll ty p e  (G o u ld  et al, 1990a) T he  
fu n c t io n  o f  in te rm e d ia te  fila m e n ts , in  genera l, o r  in  any s p e c ific  ce ll, is  s t i l l  u n c le a r N o  
d is t in c t c e llu la r  fu n c tio n s  can be ascribed  to  th em  Severa l c u ltu re d  c e ll lin e s  and tu m o u rs  
have  been fo u n d  to  la c k  in te rm e d ia te  f i la m e n t p ro te in s  and im m u n o p re c ip ita t io n  o f  
in te rm e d ia te  f i la m e n t b y  a n tib o d ie s  in je c te d  in to  l iv in g  ce lls  has resu lted  in  n on -d e tec ta b le  
dam age o r  fu n c t io n a l d is tu rba nce  in  the  ce lls  (K ly m k o w s k y  et al, 1995)
1 .7 .2 .1 . C y to k e ra t in s
T he  h u m a n  genom e  co n ta ins  at least 20  d if fe re n t genes e n co d in g  e p ith e lia l c y to k e ra t in  
p o lyp e p tid e s , in  a d d it io n  to  ano the r te n  c y to k e ra t in  p o ly p e p tid e s  c h a ra c te ris tic  o f  h a ir -  and 
n a il- fo rm m g  ce lls  (S te m e rt et al, 1988, M o l l  et al, 1990) T he  in d iv id u a l c y to k e ra t in  
p o ly p e p tid e s  d if fe r  re m a rk a b ly  in  m o le c u la r  w e ig h t T h e y  can be d iv id e d  in to  tw o  
su b fa m ilie s , th e  m o re  a c id ic  typ e  I  and the  m o re  bas ic  ty p e  I I  c y to ke ra tin s  (M a rk l et al, 
1989) T h e  tw o  su b fa m ilie s , h ow eve r, share o n ly  3 0 %  a m ino  a c id  sequence id e n t ity  in  th e ir  
best conse rved  d om a in , th e  a - h e l ic a l  “ ro d ”  (F u ch  et al, 1987, S tem ert et al, 1988) T he  
head and the  ta i l  d o m a in s  d if fe r  m a rk e d ly  be tw een  the  v a rio u s  c y to k e ra t in  p o ly p e p tid e s , even  
o f  th e  same s u b fa m ily
T he  su b u n it o f  c y to k e ra t in  f i la m e n t is  a te tram er, i e, a doub le  c o ile d -c o il c o m p ris in g  tw o  
p o ly p e p tid e s  o f  each ty p e  I  and ty p e  I I  (S te m e rt et al, 1988, Q u in la n  et al, 1984) M a n y  o f  
th e  c y to k e ra t in  bun d les  are anchored  at desm osom es, re s u ltm g  in  h ig h e r  o rd e r a rrays o f  
co rre sp o n d in g  c y to k e ra t in  f ib r i l  pa tte rns  in  ad jacen t ce lls  and hence th ro u g h o u t th e  tissue  
(F ra nke  et al, 1981, 1982) C y to k e ra tin  8 and k e ra tin  18 are th e  f ir s t  in te rm e d ia te  f i la m e n t 
p ro te in s  to  be expressed d u r in g  em bryogenes is  (O s h im a  et al, 1983) B o th  ec to -and  
end od e rm  are charac te rised  b y  ty p ic a l p o la rise d  e p ith e lia l ce lls  w ith  extended  a rrays  o f  
in te rm e d ia te  f ila m e n ts  c o n ta m in g  c y to k e ra tin s  8 and 18 th a t are m o s tly  a ttached  to
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desm osom es (Jackson  et al, 1980, O sh im a  et al, 1983) S ubsequently , c y to k e ra t in  syn thes is  
ceases in  som e c e ll types, m o s tly  n o n e p ith e lia l tissues, b u t is  m a in ta in e d  in  th e  v a rio u s  
e p ith e lia  w i th  s p e c ific  pa tte rns  o f  exp ress ion  F o r  exam ple , the re  are tw o  typ es  o f  e p ith eh a  
s im p le  and s tra t if ie d  S im p le  e p ith e lia  are d is tin g u is h a b le  in  th e ir  c y to k e ra t in  p a tte rn  
(c y to k e ra tin  7, 8, 17, 18, 19 and 2 0 ) f ro m  s tra t if ie d  e p ith e lia  (c y to k e ra tin  1, 5, 6, 10, 11, 14- 
16) ( M o l l  et al, 1983)
T he  o b se rva tio n  th a t c y to k e ra t in  syn thes is  is  g e n e ra lly  m a in ta in e d  in  m a lig n a n tly  
tra n s fo rm e d  ce lls , even  in  m o rp h o lo g ic a lly  a lte red  ones th a t have lo s t th e ir  e p ith e lia l 
s truc tu re , has resu lted  in  c y to k e ra t in  a n tib od ie s  been v a lu a b le  to o ls  in  the  d ia g n o s is  o f  
e p ith e liu m  d e r iv e d  tu m o u rs , n o ta b ly  ca rc ino m as ( M o l l  et al, 1982, O sb o rn  et al, 1983) In  
c o n ju n c tio n  w ith  desm osom a l p ro te in s , c y to ke ra tin s  p ro v id e  the  best b io c h e m ic a l m a rke rs  o f  
e p ith e lia l ch a rac te r and hence fo r  the  id e n t if ic a t io n  o f  ca rc ino m as and th e ir  m etastases ( M o l l  
etal, 1982, O sb o rn  et al, 1983)
I.7.2.2. Vimentin
V im e n t in  ( M W  5 4 k D ) is  the  in te rm e d ia te  f i la m e n t p ro te in  ty p ic a l o f  fib ro b la s ts , osteocytes, 
ch on d rocy tes , m e lanocy tes , Lange rhans ' ce lls  o f  th e  s k in  and e n d o th e lia l ce lls  and m o s t b u t 
n o t a ll ly m p h o m a s  and leukaem ias  I t  is  a substrate  fo r  ce rta in  p ro te m  k inases w i th  
p h o s p h o ry la tio n  re s tr ic te d  to  th e  head d o m a in  (E vans, 1988, In a g a k i et al, 1988, C hou ,
1989) In  c u ltu re d  ce lls  a t in terphase, v im e n tm  runs  fro m  the  c y to p la s m  near the  n uc leus  to  
the  p la sm a  m em brane  A f te r  trea tm en t w ith  c o lc h ic in e  to  d e p o lym e n se  m ic ro tu b u le s , 
v im e n t in  fo rm s  c o ils  near th e  nuc leus  T hus  in vivo in te rm e d ia te  f ila m e n ts  and m ic ro tu b u le s  
m ay  in te ra c t D ra b e ro v a  and D ra b e r (1 9 9 3 ) have id e n t if ie d  a 2 1 0 k D  m ic ro tu b u le -a sso c ia te d  
p ro te in  th a t m ig h t p la y  a ro le  in  l in k in g  v im e n t in  fila m e n ts  to  m ic ro tu b u le s  V im e n t in  is  a 
m a jo r  c e llu la r  p h o s p h o p ro te in  and its  le v e l o f  p h o s p h o ry la tio n  changes d u r in g  the  c e ll c yc le  
(L a i et al, 1993) I t  w as p roposed  th a t v im e n tm  acts as a "phospha te  s in k " b u ffe r in g  the  c e ll 
a ga ins t th e  e ffe c ts  o f  "excess km ase  a c t iv ity "  I f  th is  w e re  a rea l fu n c t io n  o f  v im e n t in , its  
e ffe c ts  on  c e llu la r  p h y s io lo g y  c o u ld  be q u ite  subtle
M o s t  m u sc le  sarcom as coexpress d esm in  and v im e n t in  K e ra t in  and v im e n tm  co exp re ss ion  in  
e p ith e lia l c e ll lin e s  is  a lso  co m m o n  C arc ino m a s o f  som e tissues have  been fo u n d  to  co ­
express k e ra tin  and v im e n tm , e g  k id n e y  and th y ro id  H o w e v e r, s tud ies have  s h o w n  th a t 
som e ca rc in o m a s  o n ly  express v im e n tm , e g  breast, w h ile  o the r ca rc ino m as o n ly  express
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k e ra tin , e g  g a s tro in te s tin a l tra c t V im e n t in  co exp re ss ion  in  node  neg a tive  b reast ca rc inom as 
m a y  be associa ted  w ith  a p o o re r  p ro gn os is  (D o m a g a la  et al, 1990) T h o m p so n  et al (1 9 9 2 ) 
re p o rte d  th a t la c k  o f  es trogen  re ce p to r (E R ) and the  presence o f  v im e n t in  ( V IM )  w as 
associa ted  w i th  p o o r  p ro gn os is  in  h um an  b reast cancer In  a pane l o f  b reast cancer c e ll lin e s , 
E R +/V 1 M ' (M C F -7 , T 4 7 D , Z R -7 5 -1 )  and E R / V IM ' (M D A -M B -4 6 8 ,  S K -B r-3 )  c e ll line s  
w e re  fo u n d  to  be n o n -in v a s iv e  w h ile  E R / V I M + (B T 5 4 9 , M D A -M B -2 3 1 ,  M D A -M B -4 3 5 ,  
M D A -M B -4 3 6 ,  H s  5 7 8 T ) lin e s  w e re  sh ow n  to  be in v a s iv e  T h is  suggests th a t h u m a n  b reast 
cancer p ro g re ss io n  resu lts  f i r s t  in  the  loss o f  E R , and subsequen tly  in  V I M  a c q u is it io n , the  
la t te r  bem g  associa ted  w ith  increased  m a tas ta tic  p o te n tia l th ro u g h  enhanced m vas iveness 
V im e n t in  e xp ress io n  m a y  p ro v id e  u s e fu l in s ig h ts  in to  the  m echan ism s o f  b reast cancer 
p ro g re ss io n
1.8 The Extracellular M atrix
T he  e x tra c e llu la r  m a tr ix  (E C M )  is  a c o m p le x  o rde red  aggregate  com posed  o f  a n u m b e r o f  
d if fe re n t m a c ro m o le cu le s  w h o se  s tru c tu ra l in te g r ity  and fu n c t io n a l c o m p o s itio n  are im p o r ta n t 
in  m a in ta in in g  n o rm a l tissue  a rch itec tu re , in  d e ve lo p m e n t and in  tissue  s p e c ific  fu n c t io n  
F o u r  m a jo r  classes o f  m a cro m o le cu le s  - the  co llagens, p ro te o g lyca n s , s tru c tu ra l g ly c o p ro te in s  
and e la s tin  c o lle c t iv e ly  co m p rise  the  E C M  o f  a n im a l ce lls  (Z e rn  and R e id , 1993) T o  date, 
tw o  m a jo r  fa m ilie s  o f  c e ll su rface  recep to rs  - the  m te g rin s  (K ra m e r et al, 1993) and the  
syndecans (R apraeger, 1993) have been id e n t if ie d  as m e d ia tin g  th e  in f lu e n c e  o f  th e  E C M  on  
ce lls
T he  E C M  p ro fo u n d ly  in f lu e n c e s  the  c e llu la r  phe no typ e  such as c o n tro l o f  g ro w th , 
d if fe re n t ia t io n , d e ve lo p m e n t and m e ta b o lic  response o f  ce lls  T he  im p o rta n c e  o f  g ro w th  
fa c to rs , cy to k in e s , ho rm ones, v ita m in s  and c e ll- to -c e ll co n ta c t as re g u la to rs  o f  th e  c e llu la r  
p h e n o typ e  has been es tab lished  Thus, tw o  im p o rta n t concepts have  em erged  f ir s t ly ,  g ro w th  
fa c to rs , c y to k in e s , v ita m in s , ho rm ones  and c e ll- to -c e ll co n ta c t e xe rt th e ir  e ffe c t th ro u g h  
re g u la tio n  o f  e x tra c e llu la r  m a tr ix  p ro d u c tio n  (E sp o s ito  and Z e rn , 1993) S econd ly , m a n y  
b io lo g ic a l changes a ttr ib u te d  to  th e  e ffe c ts  o f  g ro w th  fa c to rs , cy to k in e s , ho rm ones, v ita m in s  
and c e ll- to -c e ll co n ta c t are s im ila r  to  those  o f  the  E C M  (K le in m a n  et al, 1993)
42
T o  re c o n c ile  these obse rva tion s , a p a ra d ig m  has em erged  (K le in m a n  el al, 1993) T h is  
p a ra d ig m  states th a t fo u r  m a jo r  types o f  in te ra c tio n s  (g ro w th  fa c to rs /cy to k in e s , 
h o rm o n e s /v ita m in s , c e ll- to -c e ll con tacts , and the  E C M )  reg u la te  the  g ro w th , shape, state o f  
d if fe re n tia t io n , d e ve lo p m e n t and b io c h e m ic a l response o f  the  c e ll In  a d d it io n , each ty p e  o f  
in te ra c tio n  resu lts  in  a lte red  E C M  express ion  (L a b a t-R o b e rt et al, 1990, Sage and B o rn s te in , 
1991) - a phe no m e no n  te rm e d  "m u tu a l re c ip ro c ity "  (Sage and B o rn s te in , 1991) T h is  
c o m p le x ity  is  fu r th e r  i l lu s tra te d  b y  the  f in d in g s  d o cu m e n tin g  th a t m an y  g ro w th  fa c to rs  and 
c y to k in e s  are s p e c if ic a lly  b ou nd  b y  m a tr ix  com ponen ts  and hence are res ide n t in  th e  E C M  
(Y lo d a v s k y  et al, 1993) and th a t th e  e x tra c e llu la r  m a tr ix  can m o d u la te  th e  e xp ress io n  o f  
rece p to rs  fo r  g ro w th  fa c to rs  (M a rx  et al, 1993) Thus, i t  appears th a t no  fa c to r  in f lu e n c in g  
the  b io lo g y  o f  the  a n im a l c e ll does so w ith o u t  a ffe c tin g  e x tra c e llu la r  m a tr ix  b io syn th e s is
In  th e  past decade, c lo n in g  o f  the  e x tra c e llu la r  m a tr ix  genes and e s tab lish m en t o f  th e ir  D N A  
sequences have  led  to  th e  a c q u is it io n  o f  a la rge  b o d y  o f  ev idence  d o cu m e n tin g  m u ta tio n s  in  
these genes as u n d e r ly in g  n um erou s  in h e r ite d  co nn ec tive  tissue  diseases M u ta tio n s  in  the  
ty p e  I  co lla g e n  genes cause osteogenesis im p e rfe c ta  (B ye rs , 1993) T he  A lp o r t  syndrom e, a 
h e r ita b le  k id n e y  d iso rd e r, has been connected  w i th  m u ta tio n s  in  the  c o lla g e n  a s ( IV )  gene 
(Z h o u  et al, 1991) M a c u la r  co rnea l d y s tro p h y  (M C D )  is  an m h e n te d  h u m a n  disease 
re s u lt in g  fro m  a fa ilu re  to  synthesise  ke ra ta n  su lfa te  (H a sse ll et al, 1980) T w o  a n im a l 
m o d e ls  c a rry in g  m u ta tio n s  re s u lt in g  in  a d e fe c tive  aggrecan  co re  p ro te in  have  been  
described  n a n o m e lia  in  the  c h ic k e n  (A rg ra v e s  et al, 1981) and ca rtila g e  m a tr ix  d e fic ie n c y  in  
th e  m ouse  (K im a ta  et al, 1981) B o th  o f  these m u ta tio n s  re s u lt m  shortened  lo n g  bones, as 
w e ll  as o th e r a b n o rm a lit ie s  o f  ca rtilag e no us  tissue  In  co n tras t to  the  co lla g e n  and 
p ro te o g ly c a n  fa m ilie s , w ith  one excep tion , no  in h e rite d  diseases re s u lt in g  fro m  m u ta tio n s  m  
th e  s tru c tu ra l g ly c o p ro te in  genes have  been described  T h is  m ay  re fle c t th e  im p o rta n c e  o f  the  
m a jo r ity  o f  th e  m o le cu le s  in  th is  fa m ily  in  e m b ry o n ic  d e ve lo p m e n t (G eo rge  et al, 1993)
C hanges in  the  E C M  have  a lso com e to  be recogn ised  as c r it ic a l co m p on en ts  in  th e  in it ia t io n  
and p ro g re ss io n  o f  a v a r ie ty  o f  a cqu ire d  diseases A m o n g  these are a the rosc le ros is  (B a d im o n  
et al, 1993), l iv e r  f ib ro s is  (G ressner, 1991), g lo m e ru lo n e p h rit is  and g lo m e ru lo s c le ro s is  
(S te rze l et al, 1992), p u lm o n a ry  f ib ro s is  (K h a l i l  and G reenberg , 1991) and th e  secondary  
consequences o f  d iabe tes (Z iy a d e h  et al, 1989) E x tra c e llu la r  m a tr ix  co m p on en ts  have  a lso  
been im p lic a te d  as the  a u to im m u n e  antigens in  severa l diseases in c lu d in g  G o od pa s tu re
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syn d rom e  (an  a u to im m u n e  disease characte rised  b y  ra p id  p ro g ress ive  g lo m e ru lo n e p h r it is  and 
p u lm o n a ry  haem orrhage). F in a lly  and m ost im p o rta n t ly , changes in  e x tra c e llu la r  m a tr ix  
syn thesis, d e p o s itio n , m e ta b o lism  and m a tr ix  recep to rs  are im p o r ta n t com ponen ts  in  cancer 
d e v e lo p m e n t and m etastasis (S te tle r-S te ven son  et al., 1993). C le a rly , as w e  understand  m ore  
o f  the  c h e m is try  and fu n c t io n  o f  E C M , m ore  pa thogenesis o f  these diseases w i l l  be 
e luc ida ted .
1.8.1 Basement membrane and Matrigel
B asem en t m em brane  is a h ig h ly  spec ia lised  e x tra c e llu la r  m a tr ix . I t  appears as an am o rp ho us  
sh e e t-like  s tru c tu re  th a t is p o s itio n e d  e ithe r betw een  a c e ll la ye r and a th ic k  co lla g e n o u s  
s trom a, as e x e m p lif ie d  b y  the  d e rm a l-e p id e rm a l ju n c t io n  o f  h um an  sk in  o r  b e tw een  tw o  
laye rs  o f  ce lls , such as the  rena l g lo m e ru la r  basem ent m em brane. B asem en t m em branes n o t 
o n ly  u n d e r lie  e p ith e lia l and e n d o th e lia l ce lls , b u t a lso su rround  m uscle , fa t, and the  en tire  
n e rvou s  system . T he  m a jo r s tru c tu ra l com ponen ts  o f  basem ent m em branes are typ e  I V  
co lla ge n , la m in in , e n ta c tin  and heparan  su lfa te  p ro te o g ly c a n  (a  p o ly m e r c o n s is tin g  o f  
a lte rn a tin g  g lu co sa m in e  and g lu c u ro n ic / id u ro n ic  a c id  u n its ).
T he  im p o rta n c e  o f  basem ent m em branes in  d e ve lo p m e n t and a d u lt tissue  fu n c t io n  has been 
in fe rre d  fro m  a n u m b e r o f  observa tions . F o r  exam ple , ce lls  m ig ra te  a lo ng  basem ent 
m em branes d u r in g  d e ve lo pm e n t. B asem ent m em branes are req u ire d  fo r  the  p o la r is a t io n  o f  
ce lls  in  b o th  the  e m b ryo  and the  adu lt, and th e y  a lso  serve as substrates fo r  ce ll adhes ion  and 
m ig ra t io n  d u r in g  w o u n d  h e a lin g  and nerve  regenera tion  (S tre u li et al., 1991; Paulsson, 1992; 
E k b lo m , 1993; K le in m a n  and Schnaper, 1993). B asem ent m em brane  co m p on en ts  p ro m o te  
c e ll adhes ion  v ia  in te g rin s  and va rio u s  stud ies have sh ow n  th a t ce lls  are m o re  d if fe re n tia te d  
w h e n  in  co n ta c t w ith  basem ent m em brane. B asem ent m em branes a lso serve as d ep os ito rie s  
o f  g ro w th  fa c to rs  and m ay th e re b y  m o d u la te  access to , and a c t iv ity  o f  g ro w th  fa c to rs  
(H a ra lso n , 1993).
T he  im p o rta n c e  o f  basem ent m em brane  in  a d u lt tissue  fu n c t io n  has been d ire c t ly  
d em ons tra ted  b y  g e n e tic  diseases caused b y  m u ta tio n s  in  the  genes fo r  s tru c tu ra l besem ent 
m em brane  com ponen ts . In  ju n c t io n a l e p id e rm o ly s is  b u llo sa  (E p s te in , 1992), p a tien ts  la c k  a 
la m in in  v a r ia n t n o rm a lly  p resen t in  the sk in  basem ent m em brane. P a tien ts  w ith  A lp o r t  
syn d rom e  (w h ic h  is  a p ro g ress ive  renal disease characte rised  b y  h e m a tu ria  and h e a rin g  loss ) 
la c k  a co lla g e n  typ e  I V  v a r ia n t in  the  k id n e y  (B a rk e r et al., 1990). M o re  re ce n tly , de fec ts  in
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the  m a jo r  la m in in  v a r ia n t in  m uscle , m eros in , has been sh ow n  to  be co rre la ted  w i th  m u scu la r 
d ys tro p h ie s  m  m an  and a n im a ls  (Sunada et al, 1994)
A  re c o n s titu te d  basem ent m em brane , iso la te d  fro m  the  E H S  (E n g e lb re th -H o lm -S w a rm ) 
tu m o u r  te rm e d  "M a tn g e l"  has been the  b re a k th ro u g h  in  the  use o f  basem ent m em brane  
(K le in m a n  et al, 1986) M a tn g e l con ta ins  a ll basem ent m em brane  co m p on en ts  and is  a 
s o lu tio n  a t 4°C , b u t w h e n  the  te m p e ra tu re  is ra ised  to  2 4 -3 7°C , th e  com ponen ts  in te ra c t w ith  
each o th e r and w i th in  1 h o u r th e y  fo rm  a p o ly m e ris e d  g e l T he  g e l can  be used as a 
su bs tra tum  fo r  ce lls  o r  a lte rn a tiv e ly , the  ce lls  can be m ix e d  a t 4°C  w ith  m a tn g e l and th en  
e ith e r p la te d  o n to  c e ll c u ltu re  d ishes o r  in je c te d  in to  an im a ls  W h e n  tu m o u r  ce lls  are m ix e d  
w ith  m a tn g e l and in je c te d  in to  m ice , tu m o u rs  w i l l  ra p id ly  g ro w
A  c r it ic a l step m  m etastasis  is  th e  in v a s io n  o f  basem ent m em brane  In  the  past, s tud ies on  
m v a s io n  had been ca rr ie d  o u t u s in g  iso la te d  basem ent m em branes, p a r t ic u la r ly  f r o m  the  
a m n io n  (H e n d r ix  et al, 1989) S ince th e  use o f  m a tn g e l, m a tn g e l m v a s io n  assays have  been 
the  m o s t w id e ly  accepted  system  fo r  ana lys is  o f  tu m o u r  ce ll m v a s io n  (A lb ir n  et al, 1987) 
T h is  in vitro m v a s io n  w as  fo u n d  to  co rrespond  to  re la tiv e  m e tas ta tic  p o te n t ia l in vivo fo r  a 
w id e  v a r ie ty  o f  ce lls  E n d o th e lia l ce lls , th e  k e y  c e llu la r  e lem en t in  tu m o u r n e o vascu la n sa tio n , 
are ab le  to  b reach  th e ir  o w n  basem ent m em brane  d u r in g  ang iogenesis, a necessary even t in  
m etastas is  In d u c t io n  o f  e n d o th e lia l c e ll m v a s io n  b y  tu m o u r  c e ll p ro d u c ts  and its  in h ib it io n  
have  a lso  been s tud ied  in  m a tn g e l m v a s io n  assays (T h o m p s o n  et al, 1991)
1.8.2 Major components of basement membrane and the ECM
In v e s tig a tio n s  have  d ocum en ted  th a t fo u r  m a jo r  classes o f  m a c ro m o le cu le s  - the  co llagens, 
p ro te o g lyca n s , s tru c tu ra l g ly c o p ro te in s  and e la s tin  co m p rise  the  E C M  o f  a n im a l ce lls  (P ie z  
and R e d d i, 1984) P ro teo g lyca ns  cons is t o f  a p ro te in  co re  and one o r m o re  
g ly c o s a m in o g ly c a n  side cha ins  c o v a le n tly  b ou nd  to  the  co re  p ro te in  M e m b e rs  o f  s tru c tu ra l 
g ly c o p ro te in s  are he te rogeneous in  size, s tru c tu re  and tissue  d is t r ib u t io n  such  as f ib ro n e c t in  
and la m in in  T he  e la s tic  f ib re , w h ic h  co n fe rs  f le x ib i l i t y  and d is te n s ib ility  to  a ll v e rb ra te  
tissue, is  a c o m p le x  o f  e la s tin  w ith  severa l n o n -e la s tic  g ly c o p ro te in  te rm e d  f ib r i l la r  
co m p on en ts
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1.8.2.1 Type IV Collagen
C o lla g e n  is  th e  m o s t abundan t p ro te in  in  the  a n im a l k in g d o m , rep re sen ting  a p p ro x im a te ly  
o n e -th ird  o f  a ll p ro te in  in  tissue  (V a n  der R est and G arrone , 1991) C o llag en s  are com posed  
o f  e ith e r th re e  id e n tic a l o r  s im ila r  a  cha ins charac te rised  b y  th e  rep ea ting  - G ly - X - Y -  
sequence w h e re  X  and Y  can be any am m o a c id  T he re  is  a g ly c in e  res idue  a t e ve ry  th ird  
am m o a c id  w h ic h  a llo w s  th e  assem b ly  o f  th ree  cha ins in to  a t r ip le -h e lic a l s tru c tu re  A t  
p resent, 18 d if fe re n t typ es  o f  co lla ge ns  w i th  m o re  th a n  31 g e n e tic a lly  d is t in c t  cha ins  have  
been id e n t if ie d  ( M i l le r  and G ay, 1992) These co llagens  can fo rm  a v a r ie ty  o f  d if fe re n t 
s truc tu res  in  th e  e x tra c e llu la r  space and thus  are d iv id e d  in to  severa l classes ( 1)  f ib r i l -  
fo rm in g  co lla ge ns , (2 )  sh e e t-fo rm in g  co llagens, (3 ) f i la m e n t- fo rm in g  co lla ge ns  and  (4 )  
a n c h o rin g  f ib r i l  fo rm in g  co llagens
K e fa lid e s  (1 9 7 1 ) w as  th e  f ir s t  pe rson  to  recogn ise  th a t basem ent m em branes c o n ta in  a u n iq u e  
co lla g e n  w h ic h  w as  des ignated  typ e  I V  co lla g e n  T y p e  I V  co lla g e n  is  c la ss ifie d  as a sheet- 
fo rm in g  c o lla g e n  A t  p resent, s ix  chains, a i ( I V )  to  ot6( IV )  are k n o w n  T he  m a jo r  fo rm  o f  
co lla g e n  I V  w h ic h  is  p resen t in  a ll basem ent m em branes is  a h e te ro tn m e r c o n s is tin g  o f  tw o  
o t i ( IV )  and one 0C2( IV )  cha ins T he  genes fo r  these cha ins are m apped  v e ry  c lo s e ly  o n  h u m a n  
ch ro m o som e  13 ( G r i f f in  et al, 1987) A  s im ila r  gene o rg a n is a tio n  is  fo u n d  m  a p a ir  o f  genes 
fo r  a 3( I V )  and a 4( IV )  cha ins w h ile  the  a 5( IV )  and ct6( IV )  cha ins are m apped  o n  h u m a n  
ch ro m o som e s 2 and X  re s p e c tiv e ly  (H o s tik k a  et al, 1990) M u ta tio n s  have  been id e n t if ie d  in  
the  0C5( IV )  gene o f  p a tie n ts  w ith  X - l in k e d  fo rm  o f  A lp o r t  synd rom e  w h ic h  is  a p ro g ress ive  
ren a l d isease charac te rised  b y  h e m a tu ria  and h ea rin g  loss (B a rk e r  et al, 1990) T he  C - 
te rm in a l g lo b u la r  d o m a in  o f  th e  ot3( IV )  and a 4( IV )  cha ins have been id e n t if ie d  as ta rg e t 
reg io n s  fo r  a n tib o d ie s  fro m  pa tie n ts  w ith  G oodpas tu re  syndrom e, an a u to im m u n e  disease 
charac te rised  b y  ra p id  p ro g re ss ive  g lo m e ru lo n e p h rit is  and p u lm o n a ry  haem orrhage  (Saus et 
al,1988)
C o lla g e n  I V  n o t o n ly  p ro v id e s  a b io m e c h a m c a lly  s tab le  s c a ffo ld  in to  w h ic h  th e  o th e r 
co ns titu en ts  o f  basem ent m em branes are in co rp o ra te d , b u t i t  a lso  p la ys  an im p o r ta n t ro le  in  
th e  in te ra c tio n  o f  basem ent m em branes w i th  ce lls  T h e  c e ll-b in d in g  s ite  o f  th e  h u m a n  
[o t i ( IV ) ] 2a 2( IV )  m o le c u le  is  lo ca te d  abou t lO O nm  aw ay fro m  the  N - te rm in u s  o f  c o lla g e n  I V  
T h is  area co n ta ins  the  re c o g n itio n  s ite  fo r  the  tw o  m te g r in  recep to rs  a i(3 i and (X2P 1 
(V a n d e n b e rg  et al, 1991) T he  p ro te o ly t ic  a tta ck  o f  th e  co lla g e n  I V  s p e c ific  ge la tm ase  A  -
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M M P -2  occu rs  in  the  area w he re  the  (X2P 1 re c o g n itio n  s ite  is  des troyed  w hereas the  
re c o g n it io n  s ite  o f  0C1P 1 rem a ins  in tac t.
1.8.2.2 Laminin
L a m in in  ( L N )  is  the  m a jo r s tru c tu ra l g ly c o p ro te in  o f  basem ent m em brane . L a m in in  w as f ir s t  
p u r if ie d  in  1979 (T im p l et al., 1979) and w as in i t ia l ly  id e n t if ie d  as a p ro d u c t o f  a c u ltu re d  
m ouse ca rc in o m a  line . S ubsequen tly , th is  s tru c tu ra l g ly c o p ro te in  w as iso la te d  fro m  the  
m ouse  E H S  sarcom a w h ic h  p roduces s ig n if ic a n t q ua n titie s  o f  basem ent m em brane.
L a m in in  e x is ts  as a c ru c ifo rm - lik e  s truc tu re  fo rm e d  b y  th ree  chains: a ,  p , y. I t  is  n o w  
reco gn ised  th a t the re  is  a fa m ily  o f  la m in in s  s ince e ig h t g e n e tic a lly  d is t in c t la m in in  cha ins 
( a i ,  a 2, a 3, P i, p 2, P3, Yi, Y2)  and seven d if fe re n t assem bly  fo rm s  ( la m in in -1  to  -7 )  are k n o w n  
so fa r. T he  m ost e x te n s iv e ly  characte rised  is E H S  la m in in  w h ic h  is  te rm ed  la m in in -1  
(a iP iY i) .  T he  a  cha in  (4 0 0 k D )  is ca lle d  the  " lo n g  a rm ", h a v in g  th ree  g lo b u la r  d om a ins  at 
th e ir  a m in o  te rm in u s  w h ic h  are separated b y  E G F - lik e  repeats. I t  a lso has a c o ile d  d o m a in  
and a la rge  g lo b u la r  d o m a in  at the  ca rb o xy  te rm in u s  c o n ta in in g  f iv e  g lo bu les . T he  P and y  
cha ins are ca lle d  the  "s h o rt a rm s", c o n ta in in g  o n ly  tw o  g lo b u la r  d om a ins  and tw o  E G F  
repeats at each a m ino  te rm inu s . D is u lf id e  bonds l in k  the  cha ins near the  c a rb o xy  te rm in u s  
w h ile  th e  a m in o  te rm in i re m a in  free, g iv in g  la m in in  its  c lass ic  c ru c ifo rm  s tru c tu re  (F ig u re  
1.8 .2 .2).
•, >e'''
a  chain
(400 kD)
F ig . 1 .8 .2 .2  Schematic m odel o f  lam in in . The location o f  several active sites defined b y  synthetic 
peptides is designated by the arrows. The g lobu lar domain is defined by bracket (T im p l and Brow n, 
1994).
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L a m in in  can b in d  m an y  com ponen ts  o f  the  basem ent m em brane , in c lu d in g  co lla g e n  IV ,  
pe rle ca n  and en ta c tin , as w e ll  as b in d in g  to  i ts e lf  I t  is  l ik e ly  to  p la y  a ro le  in  o rg a n is in g  and 
p o s s ib ly  in it ia t in g  th e  fo rm a tio n  o f  the  basem ent m em brane  T h is  h ypo the s is  is  su pp o rte d  b y  
the  fa c t th a t in  the  d e v e lo p in g  e m b ryo , la m in in  is the  f ir s t  e x tra c e llu la r  m a tr ix  m o le c u le  to  be 
syn thes ised  (M a lin d a  and K le in m a n , 1996) T he  adhesion  o f  b o th  n o rm a l and m a lig n a n t ce lls  
to  la m in in  w as the  f ir s t  a c t iv ity  sh ow n  fo r  la m in in  (M a r t in  and T im p l,  1987) I t  is n o w  w e ll 
es tab lished  th a t c e ll b in d in g  occu rs  v ia  a v a r ie ty  o f  c e llu la r  rece p to rs  in c lu d in g  m te g rin s  and 
severa l le s s -w e ll-ch a ra c te rise d  n o n -in te g rm  recep to rs  (K ra m e r et al, 1993) A t  least s ix  
d if fe re n t m te g rin s  (a i(B i, 012P 1, OC3P 1, a sP i, CX7P 1, 0^ 3)  have been  id e n t if ie d  to  b in d  to  
la n n m n s  T he  cxePi m te g r in  seems to  be the  m a jo r  re ce p to r fo r  la m in in -1 (S onnenbe rg  ei al,
1990) A  s im ila r  s p e c if ic ity  w as fo u n d  fo r  the  a 7P i m te g rin , b u t show s a m o re  re s tr ic te d  
e xp ress io n  (K ra m e r  et al, 1993) T he  a 3p i m te g r in  show s p re fe rence  fo r  la m im n -5  (D e lw e l 
et al, 1994), w h ile  the  co lla g e n  recep to rs  a iP i  and a 2P i b in d  to  la m in in -1 (K ra m e r et al, 
1993) b u t n o t to  la m m in -2  o r  -4
L a m in in  a lso  p ro m o te s  the  m a lig n a n t p heno type  C e lls  cu ltu re d  o n  la m in in  in vitro fo rm  
m o re  tu m o u rs  in vivo than  ce lls  n o t cu ltu re d  on  la m in in  In  a d d itio n , ce lls  se lected b y  
a dhes ion  to  la m in in  in vitro a lso  fo rm  m ore  tu m o u rs  in vivo th an  the  c o n tro l ce lls  
F u rth e rm o re , c o - in je c tio n  o f  la m in in  w ith  tu m o u r ce lls  y ie ld s  increased  num be rs  o f  lu n g  
co lo n ie s  (B a rs k y  et al, 1994) In  a d d itio n , T o p le y  et al (1 9 9 3 ) a lso fo u n d  th a t b y  in je c t in g  a 
n u m b e r o f  c e ll lin e s  w i th  p u r if ie d  la m in in , th e  g ro w th  o f  subcu taneous tu m o u rs  in  nude  m ic e  
can be p ro m o te d  S evera l la m in m -d e n v e d  syn th e tic  pep tides  have  been  fo u n d  to  in f lu e n c e  
the  g ro w th  and m etastasis o f  tu m o u rs  (Y am ada , 1991) A  sequence o n  th e  p i ch a in  Y IG S R  
( ty r - i le -g ly -s e r -a rg ) ,  reduces tu m o u rs  g ro w th  and e xp e rim e n ta l lu n g  m etastasis  (S a ik i et al,
1989) L a m in in  a lso  increases the  secre tion  o f  co llagenase  I V  th a t is  in v o lv e d  in  tu m o u r  
spread A  sequence on  th e  a  cha in  ( lle - ly s -v a l-a la -v a l)  has been fo u n d  to  p ro m o te  p ro tease  
a c tiv ity , ang iogenes is  and the  g ro w th  and metastases o f  tu m o u rs  L a m in in  se c re tion  b y  a 
f ib ro s a rc o m a  c e ll l in e  has been co rre la ted  w ith  its  m e tas ta tic  p o te n tia l (V a ra m  et al, 1983, 
M a l in o f f  et al, 1984) M a n y  types  o f  ce n tra l and p e rip h e ra l n e u ro n a l ce lls  a lso  resp on d  to  
la m in in  (N u rc o m b e , 1992) L a m in in  can p ro m o te  ne rve  reg e n e ra tio n  in vivo and has been  
fo u n d  to  increase  th e  s u rv iv a l o f  nerve  g ra fts  in  the  b ra in
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These b io lo g ic a l a c tiv it ie s , as w e ll  as the  a b il ity  o f  la m im n  to  p ro m o te  c e ll m ig ra tio n , g ro w th  
and d if fe re n t ia t io n , suggest th a t la m im n  m ay  have  an im p o rta n t ro le  in  w o u n d  re p a ir  and 
cancer m etastasis
1.8.2.3 Fibronectin
F ib ro n e c t in  (F N )  is a la rge  g ly c o p ro te in  and an im p o r ta n t co m p on en t o f  the  e x tra c e llu la r  
m a tr ix  I t  is  a p ro d u c t o f  m o s t m esenchym a l and e p ith e lia l ce lls  and can be p u r if ie d  fro m  
p lasm a, tissue  and c u ltu re d  ce lls  D u e  to  the  re la t iv e ly  h ig h  co n te n t o f  f ib ro n e c tin  in  so lu b le  
d is u lp h id e - lin k e d  d im e r fo rm , p lasm a is  the  m os t co n ve n ie n t source
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Fig. 1.8.2.3 The m odular structure o f  fib ronectin  show ing the pos ition  o f  Fi, F2 and F3 modules, and 
a lte rna tive ly  spliced E D -A , E D -B  and III-C S  regions B ind ing  sites are also shown (Potts and 
Cam pbell, 1996)
F ib ro n e c t in  is  a m osa ic  p ro te in  com posed  a lm os t e n tire ly  o f  th ree  d if fe re n t types  o f  p ro te in  
m o d u le  (F i,  F 2 and F 3)  w h ic h  w e re  f ir s t  id e n t if ie d  in  f ib ro n e c t in  b u t have  since  been fo u n d  in  
a v a r ie ty  o f  o th e r p ro te in s  I t  has lo n g  been recogn ised  th a t the  b in d in g  sites fo r  a w id e  range  
o f  m o le cu le s  have  been associated w ith  v a rio u s  frag m en ts  o f  f ib ro n e c t in  F ib ro n e c tin s  
iso la te d  fro m  d if fe re n t sources c o n ta in  cha ins th a t d if fe r  in  size, in d ic a tin g  a n u m b e r o f  
d if fe re n t s p lic in g  va ria n ts  - a concep t p ro ve n  b y  the  sequencing  o f  c D N A  c lones  T o  date, the  
fa m ily  o f  f ib ro n e c tin s  co n ta ins  a t least e ig h t sp lice  v a ria n ts  T he  a lte rn a tiv e ly  sp lice d  re g io n s  
are te rm e d  E D -A , E D -B  and I I I -C S  (F ig u re  1 8 2  3 )
F ib ro n e c t in  b in d s  to  a n um be r o f  b io lo g ic a l m acrom o le cu le s  in c lu d in g  heparm , co lla g e n , 
f ib r in  and c e ll su rface  rece p to rs  F o r  m o s t ce lls, adhes ion  to  f ib ro n e c tin  is  m ed ia te d  b y  the  
c e n tra l c e ll-b in d in g  d o m a in  o f  f ib ro n e c t in  th ro u g h  a (G ly ) -A rg -G ly -A s p - (S e r )  (R G D )  
sequence and a second, d is t in c t re g io n  P ro -H is -S e r-A rg -A s n  (P H S R N ) sequence th a t acts
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s y n e rg is t ic a lly  w i th  the  R G D  sequence. A n o th e r  c e ll adhes ive  re g io n  is  lo ca te d  near the  
c a rb o x y -te rm in u s  in  the  a lte rn a tiv e ly  sp liced  I I IC S  m odu le . T he  c r it ic a l m in im a l sequences 
fo r  th is  re g io n  are L e u -A s p -V a l ( L D V )  and A rg -G lu -A s p -V a l (R E D V )  w h ic h  fu n c t io n  in  an 
a d d it iv e  ra th e r th an  s y n e rg is tic  fash ion .
M a n y  o f  the  P i in te g r in  fa m ily  can b in d  f ib ro n e c tin  in c lu d in g  0C3P 1, 014P 1, CX5P 1 and a vp i.  
M a n y  in te g rin s , in c lu d in g  the  0C3P1, 0C5P1, a vPi, a vP3, a vPs, a vP6 and the  ain,P3 recogn ise  the  
R G D  s ite  in  adhesive  p ro te ins . T he  f ib ro n e c tin -s p e c if ic  in te g rin , a s p i,  is  the  m a jo r 
f ib ro n e c t in  re c e p to r on  m os t ce lls. T he  as Pi in te g rin  in te rac ts  w ith  th e  ce n tra l c e ll adhes ive  
re g io n  o f  f ib ro n e c t in  and req u ires  b o th  the  R G D  and syne rgy  s ites fo r  m a x im a l b in d in g  
(A k iy a m a  et al., 1995). T he  m a jo r p la te le t in te g r in  anbP3 a lso recogn izes  a s im ila r  syn e rgy  
s ite  in  f ib ro n e c tin  fo r  m e d ia tin g  p la te le t in te ra c tio n s  w ith  f ib ro n e c t in  (B o w d itc h  et al., 1994). 
T he  a 4P i in te g r in  is the  re ce p to r fo r  the  I I IC S  reg io n  o f  fib ro n e c tin . I t  b in d s  to  b o th  the  
C S l( L D V )  and C S 5 (R E D V ) sequences o f  the  I I IC S  re g io n  (M a ss ia  and H u b b e ll,  1992).
F ib ro n e c t in  m ay  p la y  an im p o rta n t ro le  in  c e ll tra n s fo rm a tio n , c e ll m ig ra tio n , in v a s io n  and 
m etastasis. I t  w as fo u n d  th a t the  le ve l o f  c e ll-su rfa ce  f ib ro n e c tin  w as g re a tly  reduced  in  
tra n s fo rm e d  ce lls  (H yn e s , 1976). A  panel o f  a n tib od ie s  th a t b in d  to  the  as, a 4 and P i in te g r in  
su bu n its  can in h ib it  c e ll m ig ra tio n  on  f ib ro n e c tin  and c e ll in v a s io n  (Y a m a da  et al., 1990; 
Q ian , 1994).
N u m e ro u s  s tud ies have been ca rr ied  o u t u s in g  a n tib od ie s  to  the  va rio u s  in te g r in  subun its . A n  
a n tib o d y  th a t g e n e ra lly  in h ib its  a ll P i in te g rin -m e d ia te d  c e ll adhes ion  w as  fo u n d  to  in h ib it  
c e ll m ig ra tio n , p ro b a b ly  b y  in h ib it in g  c e ll adhesion  to  a leve l b e lo w  th e  th re sh o ld  re q u ire d  
fo r  tra c t io n  (A k iy a m a  et al., 1989). In  con trast, an a n tib o d y  th a t s e le c tiv e ly  in h ib its  a s - 
m ed ia ted  adhes ion  w as  fo u n d  to  a c tu a lly  increase c e ll m ig ra tio n , p o s s ib ly  b y  in h ib it in g  the  
fo rm a tio n  o f  re c e p to r c luste rs  w h ic h  co u ld  then  resu lt in  less c e ll adhes ion  (A k iy a m a  et al.,
1989). A n  a n ti-P i in te g r in  a n tib o d y  w as sh ow n  to  be a v e ry  e ffe c tiv e  in h ib ito r  o f  in v a s io n  in  
b o th  H T -1 0 8 0  fib ro s a rc o m a  ce lls  and M D A -M B -2 3 1  breast ca rc ino m a  ce lls  (Y a m a d a  et al., 
1990; N e w to n  et a l., 1995). A n  a n ti-a s  a n tib o d y  w as fo u n d  to  have no  s ig n if ic a n t e ffe c t on  
in v a s io n  in  th e  H T -1 0 8 0  ce lls  and o n ly  a sm a ll e ffe c t on  in v a s io n  o f  M D A -M B -2 3 1  ce lls  
(Y a m a d a  et al., 1990; N e w to n  et al., 1995). B o th  a n ti-P i and a n t i-a 5 a n tib o d ie s  w e re  fo u n d  to  
in h ib it  e xp e rim e n ta l m etastasis re s u lt in g  fro m  in tra ve n o u s  in je c tio n  o f  M D A -M B -2 3 1  b reast
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ca rc in o m a  ce lls  in to  a th y m ic  nude  m ice  (N e w to n  et al, 1995)
1.9 Invasion and Metastasis
B y  the  t im e  o f  d iagnos is , a h ig h  p ro p o rt io n  o f  pa tien ts  have c l in ic a l ly  de tectab le  m etastas is  I t  
is  assum ed th a t d is s e m in a tio n  is  im p o ss ib le  u n t i l  m v a s io n  has o ccu rre d  F o r  b reast cancer, 
the  p e r io d  o f  tra n s it io n  fro m  h y p e rp ro life ra t iv e  b u t n o n -in v a s iv e  disease to  in v a s iv e  cance r is 
es tim a ted  to  average 6 years (S p ra tt et al, 1986) T h e  t im e  p e r io d  a fte r th e  in v a s iv e  
ca rc in o m a  g ro w s  to  reach  th e  m in im u m  th re sh o ld  size o f  d e te c tio n  (0  25 cm  in  d ia m e te r), to  
e s ta b lish m e n t o f  th e  f ir s t  m etastasis, can be less than  a year (S p ra tt et al, 1986) Thus, 
tra n s it io n  o f  p re in v a s iv e  ca rc in o m a  to  m v a s io n  p ro v id e s  a m u c h  la rg e r w in d o w  fo r  
in te rv e n tio n  com pared  to  the  c o n ve n tio n a l g o a l w h ic h  focuses on  es tab lished  in v a s iv e  
ca rc in o m a
1.9.1 Invasion
In v a s io n  is  th e  a c tive  tra n s lo c a tio n  o f  n eo p las tic  ce lls  across tissue  b ou nd a ries  and th ro u g h  
h o s t c e llu la r  and e x tra c e llu la r  m a tr ix  b a rrie rs  In v a s io n  is  n o t s im p ly  due  to  g ro w th  pressure  
b u t in v o lv e s  a d d it io n a l g e n e tic  d e re g u la tio n  o ve r and above those  m o le c u la r  events th a t cause 
u n c o n tro lle d  p ro life ra t io n  A t  the  b io c h e m ic a l le ve l, the  m echan ism  o f  m v a s io n  used b y  
tu m o u r  ce lls , m a y  p a ra lle l, o r  be s im ila r  to , th a t used b y  n o n m a lig n a n t ce lls  w h ic h  trave rse  
tissue  b o u n d a rie s  u n d e r n o rm a l p h y s io lo g ic a l c o n d it io n s  E xa m p les  o f  p h y s io lo g ic a l m v a s io n  
are sm o o th  m usc le  c e ll m ig ra t io n  fro m  the  tu n ic a  m e d ia  (w h ic h  co n ta ins  sm o o th  m usc le  
fib e rs  and e la s tic  and co lla ge no us  tissues) to  the  m tim a  (w h ic h  is  com posed  o f  th e  e n d o th e lia l 
c e ll la y e r)  o f  b lo o d  vessels, ang iogenesis, em bryogenes is  and m orphogenes is , n e rve  g ro w th  
cone e x te n tio n  and h o m in g , and tro p h o b la s t im p la n ta tio n  In  co n tras t to  m a lig n a n t in va s io n , 
p h y s io lo g ic a l in v a s io n  is  t ig h t ly  re g u la te d  and ceases w h e n  the  s tim u lu s  is  re m o ve d  In v a d in g  
tu m o u r  ce lls  appear to  have lo s t the  c o n tro l m echan ism s w h ic h  p re v e n t n o rm a l ce lls  f ro m  
in v a d in g  n e ig h b o u rin g  tissue  a t in a p p ro p ria te  tim es  and p laces Thus, th e  fu n d a m e n ta l 
d iffe re n c e  b e tw e e n  n o rm a l and m a lig n a n t ce lls  is  re g u la tio n  T he  d iffe re n c e  m u s t l ie  in  th e  
p ro te in s  th a t start, stop, o r  m a in ta in  the  in v a s io n  p ro g ra m  a t tim e s  and p laces th a t are 
in a p p ro p ria te  fo r  n o n m a lig n a n t ce lls  A  m a jo r  goa l, th e re fo re , is  to  unders tand  w h a t s igna ls  
and s ig n a l tra n s d u c tio n  p a th w ays  are p e rp e tu a lly  a c tiva te d  o r  u n res tra in ed  in  m a lig n a n t 
m v a s io n
51
L io t ta  (1 9 7 7 ) has p roposed  a th ree-s tep  th e o ry  o f  in v a s io n  the  f i r s t  step is  tu m o u r  c e ll 
a tta chm en t v ia  c e ll su rface  rece p to rs  w h ic h  s p e c if ic a lly  b in d  to  com ponen ts  o f  th e  m a tr ix  
T he  anchored  tu m o u r  ce ll n e x t secretes h y d ro ly t ic  enzym es (o r  induces h o s t ce lls  to  secre t 
enzym es) w h ic h  can lo c a lly  degrade the  m a tr ix  T he  th ird  step is tu m o u r  c e ll lo c o m o tio n  in to  
the  re g io n  o f  the  m a tr ix  m o d if ie d  b y  p ro te o ly s is  Thus, re g u la tio n  o f  m o le c u la r  events 
necessary fo r  in v a s io n  re q u ire s  sp a tia l and te m p o ra l c o o rd in a tio n  and c y c lic  o n - o f f  processes 
a t the  le v e l o f  th e  in d iv id u a l c e ll
F o r  ce lls  m ig ra t in g  w i th in  a th ree  d im e n s io n a l e x tra c e llu la r  m a tr ix , such as p e n e tra tin g  a 
basem ent m em brane , p ro tru s io n  o f  a c y c lin d n c a l pseudopod  is  the  f ir s t  step, p r io r  to  
tra n s lo c a tio n  o f  the  w h o le  c e ll b o d y  (C ondeehs, 1993) A  n u m b e r o f  obse rva tion s  s u p p o rt the  
c e n tra l ro le  o f  c y to s k e le to n -d n v e n  pseudopod ia  as organs o f  m o t i l i t y  and in v a s io n  
P se ud o po d ia  aggregate  o r  concen tra te  ce ll surface  deg ra da tive  enzym es and a dhes ion  
rece p to rs  (G u irg u is  et al, 1987) A  ba lance  m ust s w itc h  f r o m  p ro te o ly s is  to  adhes ion  in  o rd e r 
fo r  the  a d va n c in g  pseudopod  to  g rip  the  m a tr ix  and p u ll the  c e ll fo rw a rd  G ene ra l u n re g u la te d  
p ro te o ly s is  a lone  ca n n o t be resp on s ib le  fo r  th e  e n tire  in v a s io n  cascade W h e n  th e  c e ll m oves  
in to  th e  zone  o f  lys is , adhes ion  is  re q u ire d  and p ro te o ly s is  m u s t be shut d o w n  A t  th e  re a r o f  
th e  ce ll, d is s o c ia tio n  fro m  ad jacen t ce lls , and de tachm ent f ro m  p re v io u s  a tta chm en t sites are 
necessary to  release the  c e ll
T he  basem ent m em brane  and in te rs t it ia l s trom a  a lso p la y  an im p o r ta n t re g u la to ry  ro le  in  
in v a s io n  T h e y  serve as a sto rage depo t as w e ll fo r  la te n t p ro te inase , c y to k in e s  and g ro w th  
fa c to rs  ( in c lu d in g  ang iogenes is  fa c to rs )  w h ic h  can be a c tiva te d  o r re leased b y  th e  in v a d in g  
ce lls  T h e  c r it ic a l p a th o lo g ic a l tu rn in g  p o in t is  the  in it ia t io n  o f  lo c a l in v a s io n  le a d in g  to  the  
d is s e m in a tio n  o f  tu m o u r  ce lls  T u m o u r-in d u c e d  n e o va scu la n sa tio n  occu rs  in  p a ra lle l w i th  the  
in v a s io n  and p ro v id e s  a va scu la r e n try  necessary fo r  d is s e m in a tio n  A  p o s it iv e  c o rre la tio n  
b e tw e en  tu m o u r  aggressiveness and pro tease leve ls  has been docu m e n ted  fo r  a ll fo u r  classes 
o f  p ro teases in c lu d in g  serine , aspa rty l, c y s te in y l and m a tr ix  m e ta llo p ro te in a se  (M M P )  I t  is  
n o w  w e ll  es tab lished  th a t one w a y  the  m te g r ity  o f  the  basem ent m em brane  can  be re g u la te d  
is  b y  the  ba lance  b e tw e e n  m e ta llo p ro te in ase s  and th e ir  in h ib ito rs  (T a lh o u k  et al, 1992)
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T he  m o le c u la r  ch a ra c te risa tio n  o f  in v a s io n  has le d  to  the  id e n t if ic a t io n  o f  tw o  ca tegories  o f  
ch e ckp o in ts  th a t c o n s titu te  in te rv e n tio n  ta rge ts  T he  f ir s t  ca tego ry  in c lu d e s  c e ll su rface  and 
secreted p ro te in s  such  as adhes ion  recep to rs , deg rada tive  enzym es and th e ir  in h ib ito rs , and 
m o t i l i ty - s t im u la t in g  c y to k in e s  T he  second c h e c k p o in t ca tego ry  in c lu d e s  re g u la to ry  p ro te in s  
and p a th w a ys  such  as ca lc iu m -m e d ia te d  s ig n a llin g , G -p ro te in  a c tiv a tio n  and ty ro s in e  
p h o s p h o ry la tio n  events A s  fo r  the  f ir s t  ca tegory , a n ti- in v a s io n  agents have  been d iv id e d  in to  
tw o  g ro u p s  b lo c k in g  agents and suppress ing  agents B lo c k in g  agents act as a b a rr ie r  to  
p re v e n t c a n ce r-p ro d u c in g  substances fro m  re a ch in g  o r  re a c tin g  w i th  c e llu la r  ta rg e t sites 
Suppress ing  agents p re v e n t th e  e v o lu t io n  o f  th e  n e o p la s tic  p rocess Som e supp ress ing  agents 
s tim u la te  d if fe re n t ia t io n  w h ile  o the rs  reverse  the  consequences o f  a c tiva te d  oncogenes and 
supp ressor genes
A lte re d  s ig n a llin g  p a th w a ys  have been associated w ith  the  process o f  in v a s io n  and 
m etastasis  A  p r im e  e xam p le  is  the  in tro d u c tio n  o f  a c tiva te d  c -H a -ra s  in to  p r im a ry  ra t e m b ryo  
f ib ro b la s t ce lls  (P o z z a tt i et a! , 1986) T h is  tra n s fe c tio n  resu lted  in  d e v e lo p m e n t o f  a 
m a lig n a n t and in v a s iv e  p he no typ e  characte rised  b y  p ro d u c tio n  o f  M M P -9  (see sec tion  1 10) 
and m a rke d  p u lm o n a ry  m etastasis  a fte r ta i l  v e in  in o c u la tio n  o f  tra n s fe c te d  ce lls  S im ila r  
e ffe c ts  have  been obse rved  w i th  exp ress ion  o f  o th e r oncogenes, such as H e r-2 /n e u  (Y u  et al,
1993) T h e  oncosuppresso r gene R b -1 , has been dem onstra ted  to  be able  to  in h ib it  
p ro life ra t io n  and in v a s io n  o f  tu m o u r  ce lls  (V a le n te  et al, 1996) H o w e v e r, p53 , has been 
fo u n d  to  be a w e a k e r in h ib ito r  o f  in v a s io n  ( L i  et al, 1996)
1.9.2 Metastasis
M eta s ta s is  is  th e  spread o f  cancer f ro m  a p r im a ry  tu m o u r  to  d is ta n t sites o f  th e  b o d y  and is  a 
d e fin m g  fe a tu re  o f  cancer M o s t deaths fro m  cancer are due to  m étastasés th a t are re s is ta n t to  
c o n v e n tio n a l th e rap ies  C u rre n t the rap ies  fa i l  to  e rad ica te  m etastasis fo r  th re e  m a jo r  reasons 
F irs t ly ,  w h e n  in i t ia l ly  d iagnosed , m o s t tu m o u rs  are w e ll advanced  and m etastas is  has 
o ccu rre d  S econd ly , s p e c ific  o rgan  e n v iro n m e n t can m o d ify  the  response o f  a m e ta s ta tic  
tu m o u r  c e ll to  sys tem ic  th e ra p y  and a lte r the  e ff ic ie n c y  o f  a n tica nce r agents T he  th ird  reason  
and th e  g rea tes t obstac le  to  the  success o f  the rapy, is  the  he te rogeneous c o m p o s it io n  o f  
tu m o u rs , w h e re  h ig h ly  m e ta s ta tic  ce lls  can escape fro m  the  e ffe c t o f  th e ra p e u tic  agents
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T he  m a jo r  steps in  th e  fo rm a tio n  o f  a m etastasis are as fo l lo w s  escape o f  ce lls  f r o m  the  
p r im a ry  tu m o u r , m tra va sa tio n  (e n try  o f  ce lls  in to  th e  ly m p h a tic  o r  b lo o d  c irc u la tio n ) , s u rv iv a l 
and tra n s p o rt in  the  c irc u la tio n , a rrest in  d is ta n t o rgans, e x tra vasa tio n  (escape o f  ce lls  f ro m  
th e  c irc u la tio n ) , and g ro w th  o f  ce lls  to  fo rm  secondary tu m o u rs  m  th e  n e w  o rg an  
e n v iro n m e n t A ng io ge ne s is , the  re c ru itm e n t o f  n e w  b lo o d  vessels, is  re q u ire d  fo r  p r im a ry  and 
m e ta s ta tic  tu m o u rs  to  g ro w  b eyo nd  m in im a l s ize  E v a s io n  o f  im m u n e  d e s tru c tio n  is 
necessary a t v a r io u s  steps th ro u g h o u t the  process T he  fo rm a tio n  o f  de tec tab le  m etastases can 
be  p re ve n te d  b y  in te r ru p t io n  a t any one o r m o re  o f  these steps T h e  o u tco m e  o f  th e  process is 
dependen t o n  b o th  the  in t r in s ic  p ro p e rtie s  o f  the  tu m o u r  ce lls  and the  response o f  the  h os t
M e ta s ta s is  is  k n o w n  to  be an in e f f ic ie n t  process L a rg e  num be rs  o f  c e lls  can be shed in to  the  
c irc u la t io n  fro m  a p r im a ry  tu m o u r  b u t o n ly  a s m a ll fra c t io n  o f  the  ce lls  w i l l  succeed in  
fo rm in g  m etastases R esu lts  f ro m  a series o f  e xpe rim en ts  u s in g  in t ra v ita l v id e o m ic ro s c o p y  
( I W M ) ,  a te ch n iq u e  w h ic h  p e rm its  d ire c t o b se rva tio n  o f  the  m ic ro c irc u la t io n  in vivo, 
suggest th a t e a rly  steps in  m etastasis, in c lu d in g  d e s tru c tio n  o f  ce lls  in  c irc u la t io n  and 
e x tra vasa tio n , c o n tr ib u te  less to  m etas ta tic  in e ff ic ie n c y  th a n  p re v io u s ly  assum ed R a the r, 
re g u la tio n  o f  g ro w th  o f  in d iv id u a l extravasa ted  ce lls  in  ta rg e t tissue  appears to  be th e  ra te  
l im i t in g  step (C ham bers  et al, 1995)
Som e m etastases w i l l  a rise  o n  the  basis o f  c irc u la to ry  a na tom y  T h e  lu n g s  are a c o m m o n  s ite  
o f  m etastasis  S im ila r ly , m etastases fro m  th e  c o lo n  o fte n  arise in  th e  l iv e r  as the  l iv e r  rece ives  
d ire c t d ra inage  f ro m  the  la rge  in te s tin e  M etastases also arise in  o th e r o rgans due to  "Seed 
and s o il"  th e o ry  In  1889, P age t conc luded  th a t m etastasis o ccu rre d  o n ly  w h e n  c e rta in  
fa v o u re d  tu m o u r  ce lls  (th e  "seed ") had a spec ia l a f f in i ty  fo r  c e rta in  s p e c ific  o rgans (the  
"s o i l" )  T h e  fo rm a tio n  o f  m etastases re q u ire d  the  in te ra c tio n  o f  the  r ig h t  ce lls  w ith  the  
c o m p a tib le  o rg a n  e n v iro n m e n t M etas tas is  fa v o u rs  the  s u rv iv a l and g ro w th  o f  a fe w  
s u b p o p u la tio n s  o f  ce lls  th a t p re -e x is t w ith in  the  pa ren t neop lasm  (F id le r  and K n p k e , 1977) 
T hus, m etastases can have  a c lo n a l o r ig in , and d if fe re n t m etastases can  o r ig in a te  f ro m  the  
p ro life ra t io n  o f  d if fe re n t s ing le  ce lls  (T a lm a d g e  et al, 1982)
O rga n  m ic ro e n v iro n m e n t can in f lu e n c e  the  b io lo g y  o f  cancer g ro w th  and m etastas is  in  
severa l d if fe re n t w a y s  F o r  exam ple , h um an  c o lo n  ca rc in o m a  (H C C ) ce lls  im p la n te d  
su bcu tan e ou s ly  (e c to p ic  s ite ) in to  nude m ice  p ro d u ce  lo w  le v e ls  o f  secreted ty p e  I V  
co llagenase, w he reas th e  same ce lls  g ro w in g  m  th e  w a l l  o f  th e  c o lo n  (o r th o to p ic  s ite ) p ro d u ce
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h ig h  le v e ls  o f  T y p e  I V  co llagenase  (N a k a jim a  et al, 1990) S im ila r ly , tra n sp la n te d  h um an  
rena l c e ll c a rc in o m a  ce lls  (H R C C ) ra re ly  m etastasise a fte r im p la n ta tio n  in to  the  subcu tis  in  
the  nude  m ic e  regard less o f  th e  degree o f  m a lig n a n c y  in  the  p a tie n t (F id le r , 1986) w hereas 
th e  h ig h e s t in c id e n ce  o f  m etastasis w as  p ro du ced  b y  th e  same c e ll l in e  g ro w in g  m  th e  k id n e y  
(N a ito  et al, 1986) O rg a n -s p e c ific  f ib ro b la s ts  d ire c t ly  in f lu e n c e  the  p ro d u c tio n  o f  
co llagenase  ty p e  I V  b y  H C C  (F ab ra  et al, 1992) o r  H R C C  (G o h ji et al, 1993) ce lls  T h is  
c o n c lu s io n  is  based o n  resu lts  o b ta ined  fro m  c o -c u ltu rm g  H C C  (F ab ra  et al, 1992) o r  H R C C  
(G o h ji et al, 1994) w ith  m ouse fib ro b la s ts  iso la ted  fro m  e c to p ic  o r  o r th o to p ic  tissues T h e  
in h ib it io n  o f  co llagenase  ty p e  I V  p ro d u c tio n  b y  sk in  f ib ro b la s ts  w as sh ow n  to  co rre la te  w i th  
p ro d u c tio n  o f  in te r fe ro n  be ta  ( IF N  P) (F ab ra  et al, 1992, G o h ji et al, 1994)
M e ta s ta s is  is  th e  f in a l stage in  tu m o u r  p ro g ress io n  fro m  a n o rm a l c e ll to  a fu l ly  m a lig n a n t c e ll 
in  som e cases T he  best deve loped  exam p le  is  the  ch a ra c te risa tio n  o f  m o le c u la r  p ro g re ss io n  
in  c o lo n  cancer, in  w h ic h  s p e c ific  changes (e  g  loss o f  tu m o u r-su p p re sso r genes and 
m u ta tio n  o f  oncogenes) are p re fe re n tia lly  associated w ith  s p e c ific  stages o f  p ro g re ss io n  
(F e a ro n  and V o g e ls te in , 1990, K in z le r  and V o g e ls te in , 1996) H o w e v e r, th e  f in a l stage in  
tu m o u r  p ro g re ss io n  to  a m e tas ta tic  p he no typ e  has e luded  ch a ra c te risa tio n  at a m o le c u la r  
ge n e tic  le v e l in  c o lo n  o r  o th e r cancers T ra n s fe c tio n  w i th  a v a r ie ty  o f  oncogenes (e  g  ras and 
src) has been  s h o w n  to  p ro du ce  m e tas ta tic  ce lls  (C ham bers  and T u c k , 1993) F o r  exam p le , 
m e ta s ta tic  H -ra s  tran s fe c ted  N IH -3 T 3  ce lls  had increased leve ls  o f  a v a r ie ty  o f  gene p ro d u c ts  
in c lu d in g  p ro te in ase  and adhes ive  p ro te in s  (T u c k  et al, 1991a and 1991b) L o ss  o f  tu m o u r-  
supp ressor gene fu n c t io n  a lso  has been im p lic a te d  in  the  co n ve rs io n  to  m e ta s ta tic  a b i l it y  in  
s p e c ific  tu m o u r  types, e g  nm 23 (M a c D o n a ld  et al, 1995), K A I1  (D o n g  et al, 1995), K iS S -  
1 (L e e  et al, 1996), a lth o u g h  none is  l ik e ly  to  be u n iv e rs a lly  im p lic a te d  in  a ll tu m o u r  types  
I t  appears m o re  l ik e ly  th a t re g u la tio n  o f  exp ress ion  o f  genes th a t c o n tr ib u te  fu n c t io n a lly  to  
m etastas is  can o c c u r in  a tis s u e -s p e c ific  m an ne r W h a te v e r gene is  in v o lv e d , a ll th e  re q u ire d  
tra its  have s u ff ic ie n t p ro te o ly t ic  ca p a c ity  to  co m p le te  a ll the  steps in  m etastasis  T hus , M M P s  
and th e ir  in h ib ito rs  have been rep ea te d ly  im p lic a te d  in  th is  co n te x t
55
1.10 M atrix metalloproteinase
SIGNAL SEQUENCE HEMOPEXIN DOMAIN
PROPEPTIDE
□ CATALYTIC DOMAIN
OF LAT IN BINDING DOMAIN OK t'IBHÖNEOTIN
COLLAGEN BINDING DOMAIN
F ig . 1.10 D om ain  structure o f  M M P -2  and M M P -9  (top M M P -2 , bottom  M M P -9 )(M cD o n n e ll and 
Fm gleton, 1993)
T he  m a tr ix  m e ta llo p ro tem a ses  (M M P s )  are a fa m ily  o f  a t least f if te e n  secreted o r m em brane - 
b o u n d  zm c  endopep tidases capable  o f  d eg ra d in g  a ll o f  th e  com ponen ts  o f  th e  e x tra c e llu la r  
m a tr ix  In  1962, in te rs t it ia l co llagenase, respons ib le  fo r  the  re s o rp tio n  o f  ta d p o le  ta ils  (G ro ss  
and L a p ie re , 1962), w as the  f ir s t  M M P  to  be described  and p u r if ie d  M o s t o f  these enzym es 
are secre ted b y  a v a r ie ty  o f  co n n e c tive  tissue ce lls , m c lu d m g  fib ro b la s ts , osteoblasts, 
ch o n d ro cy te s  and e n d o th e lia l ce lls , as w e l l  as in f la m m a to ry  ce lls  such as m acrophages, 
n e u tro p h ils  and ly m p h o c y te s
C o m p a ris o n  o f  th e  a m in o  ac id  sequences o f  h um an  M M P s  has revea led  a h ig h  degree o f  
h o m o lo g y  b e tw e e n  these enzym es T he  m im m a l s tru c tu re  com prises  a s ig n a l pep tide , a 
p ro p e p tid e  d o m a in  and a c a ta ly tic  d o m a in  T he  p ro te in  th a t a c tu a lly  has th is  s tru c tu re  is  the  
sm a lles t m e m b e r o f  the  M M P  fa m ily ,  m a tr ily s in  (M M P -7 )  T he  s ig n a l p e p tid e  d o m a in  d ire c ts  
the  M M P  to  th e  e n d o p la sm ic  re t ic u lu m  T he  p ro p e p tid e  d o m a in  is  in v o lv e d  in  the  
m a in ten an ce  o f  enzym e la te n c y  and is  re m o ve d  d u r in g  enzym e a c tiv a tio n  (V a n  W a r t et al,
1990) T he  c a ta ly t ic  d o m a in  is the  z in c -b in d in g  d o m a in  W ith  th e  e x c e p tio n  o f  M M P -7 ,  a ll 
M M P s  have a C -te rm in a l d o m a m  th a t has h o m o lo g y  w ith  b o th  h a e m o p e x in  and v it ro n e c t in  
(H u n t et al, 1987) M M P s  can be c la s s ifie d  in to  4 g roups  o n  the  basis o f  sequence h o m o lo g y  
and substra te  s p e c if ic ity  th e  ty p e  I  co llagenases, th e  ty p e  I V  co llagenases, s tro m e ly s m  and 
m e m b ra n e -typ e  m e ta llo p ro te in a se s  (M T - M M P )
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T he  e xp ress io n  o f  M M P s  is  v e ry  h ig h ly  reg u la ted  and occurs  at m a n y  d if fe re n t le ve ls  
R e g u la tio n  occu rs  a t th e  tra n s c r ip tio n a l le v e l b y  a v a r ie ty  o f  g ro w th  fa c to rs , cy to k in e s  and 
oncogenes and a t the  tra n s la tio n a l le v e l b y  the  la te n cy  o f  the  secreted enzym es as w e l l  as b y  
th e  presence o f  n a tu ra lly  o c c u rr in g  in h ib ito rs  T h e  la tte r  in c lu d e s  genera l p la sm a  p ro te inase  
in h ib ito rs  such as a 2-m a c ro g lo b u lin , as w e ll  as m o re  s p e c ific  in h ib ito rs  such as the  tissue  
in h ib ito rs  o f  m e ta llo p ro te in ase s , T IM P -1  to  -4  N u m e ro u s  stud ies in d ic a te  th a t m em bers  o f  
the  M M P  fa m ily  have th e  a b i l it y  to  ac tiva te  one ano the r and serine p ro te inases have  been 
sh ow n  to  a c tiva te  M M P -1  and M M P -9  v ia  p la s m in  (Sang  et al, 1995, C rabbe  et al, 1994)
M M P s  have an im p o r ta n t ro le  in  processes such as w o u n d  h ea lin g , p regnancy  and p a r tu r it io n , 
bone  re s o rp tio n  and m a m m a ry  in v o lu t io n  H o w e v e r, the  m am  in te re s t in  the  M M P s  re la tes  to  
th e ir  ro le  in  c e rta in  diseases in  w h ic h  b re a k d o w n  o f  th e  e x tra c e llu la r  m a tr ix  is  a k e y  fe a tu re  
Such diseases in c lu d e  rh e u m a to id  a rth r it is , o s te o a rth ritis , b ro nch iec ta s is , C ro hn 's  disease, 
l iv e r  c irrh o s is , e tc  and m o s t im p o r ta n t ly , cancer in va s io n , m etastasis and ang iogenesis  
E v id e n ce  th a t M M P s  p la y  a fu n c t io n a l ro le  in  m etastasis cam e o r ig in a lly  f r o m  e xpe rim en ts  
w i th  g e n e tic a lly  m a n ip u la te d  leve ls  o f  T IM P -1  S ch u ltz  et al (1 9 8 8 ) f ir s t  show ed  th a t an 
m tra p e r ito n e a l in je c t io n  o f  re c o m b in a n t T IM P -1  reduced  lu n g  c o lo n is a tio n  o f  in tra v e n o u s ly  
in je c te d  B 1 6 F 1 0  m e lan o m a  ce lls  F u rth e rm o re , a re d u c tio n  in  T IM P -1  le v e ls  b y  antisense 
R N A  in  m ouse  fib ro b la s ts  resu lted  in  the  fo rm a tio n  o f  m e ta s ta tic  tu m o u rs  in  nude  m ice  
(K h o k h a  et al, 1989) These resu lts  p ro v id e  s trong  su p p o rt fo r  a ro le  fo r  M M P s  in  the  
e s ta b lish m e n t o f  m e ta s ta tic  les ions
M M P s  are n o t th e  o n ly  enzym es w h ic h  can degrade E C M  T he re  are fo u r  m am  classes o f  
p ro teases in v o lv e d  in  p ro te o ly t ic  d e g ra da tion  o f  the  e x tra c e llu la r  m a tr ix  (S h i et al, 1993) (1 )  
serm e proteases, e g  p la sm in o g e n  a c tiva to rs , (2 ) cys te ine  proteases, e g  ca theps in  B  and 
ca thepsm  L ,  (3 )  aspa rty l proteases, e g  ca theps in  D  and (4 )  M M P s  A l l  o f  these p ro te inases 
in te ra c t in  a c o m p le x  m an ne r th a t u lt im a te ly  leads to  the  p rocess o f  E C M  d eg ra d a tio n
T he re  is  a la rge  b o d y  o f  ev idence  w h ic h  show s th a t M M P  express ion  is  increased  in  cancer 
tissue  re la t iv e  to  co rre sp o n d in g  noncancerous tissue  T h e  increase in  s tro m a l p ro d u c t io n  o f  
c e rta in  M M P s  in  ca rc ino m as  is  l ik e ly  to  be the  re s u lt o f  the  release o f  fa c to rs  b y  cance r ce lls  
In  s u p p o rt o f  th is  h ypo the s is , N o le  et al (1 9 9 3 , 1994) dem onstra ted  th a t c o n d it io n e d  m e d iu m  
ta ke n  fro m  c u ltu re s  o f  a b reast ca rc in o m a  c e ll lin e , M D A -M B 2 3 1 , increased  th e  e xp ress io n
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o f  in te rs t it ia l co llagenase  and ge la tinase  A  in  cu ltu res  o f  h um an  sk in  and breast fib ro b la s ts . 
S ince  then , a v a r ie ty  o f  g ro w th  fa c to rs , in c lu d in g  E G F , T G F , P D G F , have been sh ow n  to  
reg u la te  M M P  expression. T he  resu lts  in d ic a te  th a t cancer ce lls  have the  a b il ity  to  increase 
th e ir  p ro te o ly t ic  a c t iv ity  w ith o u t  in c rea s ing  th e ir  o w n  p ro d u c tio n  and secre tion  o f  proteases, 
and th e y  can conce n tra te  and ac tiva te  proteases in  the  p e r ic e llu la r  space. T h is  p ro v id e s  th e m  
w ith  rou tes  o f  escape aga ins t a ttem p ts  to  c o n tro l the  p ro d u c tio n  and secre tion  o f  p ro teases in  
cancer ce lls.
1.10.1 MMP2 and MMP9
F ro m  e a r ly  w o rk  o f  L io t ta  et al. (1977 , 1980) and T ryg g v a s o n  et al. (1 9 8 4 ), in te re s t w as 
focused  on  ty p e  I V  co llagenase, the  enzym e respons ib le  fo r  deg ra da tion  o f  ty p e  I V  co lla ge n . 
T he  enzym es resp on s ib le  fo r  th is  a c t iv ity  are n o w  recogn ised  to  be e ith e r M M P -2  (ge la tin ase  
A , 7 2 k D  typ e  I V  co llagenase) o r  M M P -9  (ge la tinase  B , 9 2 k D  typ e  I V  co llagenase). T h e y  are 
d is t in c t f r o m  o the r m em bers  o f  the  M M P  fa m ily  in  th a t th e y  possess a u n iq u e  re g io n  
im m e d ia te ly  ad jacen t to  the  m e ta l-b in d in g  d om a in  th a t is h o m o lo g o u s  to  the  g e la t in -b in d in g  
d o m a in  o f  f ib ro n e c tin . M M P -2  and M M P -9  d if fe r  f ro m  o the r M M P s  b y  th e ir  a b i l i t y  to  
in te ra c t, as la te n t p roenzym es, w ith  the  endogenous T IM P s  (T IM P -1  and T IM P -2 ) .  T he  
M M P -2  p ro e n zym e  fo rm s  a c o m p le x  w ith  T IM P -2 , w h ile  the  M M P -9  p ro en zym e  b in d s  w i th  
T IM P -1  (S te tle r-S te ven son  et al., 1989; G o ld b e rg  et a!., 1989). T IM P s  are n o t k n o w n  to  b in d  
o the r la te n t M M P s , b u t w i l l  in h ib it  a ll M M P s  once these enzym es are ac tiva ted . In  a d d it io n , 
M M P -2 , a lso th o u g h t to  be a c tiva ted  b y  M T 1 -M M P  (C ao  et al., 1995), can a c tiva te  M M P -9  
p ro e n zym e  to  an a c tive  fo rm .
In h ib it io n  o f  endogenous M M P -2  a c t iv ity  in  hum an  m e lan o m a  ce lls  resu lts  in  enhanced 
c e llu la r  adhesion . T h is  ind ica te s  th a t M M P -2 , in  a d d it io n  to  c o n tr ib u tin g  to  p ro te o ly s is  o f  
E C M  com ponen ts , a lso lyses c e ll su rface  com ponen ts  th a t m ed ia te  a tta chm en t o f  tu m o u r  
ce lls  to  the  E C M . Thus, M M P -2  m ay fu n c t io n  to  m o d u la te  c e ll a tta chm en t and fa c ilita te  ce ll 
m ig ra t io n  and in v a s io n  (R a y  et al., 1995). I t  has also been show n  th a t fa c to rs  w h ic h  increase 
M M P -2  express ion , e.g. I L - 8 , a lso increase in v a s io n  and m etastasis (L u c a  et al., 1997).
C o rre la t iv e  ev id en ce  fo r  the  in v o lv e m e n t o f  M M P -2  and M M P -9  in  the  in v a s iv e  p h e n o typ e  is  
abundan t (M o n te a g u d o  et al., 1990; U ra  et al., 1989; L e v y  et al., 1991; S ch u ltz  et al., 1988). 
In  one s tu dy  on  a series o f  b ro n c h ia l e p ith e lia l c e ll lin e s  c o n ta in in g  va rio u s  oncogenes (U ra  et 
al., 1989), i t  w as also fo u n d  th a t invas iveness and m e tas ta tic  ca p a c ity  w e re  p o s it iv e ly
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co rre la te d  w ith  exp ress io n  o f  the  M M P -2  gene In d u c t io n  o f  the  m a lig n a n t phe no typ e  u s in g  
the  c -H a -ra s  oncogene  has been  sh ow n  to  enhance e xp ress io n  o f  M M P -2  and M M P -9  (U ra  et 
al, 1989) M o s t in v a s iv e  c o lo n ic , g as tric , o va r ia n  and th y ro id  adenoca rc inom as and 
d e sm o p la s tic  s trom a  o f  b reas t les ions  have been  sh ow n  to  be im m u n o re a c tiv e  fo r  M M P -2 , 
w hereas b e n ig n  p ro life ra t iv e  d iso rd e rs  o f  the  breast, co lo n , g a s tr ic  m ucosa  and b e n ig n  
o v a r ia n  cys ts  sh ow  decreased o r  n ega tive  s ta in in g  fo r  th is  e nzym e  (M o n te a g u d o  et al, 1990, 
L e v y  et al, 1991) F o r  exam ple , in  su rg ica l specim ens fro m  p a tie n ts  w i th  c o lo re c ta l 
ca rc ino m a , an a n tib o d y  to  M M P -2  w as used to  com pare  the  s ta in in g  o f  m a lig n a n t tissue  w i th  
ad jacen t n o rm a l tissue  D u k e 's  stage w as h ig h ly  co rre la te d  w ith  the  percen tage  o f  ce lls  
s ta in in g  p o s it iv e ly  fo r  M M P -2  (L e v y  et al, 1991) T he  ra tio  o f  a c tiva te d  to  la te n t M M P 2  w as 
s ig n if ic a n t ly  h ig h e r in  m a lig n a n t versus b e n ig n  b reast les ions  and a h ig h e r p ro p o r t io n  o f  
a c tiva te d  enzym e  w as  re la ted  to  inc rea s ing  tu m o u r  g rade (D a v ie s  et al, 1993a, 1993b) 
H o w e v e r, the  e xp ress io n  o f  M M P -2  fa ile d  to  p re d ic t re lapse  o r  s u rv iv a l in  the  p a tie n ts  w ith  
n o d e -n e g a tive  b reast cancers (D a id o n e  et al, 1991)
A lth o u g h  o ve re xp re ss io n  o f  M M P -2  is  m o re  o fte n  observed in  m an y  tu m o u rs , M M P -9  also 
appears to  p la y  a c r it ic a l ro le  in  tu m o u r in v a s io n  Increased M M P -9  exp ress ion  has been 
dem onstra ted  in  squam ous and basa l ca rc in o m a  o f  the  s k in  (P yke  et al, 1992), b reast (D a v ie s  
et al, 1993 a), c o lo n  (D a v ie s  et al, 1993b) and b la d d e r cancer
1.10.2 TEMP
O ne o f  th e  n a tu ra lly  o c c u rr in g  in h ib ito rs  o f  pro teases is  a la rge  (7 5 0 k D )  p ro te in , ot2- 
m a c ro g lo b u lm  ( a 2M )  p ro du ced  b y  the  l iv e r  and de tectab le  in  n o rm a l se rum  0C2M  is  a n o n ­
s p e c ific  in h ib i to r  o f  a ll fo u r  classes o f  proteases T he  tissue in h ib ito rs  o f  m e ta llo p ro te in a se s  
(TE M P s) are p ro te in s  th a t s p e c if ic a lly  in h ib it  the  M M P s  T o  date, fo u r  m em bers  o f  th e  TEM P 
fa m ily  (TE M P  1-4 ) have been id e n t if ie d  T h e y  are a ll lo w -m o le c u la r -w e ig h t (a ll a ro un d  2 5 k D )  
secreted p ro te in s  th a t b in d  to  the  a c tive  fo rm  o f  M M P s , in h ib it in g  th e ir  e n z y m a tic  a c t iv ity  
M M P -2  and M M P -9  are u n iq u e  am ong  o the r M M P s  in  th a t la te n t fo rm s  o f  these p ro te inases 
can fo rm  co m p le xe s  w i th  T E M P -2  and TE M P -1, re s p e c tiv e ly  (G r ig n o n  et al, 1996) E v id e n ce  
th a t M M P s  p la y  an im p o r ta n t ro le  in  in v a s io n  and m etastasis  cam e o r ig in a l ly  f ro m  
e xp e rim e n ts  w ith  g e n e tic a lly  m a n ip u la te d  leve ls  o f  T IM P -1  S ch u ltz  et al (1 9 8 8 ) f ir s t  
show ed  th a t an m tra p e r ito n e a l in je c t io n  o f  T IM P -1  reduced  lu n g  m etastasis  o f  in tra v e n o u s ly  
in je c te d  B 1 6 F 1 0  m e lan o m a  ce lls  A  re d u c tio n  in  T IM P -1  le ve ls  b y  antisense R N A  in  m ouse
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f ib ro b la s ts  resu lted  in  the  fo rm a tio n  o f  m e tas ta tic  tu m o u rs  in  nude  m ic e  (K h o k h a  et al,
1989) A n  im p o r ta n t p o in t th a t m us t be m ade, h o w e ve r, is  th a t the  s im p lis t ic  e xp e c ta tio n  th a t 
m a lig n a n t tu m o u rs  w o u ld  have  increased M M P  exp ress ion  a ccom pa n ie d  b y  decreased T IM P  
e xp ress io n  is  o fte n  n o t m e t In  severa l cases, m a lig n a n t tu m o u rs  have been s h o w n  to  have 
increased  ra th e r th a n  decreased T IM P  leve ls  (G n g o n  et al, 1996) These s tud ies show ed  a 
c o m p le x  re la tio n s h ip  b e tw e en  M M P s , T IM P s  and cancer
K o o p  et al (1 9 9 4 ) re p o rte d  th a t w h e n  cancer ce lls  w e re  assessed u s in g  I W M  ( in tra v ita l 
v id e o m ic ro s c o p y ), the  e xp e c ta tio n  w as th a t the  reduced  m e ta s ta tic  a b il ity  o f  th e  TEM P-1 
o ve re xp re ss in g  ce lls  w o u ld  m a n ife s t i ts e lf  in  d e fe c tive  e x tra va sa tio n  H o w e v e r, b o th  T IM P -1  
o ve re xp re ss in g  ce lls  and c o n tro l ce lls  w e re  fo u n d  to  extravasa te  w i th  id e n tic a l k in e tic s  T he  
reduced  m e ta s ta tic  a b i l it y  o f  the  T IM P -1 -o v e re x p re s s in g  ce lls  w as  m a n ife s te d  at 3 days a fte r 
in je c tio n , w h e n  th e  m o rp h o lo g y  o f  m ic ro  m etas ta tic  c o lo n ie s  w as s tr ik in g ly  d if fe re n t f ro m  
th a t o f  th e  c o n tro l ce lls  T h e  T E M P -1-ove re xp re ss in g  ce lls  la cke d  adhesive  con tac ts  to  o th e r 
tu m o u r  ce lls  and vessels, and had abundan t s trom a  be tw een  the  ce lls  T E M P -2 -exp ress ing  
ce lls  a lso  d em ons tra ted  a re d u c tio n  in  g ro w th  ra te  and a d if fe re n tia te d  m o rp h o lo g y  
(M o n tg o m e ry  et al, 1994) Thus, i t  appears th a t b o th  T IM P -1  and T E M P -2  can have g ro w th  
in h ib ito ry  e ffe c ts
T h e  e ffe c ts  o f  T IM P s  on  the  g ro w th  o f  tu m o u rs  is fu r th e r  c o m p lic a te d  b y  th e  o b s e rv a tio n  th a t 
TEM P-1 and T E M P -2  also d is p la y  g ro w th -p ro m o tin g  a c t iv ity  fo r  a v a r ie ty  o f  c e ll types , th us  
d e m o n s tra tin g  th a t T IM P s  are b ifu n c t io n a l m o le cu le s  (B e rta u x  et al, 1991, N e m e th  et al, 
1996, H a y a k a w a  et al, 1994) T he re  are severa l exam p les  in  w h ic h  T IM P s  e ith e r have  no  
e ffe c t o r  enhance tu m o u r  g ro w th  a n d /o r m etastasis, e ffe c ts  c o n tra ry  to  th a t expected  fro m  
a n tim e ta llo p ro te in a s e  a c t iv ity  (S o lo w a y  et al, 1996, Sun et al, 1996) I t  is  poss ib le  th a t the  
g ro w th -p ro m o tin g  e ffe c ts  o f  TEM Ps are ce ll ty p e  sp e c ific , m an ifes te d  o n ly  in  ce lls  w h ic h  
have an a p p ro p ria te  re ce p to r fo r  the  T IM P  dom am  c o n ta in in g  the  g ro w th -p ro m o tin g  a c t iv ity  
A lte rn a t iv e ly ,  fa c to rs  such as the  re la t iv e  co nce n tra tion s  o f  s p e c ific  T IM P s  a n d /o r M M P s  and 
the  e x tra c e llu la r  e n v iro n m e n t m ay a ll a ffe c t h o w  a tu m o u r c e ll responds to  a lte ra tio n s  in  
T IM P  e xp ress io n
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1.11 Cell Adhesion Molecules
C e ll a dhes ion  c o n tr ib u te s  to  a ll m o rp h o g e n e tic  events and is  a lso  lin k e d  to  m a n y  o th e r ke y  
processes in c lu d in g  the  c o n tro l o f  c e ll d iv is io n , c e ll d if fe re n tia t io n  and a pop tos is  A lth o u g h  
n o t cove red  m  th is  s tudy, c e ll a dhes ion  a lso occurs  in  b ac te ria  and p la ys  an essen tia l ro le  
d u r in g  th e  in te ra c tio n  b e tw een  pa th og e n  and h os t C e ll adhes ion  can be m ed ia te d  b y  
n um erou s  su rface  g ly c o p ro te in s  and g ly co co n ju g a te s  th a t can be g ro u p e d  in to  fa m ilie s  T he  
m o s t e x te n s iv e ly  s tud ied  fa m ilie s  are m teg rin s , im m u n o g lo b u lin s , se lectins  and cadhenns
1 . 1 1 .1  In te g r in
In te g rm s  are a fa m ily  o f  c e ll su rface  p ro te in s  th a t m ed ia te  c e ll-e x tra c e llu la r  m a tr ix  a dhes ion  
and c e ll-c e ll a dhes ion  T he  nam e " in te g r in "  s ig n ifie s  the  ro le  o f  these p ro te in s  in  m te g ra tin g  
th e  in tra c e llu la r  c y to s k e le to n  w ith  the  e x tra c e llu la r  m a tr ix  com ponen ts , such as f ib ro n e c tin , 
la m in in , co lla g e n , f ib rm (o g e n ), en tac tin , tenasc in  and v itro n e c tin
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Subunits Ligands
Pi a i C o llag en s , la m in in
a 2 C o llagens , la m in in
a 3 F ib ro n e c tin , la m in in , co llagens
a4 F ib ro n e c tin , V C A M -1
a 5 F ib ro n e c tin
a 6 L a m in in
a 7 L a m in in
a 8 ?
a v V itro n e c tin , f ib ro n e c tin
ß2 a L IC A M -1 ,  IC A M -2
aM F ib ro n e c tin , IC A M -1
a x F ib r in o g e n
ß3 anb F ib r in o g e n , f ib ro n e c tin , v o n  W ille b ra n d  fa c to r, v itro n e c tin , 
th ro m b o s p o n d in
a v V itro n e c t in , f ib r in o g e n , v o n  W ille b ra n d  fa c to r, th ro m b o sp o n d in , 
fib ro n e c tin , o s teo po n tin , co lla ge n
ß4 a 6 L a m in in
P5 a v V itro n e c t in
ß6 a v F ib ro n e c tin
Pv a4 F ib ro n e c tin , V C A M -1
aiEL ?
P* a v ?
T a b le  1 .11.1  T he  in te g r in  re c e p to r fa m ily
In te g r in s  are transm em brane  g ly c o p ro te in s  com posed  o f  n o n -c o v a le n tly  lin k e d  a  and [3 
subun its . T he re  are c u rre n tly  15 k n o w n  a  subun its  and 8 P subunits , assem b ling  in to  m o re  
than  20  d if fe re n t in te g rin  receptors. In  genera l, the  c o m b in a tio n  o f  p a r t ic u la r  a  and P
62
su bu n its  de te rm ines  th e  lig a n d  s p e c if ic ity  o f  the  m te g r in  c o m p le x  (T a b le  1 1 1 1 )  S p e c ific  
p e p tid e  re g io n s  w ith in  e x tra c e llu la r  m a tr ix  p ro te in s  have  been  id e n t if ie d  as m te g rm -b m d in g  
sites T h e  b es t described  o f  these reg io n s  is  the  a rg im n e -g ly c in e -a s p a rtic  a c id  (R G D ) 
sequence fo u n d  in  f ib ro n e c tin , f ib ro n o g e n , v itro n e c tin , co lla g e n  and la m in in  (R u o s la h ti et al,
1987) P eptides c o n ta in in g  th is  sequence have  the  a b il ity  to  in h ib it  c e ll adhes ion  to  ce rta in  
e x tra c e llu la r  p ro te in s
In te g rm s  have  been fo u n d  in  a ll typ es  o f  tissues Som e m te g n n s  are c e ll ty p e -s p e c if ic  F o r  
exam p le , anbP3, is  expressed e x c lu s iv e ly  in  p la te le ts  and m eg aka ryo cy te s  (G in s b e rg  et al,
1988) oclP2, ctMp2 and a x P 2 are expressed o n ly  in  le u k o c y te s  (S p rin g e r, 1990) T he  
m te g r in  is  s p e c if ic  fo r  e p ith e lia l ce lls  ( K a j i j i  et al, 1989)
T w o  b in d in g  m odes have  been  id e n t if ie d  fo r  in te g rm s  c e ll-E C M , th ro u g h  b in d in g  o f  in te g rm  
and E C M  co m p on en ts , c e ll-c e ll,  th ro u g h  b in d in g  o f  in te g rm  and c e ll m em brane  p ro te in  
U p o n  lig a n d  b in d in g , in te g rm s  are aggregated  in  transm em brane  co m p le xe s  k n o w n  as fo c a l 
con tac ts , w h ic h  are en riched  in  s p e c ific  c y to s k e le ta l p ro tem s in c lu d in g  ta lin , v in c u lin ,  a -  
a c tin in  and a c tin  (B u rn d g e  et al, 1988) T he  o rg a n isa tio n  o f  in te g rm -a sso c ia te d  c y to s k e le to n  
and thus  the  a b i l it y  o f  in te g rm s  to  b in d  E C M  lig a n d s  is  reg u la ted  b y  R h o  and R as fa m ily  
m em bers  (G ua n , 1997) C o o rd in a te  re g u la tio n  o f  in te g rm  b in d in g  a f f in i ty  and c y to s k e le to n  
d y n a m ic s  is  o f  fu n d a m e n ta l im p o rta n c e  n o t o n ly  to  ce ll adhesion , b u t to  the  o v e ra ll c e llu la r  
a rch ite c tu re , c e ll m o t i l i t y  and to  m te g rm -re la te d  s ig n a lin g  events I t  has re c e n tly  been  fo u n d  
th a t in te g rm s  and o th e r adhes ion  recep to rs  have a v ita l ro le  in  s ig n a l tra n s d u c tio n  processes 
(D a ly  et al, 1 99 8 ) In te g rm -m e d ia te d  s ig n a lin g  can be ro u g h ly  d iv id e d  in to  tw o  ca tegories  
T h e  f i r s t  is  "d ire c t s ig n a llin g " , in  w h ic h  l ig a t io n  and c lu s te r in g  o f  in te g rm s  is  th e  o n ly  
e x tra c e llu la r  s tim u lu s  A d h e s io n  to  E C M  p ro te in s  can a c tiva te  c y to p la s m ic  ty ro s in e  k inases 
(e  g  fo c a l a dhes ion  k ina se  (F A K ) ) ,  and se rine /th reo n in e  k inases (such  as those  in  the  
m ito g e n -a c tiv a te d  p ro te in  k inase  cascade), ind uce  io n ic  tran s ien ts  and s tim u la te  l ip id  
m e ta b o lis m  ( e g  p h o s p h a tid y lm o s ito l-4 ,5 -b is p h o s p h a te  (P IP 2)  syn thes is) T h e  second 
ca te g o ry  o f  in te g rm  s ig n a lin g  is  "c o lla b o ra tiv e  s ig n a lin g " in  w h ic h  in te g rm -m e d ia te d  c e ll 
adhes ion  m od u la tes  s ig n a llin g  events in it ia te d  th ro u g h  o th e r types o f  recep to rs , p a r t ic u la r ly  
rece p to rs  th a t are ac tiva te d  b y  g ro w th  fa c to rs  A ls o , the  b id ire c tio n a l tra n s fe r o f  in fo rm a t io n  
can be m ed ia te d  fro m  the  o u ts id e  to  the  in s id e  o f  the  ce ll, and fro m  the  in s id e  to  th e  o u ts id e  
o f  th e  c e ll, w h ic h  has been te rm e d  "o u ts id e -m " and " in s id e -o u t"  s ig n a llin g  re s p e c tiv e ly
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O c c u p a tio n  o f  in te g rin s  at fo c a l adhes ion  sites resu lts  in  ty ro s in e  p h o s p h o ry la tio n  o f  fo c a l 
adhes ion  k inase  (F A K )  and regu la tes a c tin  cy to ske le to n  reo rg an isa tio n . T h is  is  te rm e d  
"o u ts id e - in  s ig n a llin g " . " In s id e -o u t s ig n a llin g "  re fe rs  to  changes in  the  a c tiv a tio n  state o f  
in te g rin s  via in tra c e llu la r  s ig n a llin g . C e lls  can v a ry  th e ir  adhesive  p ro pe rtie s  b y  m o d u la tin g  
the  a f f in i ty  o f  in te g rin s  th ro u g h  " in s id e -o u t"  m echan ism s a c tin g  on  the  c y to p la s m ic  dom a in s  
o f  the  in te g r in  subun its  (M a rt in -B e rm u d o  et al., 1998).
In te g r in -m e d ia te d  c e ll adhes ion  im pac ts  on  tw o  ke y  aspects o f  g ro w th  re g u la tio n . F irs t ly , 
in te g r in  m ed ia te d  adhesion  can in flu e n c e  the  a c t iv ity  o f  the  c e ll-c y c le  m a ch in e ry , co n s is tin g  
o f  v a rio u s  c y c lin -d e p e n d e n t k inase  (C D K )  com p lexes. S econd ly , in te g r in -m e d ia te d  
anchorage  is a lso  a ke y  re g u la to r  o f  apoptos is  (F r is c h  and R u o s la h ti, 1997). In te g rin s  a lso 
have been fo u n d  to  p la y  a ro le  in  p la te le t agg rega tion , im m u n e  fu n c tio n s , tissue  re p a ir  and 
tu m o u r in v a s io n  and m etastasis (D a ly  et al., 1998).
T he  p a tte rn  o f  in te g r in  express ion  in  tu m o u r  ce lls  in situ as w e ll as in  cu ltu re d  ce lls  appears 
to  be c o m p le x  and dependent on  the  in d iv id u a l tu m o u r type. Each tu m o u r  typ e  o r  c e ll lin e  
d isp lays  a g re a t deal o f  h e te ro g e n e ity  in  in te g r in  express ion . I t  is d i f f ic u l t  to  re co n c ile  a ll the  
in fo rm a tio n  c o n ce rn in g  the  ro le  o f  in te g rin s  in  tu m o u r  g ro w th  and m etastasis. In  som e cases, 
the re  is  a genera l d o w n -re g u la tio n  o f  in te g r in  subun its  in  e p ith e lia l tu m o u rs  com pared  to  th e ir  
n o rm a l tissue  coun te rparts .
1.11.1.1 Pi integrin subunit
M e m b e rs  o f  the  P i s u b fa m ily  have been co rre la ted  w ith  tu m o u r ce ll invas iveness. Severa l 
fa c to rs  have m ade i t  d if f ic u l t  to  d ra w  d e fin it iv e  co n c lu s io n s  re g a rd in g  the  ro le  o f  in d iv id u a l 
P i in te g rin s  in  tu m o u r pathogenesis. These in c lu d e  the  presence o f  d if fe re n t in te g r in s  w h ic h  
have o v e r la p p in g  b in d in g  ca p a b ilit ie s , the  fa c t th a t ce lls  u s u a lly  express m o re  than  one 
in te g rin , and e s p e c ia lly  the  h e te ro g e n e ity  w ith in  the  tu m o u r (H ynes, 1992).
I t  has been dem onstra ted  th a t m o n o c lo n a l an tib od ie s  to  P i in te g r in  b lo c k e d  tu m o u r  c e ll 
m ig ra tio n  th ro u g h  basem ent m em brane  in vitro (Y am ada , 1990). T he  d is ru p tio n  o f  b o th  
a lle le s  o f  the  P i in te g r in  gene in  the  h ig h ly  m etas ta tic  m u rin e  T -c e ll ly m p h o m a  c e ll lin e  
resu lted  in  no  a lte ra tio n  in  the  in vivo g ro w th  ca p a c ity  o f  the  ce lls , b u t a s ig n if ic a n t re d u c tio n  
in  th e ir  m e ta s ta tic  ca p a c ity  (S troe ken  et al., 1998). A l l  these data  in d ic a te  th a t P i in te g r in  is
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essen tia l fo r  in v a s io n  and m etastasis
1 . 1 1 . 1.2  012P1 in te g r in
T he  ro le  o f  a 2P i in te g r in  as a co lla g e n  and la m in in  rece p to r, in i t ia l ly  o n  p la te le ts  and 
subsequen tly  o n  o th e r c e ll types, e g  e n d o th e lia l ce lls , has been c le a r ly  estab lished  (S a n to ro  
and Z u tte r ,  1995) T he  0C2P1 b in d in g  s p e c if ic ity  m ay  be m o d u la te d  b y  c e ll- ty p e  s p e c ific  
fa c to rs  (K irc h h o fe r  et al, 1990) F o r  exam ple , the  a 2P i in te g r in  f ro m  e n d o th e lia l ce lls  can  
b in d  la m in in  w h ile  a 2P i o n  p la te le t cannot, b u t b o th  can b in d  to  co lla g e n
In  a d d it io n  to  its  exp ress ion  o n  fib ro b la s ts  and e n d o th e lia l ce lls , h ig h  le v e l o f  a 2P i exp ress io n  
has been  obse rved  o n  num erou s  e p ith e lia l ce lls  T h is  o b se rva tio n  p ro m p te d  an in v e s tig a tio n  
o f  a 2P i in te g r in  e xp ress io n  in  m a lig n a n c y  u s in g  b reast cancer as a m o d e l (Z u tte r  et al,
1990) T h e  resu lts  show ed  th a t a 2P i w as h ig h ly  expressed in  the  e p ith e liu m  o f  duc ts  and 
d uc tu les  o f  n o rm a l b reast tissue  M a rk e d ly  reduced  o r  unde tec tab le  a 2P i exp ress ion  w a s  seen 
in  p o o r ly  d if fe re n tia te d  adenocarc inom as (Z u tte r  et al, 1990, K o u k o u h s  et al, 1991, 
P ig n a te ll i et al, 1991, 1992) S tudies o f  o th e r a denoca rc inom a  (1 e co lo n , p rosta te , lu n g , 
pancreas and s k in )  have y ie ld e d  s im ila r  f in d in g s  re g a rd in g  a 2P i express ion  (K o re tz  et al, 
1991, S ta llm a c h  et al, 1992, H a ll et al, 1991, B o n k o f f  et al, 1993, S tam p and P ig n a te lli,
1991) A  re v ie w  o f  e x is t in g  lite ra tu re  revea ls  th a t decreased exp ress ion  o f  a 2P i is th e  m o s t 
c o m m o n  change m  in te g r in  e xp ress io n  m  e p ith e lia l m a lig n a n c ie s , e sp e c ia lly  in  b reast tissue  
(V a rn e r  and C heresh, 1996, Z u t te r  and Santoro , 1998) In vitro stud ies show ed  th a t 
d im in is h e d  a 2P i in te g r in  e xp ress io n  co n tr ib u te s  to  m o t i l i ty  and the  in v a s iv e  b e h a v io u r o f  
tu m o u r  ce lls  (Z u tte r  et al, 1995) w hereas ree xp ress io n  o f  the  a 2P i m te g rm  in  a p o o r ly  
d if fe re n tia te d , in v a s iv e  b reast ca rc ino m a  c e ll l in e  g re a tly  d im in is h e s  its  m a lig n a n t p o te n tia l 
(K e e ly , 1995) O ve re xp re ss io n  o f  E rb -B 2  in  m a m m a ry  ca rc in o m a  ce lls  m ay  lead  to  reduced  
a 2 in te g r in  gene exp ress ion  (Y e  et al, 1996) I t  is  suggested th a t a 2P i m ay  fu n c t io n  as a 
tu m o u r  suppressor fo r  breast and o th e r e p ith e lia l m a lig n a n c ie s  (Z u tte r  and S antoro , 1998)
T he  ro le  o f  a 2P i in te g r in  m  ce lls  o f  e p ith e lia l o r ig in  appears to  d if fe r  f ro m  a 2 in te g r in  su b u n it 
exp ress io n  m  ce lls  o f  m ese nch ym a l o r ig in  C han  et al (1 9 9 1 ) overexpressed  th e  a 2P i m te g rm  
in  a rh a b d o m yo sa rco m a  (R D )  c e ll l in e  (a  ske le ta l m usc le  tu m o u r) , w h ic h  d id  n o t express the  
a 2P i m te g rm  T he  re s u lt in g  ce lls  w e re  no  m o re  tu m o n g e n ic  th a n  th e  p a ren ta l c e ll lm e , b u t
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w e re  m o re  m e tas ta tic  S im ila r ly ,  p r im a ry  n on m e ta s ta tic  m e lanom as expressed OC2P 1 m te g r in  
a t lo w  leve ls , h o w e ve r, th e  m e lan o m a  c e ll line s  th a t w e re  h ig h ly  m e ta s ta tic  in vivo expressed 
h ig h  le v e ls  o f  th e  0C2P 1 m te g r in  (M o r ta r im  el al, 1991) These stud ies suggest th a t the
fu n c t io n  o f  th e  (X2P 1 m te g r in  m a y  be c e ll typ e -de p en de n t
1 .11 .1 .3  (X3P 1 in te g r in
T he  a 3 su b u n it fo rm s  a h e te ro d im e r c o m p le x  w i th  m te g r in  P i subu n it, th is  h e te ro d im e r is  a lso  
ca lle d  v e ry  la te  a n tig en  -3 ( V L A - 3 )  ajP i is the  o n ly  m te g r in  w h ic h  can b in d  to  co lla ge n , 
la m in m  and f ib ro n e c tm  I t  has been  dem onstra ted  th a t 0 ,3P i can b in d  d ire c t ly  to  th e  co lla g e n  
ty p e  I V  a i ( I V )  531 -543  sequence (M ile s  el al, 1995) S tud ies have sh ow n  th a t 012P 1 and a iP i  
are h ig h  a f f in i ty  recep to rs  fo r  typ e  I V  co lla g e n  w h ile  0C3P i is a lo w -a f f im ty  re c e p to r (K u h n  
and E b le , 1994) I t  is  b e lie v e d  th a t b in d in g  to  typ e  I V  co lla g e n  is  in it ia te d  v ia  th e  OC2P 1 and 
a iP i  in te g rm s , and th en  0C3P 1 m te g r in  is  re c ru ite d  to  sites o n  th e  substrate
A n tib o d ie s  aga ins t a 3P i s tim u la te  the  express ion  o f  M M P -2  (C h in ta la  el al, 1996, K u b o ta  et 
al, 1997) and M M P -9  (L a r ja v a  et al, 1993) A n tib o d ie s  to  th e  a 3 su b u n it can a lso in h ib it  
m e la n o m a  c e ll m o t i l i t y  o n  ty p e  I V  co lla g e n  (M e lc h io r i et al, 1995)
013P 1 is  w id e ly  d is tr ib u te d  n o t o n ly  in  n o rm a l tissues, b u t a lso in  v a r io u s  types  o f  tu m o u rs
Som e stud ies have  suggested th a t reduced  express ion  m a y  be in v o lv e d  in  lo c a l and m e ta s ta tic  
tu m o u r  g ro w th  I t  has been re p o rte d  th a t h ig h ly  in v a s iv e  c e ll s u b p o p u la tio n s  d e rive d  f r o m  the  
h u m a n  p ro s ta te  ca rc ino m a  lin e  P C -3  expressed lo w e r  le v e l o f  CX3P 1 (D e d h a r et al, 1993) T he  
h u m a n  c o lo n  ca rc in o m a  c e ll l in e  S W 620 , d e rive d  fro m  a m e ta s ta tic  le s io n  and w i th  h ig h e r 
m e ta s ta tic  p o te n tia l th a n  the  p a ren ta l lin e  S W 48 0 , does n o t express a .3 w h ic h  is  p resen t m  
S W 48 0  ce lls  (Sam pson-Johannes et al, 1996) R ousse l et al (1 9 9 4 ) show ed  th a t in  
c o m p a riso n  to  n o rm a l pneum ocy tes , lu n g  a denoca rc inom a  ce lls  e x h ib it  a s ig n if ic a n t 
re d u c tio n  o f  0C3P 1 R educed  express ion  o f  CX3P 1 has a lso  been s h o w n  in  b reas t cancer ce lls  
(G u i et al, 1995) H o w e v e r, o the r studies have dem ons tra ted  th a t (X3P 1 exp ress ion  increases 
d u r in g  tu m o u r  p ro g ress io n  in  cu taneous m a lig n a n t m e lan o m a  (N a ta li et al, 1993)
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1 .11 .1 .4  ot4P i in te g r in
T he  in te g r in  a 4 su b u n it is  n o n c o v a le n tly  associa ted  w ith  e ith e r (3i o r  p 7 cha ins T he  lig a n d  
b in d in g  s p e c if ic it ie s  o f  0C4P 1 and 0.4 P 7 in te g rin s  p a r t ia lly  o ve rla p  T he  va scu la r c e ll adhes ion  
m o le c u le -1  ( V C A M -1 )  and f ib ro n e c t in  are recogn ised  b y  b o th  014P 1 and ot4P7 in te g rin s  w i th  
sim i lar e ff ic ie n c y , w h ile  th e  m uco sa l va scu la r adhesion  m o le cu le -1  (M A d C A M - 1 )  is  a 
p re fe re n tia l lig a n d  fo r  in te g r in  CX4P7 (B e r l in  et al, 1993) S tud ies have  sh ow n  th a t express ion  
o f  o u P i in  C H O  B 2 C h inese  ham ste r o v a ry  ce lls  enabled  the  ce lls  to  adhere and m ig ra te  in  
response to  fib ro n e c tin , b u t n o t to  assem ble a f ib ro n e c t in  m a tr ix  (W u  et al, 1997)
E x p re s s io n  o f  (X4 in te g r in s  has been dem onstra ted  in  m an y  d if fe re n t h um an  tu m o u rs  and c e ll 
lin e s  I t  has been s h o w n  th a t 0C4 in te g rin s  are absent f ro m  c u ltu re d  m e lan o cy tes  b u t are 
de tected  o n  d if fe re n t c e ll lin e s  d e r ive d  fro m  m e ta s ta tic  m e lanom as (A lb e ld a  et al, 1990) 
H ig h ly  m v a s iv e  m e lanom as express 014 in te g rin s  m o re  fre q u e n tly  th a n  m e lanom as w i th  lo w  
m e ta s ta tic  c a p a c ity  (A ld e lb a  et al, 1990) S im ila r ly , m odera te  leve ls  o f  o uP i in te g rin s  w e re  
fo u n d  o n  p r im a ry  sarcom as, w h ile  0C4 in te g r in s  w e re  h ig h ly  expressed b y  m e ta s ta tic  sa rcom a 
ce lls  (P a von en  et al, 1994) In  a n im a l m ode ls , i t  has been d em onstra ted  th a t th e  m e ta s ta tic  
ca p a c ity  o f  m e lan o m a  and sa rcom a ce lls  w as  enhanced th ro u g h  014P 1-V C A M -1  in te ra c tio n s  
s ince  V C A M -1  p o s it iv e  e n d o th e lia l ce lls  can re ta in  th e  o uP i p o s it iv e  cancer ce lls  a fte r 1 v  
in je c t io n  o f  cance r ce lls  in to  the  b lo o d  vessels (G a ro fa lo  et al, 1995, M a tt i la  et al, 1992)
In  co n tra s t to  in tra ve n o u s  in je c t io n  o f  cancer ce lls , subcutaneous in je c t io n  m im ic s  th e  e a rly  
step o f  m etastasis , b e g in n in g  w ith  c e ll g ro w th  at a p r im a ry  tu m o u r  s ite  U n d e r these 
c o n d it io n s , B 1 6  m e lan o m a  sub lines  w ith  h ig h  exp ress ion  o f  (X4P 1 show ed  decreased a b il ity  to  
fo rm  tu m o u r  co lo n ie s  in  the  lu n g  M o re o v e r, tra n s fe c tio n  o f  h ig h ly  m e ta s ta tic  B 1 6  m e lan o m a  
ce lls  w i th  th e  0C4 in te g r in  su b u n it c D N A  ind uce d  the  lo w  m e tas ta tic  p h e n o typ e  (Q ia n  et al,
1994) These obse rva tion s  led  to  the  co n c lu s io n  th a t h o m o p h ilic  adhes ion  m e d ia te d  b y  0,4 
in te g r in s  p reven ts  th e  de tachm ent o f  m e lan o m a  ce lls  f ro m  th e  p r im a ry  tu m o u r  th e re b y  
in h ib it in g  m vas iveness and subsequent m etastasis  fo rm a tio n  In h ib it io n  o f  m a tr ix  
m e ta llo p ro te in a s e  c o u ld  p ro v id e  an a lte rn a tiv e  e x p la n a tio n  fo r  th e  reduced  m etastasis  
fo rm a tio n  o f  a 4P i m te g r in -p o s it iv e  B 1 6  m e lan o m a  ce lls  a fte r  subcutaneous in je c t io n  (Q ia n  et 
al, 1994)
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The results obtained to date suggest that the effects mediated by ou mtegrin are dependant on 
the stage o f  tumour progression at which a 4 mtegrin is induced For efficient ligand binding 
o f  mtegrins, mere expression on the cell surface is not sufficient It is essential that mtegrins 
are converted to an active state to bind their ligand (Hynes, 1992) For 014 mtegrin, several 
pathways o f  cellular activation have been identified that lead to a rapid and transient increase 
in mtegrin activity Importantly, these mechanisms do not affect the cell surface density o f  a 4 
mtegrin, but appear to operate either by modulating conformation dependent mtegrin affinity 
for ligand or cytoskeleton dependent cell surface clustering o f  mtegrin (Hynes, 1992)
1.11.1.5 OC5P1 mtegrin
Integrm asP i, a fibronectin-specific mtegrin, binds to the central RGD/PHSRN site o f  
fibronectin whereas the 0C4P1 mtegrin binds to the IIICS site 0C5P1 has been implicated in the 
regulation o f  gene expression, cell growth and tumongem city Transfection o f  human as and 
Pi cD N A  into transformed Chinese hamster ovary (CHO) cells resulted in the cells 
depositing more fibronectin in their ECM, migrating less than parental cells and showing  
reduced ability to grow These cells were also nontumoungenic when injected 
subcutaneously into nude m ice (Giancotti and Ruoslahti, 1990) This study indicates that the 
asp i mtegrin is an important determinant in the fibronectin assembly process as w ell as in 
cell growth and tumoungemcity Conversely, loss o f  asPi expression in CHO cells increased 
tum ongem city (Schreiner et a l , 1991) A  variant o f  K562 erythroleukemia cells selected for 
increased ability to attach to fibronectin showed a 5-fold up-regulation o f  a sp i and displayed 
significantly reduced growth as w ell as reduced turmongemcity (Symington, 1990) 
Overexpression o f  as Pi in human colon carcinoma HT29 cells has been shown to induce the 
transcription o f  growth arrest-specific genel (G AS-1) and block the transcription o f  
immediate early genes C-fos, C-jun and jun-B (Varner et a l , 1995)
It has been suggested that as Pi is the fibronectin receptor o f  stationary cells (Giancotti and 
Ruoslahti, 1990) Locomotory cells may use a 3Pi or a vPi to interact with fibronectin and to 
migrate on it, while interaction through the asPi would reduce migration This hypothesis 
would explain why adhesion peptides and mtegrin antibodies o f  broad specificity in h ib i t  cell 
migration (Boucaut et a l , 1984, Bronner-Fraser, 1985) whereas anti-as subunit antibodies 
can facilitate it (Akiyama et a l , 1989)
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The (X5P1 mtegrin may play a role in apoptosis It was found that cells attached through the 
asP i mtegrin survived in serum-free cultures (Zhang el a l , 1995) This response is associated 
with an elevated expression o f  the anti-apoptosis protein Bcl-2
1 .1 1 .1.6  ot6Pi and 06604 integrm s
Sonnenberg el a l  (1988) reported that the mtegrin com plex o^Pi functions as a laminin 
receptor on platelets Later it was found that a 6Pi was widely expressed in most cell types At 
least nine different integrms can function as laminin receptors, a number that probably 
reflects the diversity and specificity o f  laminm-mediated phenomena The best studied 
integrms that function as laminin receptors are a iP i, CX.2P1, (X3P1, a.6Pi and a«P4
It was reported that inhibiting a 6Pi function or its expression can reduce the m vasive and 
metastatic ability o f  several types o f  tumour cells (Lin et a l , 1993, Rabinovitz et a l , 1995, 
Ruiz el a l , 1993, Shaw et a l , 1996) For example, the metastatic potential o f  human 
melanoma cells injected into nude m ice was diminished by using anti-a6 antibodies (Ruiz et  
a l , 1993) Neoplastic transformed cells resulted in increased expression o f  ot6 mtegrin 
(Dedhar et  a l , 1990) Histopathologically, however, the picture is varied Pancreatic , 
carcinoma (W einel et a l , 1992) and head and neck squamous cell carcinomas (Van W aes and 
Carey, 1992) have been shown to have increased ct6 staming Breast carcinomas that preserve 
ot6 mtegrm expression are associated with reduced survival (Friedrichs et a l , 1995) In 
contrast, other studies have shown decreased expression in human breast (Gould et a l ,
1990) and renal carcinomas (Korhonen et a l , 1992)
The (X.6P4 mtegrm was identified initially by Falciom el a l  (1986) This mtegrm is only 
expressed on epithelial cells and the p4 is the only mtegrm subunit w hose cytoplasm ic 
domain is unusually large 0 ^ 4  mtegrm has been implicated in the formation and 
maintenance o f  hemidesmosome, a multiprotein com plex that provides the cells with a strong 
and stable anchor to the basement membrane However, a general correlation between the 
type or degree o f  malignancy and P4 mtegrm expression cannot be established Falciom et a l  
(1994) found that high clinical stage o f  colon carcinomas express high amounts o f  a<^ >A and 
this expression correlates with the degree o f  tumour aggressiveness (Serini et  a l , 1996)
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whereas normal thyroid cells do not express a s (34 In contrast, other tumours, such as breast, 
prostate and basal cell carcinomas exhibit decreased fU mtegrin expression (Gui et a l , 1995, 
Rabinovitz et a l , 1995, Korman and Hrabovsky, 1993) A  comm on observation in many o f  
these studies is that the localisation o f  the (34 mtegrin in invasive and metastatic carcinoma - 
cells is diffuse in comparison with its polarised, basal localisation in normal epithelia
It was observed that the expression o f  the 0 ^ 4  integral in RKO cells, a ^ -defic ien t rectal 
carcmoma cell line, significantly increased the ability o f  these cells to invade m atngel and 
collagen (Chao et a l , 1996) Expression o f  the ot6p4 in a human breast carcmoma cell line 
M DA -M B-435 which lacks mtegrins also results in a dramatic increase in invasion A  related 
aspect o f  oi6p4 involvem ent is that this mtegrin can promote the formation o f  pseudopodia 
because it has been noted that expression o f  acP4 in RKO cells induces the formation o f  
pseudopodia (Chao et a l , 1996) a 6p4 could also induce the release o f  specific proteases such 
as MM Ps although the direct evidence is lacking Another mechanism used by 0 ^ 4  to 
facilitate invasion is by alterrmg other adhesion receptors This is supported by the 
observation that expression o f  OC6P4 m RKO cells altered their invasion on collagen I which is 
not a ligand for 0 ^ 4  (Chao et a l , 1996)
a.6P4 has also been shown to be expressed in capillary "sprouts" and the possibility that it may 
be involved in angiogenesis has been raised (Enenstein and Kramer, 1994) The 0 ^ 4  integral 
may also have a role in apoptosis Expression o f  the p4 cytoplasmic domain in cells has been  
shown to activate P21 (an inhibitor o f  cyclin dependent kinases) and induce growth arrest 
(Clarke et a l , 1995) In addition, expression o f  p4 cD N A  in a bladder carcmoma cell line 
results in a loss o f  survival (Kim et a l , 1997)
1.11.2 E-cadherm
The cadherins are a family o f  transmembrane glycoproteins that mediate cell-cell adhesion  
through Ca2+-dependent mechanisms (Takeichi, 1988) Several subclasses o f  cadherins have 
been described, E-(epithelial), N-(neural) and P-(placental) cadherins Cadherins appear to 
function by connecting cells to each other by homophilic interactions, in which they bmd 
selectively to identical cadherm types (N ose et al, 1990) In epithelial cells, E-cadherm, also 
known as uvomorulin and L-CAM, represents a key m olecule in the establishment and
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stabilisation o f  cellular junctions The cytoplasmic domain o f  E-cadherm is complexed with  
either (3-catemn or y-catemn (plakoglobin) (3-catenm and y-catemn bind directly to a-catemn, 
giving rise to two distinct cadherin-catemn com plexes a-catem n is thought to link cadherm 
to actm filaments E-cadherm also plays a role in one o f  the earliest events in mammalian 
development known as compaction, which separates the 8-celled embryo into trophoblast and 
inner cell mass
Eidelman et a l  (1989) demonstrated a down-regulation o f  E-cadherm in poorly differentiated 
tumours compared to the corresponding normal tissues They studied 60 tumours o f  varying 
origins for their expression o f  E-cadherm and could not identify a single case o f  epithelial 
malignancy lacking E-cadherin, although they did note a decrease o f  E-cadherm staining m  
the more undifferentiated tumours In colorectal cancer, for example, some independent 
studies (Van der W uff el a l , 1992, Kinsella e t a l ,  1993, Dorudi el a l ,  1993) have shown that 
expression o f  E-cadherm is inversely correlated with tumour differentiation Similarly, in 
breast and gastric cancer, loss o f  E-cadherm expression has been found in high grade tumours 
with a poor prognosis (Oka et a l , 1993, Mayer el a l , 1993) In contrast, Shimoyama et al  
(1989) stamed 44 lung carcinomas using antibodies directed against E-cadherin They found 
that the staining intensity o f  E-cadherm varied considerably from case to case, but when 
present, staining was always restricted to cell-cell borders N o clear down regulation o f  E- 
cadherm in the primary tumours or in metastases was noted
In vitro studies have clearly demonstrated that loss o f  E-cadherin is a critical step in the 
acquisition o f  an invasive and undifferentiated phenotype Non-transformed Madin-Darby 
canine kidney epithelial cells (MDCK) (Mareel et a l , 1992) as well as a well-differentiated 
colon carcinoma cell line (Pignatelli et a l , 1992) acquire a poorly differentiated phenotype 
when intercellular adhesion is specifically inhibited by anti-E-cadherin antibodies 
Transfection o f  mouse E-cadherm cD N A  into a poorly differentiated human breast carcinoma 
cell line resulted in increased intercellular cohesion which was associated with inhibition o f  
the invasive phenotype in vitro (Fnxen et a l , 1991) Similar results have been obtained by  
transfecting the same plasmid into a poorly differentiated colon carcinoma cell line (Liu et  
a l ,  1992)
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In general, good experimental evidence exists to support the hypothesis that loss o f  E- 
cadherm expression or function is associated with increased m vasiveness in transformed 
epithelial cells Unfortunately, these observations have not been consistently confirmed in 
immunohistochemical analysis o f  human tumours which indicates that unknown host factors 
could play important roles in the heterogeneous nature o f  E-cadherm expression
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Aims of thesis
The initial aim o f  this thesis was to establish and characterise novel taxol-resistant and 
melphalan-resistant variants o f  the human nasal carcinoma cell line RPM I-2650 in order to 
investigate the mechanisms o f  multidrug resistance which is the major factor limiting the 
effect o f  chemotherapy Studies o f  drug-resistance mechanisms in vitro have been  
complicated by the fact that many human tumour cell lines already express high levels o f  
resistance-associated proteins such as Pgp and MRP1 The purpose o f  this project was to 
identify a very sensitive cell line, preferably expressing low  levels o f  active Pgp and/or 
MRP1, and then to select for resistant variants by exposure to a drug believed to be pumped 
by Pgp but not to any great extent by MRP1, such as taxol and to an MRP1 but non-Pgp 
substrate, such as melphalan It was also proposed to attempt to co-select the RPM I-2650  
cells with taxol and melphalan, to determme if  a novel mechanism exists which would confer 
cross-resistance to both drugs (obviously neither MPR1 nor Pgp alone can achieve this)
The dramatic morphological changes observed in the RPM I-2650 taxol- and melphalan- 
resistant variants during the study lead to the investigation o f  a number o f  properties o f  these 
variants including cell adhesion to extracellular matrix, cell adhesion m olecules, cell invasion  
and motility Possible mechanisms o f  invasive behaviour in these variants were then further 
investigated
To clarify whether melphalan can increase m vasiveness only in RPM I-2650 cell line or i f  it 
can have a similar effect in other cell lines, melphalan-resistant variants o f  the human lung 
carcinoma cell line, DLKP were established by both continuous exposure and pulse selection  
methods Preliminary investigation into possible mechanisms underlying their m vasiveness 
was undertaken
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2. Materials and Methods
2.1 Preparation of cell culture media
2.1.1 W ater quality
All water used in the preparation o f  cell culture media was purified by a M illi-pore ultrapure 
water system or an ELGA UHP system. The water was first prefiltered, followed by a double 
distillation step (ELGA) or passage through a reverse osm osis system (M illi-Q). It was then 
passaged through two ion-exchange filters and a carbon filter to remove organic solutes. 
Finally the water was passed through a 0.22|im  cellulose acetate filter resulting in ultrapure 
water which was continuously monitored by an on-line conductivity meter.
2.1.2 Glassware treatm ent
All items o f  glassware used in cell culture (media bottles, roller bottles, waste bottles etc.) 
were soaked in a warm 2% solution (v/v) o f  the non-ionic detergent RBS (chemical products, 
Belgium) for 1-2 hours. They were then individually scrubbed with bottle brushes and rinsed 
thoroughly with tap water to remove all RBS residue. This was followed by three separate 
washes in deionised water before a final rinse in ultra pure water.
2.1.3 Sterilisation
All glassware used in cell culture, such as media bottles, roller bottles etc. were sterilised by 
autoclaving. All items were autoclaved before use at 121°C and 15 psi pressure for 20  
minutes. Phosphate buffered saline (PBS), water and the relevant solutions for media 
preparation (HEPES, HC1, NaOH and N aH C 03) were sterilised using the above conditions. 
Filter sterilisation was employed for unstable reagents, including cell culture media and 
protein solutions. Sterile disposable 0.22|xm filters (M illex-GV, SLGV025BS) were used for 
small volumes. Larger volumes, such as culture media, were filter sterilised through a micro­
culture cell filter (Gelman 12158) which has a filtering capacity o f  10 litres.
2.1.4 Basal medium preparation
The preparation o f  basal medium was carried out under sterile conditions in a class II laminar 
flow  cabinet. All media were prepared from a 10X stock o f  liquid or powder concentrates and
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made up in batches o f  5 litres The powder was dissolved m 4 7 litres o f  ultrapure water and 
supplemented with 1M HEPES (Sigma 7365-45-9), and 7 5% NaHCOs (BDH  30151) The 
pH was adjusted with 5M NaOH (Merck 1 06482 1000) and 1 5M  HC1 (BDH  10158) to give 
the desired pH o f  7 45-7 55 The liquid concentrates were prepared by the addition o f  500 mis 
o f  the 10X stock to 4 3 liters o f  ultrapure water and were supplemented with 1M HEPES and 
7 5% NaHCOa The pH was again adjusted with 5M NaOH and 1 5M HC1 Table 2 1 4 
illustrates the components required for the preparation o f  5 litres o f  the four basal media used  
in these studies The medium w as then filter sterilised through a 0 2 jam pore size micro- 
culture capsule bell filter (Gelman Sciences 12158) into 500ml sterile bottles and aliquots 
from each bottle were removed for sterility tests The bottles were labelled and stored at 4°C 
and used only after the sterility tests proved negative
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(Sigma)
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Table 2.1.4 Preparation o f  basal medium from 10X stock 
2.1.5 Preparation of HEPES and NaHCC>3
The HEPES buffer was prepared by dissolving 23 8g o f  HEPES in 80m ls o f  ultrapure water 
and the solution was then autoclaved Following autoclaving, 5 mis o f  sterile 5M NaOH was 
added to give an approximate volum e o f  lOOmls N aH C 03 was prepared by dissolving 7 5g in 
lOOmls o f  ultrapure water and autoclaving the resulting solution
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2.1.6 Media supplements
A  200 mM solution o f  L-glutamine (Gibco 28030-024) was added to the basal media to give a 
final dilution o f  1 100 L-glutamine The L-glutamine is a relatively unstable component o f  
cell culture medium and was therefore only added to the media three days before use lOOmls 
o f  L-gluthmine was aliquoted and stored at -20°C  until required
100 mM sodium pyruvate (Gibco 11360-039) and also a 1 100 dilution o f  100X stock o f  non 
essential amino acids (NEAA) (Gibco 11140-035) were added to the M EM  basal medium to 
supplement the MEM
2.1.7 Serum
All basal media used throughout these studies were supplemented with 5% foetal ca lf serum 
(unless otherwise stated) Due to batch to batch variability o f  the serum, routine batch 
screening was carried out to select a serum suitable for the particular cell line being used 5-10  
samples o f  serum were screened on a number o f  cell lines and suitable foetal calf serum was 
chosen The serum screen was carried out using miniaturised assays similar to the toxicity  
assays described in section 2 6 The serum was purchased in bulk and stored long term at 
-20°C until required
2.1.8 Sterility tests
Sterility checks were carried out on all IX  bottles o f  basal media prior to the preparation o f  
complete growth medium A  10ml aliquot o f  medium from each bottle was removed and 
tested for both bacterial and fungal contamination 1ml samples were inoculated m tryptone 
soya broth (Oxoid CM 129) which supports the growth o f  fungus and aerobic bacteria and 
thioglycollate broth (Oxoid CM 173) which supports the growth o f  anaerobic and aerobic 
bacteria A ll sterihty tests were incubated for 14 days to test for bacterial and fungal 
contamination The media w as only used i f  all tests were negative after this tim e After the 
basal medium was supplemented with FCS, L-glutamine and other supplements required for 
the particular cell line, aliquots o f  medium were removed and sterility checked w ith tryptone 
soya agar at 37°C for three days prior to use
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2.2 Cell Culture
2.2.1 Cell lines used in studies
A ll cell culture work was performed in class II vertical down-flow recirculating laminar flow  
cabinets (Holten Cytoguard) The cell lines used throught this work are outlined m table 2 1 
The cell lines used were anchorage dependent The cells were grown in 25cm 2 (Costar 3055) 
and 75cm 2 (Costar 3375) tissue culture treated unvented flasks All cell lines were incubated 
at 37°C and were fed every two to three days
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MEM
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<#-* -VX **
ATCC Human breast carcinoma 
cell Ime
MEM
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■Mwi , #  ,
ATCC Human fibrosarcoma cell 
Ime
MEM
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Table 2.2 Cell lines used in this work
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2.2.2 Subculturmg of cell lines
Adherent cells grown as monolayers m tissue culture flasks were generally subcultured before 
confluency was reached The cells were enzymatically detached from the flask using a 
0 25% (w/v) trypsin (Gibco 25090-028) / 0 01% (w/v) ED TA (BDH  10093) solution in PBS 
(Oxoid BR 14A ) The waste medium was decanted from the flasks and the cells were 
incubated at 37°C with 5ml o f  trysin/EDTA for 5-15 minutes (depending on the cell line) until 
a smgle cell suspension was obtained, as determined m icroscopically An equal volum e o f  
complete medium w as added to inhibit the action o f  the trysin / EDTA and the resulting cell 
suspension w as pelleted by centrifugation at 1000 rpm for 5 minutes The supernatant was 
removed and the cells were resuspended in 5 ml o f  fresh complete medium An aliquot o f  cell 
suspension was removed for cell counting and the cells were reseeded at the desired 
concentration in tissue culture flasks Complete medium was added to the flasks to give  
approximately 8ml o f  medium in a 25cm 2 flask and 15ml in a 75cm 2 flask
Cells required in large numbers were cultivated in roller bottles Approximately 100ml o f  
growth medium was allowed to equilibrate in a roller bottle at 37°C after which a smgle cell 
suspension o f  approximately 2x107 cells was added The roller bottle was incubated at 
0 25rpm overnight and then the rotor speed was mcreased to 0 50 rpm The cells were allowed  
to grow to 80% confluency and were fed when necessary
2.2.3. Cell counting
An aliquot o f  the single cell suspension was removed for counting and mixed in a ratio o f  5 1 
with trypan blue dye (Gibco 043-05250H ) The suspension was left for approximately 5 
minutes to ensure equal m ixing o f  the trypan blue with the cells before a small quantity was 
applied to a haemocytometer The suspension m oved into the 0 01mm deep depression o f  the 
haemocytometer by capillary action Cells m the 16 squares o f  the four outer corner grids 
were counted (both stained and unstained cells) and averaged The average number o f  cells 
was calculated with the dilution factor taken into account and the final number was multiplied 
by 104 to give the number o f  cells per ml N on viable cells stained blue with the trypan blue 
dye w hile the viable cells remained unstained
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2.2.4 Cell freezing
A ll the cell lines used throughout this work were stored long term at -196°C in a liquid 
nitrogen tank Cells in subconfluent exponential phase were most suitable for long term 
storage The cells for freezing were trypsmised and a smgle cell suspension was obtained as 
described m section 2 2 2 The pellet was resuspended in 100% FCS An equal volum e o f  
10%(v/v) DM SO (dimethylsulphoxide, Sigma D -5879) in FCS was added dropwise w ith  
continuous m ixing over a number o f  minutes After the DM SO was added the suspension was 
transferred to sterile cryovials (Greiner 122 278) The vials were labelled with the name o f  the 
cell line, the passage number, the date and finally the operator initials before being placed m  
the vapour phase o f  the liquid nitrogen container for 3 hours After this time the cells were 
transferred to the liquid phase and stored until required A  protective face visor and protective 
gloves were worn at all tim es during handling o f  the liquid nitrogen
2.2.5 Cell thawing
The vial o f  cells to be thawed was removed from the liquid phase in the liquid nitrogen tank 
and placed in the vapour phase for 2-3 minutes to allow any liquid nitrogen present in the vial 
to evaporate The cells were then thawed rapidly in a water bath at 37°C and transferred to a 
sterile universal container containing 5ml o f  complete medium The cells were pelleted by 
centrifugation at 1000 rpm for 5 minutes The medium was decanted and the pellet 
resuspended in 5 ml o f  complete medium The cell viability was determined and the cell 
suspension w as then transferred to tissue culture flasks and incubated for 24 hours The 
follow ing day the cells were refed with fresh complete medium
2.3 Mycoplasma detection
The cell lines used during this project were routinely screened for the presence o f  
mycoplasm a infection Unlike other microbial contammation, mycoplasma are not visible  
m icroscopically and infected cells may contmue to grow and divide However, infection can 
result m decreased proliferation rates, changes in the morphology and granulation o f  the cells 
To detect the presence o f  mycoplasma, the cells were examined by a direct culture method 
and an indirect staining method (Hoechst 33258) The cells to be screened were grown for at 
least 3 passages in drug free and antibiotic free medium, and after this time the spent medium  
w as collected and used for the screening process
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2.3.1 Hoechst DNA staining method
In this method, since cell integrity is w ell maintained during the fixation procedure, an 
indicator cell lme NRK  (normal rat kidney fibroblast cell line) was used The NRK  cells 
(2x103) were grown on sterile coverslips overnight in 1ml o f  DM EM  supplemented with 5% 
FCS and 1% L-glutamine The cells were incubated at 37°C in 5% CO2 1ml o f  the culture 
medium was added to duplicate coverslips which were then incubated for 4-5 days After this 
time the cells were approximately 50% confluent The medium was removed and the cells 
were rinsed tw ice in PBS followed by one rinse in a 1 1 cold solution o f  PBS Carnoys reagent 
(1 3 glacial acetic acid (BDH  27013) to methanol (BDH  10158)) The cells were then fixed  
for 10 minutes with Carnoys solution which was kept at -20°C for at least 30 minutes before 
use After 10 minutes, Carnoys solution was removed and coverslips were air dried The cells 
were then stamed in 2ml o f  Hoechst (Sigma B -2883) working stock (50ng/m l in PBS) for 10 
minutes The Hoechst is light sensitive, so all staining was carried out in darkness The 
coverslips were then rinsed 3 times with ultrapure water and mounted on a slide in a drop o f  
mounting medium (50% glycerol (BDH  10118) in 0 1M citric acid, 0 2M  disodium sulphate 
at pH 5 5) The slides were then examined using a mercury fluorescence m icroscope The 
H oechst stain binds specifically to DNA, staining the nucleus o f  the cells and any extranuclear 
D N A  that may be present If mycoplasma contamination w as present, small fluorescent 
bodies were visible in the cytoplasma o f  the cells M ycoplasma contaminated medium and 
medium not exposed to cells were used as positive and negative controls respectively
2.3.2 Mycoplasma culture method
150mls o f  mycoplasm a agar (Oxoid CM 401) and mycoplasma broth (Oxoid CM 403) were 
prepared Each w as supplemented with 50mls serum, 25m ls yeast extract (15% w /v) and 
25m ls stock solution (12 5g dextrose and 2 5g L-argmine HC1 in 250m l ultrapure water) All 
o f  these substances were either autoclaved or filter sterilised 0 5 ml o f  the growth medium  
from the cell lines w as incubated in 5 mis o f  mycoplasma broth for 5-7 days at 37°C and then 
a streak from the broth was inoculated onto lOmls o f  the solidified agar The agar plates were 
incubated in a CO2 gaspak system for 3-4 weeks, on day 7 and 21, the plates were exammed 
for colony formation I f  mycoplasma contamination was present, typical “fried egg” type 
colonies, consisting o f  a dense centre and a less dense surround would have been visible
80
Cytotoxic drugs were treated with extreme caution in the laboratory at all times due to the 
potential risks in handling these drugs Generally two pairs o f  latex disposable gloves  
(M edical Supplies Company Ltd) and a face mask were worn when dealing w ith the 
concentrated stocks o f  the drugs and all work was carried out in cytotoxic cabinets (Gelman 
cytoguard or Holten Laminar Air cytotoxic cabinet) All drugs were stored m a safety cabinet 
at room temperature or in designated areas at 4°C or at -20°C  Table 2 4 outlines the storage 
and means o f  disposal o f  the cytotoxic drugs used m this work All liquid drug waste was 
disposed o f  in the same way as the drug
2.4 Safe handling of cytotoxic drugs
: 1 Cytotoxic agent
i,*#?, «a, -
j|À & iam ycin ’ ’ 
Sfc ' -
v j m '; “fS -•>-
4°C in darkness Inactivated with 1% 
hyperchloride solution and 
disposed with excess water
, -V incristine i 
\  j^m blastm e -
4°C in darkness Inactivated by autoclavmg 
and disposed with excess  
water
ÉT:-,.................
Room  temperature Incineration
-  .. ' '
Room  temperature Incineration
Jtelphalan
.„lì, ' % I
' i**“
, '
Room temperature in 
darkness
Incineration
§■: h '^Cisplatin Room temperature in 
darkness
Incineration
I?" * ;:5-Fluorouracil
«* *£ -•* - ...
Room temperature in 
darkness
Inactivated with 5M NaOH  
and disposed with excess  
water
Cadmium Chloride
e % f ,  :■
1 i**
Room  temperature in 
darkness
Incineration
Table 2.4. Storage and disposal o f  cytotoxic drugs
81
2.5 Adaptation of MDR variants
Throughout the course o f  this study, a number o f  M DR variants were developed by selecting 
the sensitive parental cell lines, RPM I-2650 and DLKP with taxol or melphalan.
2.5.1 Continuous selection
r\
Cells were grown to 70-80% confluency in 75cm  flasks and then exposed to an initial 
concentration o f  selecting agent which was equivalent to 80% kill when calculated using a 96 
well plate miniature toxicity assay (see section 2.6). The cells were grown at this 
concentration o f  drug until they appeared healthy and had reached approximately 70%  
confluency, after which time the concentration o f  drug to which the cells were exposed was 
increased approximately 1.5 folds. This process was continued over a number o f  months until 
desired concentration was reached. Toxicity assays were carried out to monitor any changes 
in drug sensitivity when compared with the untreated parental cells.
2.5.2 Pulse selection
Cells were grown to 70-80% confluency in 75cm 2 flasks. The cells were then exposed to 3X  
the initial drug concentration for continuous selection for 4 hours, after which time the drug 
was removed and the cells rinsed twice with fresh media. The cells were then grown in drug 
free media at 37°C for 6 days (refed with fresh media every 2-3 days). This was repeated for 
10 "pulses" after which time sensitivity to the selecting drug was monitored using 
miniaturised toxicity assay (see section 2.6).
2.6 Miniaturised in vitro toxicity assays
The toxicity profile o f  the cell lines used throughout this work was determined using 
miniaturised toxicity assays by an acid phosphatase procedure (Martin and Clynes, 1991). The 
assays were carried out when the cells grown in a 75cm 2 flask reached 80% confluency and 
were fed in complete medium the previous day.
2.6.1 Toxicity assays - 96 well plates
The cells were plated in 96 w ell plates (Costar 3596) at a concentration o f  2 x l0 3 cells/w ell in 
100(il o f  complete medium. The first lane o f  each plate was used as a cell blank to which 
100(0.1 o f  complete medium was added. The plates were gently rotated to ensure equal 
distribution o f  the cells within the wells. The cells were then allowed to attach overnight at
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37°C in 5% CO2 The following day a series o f  2X  drug dilutions were prepared ranging from  
a non toxic concentration to a concentration that resulted in 100% cell kill lOOjo.1 o f  the drug 
dilution was added to each w ell in replicates o f  eight and 100|il o f  complete medium was 
added to lanes one and tw o which served as a blank and a 100% cell survival control 
respectively
The plates were then incubated for 5-7 days until cells m the control w ells had reached 
approximately 80% confluency The medium was decanted from the w ells and the cells were 
rinsed tw ice in PBS 100|_il o f  the assay substrate (lOmM P-mtrophenyl phosphate (Sigma  
104) m 0 1M sodium acetate (Sigma S-2889), 0 1% Triton X -100 (Sigma X -100)) was added 
to each w ell The assay substrate was prepared just before use and the pH was adjusted to pH  
5 5 The plates were incubated for two hours at 37°C in 5% CO2 and then read in a dual beam  
ELISA plate reader at a wavelength o f  405nm (reference wavelength 620nm) The first lane 
o f  each plate was used to blank the ELISA plate reader I f  the colour obtained was slight it 
was enhanced by the addition o f  50 |il o f  IN  NaOH which also stopped the enzymatic 
reaction
2.6.2 Circumvention assays - 96 well plates
The cells were plated in 96 w ell plates at a concentration o f  2 x l0 3 cells per w ell in 100|il o f  
medium 100|il o f  medium was added to the first lane o f  each plate which served as a blank 
The cells w ere incubated for 24 hours at 37°C m 5% CO2 to allow the cells to attach A  series 
o f  4X  drug dilution were prepared and 50|_il was added to the w ells in replicates o f  eight A  
4X  stock o f  the circumvention agent was also prepared and 50|il w as added to each o f  the 
appropriate w ells Control w ells containing only the drug or circumvention agent were also 
set up The plates were then mcubated at 37°C in 5% CO2 for 5-7 days until the control w ells  
had reached approximately 80% confluency The medium was decanted and the cells rinsed 
twice w ith PBS before the toxicity was determined usmg the acid phosphatase method, as 
described in section 2 6 1
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2.7 Immunological studies
Throughout the course o f  this work immunological studies were carried out on both live and 
fixed cells. Immunofluorescence was performed on live cells to detect the presence o f  
cytoskeletal proteins and immunocytochemistry was performed on fixed cells to detect the 
presence o f  both intracellular and membrane associated antigens.
2.7.1 Immunofluorescence
The cells used for immunofluorescence were grown in 75cm 2 flasks until they had reached 
approximately 80% confluency. The cells were then trypsinised and pelleted by 
centrifugation. The cell pellet was resuspended in complete medium. An aliquot o f  the cell 
suspension was removed and the cells counted using a haemocytometer. 105 cells/m l were 
added to each w ell o f  a sterile multiwell slides. The multiwell slide was then placed in a 
sterile petri dish and incubated overnight at 37°C in 5% CO2 to allow the cells to attach. The 
follow ing day, the multiwell slides were washed with PBS and fixed in ice-cold acetone for 2 
minutes. The slides were then left to air dry for 15 minutes. The cells were then incubated 
with the primary antibody for 30 minutes at 4°C followed by washing three times with PBS. 
50|il o f  the secondary antibody (FITC-labelled antimouse IgG (Boehringer Mannheim  
821462) diluted to 1:50 in PBS) was added to each well and the cells were incubated for a 
further 30 minutes at 4°C in darkness since the FITC-labelled antibodies were light sensitive. 
After the incubation period the cells were washed three times with PBS. The cells were then 
mounted in vectashield (Vector Lab. Inc. H -1000) and sealed with nail varnish. The cells were 
viewed for fluorescence under ultraviolet illumination using a Nikon m icroscope equipped 
with a mercury lamp.
2.7.2 Immunocytochemistry
2.7.2.1 Preparation of cytospins
The glass micro slides (Chance Propper Ltd) used for the cytospins were washed thoroughly 
in hot water containing 0.5% Tween-20 (Sigma P-1379) and then rinsed in running water for 
approximately 15 minutes. Following this washing step, the slides were soaked in alcohol for 
15 minutes and then dried thoroughly. The slides were then coated with poly-L-lysine (Sigm a  
P-1274) by adding approximately 10|il o f  poly-L-lysine (1 mg/ml in ultrapure water) to one 
end and spreading it evenly over the slide to give an equal coating o f  the poly-L-lysine
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(Huang et al., 1983). The slides were air dried overnight and stored at room temperature until 
required.
The cells required for the cytospins were grown in 75 cm flask until they had reached 
approximately 80% confluency. The trysinisation procedure was carried out and a single cell 
suspension o f  1x10s cells per ml was prepared. Two 100|il aliquots o f  the cell suspension 
were cytofuged (Heraeus labofuge 400) onto the glass slide at 400 rpm for 4 minutes. A  
number o f  cytospins were prepared and allowed to air dry overnight. The cytospins were 
stored at -20°C  until required.
2.7.2.2 Imm unocytochem istry
All immunocytochemical studies on cytospins o f  cell lines were performed follow ing the 
method o f  Hsu et al. (1981) using an avidin-biotin horseradish peroxidase (HRP) conjugated 
kit (ABC). The cytospins were removed from -20°C and allowed to stand at room temperature 
for approximately 20 minutes prior to starting the assay. Fixation o f  the cells was carried out 
by incubating the cells in ice-cold acetone (BDH  10003) for appropriate time periods. The 
slides were then allowed to air dry for approximately 15 minutes. The cells were incubated in 
0.6% hydrogen peroxide (BDH 10128) in methanol (BDH  10158) for 5 minutes to quench 
any endogenous peroxidase activity. The slides were rinsed with water and then washed for 5 
minutes in TBS (Tris-buffered saline; 0.05M  Tris/HCl, 0.15M  NaCl, pH 7.6) containing 0.1%  
Tween-20. N on-specific background in the cells was blocked by the addition o f  a 1:5 dilution 
o f  normal serum from species which donated secondary antibody, such as normal rabbit 
serum (DAKO X 0902) for 30 minutes at room temperature, after which time the excess serum  
was tapped o ff  and the optimally diluted primary antibody was applied. Slides were then 
placed in a humidified atmosphere and incubated at room temperature for 2 hours or at 4°C 
over night. Follow ing primary antibody incubation, slides were washed 3 times in 15 minutes 
in lxT B S, 0.1% (v/v) Tween 20. The cells were then incubated with a biotinylated secondary 
antibody for 30 minutes at room temperature and then washed thoroughly three tim es with  
TBS/0.1%  Tween-20. 50|jl o f  a freshly prepared stock o f  streptavidin-binding com plex  
(DAKO K 377) was added to each o f  the sections and incubated for 30 minutes at room  
temperature. The slides were washed thoroughly and the cells incubated with 50|ol o f  the 
peroxidase substrate, 3,3-diaminobenzidine tetrahydrochloride (DAB, DAKO S3000). When 
suitable colour had developed (red-brown reacting product), the cells were rinsed in water and
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counterstained with hematoxylin (Sigm a H HS-1S) for 15 seconds, differentiated m 1% (v/v) 
hydrochloric acid in methanol for 15 seconds and differentiated m Scotts tap water for 10 
seconds, rinsing in water between each step A  series o f  dehydration steps in alcohol (70%, 
90% and 100% methanol) were carried out and slides cleared in xylene (BDH  305756G ) (2 
changes with 5 minutes each) before the cells were mounted in D P X  (BDH  36029) and 
view ed under a Nikon microscope when dry
2.7.2.2.1 P-glycoprotein
The presence o f  P-glycoprotein in a number o f  cell lines was investigated using a monoclonal 
m ouse M DR-1 antibody (BRI, BR -002) (Moran et a l , 1997) The cells were incubated with a 
1 40 dilution o f  the primary antibody for 2 hours at room temperature The cells were then 
washed thoroughly with TBS/0 1% Tween-20 and incubated with the secondary biotinylated 
rabbit anti-mouse IgG antibody (1 300) (DAKO, E354) for 30 minutes
2.1.2.2.2 cMOAT (MRP2)
The presence o f  cMOAT (M RP2) was detected using the monoclonal m ouse antibody 
cM OAT 2III-6 (a gift from Prof Rik Scheper, Holland) The cells were incubated with a 1 50 
dilution o f  the primary antibody at 4°C overnight The cells were then washed thoroughly 
with TBS/0 1% Tween-20 and incubated with the secondary biotinylated rabbit anti-mouse 
IgG antibody (DAKO E354) for 30 minutes at room temperature
2.7.2.2.3 Lung resistance protein (LRP)
The presence o f  LRP was detected using a mouse monoclonal antibody to LRP (LRP-56) 
(TCS, ZIM 1001) The cells were incubated with a 1 20 dilution o f  the primary antibody for 3 
hours at room temperature and then washed three times over a period o f  15 minutes The cells 
were then incubated with the secondary antibody (1 300 dilution o f  the biotinylated rabbit 
anti-mouse IgG antibody) for 30 minutes at room temperature
2.7.2.2.4 Topoisomerase II a
The presence o f  Topo II a  in a number o f  cell lines was mvestigated using a monoclonal 
m ouse Topo II a  antibody (BRI, BR -003) After fixation in acetone, the shde was placed for 3 
minutes in Triton solution (0 1% Tnton-X-100 in IX  TBS) which w as prepared and stored at 
4°C for at least 24 hours before use The cells were then incubated at room temperature for 2
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hours with a 1 50 dilution o f  the Topo II a  antibody After this incubation period, the slide 
was washed thoroughly with TBS/0 1% Tween-20 and incubated with the secondary 
biotinylated rabbit anti-mouse IgG antibody (DAKO E354) (1 300) for 30 minutes at room  
temperature
2.7.2.2.5 Glutathione S-transferase a , n and %
The presence o f  GST a , |i and n  in a number o f  cell lines was investigated using rabbit GST 
a  (NOVO Lab NCL-GST alpha), GST (NOVO Lab NCL-GSTmuM 2) and GST n  (DAKO  
A 3600) antibodies The cells were incubated at room temperature for 2 hours with a 1 100 
dilution o f  the GST a  antibody, or a 1 200 dilution o f  the GST |_i antibody, or a 1 200 dilution 
o f  the GST % antibody After this incubation period, the slides were washed thoroughly with  
TBS/0 1% Tween-20 and incubated with the secondary biotinylated goat anti-rabbit antibody 
(1 500) (DAKO E 0432) for 30 mmutes at room temperature
2.7.2.2.6 Metallothionein
The presence o f  metallothionein in a number o f  cell lines was investigated usm g a 
monoclonal m ouse anti-metallothionein antibody (DAKO MTM 0639) The cells were 
mcubated at 4°C for 16 hours with a 1 20 dilution o f  the primary antibody After this 
incubation period, the slides were washed thoroughly with TBS/0 1% tween-20 and the 
secondary antibody added for 30 minutes at room temperature A  1 300 dilution o f  the 
biotinylated rabbit anti-mouse IgG antibody (DAKO E354) was used as the secondary 
antibody for the detection o f  metallothioneins
2.1.2.2.1 Integrins
The presence o f  integrins in a number o f  cell lines was investigated usm g a range o f  m ouse 
mtegrin antibodies (Serotec) The cells were mcubated at room temperature for 2 hours with a 
1 50 dilution (for mtegrin subunits a 2, a 3, a 4, a 5, a 6, Pi and p4) or 1 100 dilution (for mtegrm  
subunit oti) o f  the primary antibody After this incubation period, the slides were washed 
thoroughly with TBS/0 1% Tween-20 and incubated with the secondary biotinylated rabbit 
anti-mouse antibody (DAKO E354) (1 300) for 30 mmutes at room temperature
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2.7.2.2.8 E-cadhenn
The presence o f  E-cadhenn was detected using a m ouse monoclonal antibody to E-cadherm  
(R&D BTA 1) The cells were incubated with a 1 200 dilution o f  the primary antibody for 2 
hours at room temperature The cells were then washed thoroughly w ith TBS/0 1% Tween-20 
and incubated with the secondary biotinylated rabbit anti-mouse IgG antibody (1 300) 
(DAKO E354) for 30 minutes at room temperature
2.8 Protein analysis by Western blotting
2.8.1 Whole cell extract preparation
The cells used in the preparation o f  whole cell extracts were grown in 75cm 2 flask until 
approximately lx lO 7 cells were obtained The cells were then trypsinised and pelleted by 
centrifugation at 1000 rpm for 5 minutes The cell pellet was washed three times in PBS by 
centrifugation Once the cell pellet was obtained the procedure was carried out on ice The 
cell pellet was then either suspended in 5ml o f  lysis buffer containing PBS and IX  proteinase 
inhibitor and sonicated (Labsomc U ) until lysis occurred as determined m icroscopically or the 
cell pellet was lysed in 500 |lx1s M -PER™  mammalian protein extraction reagent (Pierce 
78501) containing IX  protemase inhibitor
2.8.2 Quantification of protein
The protein levels in the cellular extracts were determined using the B C A  protein assay 
(Pierce) The bicmchonmic acid protein assay reagent is a highly sensitive reagent for the 
spectrophotometnc determmation o f  protein concentration It is based on the reaction o f  the 
protein w ith Cu2+ m an alkaline medium containing bicmchonmic acid w hich  is a detection 
reagent for Cu2+ (Smith el a l , 1985) The BC A  protein assay working reagent was prepared 
by m ixing 50 parts o f  reagent A  (containing sodium carbonate, sodium bicarbonate, BC A  
detection reagent and sodium tartrate in 0 2N  NaOH) with one part o f  reagent B (4% copper 
sulfate solution) A  set o f  protein standards o f  known concentrations were prepared by 
diluting the B S A  standard (2mg/ml stock) 0 1ml o f  each standard or unknown protein sample 
was pipetted into a test tube and 2mls o f  the working reagent was added to each tube 0 1ml o f  
diluent was used as a blank The test tubes were then incubated at 60°C for 30 minutes and the 
absorbance o f  each sample measured at 562nm A  standard curve w as plotted o f  the known 
protem standards and the protein concentration o f  the unknown samples was determmed by 
extrapolation from the standard curve
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2.8.3 Seperation of protein by SDS-Polyacrylamide gel electrophoresis (PAGE)
Prior to Western blotting, cell proteins were separated on SDS-polyacrylamide gels (Laemmli, 
1970) 7 5% polyacrylamide gels were used in this work to separate proteins present in the 
cellular extracts The gels were prepared as shown in table 2 8 3
x  "“ï#Ôel Component 1
■*S! , , > m . , .¡Si" ,j|, V  ..**.,«11
3^ 0% AtVy 1 ami d e/B i s- 
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1 88ml
m u  ipMsfHGlr pH .6 8 (BDH 0 31ml
;;10%'iSpS < Sigm a L-4509) ,„,H 1 50jji1 50|il
ÌL>0%fÌTmmoniuiri Persulphate
‘V '  7jT '* : 
t; 0 i | |a % 4 4 3 3 ) ' -  ( ' ;
60|li1 17(0,1
^ M Ê D  (Sigm a T -8 133) 10^1 5|lx1
Table 2.8.3. Preparation o f  resolving and stacking gels for electrophoresis
The resolving gels were immediately cast into two gel cassettes which comprised o f  a glass 
plate and an aluminium plate separated by two 0 75cm 2 plastic spacers The gels were allowed 
to polymerise and then the stacking gel was carefully poured on top o f  the resolving gel 
Combs o f  suitable thickness were then inserted into the stacking gel W hen the stacking gel 
had set and the w ells had been formed, the gels were transferred to an LKB m im -gel system  
to which electrode buffer was added (1 9M glycine (Sigm a G -6761), 0 25M  Tns (Sigm a T- 
8404) and 0 1% SDS-pH 8 3) The samples to be separated were adjusted to equal protein 
concentration by the addition o f  an appropriate volum e o f  loading buffer 10|ag/10|il o f  each 
sample was loaded onto the gel The gels were run for approximately 50 minutes at a voltage  
o f  250V  and at a current o f  45m A
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2.8.4 Western blotting
W estern blotting was performed by the method o f  Towbin et a l  (1979) Follow ing SDS- 
polyacrylamide gel electrophoresis (PAGE), the gels were equilibrated for 15 minutes in IX  
transfer buffer (Sigm a T-4904) The gels were then aligned onto PVDF membrane 
(Boehnnger Mannheim 1722026) which had been equilibrated in the same transfer buffer 7-8  
sheets o f  whatman 3 mm filter paper were soaked in transfer buffer and then placed 
underneath the PVDF membrane and also on top o f  the gel The transfer o f  protein from the 
acrylamide gel to the PVDF membrane w as carried out using a Bio-Rad semi-dry blotting 
system for approximately 20 minutes at 15 volts and a maximum current o f  345 mA  
Follow ing protein transfer, the PVDF membranes were placed m blocking buffer w hich  
consisted o f  5% non-fat dried milk (Marvel skimmed milk) in TBS (20mM  Tns, 500mM  
NaCl pH 7 6) for at least 2 hours The PVDF membranes were then rinsed with TBS prior to 
the addition o f  the primary antibody at 4°C overnight The PVDF membrane was then washed 
three tim es in TBS containing 0 5% Tween-20 (Sigma P1379) The membrane was exposed  
to the secondary antibody (horse radish peroxidase (HRP)-conjugated, diluted in TBS 
containing 0 1% Tween-20) for 1 5 hours at room temperature The membrane was again 
washed three times in TBS and was developed as outlined in section 2 8 5
^Prim ary antibody*'
ip#" w
’ dilution--; ^econda^r* a n t ib ^ ^ a i^ jp tic S L  'ffe ^
$ P R 5 |( B R X ; m -
Aim? * '
4 #  - ,  t
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|f iip ii(T G S -;
m * . - V 4 > * *■* 
r z u c 2 a i)
1 80 Rabbit anti-rat 
(DAKO P0450)
1 2000
Tntegnnijpi (Qhemicon
*
1 10000 Goat anti-rabbit 
(DAKO P0448)
1 2000
Table 2.8.4 Antibodies used in Western blotting
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2.8.5 Development of Western blots
Immunoblots were developed using an Enhanced Chemilluminescence kit (Amersham, 
R PN 2109) which facilitated the detection o f  bound peroxidase-conjugated secondary 
antibody Follow ing the final wash, the PVDF membranes were subjected to ECL A  layer o f  
parafilm w as flattened over a glass plate and the PVDF membrane was placed gently on the 
plate A  volum e o f  5ml o f  a 50 50 mixture (solution A  solution B) o f  ECL regents w as used  
to cover the PVDF membrane The ECL reagent mixture was completely removed after a 
period o f  one minute and the membrane wrapped in cling film A ll excess air bubbles were 
removed The PVDF membrane was then exposed to autoradiographic film (Kodak X - 
OM ATS) for various times (from 1 to 15 minutes depending on the signal) The exposed  
antoradiographic film w as developed in developer (Kodak LX24) until the bands on the film  
were visible The film w as then washed m water for 15 seconds and transferred to a fixative  
(Kodak FX -40) for 2 minutes Finally, the film was washed with water for 5-10 minutes and 
left to dry at room temperature
2.9 Subcellular distribution of adriamycin
The subcellular localisation o f  adriamycin in a number o f  cell hnes was investigated by 
fluorescence m icroscopy The cells studied were grown on glass coverslips and then view ed  
under ultraviolet illumination (Chauffert el a l , 1984)
2.9.1 Fluorescence microscopy
M icroscope glass coverslips (Chance Propper LTD) were washed with 70% alcohol and 
flamed with a bunsen burner The sterile cover slips were placed in 35mm petn dishes 
(Greiner 627160) The cells used in the studies were grown in 25 cm2 flasks until 
approximately 80% confluent and then trypsimsed at the exponential phase o f  growth The 
cells were pelleted by centrifugation and a single cell suspension o f  1x10s cells per ml was 
prepared 1ml o f  the cell suspension was added to each o f  the petn dishes which were then 
incubated overnight at 37°C in 5% CO2 to allow attachment o f  the cells to the sterile 
coverslips The following day the medium was carefully removed from the petn dishes and 
the cells incubated with 1ml o f  medium containing 10|iM  adriamycin for 4 hours
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After this time, the drug containing medium was decanted and the cells were washed twice  
with ice-cold PBS The covershps were then inverted onto clean glass slides and the edges 
sealed with silicon grease to protect the cells against dehydration The cells were view ed for 
fluorescence under ultraviolet illumination using a N ikon microscope equipped with a 
mercury lamp The ultraviolet illumination induced an orange fluorescence at the site o f  
adnamycin accumulation and as a result the localisation o f  adriamycin within the cells could 
be studied The cells were viewed immediately after mounting since fading o f  the 
fluorescence occurred very rapidly
30(j.g/ml Verapamil (Sigm a V -4629) or 10 (rg/ml Cyclosporm A  (Sandoz) were added to 1ml 
medium (containing 10|jM  adriamycin) with which the cells were incubated to determine i f  
they were effective at altering the accumulation and/or subcellular distribution o f  adriamycm  
in various cell lines
2.10 Determination of glutathione S-transferase activity
Glutathione S-transferase activity was determined using cytosolic extracts o f  the cells The 
activity was determined spectrophotometncally and the assay was based on the conjugation o f  
glutathione to 2,4-dimtrochlorobenezene forming 2,4-dimtrophenyl-glutathione which  
absorbs light at 340 nm (Evans e t a l , 1987)
2.10.1 Cytosolic extract preparation
rj
Approximately 2x10 cells at the exponential phase o f  growth were trypsmised and pelleted  
by centrifugation The pellet was washed three times with PBS and then resuspended in 2ml 
o f  lysis buffer (lOmM KC1, 1 5mM M gCl2, 2mM  PMSF and lOmM Tns-HCl, pH 7 4 ) The 
cells were sonicated until cell lysis w as observed m icroscopically The lysed cells were 
centrifuged at 7800 rpm for 10 minutes at 4°C The supernatant was collected and centrifuged 
at 38,000 rpm for 1 hour at 4°C An aliquot o f  the supernatant was retained for protein 
determmation by the BC A  assay and the remainmg supernatant was used directly in the 
glutathione S-transferase activity assay
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2.10.2 Assay for glutathione S-transferase
A  30m M  stock o f  glutathione (Sigma G-4251), a 30mM stock o f  dinitrochlorobenezene 
(BDH  10076) in ethanol and a potassium phosphate buffer (lOOmM KH2PO4 and lOOmM 
HK2PO4) were prepared. 2 cuvettes containing 0.1m l o f  the glutathione stock, 0.1ml o f  the 
dinitrochlorobenzene stock and 2.2m l o f  potassium phosphate buffer were placed in the 
constant temperature chamber o f  a dual beam spectrophotometer (Shimadzu U V  160A). 0.6ml 
o f  the cytosolic extract was added to the sample cuvette and 0.6m l o f  water was added to the 
reference cuvette. The reaction was followed at 340nm over a time period o f  three minutes. 
The change in absorbance per minute was calculated and this was related to the protein level 
o f  each sample determined by BC A assay as outlined in section 2.8.2.
2.11 Time lapse videomicroscopy
Time-lapse videom icroscopy was carried out on a Nikon Diaphot inverted m icroscope 
(Micron optical, Bray, Ireland) equipped with phase-contrast optics, linked to a Mitsubishi 
CCD-100 colour video camera. Images were recorded in S-VHS onto a Mitsubishi H S-S5600  
video recorder with time lapse capabilities. Recording speed was set at 3.22 sec/field (480 
hour mode), which at normal playback speed resulted in an acceleration factor o f  160. The 
temperature o f  the culture vessel w as controlled by a Linkam Colo2 warm stage controller. 
This controller was adjusted to keep the culture medium inside the vessel at 37°C, as 
measured using a TB3301 probe. All time-lapse video equipment was obtained from 
laboratory instruments (Ashbourne, Ireland).
Cells were seeded at l x l 0 5cells/m l one day before the recording was started. Cell motility was 
monitored by locating the initial position o f  the cell and the final position o f  the same cell 
after certain time periods.
2.12 Extracellular matrix adherence assays
2.12.1 Reconstitution of ECM  proteins
Adhesion assay w as performed using the method o f  Torimura et al. (1999). Collagen Type IV  
(Sigm a C-5533), fibronectin (Sigma F-2006) and laminin (Sigm a L-2020) were reconstituted 
in PBS to a stock concentration o f  500|j,g/ml. Stocks were aliquoted into sterile eppendorfs. 
Fibronectin and collagen stocks were stored at -20°C while laminin stocks were stored at - 
80°C. Matrigel gel (Sigm a E1270) was aliquoted and stored at -20°C until use. Matrigel
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undergoes thermally activated polymerisation when brought to 20-40°C to form a 
reconstituted basement membrane
2.12.2 Coating of plates
Each o f  the ECM proteins, collagen, fibronectin and lamimn, was diluted to 25[ig/ml while  
M atngel w as diluted to lm g/m l with PBS 250jal aliquots were placed into w ells o f  a 24-w ell 
plate The plates were tapped gently to ensure that the base o f  each w ell was completely  
covered with solution The plates were then incubated at 4°C overnight The ECM solutions 
were then removed from the w ells and the w ells rinsed twice with sterile PBS 0 5ml o f  a 
sterile 0 1% BSA /PBS solution was dispensed into each w ell to reduce non-specific binding 
The plates were incubated at 37°C for 20 minutes and then rinsed tw ice again w ith PBS
2.12.3 Adhesion assay
Cells were set up in 75cm 2 flasks and then harvested and resuspended in serum free DM EM  
medium The cells were then plated at a concentration o f  2 5x104 cells per w ell in triplicate 
and incubated at 37°C for 60 minutes Control w ells were those which had been coated but 
contain no cells After 60 minutes, the medium was removed from the w ells and rinsed gently  
with PBS The cells were then stained with 0 5ml o f  0 25% crystal violet dye for 10 minutes 
The plates were then rinsed and allowed to dry The dye was eluted with 200 |il o f  33% glacial 
acetic acid and 100|li1 aliquots were transferred to a 96-well plate and the absorbance w as read 
on an ELISA reader at 570 and 620nm  (Tonmura et a l , 1999)
2.12.4 Adhesion blockade assay
After the coating o f  the plate as in section 2 12 2, cells were harvested and resuspended in 
serum free DM EM  medium at a concentration o f  4x104 cells per ml The cells were incubated 
with 10|ig/m l o f  a range o f  anti-mtegrin antibodies (Serotec) for 30 minutes at 4°C Control 
samples were cells incubated at 4°C without addition o f  antibody The cells were then plated 
into the w ells at a concentration o f  2x104 cells per w ell and incubated for 30 minutes at 37°C  
After 30 minutes, the medium was removed from the w ells and rinsed gently w ith PBS The 
cells were then stained as in section 2 12 3
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2.13 Invasion assay
Invasion assay was performed using the method o f  Albmi (1998) M atngel (Sigm a E-1270) 
(11 mg/ml) was diluted to 1 mg/ml in serum free DM EM  100|il o f  1 mg/ml M atngel w as  
placed into each insert (Falcon 3097) (8 0 |nm pore size, 24 w ell format) which stands on 24- 
w ell plate (Costar) The inserts and the plate were incubated overnight at 4°C The follow ing  
day, the cells were harvested and resuspended in DM EM  containing 5% FCS at a 
concentration o f  lx lO 6 cells/ml The inserts were washed with serum free DM EM, then 100|il 
o f  the suspension cells were added to each insert and 250|il o f  DM EM  contaming 5% FCS 
was added to the w ell underneath the insert Cells were incubated at 37°C for 24 hours After 
this time period, the inner side o f  the insert was wiped with a w et swab while the outer side o f  
the insert was stained with 0 25% crystal violet for 10 minutes and then rmsed and allowed to 
dry The inserts were then view ed under the microscope
2.14 Motility assay
The procedure for carrying out motility assays was identical to the procedure used for 
m vasion assay with the exception that the inserts were not coated with m atngel (section 2 13) 
(Genda e t a l ,  1999)
2.15 Zymography
Zymography was used to assess the level o f  proteolytic activity o f  different proteinases The 
choice o f  substrate incorporated into the resolving gel depends on substrate specificity to the 
species o f  enzym es detected (Johansson et a l , 1986) Gelatin is a substrate for m atrix  
metalloproteinases (MMPs), serine and cysteine proteinases However, gelatin zymography is 
not suitable for the assay o f  MMPs with weak or absent gelatinase activity This is the case o f  
the stromelysin 1 and 2 (MMP-3 and M M P-10, respectively) and m atnlysin (M M P-7) for 
which casein zymograpgy is more suitable
The gel w as prepared by incorporating gelatin within the polymerised acrylamide matrix 10% 
acrylamide gels were used The amount for one gel is given below
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Gel component ' ' Resolving gel ( 1 0 % ) ^ - ^  ^ B c b T O l  ,
,.... *•.
3 0 % ^ ,  ~ 4 Acrylamide/Bis- ’ 
aciylam ide (Sigm a A-3 574)
3 3 ml 0 5 ml
3mg/mT Gelatin (S ig m a G -
j p o )  ^  .
2 5 ml
Ultrapure water;;; a  * *
* * ‘"ilt * * ‘
1 7 ml 2ml
< 3 M g r ijH 6 1 r PH"8 8 (BDH  
.M 4Q 9 Zt)j jr  ,
m .v A . *. T '  S f*
2 5ml
P ff  6 8 (BD H 0 8ml
tOSS Ammonium Persulphate 33|ol 33 |il
■TEMED.(Sigma T-8133) , 5(0.1 5(ol
Table 2.15 Preparation o f  resolving and stacking ge for zymography
Cells were grown in petn dishes (Greiner) When the cells were 80% confluent, they were  
rinsed tw ice with sterile PBS followed by 4-hour incubation with serum-free medium The 
cells were then grown in fresh serum-free medium for another 24-72 hours After the time 
period, supernatants were collected as samples Samples were mixed 3 1 with 4 X  sample 
buffer (10% glycerol, 0 25 M  Tns-HCl, pH 6 8, 0 1% (w/v) bromophenol blue) and loaded 
onto the gel The gels were run at 30 mA per gel in running buffer (0 025M  Tns, 0 19M  
glycine, 0 1% SDS) until the dye front reached the bottom o f  the gel Follow ing  
electrophoresis, the gels were soaked in 2 5% Tnton-X-100 with gentle shaking for 30 
minutes at room temperature The gels were then rinsed in substrate buffer (50mM  Tris-HCl, 
pH8 0, 5mM CaCb) and then incubated for 24 hours in substrate buffer at 37°C The gels 
were then stained with Coom assie blue (2 5mg/ml) for 2 hours by shaking and destamed in 
destain water (50ml acetic acid, 150ml isopropanol, 300 ml distilled water) until clear bands 
were visible The gels were then scanned by scanner
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Inhibitors or enhancers o f  proteinases were added to 2 5% Triton-X-100 and substrate buffer 
to identify the different classes o f  proteinases (Table 2 15 a)
J l  Inhibitor/enhancer i: ErizVme|iilhibitcd/enhanced ^ „ .^ ^ f^ C d n een tra^ S te
(inhibitor)! %7„*
#  -$$m< r r  ‘ ” <■
MMPs 30mM
j g r  PM SF.(inhibitor)
- • "* iiSfc' ! : ''Sis' . '
Serine proteinases ImM
" '5^ 8 © y ste in e  (Enhancer) Cysteine proteinases lOmM
Table 2.15.a Inhibitors or enhancers o f  different classes o f  proteinases used in gelatm-
zymography
2.16 Reverse transcriptase - Polymerase chain reaction (RT-PCR)
2.16.1 RNA extraction
Total R N A  was isolated from all cell lines using standard method (O'Dnscoll el a l , 1993) and 
quantified spectrophotometncally at 260nm  and 280nm  (Ausubel el a l , 1991)
For all procedures using RNA, most glassware, solutions and plastics were treated with 0 1% 
diethyl pyrocarbonate (DEPC) (Sigma D -5758) before use 
R N A  was extracted from the cells as follows
Cells were harvested from the 75 cm2 flask at exponential phase The pellet was washed once 
with PBS and then lysed using 1ml TRI Reagent (Sigma T-9424) (This product, a mixture o f  
guanidine thiocyanate and phenol in a mono-phase solution, effectively dissolves D N A , R N A  
and protein in samples) The samples were allowed to stand for 5 minutes at room  
temperature to allow complete dissociation o f  nucleoprotein com plexes 0 2ml o f  chloroform  
was then added per ml o f  TRI Reagent used and the sample was shaken vigorously for 15 
seconds and allowed to stand for 15 minutes at room temperature The sample was then 
centrifuged at 13000 rpm for 15 minutes at 4°C This step separated the mixture into 3 phases, 
the R N A  was contained in the colourless upper aqueous layer This layer was then transferred 
to a new eppendorf and 0 5ml o f  isopropanol was added The sample w as mixed and allowed  
to stand at room temperature for 10 minutes before being centrifuged at 13000 rpm for 10 
minutes at 4°C The R N A formed a precipitate at the bottom o f  the tube The supernatant was 
removed and the pellet was washed with 1ml o f  75% ethanol and centrifuged at 13000 rpm 
for 5 minutes at 4°C The supernatant was removed and the pellet was briefly allowed to air- 
dry 20[il o f  DEPC water was then added to the R N A to resuspend the pellet
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The concentration o f  R N A  was calculated by determining its OD at 260nm  and 280nm  and 
using the follow ing formula
OD260nm x  Dilution factor x  40 = |0g/ml RN A  
The purity o f  the R N A extraction was calculated by determining its OD at 260nm and 280nm  
An OD260nm OD280nm ratio is indicative o f  pure RNA Only those samples with ratios 
between 1 7 and 2 1 were used
2.16.2 Reverse Transcriptase Reaction of RNA isolated from cell lines
Reverse transcriptase reactions were carried out in laminar flow  cabinets 
cD N A  w as formed using the following procedure 
1(0.1 Ohgo (dT) primers (lfig /fil) (Promega C l 101) 
l|ol total R N A  (l(og/(ol) (see 2 16 1)
3(j,l water
were mixed in a 0 5ml eppendorf (Eppendorf, 0030 121 023), heated to 70°C for 10 minnt.es 
and then chilled on ice To this, the following were added
4|ol 5X  buffer (250 m M -Tns/HCl pH 8 3, 375mM-KCl and 15mM-MgCl2) (Gibco 510-8025  
SA)
2(0,1 DTT (lOOmM) (Gibco 510-8025 SA)
l|ol RNasin (40U/(ol) (Promega N 2 5 1 1)
l \ i \  dNTPs (lOmM  each o f  dATP, dCTP, dGTP and dTTP)
6(ol water
l/ol M olony murine leukaemia virus-reverse transcriptase (M M LV-RT) (40,000U/(ol)
(Gibco, 510-8025 SA)
The solutions were mixed and the mixture was incubated at 37°C for an hour to allow the 
M M LV-RT enzyme catalyse the formation o f  cD N A  on the mRN A  template The enzyme 
was then mactivated and the R N A and cD N A  strands separated by heating to 95°C for 2 
minutes The cD N A  was used immediately m the PCR reaction or stored at -20°C  until 
required for analysis
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2.16.3 Polymerase Chain Reaction
Each PCR eppendorf tube contained the following  
24 5|li1 water
5(0,1 10X buffer (lOOmM-Tris/HCl, pH 9 0, 50mM-KCl, 1% Triton X -100) (Promega N 1862) 
3|ol 25mM-MgCl2 (Promega N 1 862)
8(0,1 dNTPs (1 25mM  each o f  dATP, dCTP, dGTP and dTTP) (Promega U 1240) 
l(xl each o f  first and second strand target primers (250ng/m l)
1 |Ltl each o f  first and second strand control primers (250ng/m l) (P-actin)
0 5(0,1 o f  5U/(ol Taq D N A  polymerase enzyme (Promega N 1862)
5 |ol cD N A
The cD N A  was amplified by PCR using the following program 
95°C for 1 5 mm (denature double-stranded D N A )
30 cycles 95°C for 1 5 mm (denature double-stranded DN A)
55°C for 1 mm (anneal primers to cDNA)
72°C for 3 min (extend)
72°C for 7 mm (extend)
The reaction tubes were stored at 4°C until analysed by gel electrophoresis
2.16.4 Electrophoresis of PCR products
2 5% agarose (Promega V 3122) gel was prepared in TBE buffer (5 4g Tris, 2 75g boric acid, 
2ml 0 5M -EDTA pH 8 0 in 500ml water) and melted in a microwave oven After allowing to 
cool, 0 003% o f  a 10mg/ml ethidium bromide (Sigma E8751) solution was added to the gel 
which was then poured into an electrophoresis apparatus (BioRad) Combs were placed in the 
gel to form w ells and the gel was allowed to set
10|ol loadmg buffer (50% glycerol, lm g/m l xylene cyanol, lm g/m l bromophenol blue, ImM  
EDTA) was added to each 50|ol PCR sample and 20|ol was run on the gel at 80-90m V for 
approximately 2 hours using TBE as running buffer The ())174 DNA/Hae III marker (Promega 
G l761) was run simultaneously as size reference W hen the dye front was seen to have 
migrated the required distance, the gel was removed from the apparatus and examined on a 
transilluminator and photographed by polaroid camera
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Primersequence *** ‘ " >*«»*$& _ < > ¡^0 5 r&t ^
^ V' v  ^ wv \ * rt * *-* " *** **
k n  i n  j v i  ^ t
^S]^}gth.’olW^p ‘t*-
'7  srbd ifc& ii m  ■ Ms aneatai^y
m drl FWD GTT CAA ACT TCT GCT CCT GA 
REV CCC ATC ATT GCA ATA GCA GG
157bp 54
m rpl FWD GTACATTAACATGATCTGGTC 
REV CGTTCATCAGCTTGATCCGAT
202bp 54
cm oat (mrp2) FWD CTGCCTCTTCAGAATCTTAG 
REV CCCAAGTTGCAGGCTGGCC
241bp 54
mrp3 FWD GATACGCTCGCCACAGTCC 
REV CAGTTGGCCGTGATGTGGCTG
262bp 62
mrp4 FWD CCA TTG AAG ATC TTC CTG G 
REV GGT GTT CAA TCT GTG TGC
239bp 42
mrp5 FWD GGA TAA CTT CTC AGT GGG 
REV GGA ATG GCA ATG CTC TAA AG
381bp 49
mmp-2 FWD TGA CAT CAA GGG CAT TTC AGG AGC 
REV GTC CGC CAA ATG AAC GGT CCT TG
180bp 54
mmp-9 FWD GGTCCCCCCACTGCTGGCCCTTCTACGGCC 
REV GTCCTCAGGGCACTGCAGGATGTCATAGGT
640bp 54
timp-1 FWD TGCACCTGTGTCCCACCCCACCCACAGACG 
REV GGCTATCTGGGACCGCAGGGACTGCCAGGT
551bp 54
a 2 integrin 
subunit
FWD TGG GGT GCA AAC AGA CAA GG 
REV GTA GGT CTG CTG GTT CAG C
541bp 54
Pi integrin  
subunit
FWD GCG AAG GCA TCC CTG AAA GT 
REV GGA CAC AGG ATC AGG TTG GA
663bp 54
c-Ha-ras 129bp 60
c-myc
fj-actm  (large) 
/3-actin (small)
FWD GAAATCGTGCGTGACATTAAGGAGAAGCT 
REV TCA GGA GGA GCA ATG ATC TTG A 
FWD TGG ACA TCC GCA AAG ACC TGT AC 
REV TCA GGA GGA GCA ATG ATC TTG A
336bp
383bp
142bp
60
Table 2.16 Sequence o f  primers used for RT-PCR
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3. Results
3.1 Toxicity assays of chemotherapeutic drugs in the SKLU-1, BT-20, 
RPMI-2650, MX-1 and A-549 cell lines
3.1.1 General toxicity assays
In order to determine if certain types o f carcinomas (/ e lung or breast) display similar 
sensitivity to a range of chemotherapeutic drugs, toxicity assays were carried out m a number 
o f cell lines using various chemotherapeutic drugs The cell lines used were the lung cell 
lines SKLU-1 (squamous epithelial cell line) and A-549 (adenocarcinoma cell line), the 
breast cell lines BT-20 and MX-1 and the nasal epithelial carcinoma cell line, RPMI-2650 
The chemotherapeutic drugs used were adnamycm, vincristine, vinblastine, VP-16, taxol, 
melphalan, cisplatin and 5-FU
Table 3 1 1 represents the IC50 values obtained for each chemotherapeutic agent tested The 
cell lines showed significantly different resistance profiles for these drugs RPMI-2650 is the 
most sensitive cell line to most o f the agents It was hundreds or even in some cases 
thousands of times more sensitive than the A-549 or MX-1 cells The SKLU-1 and BT-20 
cells generally showed similar drug resistance profiles Although the SKLU-1 and BT-20 
cells displayed some resistance to most o f the agents tested, both cell lines are more sensitive 
than the A-549 and MX-1 cells In contrast, A-549 and MX-1 showed very high IC50 values 
Both cell lines are more resistant to the group of drugs tested In conclusion, lung cancer and 
breast cancer cell lines do not display similar sensitivities to the range of chemotherapeutic 
drugs tested The resistance profile appears to be dependent on the particular cell line studied 
rather than on the site o f origin o f the tumour
r
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ICso (nM) SKLU-1 BT-20 RPMI-2650 A-549 MX-1
Adriamycm 38 ± 1 35 ± 5 18 5 ± 3 5 991 ±23 5117 ± 2130
Vincristine 2 8 ± 0 2 2 ± 0 1 2 4 ± 0 4 145 ± 42 1071 ±353
Vinblastine 1 4 ± 0  1 1 ± 0 2 1 78 ± 0  12 94 ±11 3323 ± 932
VP-16 63 ±10 64 ±13 23 ± 3 1706 ± 347 166 ± 60
Taxol 14 ±1 6 ± 1 2 3 ± 0 9 15 ± 0 8 336 ±110
Melphalan 6085 ± 2522 11468±1158 582 ± 10 48952±9221 6129 ±2209
5-FU 9071± 1305 4295 ±313 1624 ± 164 5612 ±109 4728 ± 163
Cisplatin 1924± 12 542 ±150 1494 ± 39 10887±1777 942 ± 12
Table 3.1.1 IC50 values o f a group o f chemotherapeutic drugs for SKLU-1, BT-20, RPMI- 
2650, A-549 and BT-20 cell lines
3.1.2 Heavy metal drug toxicity studies in A-549, SKLU-1 and MX-1
3.1.2.1 Toxicity assays with cisplatin and cadmium chloride
It was noted from the results shown in section 3 1 that the cell lines A-549 and SKLU-1 were 
resistant to cisplatin, with A-549 exhibiting the higher level o f resistance to this drug These 
results also illustrated that the human breast cell line MX-1 was very sensitive to cisplatin 
Since cisplatin is a heavy metal drug, sensitivities to another heavy metal drug, cadmium 
chloride, were studied in these three cell lines The results indicated that the trends o f 
sensitivities to cadmium chloride were consistent with those to cisplatin
IC50 (nM) A-549 SKLU-1 MX-1
Cisplatm 10887± 1777 1924 ± 12 942 ± 12
Cadmium chlonde 36957 2820 655
Table 3.1.2 ICso of cisplatin and cadmium chloride in the A-549, SKLU-1 and MX-1 cell 
lines
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3.1.2.2 Immunocytochemical detection of metallothionein
Metallothioneins are a family o f the proteins which are related to heavy metal drug resistance 
m cells Immunocytochemical detection o f metallothionein was earned out in the A-549, 
SKLU-1 and M X-1 cell lines No difference o f the expresssion o f metallothionein was 
observed between A-549, SKLU-1 and MX-1 This suggests that some other factor might be 
involved m the different resistance levels to the cadmiun chlonde and cisplatm in these three 
cell lines
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(a)
(b)
(c)
Fig. 3.1.2 Im m unocytochem ical staining for m etallothionein (40 x ) in the (a) A -5 4 9  ce ll line  
(b) SK LU -1 ce ll line (c) M X -1 cell line
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3.2 Establishment of novel MDR variants of RPMI-2650 and DLKP cell 
lines
The RPMI-2650 cell line was established in 1962 by G E Moore and A A Sandberg from 
the pleural effusion of a patient with an extensive malignant tumour o f the nasal septum The 
tumour was diagnosed as an anaplastic squamous cell carcinoma
As described in section 3 1, RPMI-2650 is very sensitive to a number o f chemotherapeutic 
drugs Consequently, attempts were made to produce multidrug resistant variants o f this cell 
line The cells were cultured in increasing concentrations o f drug until MDR variants were 
established Toxicity assays were conducted in order to determine the level of resistance of 
the MDR variant relative to the parental cells
A poorly differentiated squamous lung cancer cell line, DLKP, was established from a lymph 
node metastasis biopsy by bronchoscopy m this centre (Law et a l , 1992) Toxicity assays 
indicated that DLKP was very sensitive to adnamycin, vincristine, VP-16 and cisplatm 
(Clynes et a l , 1992) Melphalan-resistant variants o f the DLKP cell line were established by 
both continuous exposure and pulse selection methods
3.2.1 Establishment of the RPMI-2650 MDR variants
3.2.1.1 Establishment of the RPMI-2650 taxol-resistant variant
The RPMI-2650 cells were initially exposed to 4ng/ml taxol However, after a few days, the 
cells appeared to have stopped proliferation and after approximately one week, very few 
viable cells were visible The cells were then cultured m drug free medium until the cells 
were approximately 60% confluent After this time the cells were again exposed to 4ng/ml of 
the drug After approximately 1 month, the concentration o f drug was increased to 20ng/ml 
Cells were adjusted to growth in 80ng/ml after a further month and a final concentration of 
200ng/ml was achieved within another one and a half months Cells were frozen and stored at 
the stages when they were adjusted to growth m 80ng/ml and 160 ng/ml taxol
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3.2.1.2 Establishment of the RPMI-2650 melphalan-resistant variant
The RPMI-2650 cells were initially exposed to 1 25jug/ml melphalan and adjusted to growth 
in 1 7|utg/ml after approximately 2 months, to 5 jog/ml after another two months and to a final 
concentration of 6 5|ag/ml after a further 4 months exposure During the selection period, the 
cytoplasm was elongated like the axon o f the nerve cell Cells became spindle-shaped after 
the selection was finished
3.2.1.3 Establishment of the RPMI-2650 taxol and melphalan co-selection variant
The cells were initially exposed to lOng/ml taxol and ljxg/ml melphalan It was observed that 
this concentration was very toxic to the cells The selection procedure was initiated on 2 
further occasions at lower drug concentrations (6ng/ml taxol and 1 jog/ml melphalan, 4ng/ml 
taxol and 1 jiig/ml melphalan), however, these combinations also proved to be extremely toxic 
to the RPMI-2650 cells These observations indicate that the combination o f taxol and 
melphalan was lethal to the RPMI-2650 cells It is possible that the cells could not find an 
alternative way to survive the combination of toxicity effects o f taxol and melphalan This 
suggests the usefulness o f co-admimstration o f taxol and melphalan in cancer treatment
3.2.2 Establishment of the novel MDR variants of the DLKP cell line
3.2.2.1 Establishment of the DLKP melphalan-resistant variant by long term selection
The DLKP cells were initially exposed to 2jog/ml melphalan and adjusted to growth in 
4fxg/ml after approximately 2 months Due to the poor proliferation, the cells were then 
grown in drug-free medium for a month After this time, the cells were exposed to 5fig/ml 
melphalan for a month and to a final concentration of 6 5|og/ml within a further 2 months 
During the selection procedure, the cells seemed to become larger and slightly more 
elongated than the parental cells (see section 3 2 3 2)
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3.2.2.2 Establishment of the DLKP melphalan-resistant variant by pulse selection
The DLKP cells were exposed to 6]ug/ml melphalan for four hours per week for 1 week The 
selection for the following week was suspended due to the poor growth of the cells The 
selection process was resumed as soon as the cells began to proliferate After ten pulses, the 
melphalan-resistant variant was established by checking the melphalan resistance fold by 
toxicity assay During the selection procedure, the cells seemed to be slightly more elongated 
than the parental cells (see section 3 2 3 2)
3.2.3 Morphology of the RPMI-2650, DLKP and their MDR variants
3.2.3.1 Morphology of the RPMI-2650 and its MDR variants
During the selection procedure with taxol or melphalan, the morphology o f the RPMI-2650 
cells changed dramatically Figure 3 2 3 1 illustrates the morphology o f the parental RPMI- 
2650 cells and the two resistant variants The RPMI-2650 cells are very small and grow in 
dense clusters which fuse to form a thick layer of cells The RPMI-2650 taxol-resistant cells 
are larger and rounder than their parental cells, but they still grow m dense clusters The 
RPMI-2650 melphalan-resistant cells are spindle-shaped, more elongated than their parental 
cells and do not grow in clusters
3.2.3.2 Morphology of the DLKP and its MDR variants
During the selection procedure with melphalan, both the DLKP long term melphlan-selection 
variant and the DLKP melphalan-pulse selection variant became slightly more elongated than 
the parental cell line, especially the long term selection line (Figure 3 2 3 2)
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(a)
Fig. 3.2.3.1 The morphology o f the RPMI-2650 and its MDR variants (lOx)
(a) RPMI-2650 parental cell line (b) RPMI-2650 taxol-resistant variant (c) RPMI-2650 
melphalan-resistant variant
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(a)
Fig. 3.2.3.2 Morphology o f the DLKP cell line and its MDR variants (20x) (a) DLKP (b) 
DLKP long term melphalan-selected variant (c) DLKP melphalan-pulse selected variant
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3.2.4 Cross resistance profiles of the MDR variants of RPMI-2650 and DLKP cell lines
When cells are repeatedly treated with a chemotherapeutic drug, the drug resistant variant 
which is eventually produced usually not only displays resistance to this selective drug, but 
also to different groups o f drugs
To investigate the resistance profiles o f the MDR variants o f RPMI-2650 and DLKP cell 
lines, toxicity assays were conducted as described in section 2 6 2 The chemotherapeutic 
agents included the selective drug, taxol or melphalan, adnamycm, vincristine, vinblastine, 
VP-16, cisplatm, cadmium chloride and 5-FU
3.2.4.1 Cross resistance profile of the RPMI-2650 taxol-resistant variant
Table 3 2 4 1 a represents the IC50 values o f each o f the chemotherapeutic agents for the 
parental RPMI-2650 cell line and the taxol-selected variant The results demonstrate that the 
taxol-resistant variant exhibited cross resistance to all the chemotherapeutic drugs tested with 
the exception o f the alkylating agent cisplatm In particular, the taxol-resistant cells appeared 
to be highly resistant to the classical MDR drugs such as adraimycin, vincristine, vinblastine 
and VP-16, all o f which are substrates o f P-glycoprotein
ICso (nM) RPMI-2650 parental cells RPMI-2650 taxol sele Cells
Adnamycm 18 5 ± 3 5 4030 ± 350
Vincristine 2 4 ± 0 4 1427 ± 377
Vinblastine 1 78 ± 0  12 168 ± 18
VP-16 23 ± 3 464 ± 53
Taxol 2 3  + 0 9 519 ± 18
Melphalan 582 ± 10 2621± 164
5-FU 1624 ± 164 5898 ± 98
Cisplatm 1494 ± 39 1600 ± 267
Cadmium Chlonde 709 ± 68 5891 ±465
Table 3.2.4.1.a IC50 values for RPMI-2650 and the RPMI-2650 taxol-resistant variant 
(Toxicity assays were repeated at least three tunes for each drug m each cell line )
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Drug Fold resistance
Adnamycin 218
Vincristine 595
Vinblastine 94
VP-16 20
Taxol 226
Melphalan 4 5
5-FU 3 6
Cisplatin 1 1
Cadmium Chloride 83
Table 3.2.4.1.b Fold resistance o f the RPMI-2650 taxol-resistant variant relative to the 
parental RPMI-2650 cell line
3.2.4.2 Cross resistance profile of the RPMI-2650 melphalan-resistant variant
The sensitivity o f the RPMI-2650 melphalan-resistant variant to the same range of 
chemotherapeutic agents was also determined Table 3 2 4 2 a represents the IC50 values of 
each of the agents for the parental RPMI-2650 cell line and the RPMI-2650 melphalan- 
resistant variant The results showed that the RPMI-2650 melphalan-resistant variant was 11 
times more resistant to melphalan than the parental cells This variant showed highest cross 
resistance to cadmium chloride The variant also exhibited cross-resistance to adnamycin, 
vinblastine, VP-16 and to a lesser extent to vincristine and cisplatin compared to its parental 
cell line No significant cross resistance was observed with taxol and 5-FU
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ICso (nM) RPMI-2650 parental cells RPMI-2650 mel sele cells
Adnamycin 18 5 ± 3 5 425 ± 70
Vincnstme 2 4 ± 0 4 15 ± 2 4
Vinblastine 1 78 + 0 12 42 ± 3 4
VP-16 23 ± 3 587 ± 60
Taxol 2 3 ± 0 9 3 85 ± 1 05
Melphalan 582 ± 10 6135 ±172
5-FU 1624 ± 164 1784± 16
Cisplatm 1494 ± 39 3874 ±125
Cadmium Chloride 405 ± 102 22038 ±218
Table 3.2.4.2.a IC50 values for RPMI-2650 and RPMI-2650 melphalan-resistant vanant 
(Toxicity assays were repeated at least three times for each drug m each cell lm e)
Drug Fold resistance
Adnamycin 23
Vincnstme 6
Vinblastine 24
VP-16 26
Taxol 17
Melphalan 11
5-FU 1 1
Cisplatm 2 6
Cadmium Chlonde 54
Table 3.2.4.2.b Fold resistance of the RPMI-2650 melphalan-resistant vanant relative to the 
parental RPMI-2650 cell lme
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3.2.4.3 Cross resistance profile of the DLKP long term melphalan-selected variant
Table 3 2 4 3 a  represents the IC50 values o f adnamycin, vinblastine, taxol, melphalan, 
cisplatin and cadmium chloride for the DLKP cell line and its long term melphalan-selected 
variant The results showed that the DLKP long term-selected variant was 3 3 times more 
resistant to melphalan than the DLKP cells This variant exhibited high cross-resistance to 
cadmium chloride and cisplatin, and to a much lesser extent to adnamycin and vinblastine 
No significant cross resistance was observed with taxol
3.2.4.4 Cross resistance profile of the DLKP melphalan-pulse selected variant
Table 3 2 4 4 a  represents the IC50 values o f the same range o f drugs for the DLKP 
melphalan-pulse selected vanant The results showed that the variant was 2 1 times more 
resistant to melphalan than the parental cells The vanant also exhibited cross resistance to 
adnamycin and cisplatin, and to a greater extent to cadmium chloride No significant cross 
resistance was observed with taxol or vinblastine
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IC50 (nM) DLKP parental cells DLKP long term melphalan- 
selected cells
Adnamycm 44 8 ± 6 8 82 8 ± 7 7
Vinblastine 1 ± 0 14 1 9 ± 0  16
Taxol 0 84 ± 0 23 1 1 ± 0  14
Melphalan 2834 ± 69 5 9220 ± 400
Cisplatm 940 ± 36 7 7615 ±307
Cadmium Chlonde 1800 ± 25  6 17592± 1735
Table 3.2.4.3.a IC50 values for the DLKP and DLKP long term melphalan-selected cells 
(Toxicity assays were repeated twice for each drug m each cell line )
Drug Fold resistance
Adnamycm 1 8
Vmblastme 1 9
Taxol 1 3
Melphalan 33
Cisplatm 8 1
Cadmium chlonde 9 8
Table 3.2.4.3.b Fold resistance o f the DLKP long term melphalan-selected variant relative 
to the DLKP parental cell line
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IC50 (nM ) DLK P parental cells D LK P m elphalan-pulse  
selected  ce lls
A d n am ycm 44  8 ±  6 8 67  2 ±  8 6
V inblastine 1 ±  0 14 1 2 ± 0  19
T axol 0 84 ±  0 23 1 ± 0 2 1
M elphalan 2834  ±  69 5 5951 ± 8 7
C isplatm 940 ±  36 7 2933 ±  25
Cadm ium  C hloride 1800 ±  25 6 13092 ±  1472
Table 3.2.4.4.a IC50 values for the DLK P and DLK P m elphalan-pulse selected  variant 
(T oxicity  assays w ere repeated tw ice for each drug in each  cell line )
Drug F old  resistance
A dnam ycm 1 5
V inblastine 1 2
Taxol 1 2
M elphalan 2 1
C isplatm 3 1
Cadm ium  C hloride 7 3
Table 3.2.4.4.b Fold resistance o f  the DLKP m elphalan-pulse selected  variant relative to the 
DLK P parental cell line
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3.2.5 Doubling time of the RPMI-2650 cell line and its MDR variants
The rate o f cell growth was determined in the RPMI-2650 parental cells and the RPMI-2650 
MDR variants over a time period o f 7 days as described m section 2 2 3 The results obtained 
are presented m table 3 2 4 No significant difference in doubling time between the parental 
and resistant cells was observed
Cell lme Doubling time (hours)
RPMI-2650 parental cell line 30
RPMI-2650 taxol resistant variant 34 3
RPMI-2650 melphalan resistant variant 31 6
Table 3.2.5 Doubling time o f the RPMI-2650 cell line and its MDR variants
3.3 Protein analysis of MDR markers in the RPMI-2650 and DLKP MDR 
variants
P-glycoprotein and MRP are very important MDR markers Both o f these markers are 
glycoproteins mamly located at the cell membrane Protein analysis o f these two markers by 
Western blotting was carried out in the RPMI-2650 and DLKP parental cell lines and their 
MDR variants as described m section 2 8
3.3.1 Western blotting of P-glycoprotein
3.3.1.1 In the RPMI-2650 cell line and its MDR variants
DLKP-A, an adriamycm-selected variant o f a human lung epithelial carcinoma cell line, 
DLKP (Law et a l , 1992), was used in these studies as a positive control This cell line, 
DLKP-A, has previously been shown to overexpress P-glycoprotein (Clynes et a l , 1992) 
The anti-P-glycoprotein monoclonal antibody, BRIM AB MDR-1 (clone 6/lc) (BR-002) was 
used to detect P-glycoprotem
Figure 3 3 1 illustrates the results obtained for each of the cell lines A P-glycoprotem band at 
a molecular weight o f approximately 170kD is visible in all cell line with the DLKP-A 
showing the strongest immunoreactivity indicating high Pgp expression The RPMI-2650 
taxol-resistant variant also shows strong immunoreactivity while weaker bands can be seen 
with the parental line and the melphalan-resistant variant
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3.3.1.2 In the DLKP cell line and its MDR variants
N o bands at a molecular weight o f  approximately 170kD are visible in the DLKP cell line 
and its M DR variants.
Fig. 3.3.1 Western blot o f  P-glycoprotein in the RPM I-2650 and DLKP cell lines and their 
M DR variants. DLKP-A served as positive control.
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3.3.2 Western blotting of MRP1
3.3.2.1 In the RPMI-2650 cell line and its MDR variants
The human lung adenocarcinoma cell line, A-549, was used as a positive control to analyse 
the expression o f MRP 1 m the RPMI-2650 and its MDR variants An anti-MRP monoclonal 
antibody was used to detect MRP1 as described in section 2 8 Figure 3 3 2 illustrates a band 
in the RPMI-2650 parental cell line and its melphalan-resistant variant at a molecular weight 
o f approximately 190kD corresponding to MRP1 Stronger immunoreactivity is observed in 
the RPMI-2650 melphalan-resistant variant than in the parental cell line, indicating that 
MRP1 is overexpressed in this cell line A very weak band was visible in the taxol-resistant 
variant
3.3.2.2 In the DLKP cell line and its MDR variants
Figure 3 3 2 illustrates a band in the DLKP parental cell line and its melphalan-resistant 
variants at a molecular weight o f approximately 190kD corresponding to MRP1 Stronger 
immunoreactivity was observed in the DLKP long term and pulse selection variants than in 
the parental cell line, indicating that MRP1 was overexpressed m these variants
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Fig. 3.3.2 Western blot o f  MRP1 in the RPM I-2650 and DLKP cell lines and their M DR  
variants. A -549 served as positive control.
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3.3.3 Western blotting o f cMOAT (MRP2)
A-549 was used again as positive control to analyse the expression o f cMOAT (MRP2) in the 
RPMI-2650 and its resistant variants Figure 3 3 3 illustrates a strong band in the RPMI-2650 
melphalan-resistant variant at a molecular weight o f approximately 190kD corresponding to 
cMOAT No band was observed in the DLKP and RPMI-2650 parental lines and the RPMI- 
2650 taxol-resistant variant (figure 3 3 3) This work was carried out by Lisa Connolly
Fig. 3.3.3 Western blot o f cMOAT (MRP2) m the RPMI-2650 cell lme and its MDR 
variants (carried out by Lisa Connolly) A-549 served as positive control
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3.4 Immunological studies in the RPMI-2650 MDR variants
3.4.1 Immunocytochemical detection of MDR markers
Immunocytochemistry, as described in section 2 7 2, was carried out to detect the presence of 
a range o f MDR markers in the RPMI-2650 parental cell line and its MDR variants
3.4.1.1 P-glycoprotein
The presence o f P-glycoprotein was investigated m  the parental RPMI-2650 cell line and its 
MDR variants, using the BRI MDR-1 (Clone 6/1C) monoclonal antibody as described in 
section 2 7 2 2 1 Figure 3 4 11 illustrates that the RPMI-2650 cell line and its MDR variants 
were all stained with P-glycoprotein antibody around the cell membrane However, more 
intense staining is noted in the RPMI-2650 taxol-resistant variant
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(a)
(c)
Fig. 3.4.1.1 Immunocytochemical staining o f Pgp (40x) in the (a) RPMI-2650 parental cell
line (b) RPMI-2650 taxol-resistant variant (c) RPMI-2650 melphalan-resistant variant
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3.4.1.2 cMOAT
The presence o f cMOAT, also called MRP2, was investigated m the RPMI-2650 cell line and 
the RPMI-2650 melphalan-resistant variant using cMOAT 2III-6 antibody as described in 
section 2 7 2 2 2 DLKPC which is the cisplatin-selected variant o f DLKP was used as the 
positive control Faint staining was observed in the RPMI-2650 cell line while strong staining 
was observed in the RPMI-2650 melphalan-resistant variant (figure 3 4 12)
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(b)
(c)
Fig. 3.4.1.2 Immunocytochemical staining o f cMOAT (40x) in the (a) DLKP-C (b) RPMI-
2650 (c) RPMI-2650 melphalan-resistant variant
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3.4.1.3 LRP
LRP was found to be involved m the mechanism of MDR in 1996 and later was identified as 
the major protein o f vault LRP has been shown to be localised predominantly m the 
cytoplasmic regions of the cells The presence o f LRP was investigated using the mouse 
monoclonal antibody LRP-56 as described in section 2 7 2 2 3 LRP expression was not 
observed in the RPMI-2650 parental cell lme and its taxol-resistant and melphalan-resistant 
variants as shown in figure 3 4 13
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(a)
Fig. 3.4.1.3 Immunocytochemical staining o f  LRP in the RPM I-2650 and its M DR variants 
(a) RPM I-2650 (40x) (b) RPM I-2650 taxol-resistant variant (40x) (c) RPM I-2650 melphalan- 
resistant variant (lOx)
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3.4.1.4 GST a , p, it
Since alteration in the level o f GST has been shown to be associated with resistance, the 
expression o f the three main classes o f GST, a , |i, it was investigated in the RPMI-2650 
parental and resistant cells Rabbit polyclonal anti-GST a , ja and it antibodies were used to 
detect the presence o f the GSTs in these cell lines as described in section 2 7 2 2 5 No 
staimng for GST a  and GST ¡a was noted in the RPMI-2650 parental cell line and its MDR 
variants as shown in figure 3 4 14  (pictures were not shown for GST fj. since they were 
similar to those o f GST a ) Expression o f GST it was observed in the cytoplasm o f all the 
cell lines as shown in figure 3 4 1 4 a  However, no significant difference in the level of 
staining was noted between these cell lines
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(a)
Fig. 3.4.1.4 Immunocytochemical staining o f  GST a  in the RPMI-2650 cell line and its
MDR variants (40x) (a) RPMI-2650 (b) RPMI-2650 taxol-resistant variant (c) RPMI-2650
melphalan-resistant variant
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(a)
Fig. 3.4.1.4.a Immunocytochemical staining for GST n in the RPMI-2650 cell line and its
MDR variants (40x) (a) RPMI-2650 (b) RPMI-2650 taxol-resistant variant (c) RPMI-2650
melphalan-resistant variant
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3.4.1.5 Topoisomerase II a
T h e  exp ress io n  o f  the  enzym e, to po isom erase  I I  a ,  w as a lso  s tu d ie d  m  th e  R P M I-2 6 5 0  
p a ren ta l and  res is ta n t c e lls  u s in g  a m ouse  to po isom erase  I I  a  m o n o c lo n a l a n tib o d y  as 
de sc rib e d  m  se c tion  2 7  2 2  4  T h e  resu lts  o b ta in e d  dem ons tra ted  th e  presence o f  
to po isom erase  I I  a m  the  n u c le i o f  each o f  the  c e ll lin e s  ( f ig u re  3 4 1 5 )  H o w e v e r, no  
s ig n if ic a n t d iffe re n c e  in  the  le v e l o f  topo isom erase  exp ress io n  b e tw e en  the  c e ll lin e s  w as 
observed
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Fig. 3.4.1.5.a Im m u n o c y to c h e m ic a l s ta in in g  o f  T o p o  I I  a  in  the  R P M I-2 6 5 0  c e ll l in e  and its  
M D R  v a ria n ts  (4 0 x )  (a ) R P M I-2 6 5 0  (b )  R P M I-2 6 5 0  ta x o l-re s is ta n t v a r ia n t (c ) R P M I-2 6 5 0  
m e lp h a la n -re s is ta n t v a r ia n t
(a)
(b)
(c)
Fig. 3.4.1.5.b Immunocytochemical staining o f  Topo II a  in the RPMI-2650 cell line and its
MDR variants (lOOx) (a) RPMI-2650 (b) RPMI-2650 taxol-resistant variant (c) RPMI-2650
melphalan-resistant variant
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3.4.1.6 Metallothionein
M e ta llo th io n e m  is  re la te d  to  res is tance  to  h ea vy  m e ta l d ru g  and  a lk y la t in g  agents T h e  
presence o f  m e ta llo th io n e m  w as in ve s tig a te d  u s in g  th e  m ouse  m o n o c lo n a l m e ta llo th io n e m  
a n tib o d y  as d escrib e d  in  sec tion  2  7  2  2  6 E x p re s s io n  o f  m e ta llo th io n e m  w as obse rved  in  the  
c y to p la s m  o f  the  R P M I-2 6 5 0  p a ren ta l c e ll l in e , its  ta x o l-  and m e lp h a la n -re s is ta n t va rian ts  
H o w e v e r, no  s ig n if ic a n t d iffe re n c e  in  the  le v e l o f  m e ta llo th io n e m  e xp ress io n  b e tw e en  the  c e ll 
lin e s  w as obse rved  ( f ig u re  3 4 1 6 )
133
(a)
Fig. 3.4.1.6 Immunocytochemical staining for metallothionein in the RPMI-2650 cell line
and its MDR variants (40x) (a) RPMI-2650 (b) RPMI-2650 taxol-resistant variant (c) RPMI-
2650 melphalan-resistant variant
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3.4.2 Indirect immunofluorescence studies in the RPMI-2650 MDR variants
R esis tance  to  ta x o l has been a ttr ib u te d  to  a lte red  a  o r  p  tu b u lin  su bu n its  in  som e ta x o l-  
re s is ta n t c e ll lin e s  In te rm e d ia te  fila m e n ts  such as c y to k e ra t in  and  v im e n tm  have a lso  been 
fo u n d  to  c o n tr ib u te  to  the  resis tance phe no typ e  o f  e p ith e lia l ce lls  T hu s , im m u n o flu o re sce n ce  
stud ies  o n  tu b u lm , c y to k e ra t in  and  v im e n tm  w ere  ca rr ie d  o u t in  the  R P M I-2 6 5 0  c e ll l in e  and  
its  M D R  v a ria n ts  as d esc rib e d  in  se c tion  2 7 1
3.4.2.1 a-tubulin
A n  a n t i- a - tu b u lin  m o n o c lo n a l a n tib o d y  w as used as the  p r im a ry  a n tib o d y  to  d e te c t the  
presence o f  a - tu b u l in  R P M I-2 6 5 0  p a ren ta l c e ll l in e , its  ta x o l-  and  m e lp h a la n -re s is ta n t 
va ria n ts  a ll  show ed  c y to p la s m ic  flu o resce nce  as s h o w n  in  f ig u re  3 4  2 1 H o w e v e r, m o re  
in tense  flu o resce nce  w as n o te d  in  th e  R P M I-2 6 5 0  c e ll l in e
3.4.2.2 (3-tubulin
A n  a n ti-P - tu b u lm  m o n o c lo n a l a n tib o d y  w as used as the  p r im a iy  a n tib o d y  to  d e te c t the 
presence o f  p - tu b u lm  T h e  le v e l o f  flu o resce nce  in  th e  R P M I-2 6 5 0  p a re n ta l c e ll l in e  and  its  
ta x o l-  and  m e lp h a la n -re s is ta n t v a ria n ts  is s im ila r  as sh ow n  in  f ig u re  3 4  2 2
3.4.2.3 Cytokeratin 18
A  c y to k e ra t in  18 m o n o c lo n a l a n tib o d y  w as used as th e  p r im a ry  a n tib o d y  to  d e tec t the  
presence o f  c y to k e ra t in  18 F ig u re  3 4 2 3 illu s tra te s  th a t th e  R P M I-2 6 5 0  p a re n ta l c e ll l in e  
and  th e  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t sh o w  v e ry  fa in t  c y to p la s m ic  flu o resce nce  fo r  
c y to k e ra t in  18 w h ile  l i t t le  o r  no  im m u n o flu o re s c e n t s ta in in g  fo r  c y to k e ra t in  18 w as obse rved  
m  th e  ta x o l-re s is ta n t v a r ia n t
3.4.2.4 Vimentm
A  m ouse  m o n o c lo n a l a n ti-v im e n tm  a n tib o d y  w as used as th e  p r im a ry  a n tib o d y  to  d e te c t the  
presence o f  v im e n tm  T he  R P M I-2 6 5 0  p a re n ta l c e ll l in e  and  its  M D R  va ria n ts  show ed  s im ila r  
flu o resce nce  le v e l o f  v im e n tm  as s h o w n  m  f ig u re  3 4 2 4
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(a)
Fig. 3.4.2.1 Immunofluorescence o f  a-tubulin in the RPMI-2650 cell line and its MDR
variants (40x) (a) RPMI-2650 (b) RPMI-2650 taxol-resistant variant (b) RPMI-2650
melphalan-resistant variant
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(a)
(b)
Fig. 3.4.2.1.a Im m u n o flu o re s c e n c e  o f  a - tu b u lin  ( lO O x) in  the  (a ) R P M I-2 6 5 0  ta x o l-re s is ta n t 
v a r ia n t (b )  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t
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(a)
Fig. 3.4.2.2. Immunofluorescence o f  [3-tubulin in the RPMI-2650 and its MDR variants (40x)
(a) RPMI-2650 (b) RPMI-2650 taxol-resistant variant (c) RPMI-2650 melphalan-resistant
variant
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(b)
Fig. 3.4.2.2.a Im m u n o flu o re s c e n c e  o f  P - tu b u lin  ( lO O x) in  the  (a ) R P M I-2 6 5 0  ta x o l-re s is ta n t 
v a r ia n t (b )  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t
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(a)
Fig. 3.4.2.3 Immunofluorescence o f  cytokeratin 18 in the RPMI-2650 and its MDR variants
(40x) (a) RPMI-2650 (b) RPMI-2650 taxol-resistant variant (c) RPMI-2650 melphalan-
resistant variant
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(a)
(b)
(c)
Fig. 3.4.2.4 Immunofluorescence o f  vimentin in the RPMI-2650 and its MDR variants (40x)
(a) RPMI-2650 (b) RPMI-2650 taxol-resistant variant (c) RPMI-2650 melphalan-resistant
variant
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3.5 RT-PCR of MDR markers in the RPMI-2650, DLKP cell lines and their 
MDR variants
T o  d e tec t the  e xp ress io n  o f  M D R  m arke rs  a t th e  R N A  le v e l, R T -P C R  w as ca rr ie d  o u t as 
describ e d  in  se c tion  2 16 S ince  M R P 3 , M R P 4  and M R P 5  are v e ry  n e w  m em bers  o f  the  M R P  
fa m ily  and  there  are n o  c o m m e rc ia lly  a v a ila b le  a n tib o d ie s  fo r  th e m , R T -P C R  can serve as a 
g u ide  to  the  exp ress ion  o f  m rp 3 , m rp 4  and  m rp 5
3.5.1 mdr-1
3.5.1.1 mdr-1 expression in,the RPM I-2650 cell line and its M DR variants
R T -P C R  a na lys is  show ed  th a t m d r-1  exp ress ion  w as  und e te c ta b le  m  th e  R P M I-2 6 5 0  p a ren ta l 
c e ll l in e  w h ile  the  s trongest band  w as  obse rved  in  th e  ta x o l-re s is ta n t v a r ia n t T he  m dr-1  w as 
s l ig h t ly  ove rexp ressed  m  the  m e lp h a la n -re s is ta n t v a r ia n t co m p a red  to  its  p a re n ta l c e ll lin e
Fig. 3.5.1.1 R T -P C R  a na lys is  o f  m d r-1  e xp ress io n  m  th e  R P M I-2 6 5 0  c e ll lm e , the  R P M I-  
2 65 0  ta x o l-re s is ta n t v a r ia n t and  m e lp h a la n -re s is ta n t v a r ia n t D L K P - A  served  as the  p o s it iv e  
c o n tro l (T h e  R T -P C R  ana lys is  w as  repeated  th re e  tim e s  R N A  e x tra c tio n  w as  p e rfo rm e d  
o n c e )
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3.5.1.2 mdr-1 expression in the DLKP and DLKP long term melphalan-selection variant
R T -P C R  a na lys is  show ed  th a t m d r-1  e xp ress io n  w as und e te c ta b le  m  the  D L K P  c e ll l in e  and 
its  lo n g  te rm  m e lp h a la n -s e le c tio n  v a r ia n t ( f ig u re  3 5 1 2 )
fi-actin
mdr-1
Fig. 3.5.1.2 R T -P C R  ana lys is  o f  m d r-1  e xp ress io n  m  D L K P  and the  D L K P  lo n g  te rm  
m e lp h a la n -se le c tio n  v a r ia n t, D L K P - A  served as p o s it iv e  c o n tro l (R T -P C R  a na lys is  w as 
repeated  tw ic e  R N A  e x tra c tio n  w as  p e rfo rm e d  once )
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3.5.2 m rpl
3.5.2.1 m rp l expression in the RPM I-2650 and its M DR variants
R T -P C R  ana lys is  il lu s tra te d  th a t the  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t expressed a 
s l ig h t ly  s tro n g e r m r p l  band  th a n  its  p a re n ta l c e ll l in e  w h ile  a v e ry  w e a k  band  w as obse rved  
in  the  ta x o l-re s is ta n t v a r ia n t
Fig. 3.5.2.1 R T -P C R  a na lys is  o f  m r p l  e xp ress io n  in  the  R P M I-2 6 5 0  c e ll l in e , the  R P M I-  
2 65 0  ta x o l-re s is ta n t v a r ia n t and m e lp h a la n -re s is ta n t v a r ia n t A -5 4 9  se rved  as the  p o s it iv e  
c o n tro l (T h e  R T -P C R  a na lys is  w as  repea ted  th ree  tim e s  R N A  e x tra c tio n  w as  p e rfo rm e d  
o n c e )
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R T -P C R  a na lys is  dem ons tra ted  th a t the  D L K P  lo n g  te rm  m e lp h a la n -s e le c tio n  v a r ia n t 
expressed a s l ig h t ly  s tro n g e r m r p l  band  th an  the  D L K P  c e ll lm e  ( i t  w as c lea re r m  the  o r ig in a l 
p h o to )
3.5.2.2 m rpl expression in the DLKP and DLKP long term melphalan-selection variant
Fig. 3.5.2.2 R T -P C R  a na lys is  o f  m r p l  exp ress ion  in  the  D L K P  and  D L K P  lo n g  te rm  
m e lp h a la n -s e le c tio n  v a ria n t, A -5 4 9  served as p o s it iv e  c o n tro l
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3.5.3 cMOAT (mrp2)
3.5.3.1 cM OAT mRNA expression in the RPM I-2650 and its M DR variants
N o  detectab le  e xp ress io n  fo r  c M O A T  (M R P 2 )  m R N A  w as  obse rved  m  the  R P M I-2 6 5 0  
p a re n ta l c e ll lm e  and  its  ta x o l-re s is ta n t v a r ia n t b y  R T -P C R  a na lys is  H o w e v e r, the  R P M I-  
2 65 0  m e lp h a la n - res is ta n t v a r ia n t show ed  a s tro n g  band  fo r  cm o a t
cmoat
¡3-actin
Fig. 3.5.3.1 R T -P C R  a na lys is  o f  c M O A T (M R P 2 )  m R N A  e xp ress io n  m  th e  R P M I-2 6 5 0  c e ll 
lm e , th e  R P M I-2 6 5 0  ta x o l-re s is ta n t and  m e lp h a la n -re s is ta n t va ria n ts  A -5 4 9  se rved  as the  
p o s it iv e  c o n tro l (T h e  R T -P C R  ana lys is  w as repea ted  th ree  tim e s  R N A  e x tra c tio n  w as 
p e rfo rm e d  o n c e )
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3.5.3.2 cM OAT mRNA expression in the DLKP and DLKP long term melphalan- 
selection variant
N o  detectab le  exp ress ion  fo r  c M O A T  (M R P 2 )  m R N A  w as obse rved  in  e ith e r the  D L K P  o r 
the  D L K P  lo n g  te rm  m e lp h a la n -s e le c tio n  c e ll lm es  ( f ig u re  3 5 3 2 )
Fig. 3.5.3.2 R T -P C R  a na lys is  o f  c M O A T (M R P 2 )  m R N A  e xp ress io n  in  the  D L K P  and  D L K P  
lo n g  te rm  m e lp h a la n -s e le c tio n  v a r ia n t, A -5 4 9  se rved  as p o s it iv e  c o n tro l (T h e  R T -P C R  
ana lys is  w as repea ted  tw ic e  R N A  e x tra c tio n  w as p e rfo rm e d  once )
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3.5.4 mrp3
A  v e ry  w e a k  band  o f  m rp 3  w as obse rved  in  the  R P M I-2 6 5 0  p a re n ta l c e ll l in e  b y  R T -P C R  
T he  exp ress ion  o f  m rp 3  w as  unde tec tab le  in  the  ta x o l-re s is ta n t v a r ia n t w h ile  there  w as  an 
o ve rexp re ss ion  o f  m rp 3  in  the  m e lp h a la n -re s is ta n t v a r ia n t co m p a red  to  its  p a ren ta l c e ll l in e
§
I I
»as#.
mrp3
/3-actm
Fig. 3.5.4 R T -P C R  a na lys is  o f  m rp 3  e xp ress io n  in  the  R P M I-2 6 5 0  p a re n ta l c e ll lin e , R P M I-  
2 6 5 0  ta x o l- re s is ta n t v a r ia n t and  m e lp h a la n -re s is ta n t v a r ia n t A -5 4 9  served as the  p o s itiv e  
c o n tro l (T h e  R T -P C R  a na lys is  w as  repea ted  th ree  tim e s  R N A  e x tra c tio n  w as  p e rfo rm e d  
once )
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3.5.5.mrp4
T he  e xp ress io n  o f  m rp 4  w as  u nde tec tab le  in  the  A -5 4 9 , R P M I-2 6 5 0  and its  ta x o l-re s is ta n t 
v a r ia n t and  m e lp h a la n -re s is ta n t v a r ia n t b y  R T -P C R  ana lys is
Fig. 3.5.5 R T -P C R  a na lys is  o f  m rp 4  exp ress io n  in  th e  R P M I-2 6 5 0  p a re n ta l c e ll l in e , its  
ta x o l-  and m e lp h a la n -re s is ta n t va ria n ts  (T h e  R T -P C R  a na lys is  w as repeated  th re e  tim e s  
R N A  e x tra c tio n  w as  p e rfo rm e d  o n c e )
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3.5.6 mrp5
T h e  e xp ress io n  o f  m rp 5  w as u nde tec tab le  in  the  A -5 4 9 , R P M I-2 6 5 0  and its  ta x o l-  and 
m e lp h a la n -re s is ta n t v a ria n ts  b y  R T -P C R  ana lys is
Fig. 3.5.6 R T -P C R  a na lys is  o f  m rp 5  exp ress io n  in  the  R P M I-2 6 5 0  p a re n ta l c e ll l in e , its  ta x o l-  
and m e lp h a la n -re s is ta n t va ria n ts  (T h e  R T -P C R  a na lys is  w as  repeated  th ree  tim e s  R N A  
e x tra c tio n  w as p e rfo rm e d  o n c e )
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3.5.7 c-Ha-ras and c-myc
R T -P C R  ana lys is  show ed  th a t e xp ress io n  o f  c -H a -ra s  w as  unde tec tab le  in  the  R P M I-2 6 5 0  
c e ll l in e  and its  ta x o l-  and  m e lp h a la n -re s is ta n t v a ria n ts  w hereas c -m y c  w as overexp ressed  m  
the  ta x o l-  and m e lp h a la n -re s is ta n t va ria n ts  co m p a red  to  th e ir  p a re n ta l c e ll lin e
(a) (b)
F ig . 3 .5 .7  R T -P C R  a na lys is  o f  (a ) c -H a -ra s  (b) c -m y c  m  the  R P M I-2 6 5 0  c e ll lm e  and  its  
ta x o l-re s is ta n t v a r ia n t and  m e lp h a la n -re s is ta n t v a r ia n t (T h e  m a rk e r fo r  c -m y c  is  th e  same as 
c -H a - ra s ) (T h e  R T -P C R  a na lys is  w as repeated  tw ic e  R N A  e x tra c tio n  w as  p e rfo rm e d  once )
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3.6 Adriamycin distribution studies in the RPMI-2650 MDR variants
3.6.1 Subcellular distribution o f adriamycin in the RPM I-2650 M DR variants
A d r ia m y c in  is  a flu o re s c e n t ch e m o th e ra p e u tic  d ru g  w h ic h  exerts  its  c y to to x ic  e ffe c t m a m ly  
m  the  n u c le i o f  the  c e lls  I t  can  be  e ff lu x e d  fro m  the  c e lls  b y  P -g ly c o p ro te m  and M R P  T he  
lo c a lis a tio n  o f  a d r ia m y c in  in  R P M I-2 6 5 0 , and  in  its  ta x o l- re s is ta n t and  m e lp h a la n - res is ta n t 
v a ria n ts  w as in ve s tig a te d  b y  f lu o re s c e n t m ic ro s c o p y  as d esc rib e d  in  sec tion  2 9 F ig u re  3 6 1 
illu s tra te s  th e  flu o resce nce  p a tte rn  obse rved  in  these th ree  c e ll lin e s  fo l lo w in g  fo u r  hou rs  
in c u b a tio n  w ith  a d n a m y c in  (10  jo M ) T h e  resu lts  o b ta in e d  show ed  in tense  n u c le a r 
flu o resce nce  in  th e  R P M I-2 6 5 0  c e lls  in d ic a t in g  th e  lo c a lis a tio n  o f  a d r ia m y c in  w ith m  the  
n u c le i o f  these c e lls  A  s im ila r  flu o resce nce  p a tte rn  w as obse rved  in  the  R P M I-2 6 5 0  
m e lp h a la n -re s is ta n t v a r ia n t a lth o u g h  th e  in te n s ity  w as less th a n  th a t obse rved  in  the  pa ren ta l 
c e ll l in e  In  con tras t, fa in t  n u c le a r flu o resce nce  w as obse rved  in  the  ta x o l-re s is ta n t v a r ia n t 
H o w e v e r, the  flu o resce nce  pa tte rns  dem on s tra te d  the  lo c a lis a tio n  o f  a d n a m y c m  in  the  
cy to p la s m  o f  these ce lls
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(a)
(c)
Wmk m
Fig. 3.6.1 Adriamycin localisation in the RPMI-2650 cell line and its MDR variants (40x)
(a) RPMI-2650 (b) RPMI-2650 taxol-resistant variant (c) RPMI-2650 melphalan-resistant
variant
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3.6.2 Effect of verapamil on adriamycin distribution
T h e  a d d it io n  o f  v e ra p a m il ( 3 0 | ig /m l)  w h ic h  is  a M D R  m o d u la to r  caused enhancem en t o f  
n u c le a r fluo rescence  in  th e  R P M I-2 6 5 0  ta x o l-re s is ta n t v a r ia n t and  m e lp h a la n -re s is ta n t 
v a r ia n t N o  s ig n if ic a n t d iffe re n c e  w as obse rved  in  th e  R P M I-2 6 5 0  p a re n ta l ce lls  T he  resu lts  
in d ic a te  th a t v e ra p a m il can  increase  th e  co n c e n tra tio n  o f  a d r ia m y c in  w ith in  the  nuc leus  and 
th us  c irc u m v e n t d ru g  res is tance  in  the  R P M I-2 6 5 0  ta x o l-  and  m e lp h a la n -re s is ta n t va ria n ts  
(F ig u re  3 6 2 )
3.6.3 Effect of cyclosporin A on adriamycin distribution
C y c lo s p o r in  A  is  a lso  a M D R  c irc u m v e n tio n  agent T he  a d d it io n  o f  c y c lo s p o r in  A  (1 0  |ug /m l) 
a lso  g re a tly  enhanced a d r ia m y c in  n u c le a r flu o resce nce  in  the  R P M I-2 6 5 0  ta x o l-re s is ta n t and 
m e lp h a la n -re s is ta n t v a ria n ts  C y c lo s p o r in  A  re su lte d  in  a v e ry  s lig h t increase  in  th e  in te n s ity  
o f  n u c le a r flu o resce nce  in  th e  R P M I-2 6 5 0  p a re n ta l c e ll l in e  (F ig u re  3 6  3 )
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Fig. 3.6.2 A d r ia m y c in  lo c a lis a tio n  a fte r  in c u b a tio n  w ith  v e ra p a m il in  the  R P M I-2 6 5 0  c e ll 
l in e  and its  M D R  v a ria n ts  (4 0 x )  (a ) R P M I-2 6 5 0  (b )  R P M I-2 6 5 0  ta x o l-re s is ta n t v a r ia n t (c ) 
R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t
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Fig. 3.6.3 A d r ia m y c in  lo c a lis a tio n  a fte r  in c u b a tio n  w ith  c y c lo s p o r in  A  in  the  R P M I-2 6 5 0  c e ll 
lin e  and its  M D R  v a ria n ts  (4 0 x )  (a ) R P M I-2 6 5 0  (b )  R P M I-2 6 5 0  ta x o l-re s is ta n t v a r ia n t (c ) 
R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t
156
A lte ra t io n  m  the  a c t iv ity  o f  g lu ta th io n e  S -transferase w as in v e s tig a te d  in  the  R P M I-2 6 5 0  
p a ren ta l c e ll l in e  and  its  M D R  va ria n ts  u s in g  c y to s o lic  c e llu la r  e x trac ts , p repa red  as described  
m  se c tion  2 10 A  s lig h t increase  m  G S T  a c t iv ity  w as obse rved  in  th e  R P M I-2 6 5 0  m e lp h a la n - 
res is ta n t and  R P M I-2 6 5 0  ta x o l- re s is ta n t v a ria n ts  w h e n  co m p a red  to  th e  pa ren ta l ce lls
3.7 Determination of glutathione S-transferase activity in the RPMI-2650
MDR variants
C e ll lin e G S T  a c t iv ity
R P M I-2 6 5 0  p a re n ta l c e ll l in e 0 55 A a b s /m in /m g  p ro te in
R P M I-2 6 5 0  ta x o l- re s is ta n t v a r ia n t 0 62  A a b s /m in /m g  p ro te in
R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t 0 7  A a b s /m in /m g  p ro te in
Table 3.7 G lu ta th io n e  S -transferase a c t iv ity  m  th e  R P M I-2 6 5 0  p a ren ta l c e ll l in e  and  its  
ta x o l-re s is ta n t and m e lp h a la n -re s is ta n t va ria n ts
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3.8 Circumvention studies
3.8.1 Circumvention studies with verapamil and cyclosporin A
V e ra p a m il and c y c lo s p o r in  A  are b o th  M D R  m o d u la to rs . T o  in ve s tig a te  w h e th e r these tw o  
agents can  c irc u m v e n t d ru g  res is tance in  the  R P M I-2 6 5 0  p a ren ta l c e ll lin e  and  its  M D R  
v a ria n ts , to x ic ity  assays w ere  ca rr ie d  out. A s  p resen ted  in  ta b le  3 .8 , the  a d d it io n  o f  ve ra p a m il 
resu lte d  in  a decrease in  the  IC 50 o f  a d r ia m y c in  in  the  R P M I-2 6 5 0  ta x o l-re s is ta n t and 
m e lp h a la n -re s is ta n t va rian ts  w ith  the  greatest decrease obse rved  in  the  m e lph a la n -res is ta n t 
v a ria n t. T h e  a d d it io n  o f  c y c lo s p o r in  A  a lso  resu lted  in  a decrease in  the  ICso o f  a d r ia m y c in  in  
the  R P M I-2 6 5 0  ta x o l-re s is ta n t and  m e lp h a la n -re s is ta n t va ria n ts , e sp e c ia lly  in  the  ta x o l-  
res is tan t v a ria n t. A  s lig h t decrease o f  IC 50 o f  a d r ia m y c in  in  the  R P M I-2 6 5 0  p a ren ta l c e lls  b y  
b o th  v e ra p a m il and  c y c lo s p o r in  A  w as a lso  observed. D L K P -A ,  w h ic h  is  a P -g ly c o p ro te in  
o ve rexp ress ing , a d r ia m y c in -s e le c te d  v a r ia n t o f  D L K P  and C O R -L 2 3 R , w h ic h  is  a M R P  
o ve rexp re ss ing , a d r ia m y c in -s e le c te d  v a r ia n t o f  C O R -L 2 3 S  served as p o s itiv e  co n tro ls .
3.8.2 Circumvention studies with sunlindac and indomethacin
S u lin d a c  and in d o m e th a c in  are b o th  n o n s te ro id a l a n tiin f la m m a to ry  (N S A ID )  com pounds  
w h ic h  w ere  fo u n d  to  c irc u m v e n t a d r ia m y c in  to x ic it y  in  som e M R P -o ve re xp re sse d  c e ll lin e s  
(D u f fy  et al., 1998). T o  test w h e th e r these tw o  co m p ou nd s  c o u ld  c irc u m v e n t d ru g  to x ic it y  in  
the  n o ve l M D R  va ria n ts  e s tab lished  in  th is  s tudy , to x ic it y  assays in  R P M I-2 6 5 0 , D L K P  c e ll 
l in e s  and th e ir  M D R  va ria n ts  w ere  f i r s t  ca rr ie d  o u t to  d e te rm in e  the  co n ce n tra tio n  w h ic h  
c o u ld  be used in  the  c irc u m v e n tio n  studies. T he  resu lts  show ed  th a t in d o m e th a c in  w as abou t 
2 - fo ld  m ore  to x ic  than  su lindac . T he  D L K P  M D R  va ria n ts  seem ed to  be m ore  res is tan t to  
su lin d a c  than  the  D L K P  ce lls . N o  s ig n if ic a n t d iffe re n c e  in  to x ic ity  fo r  these tw o  com pounds 
w as obse rved  b e tw een  R P M I-2 6 5 0  and its  m e lp h a la n -re s is ta n t va ria n t. P re lim in a ry  
c irc u m v e n tio n  s tudy  d em ons tra ted  th a t su lin d a c  and in d o m e th a c in  can c irc u m v e n t m e lph a la n  
to x ic ity  in  the  M R P -o v e re x p re s s in g  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a ria n t, b u t n o t in  the  
pa ren ta l c e ll lin e . (T h is  c irc u m v e n tio n  s tudy  w as o n ly  ca rr ie d  o u t once. T h e  resu lts  w i l l  be 
c o n firm e d  b y  fu tu re  w o rk .)
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ICso (n M ) A D R A D R + V e ra p a m il 
(0  5 jj.g /m l)
A D R + V e ra p a m il
( lju tg /m l)
C O R -L 2 3 R 2 09 7  ±  364 1067 ± 1 5 9 938  ± 1 4 6
D L K P A 5750  ±  275 1196 ± 1 2 4 * 4 4 1 ± 157*
R P M I-2 6 5 0 110 ±  37 74  ± 2 8 59 ±  18
R P M I-2 6 5 0  ta x o l-  
re s is ta n t v a n a n t
5750  ±  224 450 8  ±  263 2171 ± 1 9 5
R P M I-2 6 5 0
m e lp h a la n -re s is ta n t
v a n a n t
690  ± 1 3 8 83 ± 2 4 48  ±  15
( * T h e  co n ce n tra tio n s  o f  v e ra p a m il used m  th e  D L K P - A  c e ll l in e  w e re  1 5 jj,g /m l and  3 |ng /m l 
re s p e c t iv e ly )
ICso (n M ) A D R A D R + C y c lo s p o n n  
A  (0  5 j_ ig /m l)
A D R + C y c lo s p o n n  
A  (1 jj-g /m l)
C O R -L 2 3 R 2 09 7  ±  364 1 0 5 8 ± 143 1435 ± 129
D L K P A 5750  ±  275 / 1 5 8 2 ± 1 67*
R P M I-2 6 5 0 110 ±  37 64  ± 2 1 77  ±  19
R P M I-2 6 5 0  ta x o l-  
re s is ta n t v a n a n t
5750  ±  224 377  ± 129 497  ± 1 1 8
R P M I-2 6 5 0
m e lp h a la n -re s is ta n t
v a r ia n t
690  ± 138 322  ±  98 304  ±  125
( * T h e  c o n c e n tra tio n  o f  c y c lo s p o r in  A  used in  the  D L K P - A  c e ll l in e  w as 5 jo g /m l)
Table 3.8.1 Circumvention studies with verapamil and cyclosporin A in the RPMI-2650 cell
line and its taxol- and melphalan-resistant variants
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IC 50 (M g /m l) S u lin d a c In d o m e th a c in
D L K P 34 3 ±  2 5 31 8 ±  2 4
D L K P  m e lp h a la n -p u lse  
se lected  v a r ia n t
68 3 ±  5 7 25 1 ±  4  2
D L K P  lo n g  te rm  m e lp h a la n - 
se le c tio n  v a r ia n t
77  2 ±  9 6 32 8 ±  5 3
R P M I-2 6 5 0 71 4 ± 8  9 34 3 ±  6 2
R P M I-2 6 5 0  m e lp h a la n - 
res is ta n t v a r ia n t
58  6 ±  2  7 40 5 ±  2 1
Table 3.8.2.a IC 50 va lu es  fo r  D L K P  and R P M I-2 6 5 0  c e ll lin e s  and th e ir  M D R  va rian ts
IC 50 (n M ) M e lp h a la n M e lp h a la n + S u lin d a c
(1 0 |itg /m l)
M e lp h a la n  +  
In d o m e th a c in  
(5 y g /m l)
R P M I-2 6 5 0 852 917 786
R P M I-2 6 5 0
m e lp h a la n -re s is ta n t
v a r ia n t
5998 3670 3014
Table 3.8.2.b C irc u m v e n t io n  stud ies w ith  su lin d a c  and m d o m e th a c in  in  the  R P M I-2 6 5 0  c e ll 
l in e  and its  m e lp h a la n -re s is ta n t v a r ia n t
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3.9 Western blotting of Pi integrin in the RPMI-2650 variants
In te g r in s  are a w id e ly  expressed fa m ily  o f  c e ll su rface  adhes ion  recep to rs . A l l  in te g rin s  are 
a P  h e te ro d im e rs . T he  Pi in te g r in  su b u n it can m ake  h e te ro d im e r w ith  ai, 012, 0C3, ct4, 015, ot6, 
etc. T o  c o n f irm  th e  express ion  o f  p i in te g r in  in  the  R P M I-2 6 5 0  p a ren ta l c e ll lin e  and its  
M D R  va ria n ts , W e s te rn  b lo tt in g  w as c a rr ie d  o u t as described  in  sec tion  2 .8.
T he  resu lts  in  f ig u re  3 .9  show ed  th a t b o th  the  R P M I-2 6 5 0  ta x o l-re s is ta n t and m e lp h a la n - 
res is tan t va ria n ts  had s tron ge r P i in te g r in  bands th an  the  p a ren ta l ce lls . D L K P -A ,  w h ic h  is  a 
lu n g  ca rc in o m a  c e ll l in e , w as used as the  p o s it iv e  c o n tro l.
I  I
O
3
or 5 *
< sB. I
«  *
175KD m
83 KD ■
M  m » * *
— irnmmmm Pi integrin
F ig . 3 .9  W este rn  b lo t t in g  o f  P i in te g r in  s u b u n it in  the  R P M I-2 6 5 0  p a ren ta l c e ll l in e  and its  
M D R  va rian ts . D L K P - A  served as p o s it iv e  c o n tro l.
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3.10 Immunocytochemical detection of integrins and E-cadherin
T o  de tec t the  presence o f  a i ,  ai, 0C4, as , as, P i in te g r in  su bu n its  and  E -c a d h e n n  m  the 
R P M I-2 6 5 0  and  D L K P  p a ren ta l c e ll lin e s  and  th e ir  M D R  va ria n ts , im m u n o c y to c h e m is try  
w as c a rr ie d  o u t as described  in  sec tion  2 7  2
3.10.1 a i  integrin subunit
A  m ouse  m o n o c lo n a l a n t i- a i- in te g r in  a n tib o d y  w as used to  d e te c t a i  in te g r in  A s  s h o w n  in  
f ig u re  3 10 1, no  c e ll m em brane  s ta in in g  fo r  a i  in te g r in  w as obse rved  in  th e  R P M I-2 6 5 0  c e ll 
l in e  W e a k  s ta in in g  fo r  the  a i  s u b u n it w as v is ib le  in  the  ta x o l-re s is ta n t and m e lp h a la n - 
res is ta n t va ria n ts
3.10.2 a 2 integrin subunit
A  m ouse  m o n o c lo n a l a n t i-a 2-m te g n n  a n tib o d y  w as used to  d e te c t th e  presence o f  the  a 2 
m te g r in  su b u n it as describ e d  m  se c tion  2 7  2 2 7 T h e re  is  q u ite  u n ifo rm  s ta in in g  in  the  
R P M I-2 6 5 0  p a ren ta l c e ll l in e  as sh ow n  m 3  10 2 a M o re  in tense  s ta in in g  o f  a 2 m te g r in  w as 
obse rved  in  th e  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t co m p a red  to  its  p a ren ta l c e ll l in e  
In te re s tin g ly , in  th e  R P M I-2 6 5 0  ta x o l- re s is ta n t v a r ia n t, a 2 m te g r in  s ta in in g  seem ed to  
concen tra te  o n  c e rta in  subc lones o f  th e  c e lls , the  rest o f  the  ce lls  d id  n o t have  a n y  s ta in in g  
(F ig u re  3 10 2 b )  T o  d e te rm in e  w h e th e r th is  p h e no m e no n  e x is ts  in  o th e r M D R  c e ll lines , 
exp ress io n  o f  012 w as in v e s tig a te d  in  th e  M D R  c e ll lin e s  D L K P -A ,  D L K P  m e lp h a la n - lo n g  
te rm  and  pu lse  se le c tio n  v a ria n ts  and  th e ir  se ns itive  p a ren ta l lin e  D L K P  A s  s h o w n  in  f ig u re  
3 10 2 c, th e  s ta im n g  fo r  a 2 m te g r in  co nce n tra ted  o n  c e rta in  subclones m  b o th  D L K P  and  
D L K P A  c e ll line s , th is  e ffe c t w as m o s t e v id e n t in  th e  D L K P - A  c e lls  S tro n g  u n ifo rm  s ta in in g  
w as n o te d  in  th e  D L K P  lo n g  te rm  m e lp h a la n -s e le c tio n  v a n a n t w hereas v e ry  w e a k  s ta in in g  
w as obse rved  in  th e  pu lse  s e le c tio n  ce lls
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(a)
Fig. 3.10.1 Immunocytochemical staining for integrin a i subunit in the RPMI-2650 cell line
and its MDR variants (40x) (a) RPMI-2650 cell line (b) RPMI-2650 taxol-resistant variant
(c) RPMI-2650 melphalan-resistant variant
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(a)
(b)
F ig . 3 .10 .2 .a  Im m u n o c y to c h e m ic a l s ta in in g  fo r  in te g r in  012 su b u n it (4 0 x )  in  the  (a ) R P M I-  
2 65 0  c e ll lin e  (b )  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t
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F ig . 3 .1 0 .2 .b  Im m u n o c y to c h e m ic a l s ta in in g  fo r  in te g r in  a .2 su b u n it in  the  R P M I-2 6 5 0  ta x o l-  
res is ta n t v a r ia n t (a ) 2 0 x  (b )  4 0 x
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(C )
F ig . 3.10.2.C Im m u n o c y to c h e m ic a l s ta in in g  fo r  in te g r in  a .2 su b u n it in  the  D L K P  and its  M D R  
v a ria n ts  (4 0 x )  (a ) D L K P  (b ) D L K P - A  (c ) D L K P  lo n g  te rm  m e lp h a la n -s e le c tio n  v a r ia n t (d )  
D L K P  m e lp h a la n -p u lse  se le c tion  v a r ia n t
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3.10.3 (X3 integrin subunit
A  m ouse  m o n o c lo n a l a n t i-a 3- in te g rm  a n tib o d y  w as used to  d e te c t (X3 in te g r in  su b u n it as 
desc rib e d  in  se c tion  2  7 2 2 7  A s  sh ow n  in  f ig u re  3 10 3 , th e re  is  w e a k  s ta in in g  fo r  0 1 3  
m te g n n  m  th e  R P M I-2 6 5 0  p a re n ta l c e ll l in e , its  ta x o l-re s is ta n t and  m e lp h a la n -re s is ta n t 
va ria n ts  N o  s ig n if ic a n t d iffe re n c e  in  the  le v e l o f  s ta in in g  o f  (X3 in te g r in  w as obse rved  in  a ll  
these c e ll lin e s  ( f ig u re  3 10 3 )
3.10.4 014 integrin subunit
A  m ouse  m o n o c lo n a l a n t i-a 4- in te g n n  a n tib o d y  w as used to  d e te c t 014 in te g r in  s u b u n it as 
d escrib e d  in  se c tion  2 7 2 2 7  T h e  resu lts  o b ta in e d  dem on stra te d  s tron g  s ta in in g  fo r  014 
m te g n n  in  the  R P M I-2 6 5 0  p a re n ta l c e ll l in e , b u t no  s ig n if ic a n t s ta in in g  m  its  ta x o l-re s is ta n t 
and  m e lp a h a ln -re s is ta n t v a ria n ts  N o  s ta in in g  w as obse rved  in  D L K P  and its  M D R  va rian ts  
( f ig u re  3 10 4  1 and  3 10 4  2 )
3.10.5 as integrin subunit
A  m ouse  m o n o c lo n a l a n ti-a s - in te g rm  a n tib o d y  w as used to  d e te c t as in te g r in  s u b u n it as 
describ e d  m  se c tio n  2 7 2 2 7  A s  s h o w n  in  f ig u re  3 10 5, th e re  is  w e a k  s ta in in g  fo r  as 
in te g r in  in  th e  R P M I-2 6 5 0  p a re n ta l c e ll l in e  and  its  ta x o l-re s is ta n t v a r ia n t T he  s ta in in g  in  the  
m e lp h a la n -re s is ta n t v a r ia n t appears to  be m o re  in tense  th a n  in  the  o th e r tw o  c e ll lin e s
3.10.6 a 6 integrin subunit
A  m ouse  m o n o c lo n a l a n t i-a 6- in te g rm  a n tib o d y  w as used to  d e te c t 06  in te g r in  s u b u n it as 
d esc rib e d  in  se c tion  2 7  2 2 7  T he  resu lts  o b ta in e d  sh o w  w e a k  s ta in in g  fo r  0^  in te g r in  in  the  
R P M I-2 6 5 0  p a re n ta l c e ll l in e  and its  ta x o l-re s is ta n t v a r ia n t T h e  s ta in in g  in  the  m e lp h a la n - 
res is ta n t v a r ia n t is  m o re  in tense  th a n  in  th e  o th e r tw o  c e ll lin e s  ( f ig u re  3 10 6 )
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(a)
s ' ■
Fig. 3.10.3 Immunocytochemical staining for 013 integrin subunit in the RPMI-2650 and its
MDR variants (40x) (a) RPMI-2650 cell line (b) RPMI-2650 taxol-resistant variant (c)
RPMI-2650 melphalan-resistant variant
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(a)
(c)
Fig. 3.10.4.1 Immunocytochemical staining for a 4 integrin subunit in the RPMI-2650 cell
line and its MDR variants (40x) (a) RPMI-2650 cell line (b) RPMI-2650 taxol-resistant
variant (c) RPMI-2650 melphalan-resistant variant
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(a)
(b)
(c)
Fig. 3.10.4.2 Immunocytochemical staining for 014 integrin subunit in the DLKP cell line and
its MDR variants (a) DLKP cell line (b) DLKP long term melphalan-selection variant (c)
DLKP melphalan-pulse selection variant
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(a)
P
(b)
(c)
Fig. 3.10.5 Immunocytochemical staining for as integrin subunit in the RPMI-2650 cell line
and its MDR variants (40x) (a) RPMI-2650 cell line (b) RPMI-2650 taxol-resistant variant
(c) RPMI-2650 melphalan-resistant variant
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(b)
F ig . 3 .1 0 .6  Im m u n o c y to c h e m ic a l s ta in in g  fo r  CC6 in te g r in  su b u n it in  the  R P M I-2 6 5 0  c e ll lin e  
and  its  M D R  va ria n ts  (4 0 x )  (a ) R P M I-2 6 5 0  c e ll l in e  (b )  R P M I-2 6 5 0  ta x o l-re s is ta n t v a r ia n t 
(c )  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t
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3.10.7 Pi integrin subunit
A  m ouse  m o n o c lo n a l a n t i-P i- in te g r in  a n tib o d y  w as used to  d e te c t the  presence o f  p i  m te g n n  
s u b u n it as d esc rib e d  in  se c tion  2 7  2 2 7 A s  s h o w n  m  f ig u re  3 10 7 a, th e re  is  s ta in in g  fo r  P i 
m te g r in  in  the  R P M I-2 6 5 0  p a re n ta l c e lls  T h e  resu lts  o b ta in e d  in d ic a te  a s ig n if ic a n t ly  h ig h e r 
le v e l o f  e xp ress io n  o f  p i m te g r in  in  th e  R P M I-2 6 5 0  ta x o l- re s is ta n t and  m e lp h a la n -re s is ta n t 
va ria n ts , e s p e c ia lly  m  th e  m e lp h a la n -re s is ta n t v a r ia n t T he  resu lts  a lso  sh o w  a s ig n if ic a n t ly  
h ig h e r le v e l o f  P i m te g r in  e xp ress io n  in  th e  D L K P - A  and  D L K P  lo n g  te rm  m e lp h a la n - 
se lected  c e ll lin e s  th a n  in  the  D L K P  and its  pu lse  se le c tio n  c e ll lin e s  ( f ig u re  3 10 7 b )
3.10.8 p4 integrin subunit
p 4 m te g r in  s u b u n it fo rm s  h e te ro d im e r w ith  ot6 0 ^ 4  is  expressed e x c lu s iv e ly  in  e p ith e lia l 
c e lls  T o  de tec t the  presence o f  P4 m te g r in , a m ouse  m o n o c lo n a l a n ti-P 4- in te g r in  a n tib o d y  
w as used as described  m  se c tion  2 7 2 2 7  A s  sh ow n  in  f ig u re  3 10 8 , the  R P M I-2 6 5 0  
m e lp h a la n -re s is ta n t v a r ia n t expressed P4 in te g r in  w hereas the  R P M I-2 6 5 0 , its  ta x o l-re s is ta n t 
v a r ia n t, D L K P  and  its  M D R  v a ria n ts  d id  n o t
3.10.9 E-cadherm
E -c a d h e rm  is  the  m a jo r  c e ll-c e ll a dhes ion  m o le c u le  Im m u n o c y to c h e m ic a l d e te c tio n  o f  E - 
ca dh erm  m  R P M I-2 6 5 0  a nd  its  M D R  v a ria n ts  w as  e a rn e d  o u t as d escrib e d  m  sec tion  
2 7  2 2 8 b y  u s in g  a m ouse  m o n o c lo n a l a n ti-E -c a d h e rm  a n tib o d y  M C F -7 , a b reas t ca rc in o m a  
c e ll l in e , w as used as th e  p o s itiv e  c o n tro l T ra ce  le v e l o f  s ta in in g  fo r  E -c a d h e n n  w as 
obse rved  m  th e  R P M I-2 6 5 0  p a ren ta l c e ll l in e  H o w e v e r, no  s ta in in g  w as obse rved  m  the  
ta x o l-re s is ta n t and  m e lp h a la n -re s is ta n t v a ria n ts  as s h o w n  in  f ig u re  3 10 9
174
F ig . 3 .10 .7 .a  Im m u n o c y to c h e m ic a l s ta in in g  fo r  (3i in te g r in  su b u n it in  the  R P M I-2 6 5 0  c e ll 
lin e  and its  M D R  va ria n ts  (4 0 x )  (a ) R P M I-2 6 5 0  c e ll l in e  (b )  R P M I-2 6 5 0  ta x o l-re s is ta n t 
v a r ia n t (c )  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t
F ig . 3 .1 0 .7 .b  Im m u n o c y to c h e m ic a l s ta in in g  fo r  (3i in te g r in  su b u n it in  the  D L K P  and  its  
M D R  va ria n ts  (4 0 x )  (a ) D L K P  (b ) D L K P - A  (c ) D L K P  lo n g  te rm  m e lp h a la n -s e le c tio n  v a r ia n t 
(d )  D L K P  m e lp h a la n -p u lse  se le c tion  v a r ia n t (see n e x t page)
(C )
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(a)
Fig. 3.10.8.a Immunocytochemical staining for integrin (34 subunit in the RPMI-2650 cell
line and its MDR variants (40x) (a) RPMI-2650 cell line (b) RPMI-2650 taxol-resistant
variant (c) RPMI-2650 melphalan-resistant variant
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F ig . 3 .1 0 .8 .b  Im m u n o c y to c h e m ic a l s ta in in g  fo r  p 4 in te g r in  s u b u n it in  D L K P  and its  M D R  
va rian ts  (4 0 x )  (a ) D L K P  c e ll l in e  (b )  D L K P  lo n g  te rm  m e lp h a la n -s e le c tio n  v a r ia n t (c ) D L K P  
m e lp h a la n -p u lse  se le c tion  v a ria n t
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(a)
F ig . 3 .10 .9  Im m u n o c y to c h e m ic a l s ta in in g  fo r  E -ca d h e rin  in  the  R P M I-2 6 5 0  c e ll lin e  and its  
M D R  v a ria n ts  (4 0 x ) (a ) M C F -7  c e ll l in e , served as p o s it iv e  c o n tro l (b )  R P M I-2 6 5 0  (c ) 
R P M I-2 6 5 0  ta x o l-re s is ta n t v a r ia n t (d )  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t (see n e x t 
page)
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(C )
m,
Is-v!'
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Integrin
subunit
RPM I-
2650
RPM I-
2650
taxol-
resis.
variant
RPM I- 
2650 mel- 
resis. 
variant
DLKP DLKP  
long term  
meL-sele. 
variant
DLKP
mel.-pulse
sele.
variant
at - ± ± ND ND ND
a% ++ clonal +++ clonal +++ ±
a$ ± ± ± ND ND ND
a* -H - - - - - -
a s ± ± + ND ND ND
aa ± ± + ND ND ND
Pi ++ +++ ++++ ++ +++ +
04 - - + - - -
E-
cadherin
+ ND ND ND
Table 3.10 Summary o f the immunocytochemical staining for integrin subunits in the 
RPM I-2650, DLKP cell lines and their M DR variants
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3.11 RT-PCR of integrin a2 and Pi subunits
F ro m  th e  resu lts  o b ta ine d  fro m  the  im m u n o c y to c h e m ic a l s tud ies s h o w n  in  sec tion  3 10, 
in te res t w as  concen tra ted  on  the  exp ress ion  o f  az and  (3i in te g ra l su bu n its  a t the  R N A  le v e l in  
the  R P M I-2 6 5 0  p a re n ta l c e ll lm e  and  its  M D R  v a ria n ts
T he  resu lts  o f  R T -P C R  a na lys is  in  f ig u re  3 11 show ed  th a t th e  R P M I-2 6 5 0  m e lp h a la n - 
res is ta n t v a r ia n t had  the  h ig h e s t e xp ress io n  o f  b o th  (X2 and  P i in te g r in  su bu n its  com pared  to  
the  o th e r tw o  c e ll lin e s  T h e  lo w e s t le v e l o f  P i in te g r in  s u b u n it e xp ress io n  w as  obse rved  in  
the  R P M I-2 6 5 0  w h ile  the  R P M I-2 6 5 0  ta x o l-re s is ta n t v a r ia n t d isp la ye d  the  lo w e s t le v e l o f  az 
in te g ra l s u b u n it exp ress ion  T he  resu lts  o b ta in e d  fo r  R T -P C R  a na lys is  w e re  co ns is te n t w ith  
the  resu lts  f ro m  the  im m u n o c y to c h e m ic a l s tud ies
Fig. 3.11 R T -P C R  a na lys is  o f  0C2 and p i in te g ra l su bu n its  m  the  R P M I-2 6 5 0  c e ll lm e , its  
ta x o l-re s is ta n t and  m e lp h a la n -re s is ta n t va ria n ts  A -5 4 9  served as p o s it iv e  c o n tro l (T h e  
m a rk e r fo r  P i in te g ra l is  the  same as 012 in te g ra l)  (T h e  R T -P C R  a na lys is  w as  repeated  th ree  
tim e s  R N A  e x tra c tio n  w as p e rfo rm e d  once )
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3.12 Adhesion assays in the RPMI-2650 MDR variants
C e lls  u t i lis e  m te g n n s  to  in te ra c t w ith  e x tra c e llu la r  m a tr ix  co m p on en ts  such  as co lla g e n  typ e  
IV ,  la m im n  and  f ib ro n e c tm  T o  d e tec t adhesiveness o f  th e  R P M I-2 6 5 0  p a ren ta l c e ll l in e  and  
its  M D R  v a ria n ts  to  c o lla g e n  typ e  IV ,  la m im n , f ib ro n e c tm  and  m a tn g e l, adhes ion  assay w as 
e a rn e d  o u t as desenbed  in  sec tion  2 12
3.12.1 Collagen type IV
A s  sh ow n  in  f ig u re  3 12 2, the  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t w as m o s t adhesive  to  
c o lla g e n  ty p e  I V  w h ic h  is  th e  m a jo r  co m p o n e n t o f  basem ent m em brane  T he  R P M I-2 6 5 0  c e ll 
l in e  had  less adhesiveness th an  m e lp h a la n -re s is ta n t v a n a n t, b u t w as m o re  adhes ive  to  
co lla g e n  typ e  I V  th a n  the  R P M I-2 6 5 0  ta x o l-re s is ta n t v a r ia n t
3.12.2 Laminin
A s  sh ow n  in  f ig u re  3 12 1, the  R P M I-2 6 5 0  p a ren ta l c e ll l in e  and  its  M D R  v a n a n ts  had  v e ry  
w e a k  adhesiveness to  la m im n  w h ic h  is  ano the r m a jo r  c o m p o n e n t o f  basem ent m em brane  
T h e  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t show ed  s lig h t ly  s tro n g e r adhesiveness to  
la m im n  co m p a red  to  th e  o th e r tw o  c e ll lin e s
3.12.3 Fibronectin
F ib ro n e c tm  is  th e  m a jo r  co m p o n e n t o f  e x tra c e llu la r  m a tr ix  and v e ry  l i t t le  f ib ro n e c tm  is  fo u n d  
in  the  basem ent m em brane  F ig u re  3 12 1 show ed  th a t th e  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t 
v a n a n t w as m o s t adhes ive  to  f ib ro n e c t in  T he  R P M I-2 6 5 0  ta x o l-re s is ta n t v a n a n t w as less 
adhes ive  th a n  m e lp h a la n -re s is ta n t v a r ia n t, b u t w as m o re  adhes ive  th a n  the  p a ren ta l c e ll l in e
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3.12.4 Matrigel
M a tn g e l is  th e  a r t i f ic ia l re co n s titu te d  basem ent m em brane  I t  b a s ic a lly  co n ta ins  e ve ry  
c o m p o n e n t o f  the  n a tu ra l basem ent m em brane  T h e  adh es ion  assays w ith  m a tn g e l (F ig u re  
3 12 2 )  show ed  th a t the  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t w as m o s t adhes ive  to  
m a tn g e l T he  R P M I-2 6 5 0  ta x o l- re s is ta n t v a n a n t w as less adhes ive  to  m a tr ig e l th a n  the  
m e lp h a la n -re s is ta n t v a n a n t, b u t w as m u c h  m o re  adhes ive  th a n  the  R P M I-2 6 5 0  p a ren ta l ce lls
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parental taxol rnelphalan
cell tines
Fig. 3.12.1 A d h e s io n  assays o f  the  R P M I-2 6 5 0  c e ll lin e , its  ta x o l-re s is ta n t and  m e lp h a la n - 
res is tan t v a ria n ts  w ith  f ib ro n e c t in  and la m in in
Fig. 3.12.2 A d h e s io n  assays o f  the  R P M I-2 6 5 0  c e ll lin e , its  ta x o l-re s is ta n t and m e lp h a la n - 
res is ta n t v a ria n ts  w ith  co lla g e n  ty p e  I V  and m a tr ig e l
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3.13 Invasion assays in the RPMI-2650 and DLKP MDR variants
3.13.1 Invasion assays in the RPMI-2650 and its MDR variants
A d h e s io n  o f  ce lls  to  e x tra c e llu la r  m a tr ix  o r  basem ent m em brane  is  the  f ir s t  step o f  c e ll 
in va s io n . T he n  c e ll w i l l  u t i lis e  d if fe re n t m echan ism s to  degrade e x tra c e llu la r  m a tr ix  o r  
basem ent m em brane  to  m ove  about. In  o rd e r to  in ve s tig a te  the  in v a s iv e  a b i l i t y  o f  the  R P M I-  
2650  p a ren ta l c e ll lin e  and its  M D R  va ria n ts , in v a s io n  assays w ere  ca rr ie d  o u t as described  in  
sec tion  2 .13 . C e ll c u ltu re  inse rts  w h ic h  stand in  m e d iu m -c o n ta in in g  2 4 -w e ll p la tes w ere  
coated  w ith  m a tr ig e l b e fo re  ce lls  w e re  added. A f te r  a c e rta in  p e r io d  o f  t im e , in va s ive  ce lls  
can m ig ra te  th ro u g h  the  m in ih o le s  on  the  b o tto m  o f  the  c e ll c u ltu re  in se rt to  the  o the r s ide  o f  
the  b o tto m . A s  in s tru c te d  b y  B e c to n -D ic k e n s o n  co m p a n y  w he re  the  c e ll c u ltu re  inserts  w e re  
b o u g h t, H T -1 0 8 0 , a h ig h ly  in va s ive  fib ro s a rc o m a  c e ll l in e  and N IH -3 T 3 ,  a p o o r ly  in va s ive  
c e ll lin e  sh o u ld  be used as co n tro ls .
A s  sh ow n  in  fig u re  3 .13 .2 , the  R P M I-2 6 5 0  m e lp h a la n -re s is ta n t v a r ia n t w as s ig n if ic a n t ly  
m o re  in v a s iv e  th an  the  R P M I-2 6 5 0  p a ren ta l c e ll l in e  and  its  ta x o l-re s is ta n t v a r ia n t w h ic h  
w e re  unab le  to  invade  th ro u g h  the  b o tto m  o f  the  inserts.
Fig. 3.13.1 In v a s io n  assays s h o w in g  the  c e lls  in v a d in g  th ro u g h  to  the  b o tto m  side o f  the  c e ll 
c u ltu re  inse rts  (T o p  le f t :  H T -1 0 8 0 , to p  r ig h t:  N IH -3 T 3 , lo w e r le f t :  R P M I-2 6 5 0 , lo w e r  m id d le : 
ta x o l-re s is ta n t v a ria n t, lo w e r  r ig h t :  m e lp h a la n -re s is ta n t v a ria n t) .
187
(a)
Fig. 3.13.2.a In v a s io n  assays o f  (a ) H T -1 0 8 0  (b )  N IH -3 T 3
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Fig. 3.13.2.b In v a s io n  assays o f  the  R P M I-2 6 5 0  c e ll lin e  and its  M D R  va ria n ts  (4 0 x )  (a ) 
R P M I-2 6 5 0  c e ll l in e  (b )  R P M I-2 6 5 0  ta x o l-re s is ta n t v a r ia n t (c ) R P M I-2 6 5 0  m e lp h a la n - 
res is ta n t v a r ia n t
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3.13.2 Invasion assays with sulindac and indomethacin
As shown m section 3 8 2, sulmdac and indomethacin which are known to be MRP1 
inhibitors can partially circumvent melphalan toxicity in RPMI-2650 and its melphalan- 
resistant variant To determine whether these two compounds can affect the mvasiveness of 
this variant, invasion assays were carried out The results obtained demonstrate that the 
mvasiveness of the RPMI-2650 melphalan-resistant variant was not affected by either 
sulmdac or indomethacin (figure 3 13 2 c)
3.13.3 Invasion assays in DLKP and its MDR variants
As shown m figure 3 13 3, both the DLKP long term melphalan-selection and DLKP 
melphalan-pulse selection variants were more invasive than DLKP parental cell line, 
especially the long term selection variant
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(a)
Fig. 3.13.2.C Invasion assays with sulindac and indomethacin in the RPMI-2650 melphalan- 
resistant variant (a) RPMI-2650 melphalan-resistant variant (b) with sulindac (c) with 
indomethacin
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(a)
(b)
(c)
Fig. 3.13.3 Invasion assays in DLKP and its MDR variants (a) DLKP cell line (b) DLKP
long term melphalan-selection variant (c) DLKP melphalan-pulse selection variant
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3.14 Motility assays in the RPMI-2650 MDR variants
Motility assays were conducted to compare the locomotive ability of RPMI-2650 parental 
cell line and its MDR variants. The procedure used to demonstrate cell motility was similar to 
that used for the invasion assays except that the inserts were not coated with matrigel prior to 
the addition of the cells. The results obtained illustrated that the RPMI-2650 melphalan- 
resistant variant showed significantly higher motility than the RPMI-2650 taxol-resistant 
variant while the parental cells showed little or no motility (figure 3.14.1 and 3.14.2). HT- 
1080 andNIH-3T3 cell lines were used as positive and negative control respectively.
Fig. 3.14.1 Motility assays showing the cells migrating to the bottom side of the cell 
culture inserts (Top left: HT-1080, top right: NIH-3T3, lower left: RPMI-2650, lower middle: 
taxol-resistant variant, lower right: melphalan-resistant variant).
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(a)
Fig. 3.14.2.a Motility assays of the (a) HT-1080 cell line (b) NIH-3T3 cell line
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(a)
Fig. 3.14.2.b Motility assays of the RPMI-2650 cell line and its MDR variants (40x) (a)
RPMI-2650 cell line (b) RPMI-2650 taxol-resistant variant (c) RPMI-2650 melphalan-
resistant variant
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3.14.A Time lapse videomicroscopy
Time lapse videomicroscopy as outlined in section 2 11 was used to determine the speed of 
motility in the RPMI-2650 cell line and its MDR variants Cell motility was momtored by 
locating the initial position of the cell and the final position of the same cell and measuring 
the distance between the two positions Take the RPMI-2650 melphalan-resistant variant as 
an example, figure 3 14 A demonstrated the movement of the cells during certain time 
period Results indicate that the HT-1080 moved fastest, melphalan-resistant vanant moved 
much faster than the taxol-resistant vanant and the parental cell line RPMI-2650 cells 
showed lowest movement which was consistent with the results of the motility assays
Cell line Motility speed (p.m/hour)
HT-1080 13 54 ±11 8(n=12)
RPMI-2650 0 55 ± 0 16 (n=13)
RPMI-2650 taxol-resistant vanant 0 76 ± 0  31 (n=15)
RPMI-2650 melphalan-resistant variant 6 83 ± 2  63 (n=21)
Table 3.14.A Motility speed of the RPMI-2650 cell line and its MDR variants, HT-1080 
served as positive control (n value is the number of the cells monitored)
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Fig. 3.14.A Pictures a-f demonstrated the movement of the RPMI-2650 melphalan-resistant 
variant cells during certain time period.
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Matrix metalloproteinases (MMPs) which are secreted by cells, play an important role in 
degrading extracellular matrix. To investigate the mechanisms underlying the invasion 
phenotype of the RPMI-2650 parental cell line and its MDR variants, studies of MMPs were 
carried out as described in section 2.15.
3.15.1 Zymograph of MMPs in the RPMI-2650 cell line and its MDR variants
BHK (Baby hamster kidney) cell line which secrets MMP-2 and MMP-9 was used as the 
positive control in these studies. Figure 3.15.1 showed that the RPMI-2650 melphalan- 
resistant variant had a band for MMP-2 and a band for MMP-9 whereas the RPMI-2650 
parental cells and taxol- resistant variant cells did not show any of these bands. However, the 
RPMI-2650 parental cell line showed three other bands which were not MMP-2 and MMP-9.
3.15 Studies of MMPs in the RPMI-2650, DLKP cell lines and their MDR
variants
1 2  3 4
Fig. 3.15.1 Zymograph of proteinases in the RPMI-2650 cell line and its MDR variants,
BHK serves as positive control lane 1- RPMI-2650; lane 2- RPMI-2650 taxol-resistant
variant; lane 3- RPMI-2650 melphalan-resistant variant; lane 4 - BHK
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To confirm that the two bands of the RPMI-2650 melphalan-resistant variant were MMPs 
and also to detect the nature of the three bands visible for the RPMI-2650 parental cells, 
proteinase inhibitors were added to inactivate their corresponding substrates.
3.15.2.1 The effect of EDTA
£DTA is a chelating agent which can bind the zinc and calcium which are needed for the 
activation of MMPs. After the gel was incubated with EDTA, the two bands of the BHK cell 
line and the RPMI-2650 melphalan-resistant variant disappeared. Thus, all these bands 
proved to be MMPs. However, EDTA had no effect on the expression of the three bands of 
RPMI-2650 cell line (See figure 3.15.2.1).
3.15.2 Zymograph with proteinase inhibitors or enhancer in the RPM1-2650 cell line
and its MDR variants
1 2  3 4
Fig. 3.15.2.1 Zymograph of proteinases in the RPMI-2650 and its MDR variants with EDTA, 
BHK serves as negative control, lane 1- BHK ; lane 2- RPMI-2650 ; lane 3- RPMI-2650 
taxol-resistant variant; lane 4 - RPMI-2650 melphalan-resistant variant
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3.15.2.2 The effect of PMSF
PMSF is a serine protease inhibitor. After the gel was incubated with PMSF, only MMP-2 
and MMP-9 bands of the melphalan-resistant variant and BHK were visible. The three bands 
of the RPMI-2650 became very weak. This suggests that the three bands of the RPMI-2650 
cell line are serine proteinases.
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Fig. 3.15.2.2 Zymograph of proteinases with PMSF in the RPMI-2650 cell line and its 
MDR variants. BHK serves as positive control.
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3.15.2.3 The effect of cysteine
If the three bands of the RPMI-2650 cell line were cysteine proteases, they would become 
stronger after the gel was incubated with cysteine. (Cysteine keeps cysteine protease in its 
reduced form, thus making it more active.) (Dalton and Brindley, 1997). The result shown in 
figure 3.15.2.3 suggests that the three bands of the RPMI-2650 on the zymograph are not 
cysteine proteases since no stronger bands appeared on the gel.
Fig. 3.15.2.3 Zymograph of proteinases (left: without cysteine in the RPMI-2650 cell line, 
right: with cysteine in the RPMI-2650 cell line).
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3.15.3 Zymograghy of proteinases in the DLKP and its MDR variants
No band was visible in the DLKP cell line whereas DLKP long term melphalan-selection and 
melphalan-pulse selection variants expressed MMP-2 and MMP-9 at the similar level (figure
3.15.3).
1 2  3 4
Fig. 3.15.3 Zymograph of proteinases in the DLKP cell line and its MDR variants, BHK 
served as positive control, lane 1- BHK; lane 2- DLKP; lane 3- DLKP long term 
melphalan-selection variant; lane 4 - DLKP melphalan-pulse selection variant.
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3.15.4 RT-PCR of MMP-2 and MMP-9
The expression of MMP-2 and MMP-9 was undetectable in the RPMI-2650 cell line and its 
MDR variants by RT-PCR as shown in figure 3.15.4.
RT-PCR of MMP-2 RT-PCR of MMP-9
Fig. 3.15.4 RT-PCR analysis of MMP-2 and MMP-9 in the RPMI-2650 cell line, its taxol- 
resistant and melphalan-resistant variants. (The RT-PCR analysis was repeated twice. RNA 
extraction was performed once.)
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3.15.5 RT-PCR of TIMP-1
The expression of TIMP-1 (MMP inhibitor) was undetectable in the RPMI-2650, its taxol- 
resistant and melphalan-resistant variants by RT-PCR (figure 3.15.5).
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Fig. 3.15.5 RT-PCR analysis of TIMP-1 in the RPMI-2650, its taxol-resistant and 
melphalan-resistant variants. (The RT-PCR analysis was repeated twice. RNA extraction was 
performed once.)
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3.16 Relationship between melphalan resistance and invasion phenotype 
in the HT-1080, NIH 3T3, A-549, DLKP, DLKP-C, COR-L23S and 
COR-L23R cell lines
Since RPMI-2650 melphalan-resistant variant was much more invasive than its parental cell 
line, studies were carried out to determine whether any relationship existed between 
melphalan resistance and cell invasion.
3.16.1 Toxicity assays with melphalan in the HT-1080, NIH-3T3, A-549, DLKP, 
DLKP-C, COR-L23S and COR-L23R cell lines
DLKP-C is a cisplatin-resistant variant of the parental DLKP cell line, a human lung 
carcinoma cell line. COR-L23R is an adriamycin-resistant variant of the parental COR-L23S 
cell line, a human large cell lung cancer cell line. As shown in table 3.16.1, A-549, DLKP-C, 
NIH-3T3 were quite resistant to melphalan while the rest of the cell lines did not display 
significant resistance to this drug.
Cell line IC50 (nM)
A-549 4895219221
DLKP 2949± 139
DLKPC 10114 ±2086
COR-L23S 6225 ± 983
COR-L23R 2064 ± 629
HT-1080 4751 ±885
NIH-3T3 9996± 1804
Table 3.16.1 IC50 values of melphalan for the A-549, HT-1080, NIH-3T3, DLKP, DLKP-C, 
COR-L23S, COR-L23R cell lines
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3.16.2 Invasion assays in the A-549, HT-1080, NIH-3T3, DLKP, DLKP-C, COR-L23S 
and COR-L23R cell lines
The results obtained by invasion assays showed that the HT-1080 and A-549 cell lines were 
the most invasive lines studied. The rest of the cell lines were not quite as invasive. Slight 
difference of invasiveness was observed between the COR-L23S and its resistant variant, 
COR-L23R. However, the DLKP-C cell line did appear to be more invasive than its parental 
cell line (figure 3.16.2).
(a)
Fig. 3.16.2.a Invasion assays of (a) HT-1080 (b) NIH-3T3
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(a)
Fig. 3.16.2.b Invasion assays in the (a) A-549 (b) DLKP (c) DLKP-C
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(a)
Fig. 3.16.2.C Invasion assays in the (a) COR-L23S (b) COR-L23R
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3.16.3 Zymography of proteinases in the A-549, HT-1080, NIH-3T3, DLKP, DLKPC, 
COR-L23S and COR-L23R cell lines
To investigate the mechanism underlying the behaviour of invasion in these cell lines, 
zymography was carried out to detect proteinases secreted by these cell lines. As shown in 
figure 3.16.3.1 and 3.16.3.2, A-549 cell line only expressed MMP-2. HT-1080, NIH-3T3 and 
COR-L23S cell lines expressed both MMP-2 and MMP-9. No proteinase was detected in the 
COR-L23R, DLKP and DLKP-C cell lines.
Fig. 3.16.3.1 Zymograph of proteinases in the A-549, HT-1080 and NIH-3T3 cell lines.
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Fig. 3.16.3.2 Zymograph of proteinases in the COR-L23S, COR-L23R, DLKP and DLKP-C 
cell lines
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3.17 Studies in the subclones of the RPMI-2650 cell line
The apparent clonal expression of a .2 integrin subunit in the RPMI-2650 taxol-resistant 
variant led to the studies in subclones of the RPMI-2650 cell line which were established in 
this centre about ten years ago. Unfortunately, it was found later that all of these clones were 
contaminated by mycoplasma, so that the work was discontinued.
3.17.1 Morphological changes in the subclones of the RPMI-2650 cell line
As shown in figure 3.17.1, the morphology varied in the subclones of the RPMI-2650 cells, 
especially in clone 6 .
(a)
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(g)
Fig. 3.17.1 Morphology of subclones of the RPMI-2650 cell line (lOx) (a) clone 1 (b) clone 3 
(c) clone 6 (d) clone 7 (e) clone 8 (f) clone 9 (g) clone 12
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3.17.2 Immunocytochemistry studies of integrins and MDR-1
The immunocytochemistiy studies showed that the expression of integrin subunits varied in 
different clones. The most significant variation was observed for 0C5 and Pi integrin subunits 
which were significantly overexpressed in clone 6 and 9. Clone 6 was also found to 
overexpress MDR-1 (figure 3.17.2).
Clonel Clone 3 Clone 6 Clone 7 Clone 8 Clone 9
Integrin
oti
Integrin
0.2
+ + + + + +
Integrin
a 3
■
+ + + + +
Integrin
a 5
+ ++++ ++ +++ ++++
Integrin
Ofi
+ + +
Integrin
Pt
+ ++++ ++ +++ ++++
MDR-1 - + +++ + + +
Table 3.17.2 Immunocytochemistry for integrin subunits and MDR-1 in the subclones of the 
RPMI-2650 cell line
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Fig. 3.17.2.a Immunocytochemistry for integrin as subunit in the subclones of RPMI-2650 
cell line (a) clone 6 (b) clone 7 (c) clone 8 (d) clone 9
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(a) (b)
Fig. 3.17.2.b Immunocytochemistry for (3i integrin subunit in the subclones of RPMI-2650 
cell line (a) clone 6 (b) clone 7 (c) clone 8 (d) clone 9
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(a)
(b)
Fig. 3.17.2.C Immunocytochemical staining for MDR-1 in the clone 6 of RPMI-2650 cell 
line compared to RPMI-2650 parental cell line (40x) (a) clone 6 (b) RPMI-2650
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3.17.3 Adhesion assays in subclones of the RPMI-2650 cell line with collagen type IV, 
laminin and fibronectin
Figure 3.17.3 illustrated that adhesiveness to collagen type IV, laminin and fibronectin varied 
significantly in the different clones of the RPMI-2650 cell line. Strong adhesion to collagen 
type IV and fibronectin was observed in clone 9.
(UJUQ2.S) Sjueqjoaqe
Fig. 3.17.3 Adhesion assays in subclones of the RPMI-2650 cell line with collagen type IV, 
laminin and fibronectin
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4. Discussion
4.1 Toxicity of chemotherapeutic drugs in the SKLU-1, BT-20, 
RPMI-2650, A-549 and MX-1
As the initial part of this project, toxicity assays were carried out in the SKLU-1, BT- 
20, RPMI-2650, A-549 and MX-1 cell lines to determine the chemosensitivity of 
these cell lines to various chemotherapeutic agents (see section 3.1). The purpose of 
this study was to find a relatively sensitive cell line and also to determine if drug 
sensitivity or resistance patterns could be observed in certain kinds of cell lines, e.g. 
breast cancer cell lines such as BT-20 and MX-1 or lung cancer cell lines such as A- 
549 and SKLU-1. The panel also included a human nasal carcinoma cell line, RPMI- 
2650. None of these cell lines had been treated previously with chemotherapeutic 
drugs. The results of this study indicated that the A-549 cell line is much more 
resistant to chemotherapeutic drugs which are substrates of MRP family (such as 
adriamycin, vincristine, vinblastine, VP-16, melphalan and cisplatin) than the SKLU- 
1 cell line whereas the resistance to taxol and 5-FU which are not MRP substrates was 
similar in these two cell lines. These results agree with levels of MRP 1 expression in 
A-549 and SKLU-1 cells reported by Berger et al. (1997). This group reported that 
among 15 NSCLC (non-small-cell lung cancer) cell lines investigated, A-549 
expressed MRP1 at level comparable to drug-selected MDR cell lines while SKLU-1 
cells expressed very low levels of MRP1.
To date, a number of studies have been carried out investigating the expression of 
oncogenes in the A-549 cell line. In one study, Kiefer et al. (1990) reported that v-src 
oncogene was highly expressed in the A-549. Lower levels of c-myc, v-erbB, c-rafl, 
c-Ha-ras, Ki-ras and N-ras were also expressed in this cell line. Whether the intrinsic 
resistance to the chemotherapeutic drugs in the A-549 cell line is related to the 
expression of these oncogenes needs to be clarified.
Of the two breast cell lines used in this study, more work has been carried out using 
the BT-20 cell line. This is an oestrogen-independent human breast adenocarcinoma 
cell line (Cappelletti et al., 1991). Studies have shown that neither MRP1 nor Pgp are 
expressed in this cell line. The toxicity tests of this study showed that BT-20 cell line
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was relatively sensitive to all the drugs tested with the exception of melphalan. No 
further studies were carried out to detect the mechanisms involved in its resistance to 
melphalan. To date, very little characterisation studies have been carried out in the 
human breast ductal carcinoma cell line, MX-1.
In contrast to the BT-20 cell line, the results obtained in this study showed that MX-1 
cells are intrinsically resistant to many anticancer drugs. Overall, no generalisation 
can be made from these results in the breast and lung cancer cell lines regarding their 
sensitivities to chemotherapeutic drugs.
The results obtained demonstrated that a human nasal carcinoma cell line, RPMI- 
2650, was most sensitive to a wide range of drugs in all the cell lines investigated. 
Since the RPMI-2650 cell line was sensitive to a number of different 
chemotherapeutic drugs, work was carried out to establish resistant variants of this 
cell line.
4.2 Characterisation of RPMI-2650 and DLKP cell lines 
4.2.1 Characterisation of RPMI-2650 cell line
RPMI-2650, the main cell line used throughout this work, was established by Moore 
and Sandberg in 1962 (Moore and Sandberg, 1963). This cell line was derived from a 
52-year-old male. The pathological diagnosis of the tumour removed from his nasal 
septum was anaplastic squamous cell carcinoma. Subsequently, bilateral cervical 
lymph node metastases developed. A pleural effusion accumulated and it contained 
numerous tumour cells. Cell cultures were initiated from fresh pleural fluid. Moore 
and Sandberg found that there were a diploid number of chromosomes in the cell line 
and the karyotype was consistent with that of the normal human male. This finding 
was contrary to their experience with approximately 200 malignant cell specimens 
from effusions and biopsy specimens. In the rare instance a tumour had cells with 46 
chromosomes, at least 1 chromosome was distinctly abnormal.
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The results presented in this thesis indicate that Pgp and MRP1 are expressed in the 
RPMI-2650 cell line as demonstrated by Western blotting, immunocytochemistry and 
RT-PCR analysis. GST n, topoisomerase II a  and metallothionein were also detected 
in this cell line by immunocytochemistry. However, the results obtained from toxicity 
assays with different groups of chemotherapeutic agents indicate that the RPMI-2650 
cell line is very sensitive to anticancer drugs. This result suggests that the P- 
glycoprotein and/or MRP1 expressed in the cells may be non-functional. The most 
conclusive result to support this assumption is the result obtained from adriamycin 
distribution studies (see section 3.6.1). After a four-hour incubation period with 
adriamycin, strong adriamycin accumulation was noted in the nuclei of RPMI-2650 
cells. This indicated that very little drug efflux was occurring in the cells which 
strongly suggested that P-glycoprotein and/or MRP1 were non-functional. Similarly, 
Marks et al. (1995) reported that treatment of K562 cells (human leukaemia cell line) 
and its epirubicin-selected MDR variant K562/E15B with sodium butyrate, a 
differentiating agent, resulted in an increase in P-glycoprotein expression in the 
K562/E15B cell line. However, no increase in drug resistance or decrease in 
rhodamine-123 accumulation was observed in the K562/E15B. They concluded from 
these studies that the P-glycoprotein was non-functional. They stressed the 
importance of examining not only the expression of P-glycoprotein, but also its 
functionality. The addition of verapamil or cyclosporin A did not lead to an obvious 
enhancement of adriamycin accumulation in the RPMI-2650 parental cell line 
whereas a significant enhancement was observed in the RPMI-2650 taxol- and 
melphalan-resistant variants (see section 3.6.2), This agrees with the report that the 
sensitivity of most intrinsically sensitive cells to cytotoxic drugs is not significantly 
affected by verapamil or cyclosporin A (Ford and Hait, 1993).
Previous studies have been carried out to investigate the expression of cytokeratins in 
the RPMI-2650 cells. Moll et al. (1983) have reported that cytokeratins 7, 8, 18, 19 
are typical of simple epithelia while cytokeratins 1, 5, 6, 10, 11, 14-17 are typical of 
stratified epithelia. These authors also reported that the RPMI-2650 cell line contained 
cytokeratins 5, 7, 8, 17, 18, 19 which belong to complex pattern of cytokeratins. 
Sandoz Pharma (De Fraissinette et a l, 1995) carried out a study in the RPMI-2650 
cell line and reported that the intermediate filament, vimentin, was strongly expressed
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in RPMI-2650 whereas desmin which is mainly expressed in muscle cells was not. 
Normally, epithelial cells express cytokeratins but not vimentin. These results 
suggested that the RPMI-2650 cell line expressed inappropriate intermediate filament 
which may be an indicator of its malignancy. They also reported that the cells were 
not polarised (differentiation into apical and basal parts), had no cilia and were not 
connected by tight junctions which indicated that the RPMI-2650 cells express 
transformed or undifferentiated phenotypes.
The patient from whom this cell line was derived developed cervical lymph node 
metastases and the tumour finally affected the lung. However, experiments reported in 
this thesis demonstrated the non-invasiveness of RPMI-2650 in vitro (see section 
3 .13). All these results suggested that the final outcome of metastases depends on the 
interaction of the host and the tumour. RPMI-2650 cells may be activated by the 
environment of the host whereas they were non-invasive in vitro.
Like many other cancer cell lines, the RPMI-2650 line has a heterogeneous 
population. The concept of tumour progression was introduced by Foulds (1954) who 
stated that tumour progression is a process of independent, stepwise and permanent 
changes in one or more different properties of a malignant tumour. The process of 
progression is thought to result from genetic instability, leading to continuous 
emergence of various clones. Antigen expression, immunogenic specificity, 
karyotype, DNA content, degree of differentiation, morphology, growth 
characteristics, drug sensitivity, hormone-dependency and metastatic potential are 
some of the characteristics which can change as a tumour develops. The mechanisms 
of cellular interaction among subpopulations of tumours have not been elucidated. Its 
understanding can help to clarify tumour evolution, spontaneous tumour regression, 
involution of the primary tumour in metastatic cancer, development of resistance to 
therapy and remission and relapse. In this study, different clones derived from RPMI- 
2650 parental cells showed different morphology, Pgp and integrin expression and 
adhesiveness to the extracellular matrix. The overexpression of Pgp in clone 6 
indicates that although cells can acquire resistance after exposure to chemotherapeutic 
drugs, small population of resistant cells are already present in the tumour before 
chemotherapy (see section 3.17.2). It may thus be concluded that repeated low-dose 
chemotherapy with tumour which is dominated by chemosensitive subpopulations
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may lead to a better outcome of treatment whereas the application of an initial 
maximal tolerated dose may reduce the chemosensitive populations to an extent 
which these populations can no longer inhibit the growth of the resistant population. 
The dogma that maximal tolerated drug dose used in a regimen of cancer treatment 
gives the optimal outcome may not always be true (Aabo, 1996). In the same manner, 
metastasis favours the survival and growth of a few subpopulations of cells that pre­
exist within the parental cells (Fidler and Kripke, 1977). Thus, metastases can have a 
clonal origin, and different metastases can originate from the proliferation of different 
single cells (Talmadge et al., 1982; Fidler and Talmadge, 1986). Chen et al. (1994) 
reported the establishment and characterisation of 117 clones derived from the 
primary culture of cells obtained from biopsy tissue of an aggressive human 
squamous cell lung tumour. These clones exhibited different phenotypes with respect 
to the expression of integrins, attachment to ECM, tumourigenicity and experimental 
metastasis. The matastatic ability of different clones of RPMI-2650 with different 
properties of integrin expression and adhesiveness to ECM should be studied further.
4.2.2 Characterisation of DLKP cell line
DLKP, a poorly differentiated squamous lung cancer cell line, was established from a 
lymph node metastasis biopsy by bronchoscopy in this centre (Law et al., 1992). 
Results obtained from toxicity assays indicated that the DLKP cells were very 
sensitive to adriamycin, vincristine, VP-16 and cisplatin (Clynes et al., 1992). RT- 
PCR analysis showed that while the cells expressed low levels of mrpl, no mdr-lwas 
detected (NicAmhlaoibh et al., 1999). The results of RT-PCR and Western Blotting 
analysis presented in this thesis confirm these findings (see section 3.3 and 3.5). 
Adriamycin distribution studies demonstrated a high level of adriamycin 
accumulation in the nuclei of DLKP cells after two-hour-incubation with this drug 
(Cleary et al., 1997), suggesting that adriamycin was not effectively pumped out 
from the cell by MRPl. An adriamycin-selected variant (DLKP-A) (Clynes et al., 
1992) and a carboplatin-selected variant (DLKP-C) (Irene Cleary, Ph.D. thesis, DCU, 
1995) of DLKP have also been established. These variants were used as controls 
throughout this work.
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Similar to the RPMI-2650 cell line, DLKP was derived from a secondary site of the 
original tumour. However, invasion assays demonstrated a low level of invasiveness 
in this cell line and no MMP-2 and MMP-9 was detected by zymography. This 
suggests that, similar to RPMI-2650, DLKP was metastatic in vivo but not in vitro. 
The explanation for this could be the interaction of organ microenvironment and 
cancer cells.
Grant (1993) reported that cytokeratin 18 was not detected in DLKP cell line by 
immunofluorescence, possibly due to its poor differentiation state. Again, 
immunofluorescence staining was not observed using anti-cytokeratin pan (a 
combination of all the cytokeratins) as the primary antibody in this cell line 
(Geraldine Grant, Ph.D. thesis, DCU, 1993).
Similar to the RPMI-2650 cell line, DLKP cells also display a heterogeneous 
population. McBride et al. (1998) reported that DLKP contains three morphologically 
distinct populations. These subclones displayed different growth characteristics, 
chromosome numbers and adhesiveness to ECM.
4.3 Taxol resistance
Taxol, a potent anticancer drug first extracted from the bark of the Pacific yew tree, 
has become increasingly important in the treatment of ovarian cancer, breast cancer 
and non-small cell lung cancer. Studies carried out with taxol-resistant tumour cells 
have clearly demonstrated that the cellular transport of taxol and its microtubule 
binding activity are important factors in the development of resistance to taxol. 
Recently, studies have also shown that a panel of oncogenes are involved in the taxol 
resistance (see later part of this section).
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Findings in the RPMI-2650 taxol-resistant variant Methods used
Overexpression of Pgp Western blotting, RT- 
PCR,
Immunocytochemistry
Down-regulation of MRP 1 Western blotting, RT- 
PCR
Lack of expression of cMOAT (MRP2), MRP3, MRP4 and 
MRP5
RT-PCR
Cross-resistant to adriamycin, vincristine, vinblastine and 
VP-16, but not significantly resistant to melphalan, 
cadmium chloride, cisplatin and 5-FU
Toxicity assay
Very weak adriamycin accumulation in the nuclei Adriamycin 
distribution study
Cyclosporin A seems to be more effective than verapamil on 
circumventing adriamycin toxicity in this variant
Circumvention studies
Increase of c-myc expression, undetectable level of c-Ha-ras RT-PCR
Undetectable level of LRP Immunocytochemistry
Similar expression level of GST %, metallothionein and 
topoisomerase II a  as the RPMI-2650 parental cells
Immunocytochemistry
Decreased expression of cytokeratin 18 I mmuno fluorescence
Table 4.3 Summary of findings in the RPMI-2650 taxol-resistant variant
Numerous studies indicate that taxol resistant cancer cell lines overexpress P- 
glycoprotein, but not MRP (Van Ark-Otte et al., 1998; Huang et al., 1997; Dumontet 
et al., 1996; Bhalla et al., 1994). In an attempt to identify the mechanisms of 
resistance in the RPMI-2650 taxol-resistant variant, alterations in the levels of a 
number of MDR markers were investigated in this thesis. Overexpression of P- 
glycoprotein was detected in the RPMI-2650 taxol-resistant variant by Western 
blotting, immunocytochemistry and RT-PCR compared to its parental cell line 
(section 3.3.1.1; 3.4.1.1; 3.5.1.1). Western blotting and RT-PCR demonstrated that the 
level of MRP 1 expression was greatly decreased in the RPMI-2650 taxol-resistant 
variant compared to its parental cell line (section 3.3.2.1; 3.5.2.1). The expression of
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mrp2-mrp5 was undetectable by RT-PCR in the taxol-resistant variant (section 
3.5.3.1; 3.5.4; 3.5.5; 3.5.6). The exact mechanism of down-regulation of MRP1 in the 
taxol-resistant variant is unknown. Other investigators have also observed decreased 
levels of MRP 1 in cell lines and tumours that overexpress Pgp or vice verse. For 
example, in OAW42-S cells, a drug-sensitive clone of the ovarian cancer cell line 
OAW42, MRP 1 was expressed at a higher level than in OAW42-A1 and OAW42-A 
cell lines which are two adriamycin-selected variants. However, Pgp was 
overexpressed in OAW42-A and OAW42-A1 cells, but not in OAW42-S cells (Moran 
et al., 1997). Larkin et al. (1998) carried out immunohistochemical analysis on pre- 
and post-treatment samples from breast cancer patients. The results showed that in 
tumours where intense MRP1 positivity was observed, the level of Pgp expression 
was low. The expression of another resistance marker LRP was also investigated in 
the RPMI-2650 taxol-resistant variant by immunocytochemistry, however, no 
significant level of LRP was observed (see section 3.4.1.3). These results suggest that 
P-glycoprotein, but not LRP and MRP family members, plays a major role in the drug 
resistance phenotype in the RPMI-2650 taxol-resistant variant.
Fluorescence microscopy was carried out to determine if the resistance phenotype in 
the RPMI-2650 taxol-resistant variant was due to a reduction in cellular drug 
accumulation. The studies revealed that adriamycin predominantly localised in the 
nucleus of the RPMI-2650 parental cell line whereas very faint nuclear fluorescence 
was observed in the taxol-resistant cells (section 3.6). Faint cytoplasmic fluorescence 
was also observed in these cells, consistent with the localisation of drug within 
cytoplasmic vesicles. This result together with the results obtained from 
circumvention studies with verapamil and cyclosporin A (section 3.8) strongly 
suggest that P-glycoprotein is involved in drug resistance in the RPMI-2650 taxol- 
resistant variant. Numerous studies have been carried out to determine the effect of 
chemosensitisers on taxol resistance. In one study, Lehnert et al. (1993) tested the 
potential usefulness of currently available chemosensitisers for clinical reversal of 
Pgp-mediated taxol resistance. The 8226/Dox6 human myeloma cells, which 
overexpress Pgp and are approximately 40-fold resistant to taxol, were used to 
evaluate the effects of cyclosporin A, verapamil, quinidine and quinine on taxol 
resistance. Of these four modulators, cyclosporin A proved to be the most effective 
agent in reversing taxol resistance in the 8226/Dox6 cells, which agrees with the
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result obtained from circumvention studies reported in this thesis. Cyclosporin A and 
its analogue SDZ PSC 833 were also found to be more effective than verapamil in 
modulating efflux of the Pgp substrate, rhodamine 123 in vinblastine-selected, Pgp- 
overexpressing Chinese hamster ovary CHO cell lines (Petriz et al., 1997).
The cross resistance profile (as shown in section 3.2.4.1) of the RPMI-2650 taxol- 
resistant variant illustrates that this variant is cross resistant to a number of 
chemotherapeutic drugs (i.e. it displays MDR). This variant also displays a cross 
resistance pattern consistent with the overexpression of P-glycoprotein. Taxol- 
resistant cell lines which overexpress P-glycoprotein usually exhibit cross resistance 
to adriamycin, vincristine, vinblastine, VP-16 and show little or no cross resistance to 
alkylating agents, platinum drugs and antimetabolites. In this study, the RPMI-2650 
taxol-resistant variant was found to be resistant to taxol (226-fold) and cross resistant 
to adriamycin, vincristine, vinblastine and VP-16. However, there was no significant 
resistance to melphalan, cisplatin and 5-FU.
In a study on taxol-resistant populations of the human sarcoma cell line MES-SA 
(Dumontet et al., 1996), all the resistant cell populations were found to be cross 
resistant to the tubulin depolymerising agents vincristine and vinblastine. Among 
these populations, MDR-1-positive clones demonstrated resistance to adriamycin and 
VP-16 which are substrates for the Pgp efflux pump whereas MDR-1-negative clones 
displayed sensitivities to adriamycin and VP-16. Taxol-resistant clones from a human 
ovarian carcinoma cell line 2008 were established. The 2008/17 clone displayed a P- 
glycoprotein-mediated drug resistance phenotype. Similar to the results obtained with 
the RPMI-2650 taxol-resistant variant, this clone was found to be highly cross- 
resistant to adriamycin, VP-16 and vincristine, but not to cisplatin (Parekh et al.,
1997).
A taxol-resistant subline (HL-60/ TAX 1000) of the myeloid leukaemia cell line HL- 
60 has also been shown to be cross-resistant to vincristine, adriamycin, but sensitive 
to the antimetabolite Ara-C (Bhalla et a l, 1994). In a study on the murine 
macrophage like cell line J774.2, a taxol-resistant subline J7/Tax-50 was developed 
(Roy et al., 1985). I7/Tax-50 was shown to be 800-fold resistant to taxol and to
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display cross-resistance to colchicine, vinblastine, adriamycin and actinomycin D, but 
remained sensitive to the alkylating agent bleomycin.
No difference in the expression of topoisomerase II a  was observed by 
immunocytochemistry in the RPMI-2650 cell line and its taxol-resistant variant (see 
section 3.4.1.5). This would rule out the possible involvement of topoisomerase II in 
the resistance to adriamycin and VP-16 which exert cytotoxicity on topoisomerase II 
in the taxol-resistant variant. No significant difference in the expression of 
metallothionein was observed by immunocytochemistry in the RPMI-2650 parental 
cell line and its taxol-resistant variant which indicates that metallothionein does not 
play a major role in drug resistance in this taxol-resistant variant (section 3.4.1.6).
Microtubules are dynamic polymers and alterations in assembly and disassembly 
dynamics play a key role in the antimitotic effects of depolymerising agents, such as 
vincristine and stabilising agents, such as taxol. Thus, a number of mechanisms may 
be involved in the induction of resistance to these agents: (1) reduced binding of the 
drug (Boggs et al., 1993). (2) reduced amounts of the target molecule tubulin (Minotti 
et al., 1991) and (3) altered dynamic properties of microtubules (Rowinsky et al., 
1988).
In agreement with this, other studies have reported that taxol-resistant cancer cell 
lines that do not overexpress P-glycoprotein have altered a- or P-tubulin isotypes. 
Schibler et al. (1986) reported the isolation of 139 Chinese hamster ovary cell mutants 
resistant to taxol. Of these mutants, 59 exhibited an absolute requirement for taxol for 
normal growth and division, 13 had a partial requirement and 69 grew normally 
without the drug. Two dimentional gel analysis of whole cell proteins revealed "extra" 
spots representing altered tubulins in 13 of the mutants. Six of these had an altered a- 
tubulin and seven had an altered P-tubulin. Cabral et al. (1986) also reported that, 
when compared with wild-type cells, taxol-dependent mutants had normal arrays of 
cytoplasmic microtubules but formed much smaller mitotic spindles in the presence of 
taxol. When deprived of the drug, however, complete assembly of the mitotic spindle 
apparatus did not occur in these mutants. Thus, the defects leading to taxol
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dependence in these mutants with defined alterations in a - and (3-tubulin appear to 
result from the inability of the cells to form a functional mitotic spindle.
In section 3.4.2 of this thesis, immunofluorescence studies revealed that the RPMI- 
2650 taxol-resistant cells displayed slightly fainter a - and (3-tubulin fluorescence 
compared to the RPMI-2650 parental cells. The results of studies carried out to date 
regarding tubulin content in taxol-resistant cell lines are conflicting. Jaffrezou et al. 
(1995) noted no difference in total tubulin content between the parental K562 cell line 
and its 9-fold taxol- resistant variant KPTA5. However, they found that the taxol- 
resistant cells presented a 2-fold increase in both 5 P-tubulin mRNA expression and in 
the corresponding tubulin protein class IV isotype content, as revealed by RT-PCR 
and immunostaining respectively. Dumontet et al. (1996) reported that total tubulin 
content was significantly decreased in one of the taxol-resistant variants of MES-SA 
sarcoma cells. Reduced expression of the 5(3 and the P4 tubulin isotype transcripts in 
this variant was also observed compared to the parental cells.
Ohta et al. (1994) established a taxol-resistant variant (H69/TX1) of the human small­
cell lung cancer cell line H69. No significant levels of Pgp were detected in this 
variant. However, altered a-tubulin isoform and increased acetylation of a-tubulin 
was observed in the H69/TX1 cells compared to the parental cells. Kavallaris et al. 
(1997) selected the human lung cancer cell line A-549 with taxol resulting in cell 
variants that were 9- and 17-fold resistant. These cells displayed an altered ratio of 
classes I, n, III and IVa P-tubulin isotypes. Four taxol-resistant ovarian tumour- 
bearing ascites also displayed significant increases in class I, III and IVa P-tubulin 
isotypes as compared to untreated primary ovarian tumours.
Although the mechanism underlying the alteration in tubulin content in taxol 
resistance is not clear, reduced amounts of the target molecule, tubulin, may 
contribute to taxol resistance. In mammals, there are at least six isoforms of a-tubulin 
and a similar number of P tubulin isoforms, each encoded by a different gene 
(Sullivan, 1988). The role of the various tubulin isotypes remains controversial. 
Functional differences between tubulin isotypes have not been identified. The
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alteration in the content of the isotypes of a  and p-tubulin is not explored in this 
thesis.
Microtubules are composed of a-tubulin and P-tubulin which have 12 and 8 cysteine 
residues respectively (Cowan et al., 1983). Oxidation of tubulin sulfhydryl groups has 
been shown to prevent the polymerisation of tubulin and the formation of 
microtubules (Ikeda et al., 1978). Subsequent reduction of sulfhydryl moieties 
restores the ability of tubulin monomers to polymerise and form microtubules. Further 
evidence of a crucial role for sulfhydryls in microtubule assembly comes from studies 
using BSO, a potent inhibitor of glutathione synthesis, and CDNB, a compound which 
causes the rapid consumption of GSH. Exposure of the human lymphoid cell line 3T3 
to both BSO and CDNB resulted in a complete loss of microtubules within the cells 
since the sulfhydryl groups of tubulins could not be reduced (Leung et al., 1989). 
Preincubation of the 3T3 cells in taxol prevented the disaggregation of microtubules 
when GSH was subsequently lowered by CDNB (Chou et al., 1984). Liebmann et al.
(1993) reported that the depletion of glutathione by BSO antagonised the cytotoxicity 
of taxol and this effect was not due to altered uptake of drug. It has been suggested 
that the cysteine residues in a - and P-tubulin may undergo increased oxidation of 
their sulfhydryl groups when cellular glutathione levels are reduced, thereby altering 
their ability to polymerise. The effect of BSO on the RPMI-2650 taxol-resistant cells 
was not explored in this work. GST activity assay revealed that the RPMI-2650 taxol- 
resistant cells had only slightly higher GST activity than the parental cells, thus 
suggesting that GST does not play a major role in mediating resistance in the taxol- 
resistant variant.
Apart from Pgp overexpression and the development of altered a - or P-tubulin 
isotypes, reports have suggested that other mechanisms may be involved in taxol 
resistance. It was reported that taxol is metabolised by the cytochrome P-450 system 
and its metabolism may be altered by other drugs affected by this system (Rahman et 
al., 1994). Consequently, this system may also be involved in the mechanisms of 
resistance to taxol. It has also been reported that a good correlation exists between the 
presence of a 135kDa phosphoglycoprotein and resistance to taxol (Samar et al., 
1985). In this report, a taxol-resistant subline was developed from the murine
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macrophage-like cell line J774.2. Analysis of plasma membranes by SDS gel 
electrophoresis followed by silver staining revealed the presence of a prominent 
protein with an approximate molecular weight of 135,000 daltons in the resistant cell 
line which was absent from the parental cell line.
In section 3.4.2.3, the results of immunofluorescence demonstrated that the RPMI- 
2650 taxol-resistant variant displays a significant decrease in cytokeratin 18 levels 
compared to the RPMI-2650 parental cells. No significant difference in the levels of 
vimentin between these two cell lines was noted. Parekh et al. (1995) reported that the 
cisplatin-resistant human ovarian 2008/cl3* cell line contained markedly lower levels 
of cytokeratin 18 when compared to the cisplatin-sensitive 2008 cell line. 
Transfection of full-length cytokeratin 18 cDNA into the cisplatin-resistant 2008/Cl 3* 
cells resulted in a marked increase in sensitivity to cisplatin. Thus, a relationship 
exists between cytokeratin 18 and the anticancer drug. (Cytokeratin dependent drug 
resistance (C-MDR) has been introduced in section 4.4). So far, no study regarding 
the relationship between the cytokeratin 18 and taxol resistance has been reported. 
Although the mechanism underlying the decrease of cytokeratin 18 in the RPMI-2650 
taxol-resistant variant is not clear, it is possible that cytokeratin 18 may be involved in 
mediating taxol resistance. Vimentin does not appear to play a role in mediating taxol 
resistance in the RPMI-2650 taxol-resistant variant since no alteration in vimentin 
levels was noted.
Many recent reports focus on the relationship between apoptosis, oncogene 
expression and taxol resistance. Rasouli et al. (1998) reported that Raf-1 protein 
kinase may have a profound influence on the level of taxol-induced apoptosis. In the 
12 human cervical tumour cell lines studied, Raf-1 kinase activity was inversely 
correlated with the level of cytotoxicity induced by taxol. It was shown that Raf-1 
kinase acts to suppress taxol-induced apoptosis. This data suggests that the clinical 
effectiveness of taxol could be improved by the use of Raf-1 kinase inhibitors. Other 
oncogenes have also been shown to be involved in taxol resistance. Human c-erbB-2 
gene which encodes P I85 protein was transfected into MDA-MB-435 human breast 
cancer cells. The PI 85-over expressing MDA-MB-435 transfectants were more 
resistant to taxol than the parental cells. No increase in P-glycoprotein expression was 
observed in the PI 85-overexpressing MDA-MB-435 transfectants. This data
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demonstrated that overexpression of c-erbB-2 could lead to intrinsic taxol resistance 
independent from P-glycoprotein (Yu et a l, 1996). It was found that taxol activates 
P34Cdc2 kinase in MDA-MB-435 breast cancer cells, leading to cell cycle arrest at 
the G2/M phase and subsequently, apoptosis. Over expression of PI 85 ErbB2 in 
MDA-MB-435 cells resulted in the upregulation of P21Cipl, which associates with 
P34Cdc2, inhibits taxol-mediated P34Cdc2 activation, delays cell entrance to G2/M 
phase, and thereby inhibits taxol-induced apoptosis (Yu et al., 1998). Huang et al. 
(1997) demonstrated by immunoblot analysis that the taxol-resistant variant HL- 
60/TAX1000, derived from the human leukaemia cell line HL-60, had higher Bcl-2 
and Bcl-xl levels than HL-60. Transfection of bcl-2 or bcl-xl into the HL-60 cells 
significantly reduced taxol-induced apoptosis. C-myc also appears to be involved in 
resistance to many chemotherapeutic drugs (Niimi et al., 1991; NicAmhlaoibh et al., 
1999). Preliminary results of RT-PCR analysis described in section 3.5.7 suggests that 
overexpression of c-myc might also be involved in taxol resistance in the RPMI-2650 
taxol-selected variant.
4.4 Melphalan resistance
Melphalan is an alkylating agent which results in cross-linking between DNA strands 
or linkages between bases within the same strand of DNA (section 1.2.2). Melphalan 
has been used extensively in the treatment of a number of tumours. For multiple 
myeloma, no available treatment is curative, but about two thirds of patients achieve a 
stable response to combination chemotherapy (MacLennan et al., 1994). Standard 
chemotherapy (melphalan and prednisone, MP) has been the main regimen of 
multiple myeloma for about 3 decades (Huang et a l, 1999). However, it is no longer 
considered the "gold standard". Chemotherapy including adriamycin and carmustine 
with the alkylating agents cyclophosphamide and melphalan achieves a higher stable 
response rate than conventional treatment with melphalan and prednisone without 
additional haematological toxicity (MacLennan et a l, 1994).
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Chemotherapy is applied to almost all patients with advanced breast cancer. Response 
rates have been increased by the use of combination of taxoids and anthracyclines 
and/or alkylating agents. To improve access to chemotherapy, orally administered 
drugs are very useful for those patients when access to hospital is limited by financial 
considerations, long journeys or patient reluctance. In the past, only alkylating agents 
(cyclophosphamide, chlorambucil, melphalan) could be administered orally. 
Development of new oral drugs will simplify maintenance regimens on an outpatient 
basis (Marty et al., 1999).
The three-drug combination of melphalan, etoposide (VP-16) and carboplatin 
followed by autologous stem-cell rescue has been recently evaluated by the French 
Society of Pediatric Oncology in treatment of pediatric Wilm's tumour patients (Pein 
et al., 1998). About half of the patients tested remained disease-free for 3 years, 
indicating that this regimen is satisfactory.
Melphalan has also been extensively used in colorectal cancer hepatic metastases, 
melanoma, ovarian, testes and thyroid cancers, as well as in leukaemia, lymphoma 
and conditioning regimens for bone marrow transplantation (Samuels and Bitran, 
1995).
There are many mechanisms involved in the drug resistance to melphalan. The most 
recent reports emphasised the enhancement of GS-X pump activity in melphalan 
resistance. The GS-X pump is an ATP-dependent export pump for organic anions 
such as cysteinyl leukotrienes, glutathione disulfide and glutathione S-conjugates. 
Studies by Muller et al. (1994) and Leier et al. (1994) have provided important 
evidence that the multidrug resistance-associated protein (MRP) gene encodes a GS-X 
pump. ledlitschky et al. (1996) demonstrated MRPl-mediated ATP-dependent 
transport for the monochloro-mono[3H]glutathionyl melphalan which proved again 
that glutathione conjugation is an important way to detoxify melphalan. Ishikawa et 
al. (1996) reported that in a cisplatin-resistant variant (HL-60/R-CP) of the human 
myelocytic leukaemia HL-60 cell line, MRP1 was overexpressed. Culturing the HL- 
60/R-CP cells in cisplatin-free medium resulted in a reduction in mrpl mRNA level, 
but the level could be induced to rise within 30 hours by exposure to cisplatin and 
heavy metals such as arsenite, cadmium and zinc, y-glutamylcysteine synthetase
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expression in the cisplatin-resistant cells was also induced within 24 hours exposure 
to cisplatin, resulting in a significant increase in cellular GSH level since y- 
glutamylcysteine synthetase catalyses the first step in GSH formation. HL-60/R-CP 
cells were found to be cross-resistant to melphalan, chlorambucil, arsenite and 
cadmium. These observations suggested that elevated expression of the MRP/GS-X 
pump and increased GSH biosynthesis may play an important role in mediating 
resistance to cisplatin, melphalan and heavy metals.
To date, newly identified MRP1 homologues, cMOAT (MRP2), MRP3, MRP4, 
MRP5, MRP6 have not been linked directly to melphalan resistance. However, it is 
quite possible that cMOAT and MRP3 could be responsible for melphalan resistance. 
cMOAT is also a GS-X pump whose substrate specificity is very similar to that of 
MRP1. It also contributes to the transport of some anticancer drugs and heavy metals. 
Mutant rats which did not express normal cMOAT showed a reduced biliary clearance 
of methotrexate (Masuda et a l, 1997), mercury, cadmium and arsenite (Kool et al, 
1999). Cells transfected with cMOAT cDNA were found to transport vinblastine 
(Evers et a l, 1998). Moreover, overexpression of the cMOAT gene has been found in 
several cisplatin-resistant cell lines (Taniguchi et al., 1996; Kool et al., 1997) and 
transfection of cMOAT-antisense constructs into liver cells was reported to confer an 
increased sensitivity to cytotoxic drugs (Koike et al., 1997). All these observations 
strongly suggest that cMOAT may confer resistance to melphalan.
MRP3 has also been shown to be a GS-X pump. Of all the MRP family members, 
MRP3 displays the strongest homology to MRP1 (58% amino acid identity). MOR/P, 
the lung adenocarcinoma cell line and KB-3-1, an epidermoid carcinoma cell line, 
showed high expression of MRP3 together with high expression of cMOAT (Kool et 
al., 1997). Several adriamycin-resistant sublines of a non-small cell lung cancer cell 
line, SW 1573/S 1, and the cisplatin-resistant colon carcinoma cell line, HCT8/DDP, 
have also been found to overexpress MRP3 (Kool et al., 1997). MRP3 is also able to 
confer resistance to methotrexate, VP-16 (etoposide), teniposide (Kool et al., 1999) 
and vincristine (Young et a l, 1999). All these results suggest that MRP3 is likely to 
play a role in melphalan resistance although direct evidence needs to be established.
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The RPMI-2650 melphalan-resistant variant was established by stepwise selection of 
the RPMI-2650 parental cells in increasing concentrations of melphalan. DLKP 
melphalan-resistant variants were obtained by either continual or pulse selection of 
DLKP to melphalan as described in section 2.5. The main results reported in this 
thesis are summarised below:
Findings in theRPM3-2650 melphalan-resistant variant Methods used
Slight increase of Pgp expression RT-PCR, Western 
Blotting and 
Immunocytochemistry
Overexpression of MRP 1 RT-PCR and Western 
Blotting
Overexpression of cMOAT(MRP2) and MRP3 RT-PCR and 
Immunocytochemistry
Increase of c-myc expression, undetectable level of c-Ha-ras RT-PCR
Cross-resistant to cadmium chloride, adriamycin, 
vinblastine, vincristine, VP-16, cisplatin, but not to taxol 
and 5-FU
Toxicity assay
Weak adriamycin accumulation in the nuclei, could be 
reversed by verapamil and cyclosporin A
Adraimycin 
distribution study
Verapamil seems to be more effective than cyclosporin A in 
circumventing adriamycin toxicity in this variant. Both 
sulindac and indomethacin can circumvent adriamycin 
toxicity in this variant.
Toxicity assay
Slightly higher activity of GST than the RPMI-2650 GST assay
Undetectable level of LRP expression Immunocytochemistry
Similar levels of expression of GST71, metallothionein and 
topoisomerase II a  as RPMI-2650
Immunocytochemistry
Table 4.4.1 Summary of findings in the RPMI-2650 melphalan-resistant variant.
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Findings in DLKP long-term melphalan-selected variant Methods
used
Undetectable level of Pgp expression RT-PCR and
Western
Blotting
Increase of MRP 1 expression RT-PCR and 
Western 
Blotting
Cross-resistant to cadmium chloride, cisplatin, adriamycin, 
vinblastine, but not to taxol
Toxicity
assay
Undetectable level of cmoat (mrp2) expression RT-PCR
Table 4.4.2 Summary of findings in the DLKP long term melphalan-selected variant
Findings in DLKP melphalan-pulse selected variant Methods
used
Undetectable level of Pgp expression Western
blotting
Increase of MRP 1 expression Western
blotting
Cross-resistant to cadmium chloride, cisplatin, adriamycin, but not to 
taxol and vinblastine
Toxicity
assay
Table 4.4.3 Summary of findings in the DLKP melphalan-pulse selected variant
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In an attempt to identify the mechanisms of MDR in the RPMI-2650 and DLKP 
melphalan-resistant variants, alterations in a number of MDR markers were 
investigated. Western blotting analysis demonstrated MRP1 and cMOAT (MRP2) 
overexpression and a slight increase in Pgp expression in the RPMI-2650 melphalan- 
resistant variant compared to the parental cell line (see section 3.3.1.1, 3.3.2.1 and
3.3.3). RT-PCR analysis demonstrated the overexpression of mrpl, cmoat (mrp2), 
mrp3 and a slight increase of Pgp at mRNA levels in the RPMI-2650 melphalan- 
resistant variant compared to the parental cells (see section 3.5). Results of 
fluorescence microscopy studies showed that the intensity of adriamycin nuclear 
fluorescence was greater in the RPMI-2650 cells than in the melphalan-resistant 
variant (see section 3.6). This implicates decreased drug accumulation as a 
mechanism of resistance in the melphalan-resistant variant. Overexpression of MRP 1, 
cMOAT (MRP2), MRP3 or possibly P-glycoprotein may lead to the decreased 
accumulation of adriamycin in the variant. Results obtained from fluorescence 
microscopy studies also demonstrated that adriamycin accumulation can be increased 
by verapamil and cyclosporin. This result together with the results of circumvention 
studies with verapamil and cyclosporin A support the hypothesis that MRP family 
members may play a major role in drug resistance in the RPMI-2650 melphalan- 
resistant variant. Previous studies have shown that although cyclosporin A was more 
effective than verapamil on circumventing adriamycin resistance in vincristine- 
selected, Pgp-overexpresing myelocytic leukaemia cell line HL60/vinc (McGarth et 
al., 1988), verapamil was the more effective agent on reversing either adriamycin or 
etoposide (VP-16) resistance in adriamycin-selected, MRP 1-overexpressing 
HL60/ADR (Germann et al., 1997). Other studies performed in several different 
MRP 1-overexpressing cell lines including small cell lung cancer cell line H69AR, 
fibrosarcoma cell line HT-1080/DR4 and large cell lung cancer cells COR-L23R have 
also suggested that verapamil was somewhat more effective than cyclosporin A as a 
chemosensitiser (Germann et al., 1997; Barrand et al., 1993; Cole et al., 1989). The 
results of the circumvention studies reported in this thesis are consistent with the data 
mentioned above (see section 3.8). Similar to the results obtained for the RPMI-2650 
melphalan-resistant variant, MRP 1 was found to be overexpressed in the DLKP long 
term melphalan-selected and melphalan-pulse selected variants as detected by 
Western blotting and RT-PCR (section 3.3.2.2, 3.5.2.2). Significant levels of Pgp 
were not detected at either protein or mRNA levels in the DLKP cells and its
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melphalan-resistant variants (section 3.3.1.2; 3.5.1.2). This suggests that MRP1 may 
be responsible for melphalan resistance in these variants.
The circumvention studies with sulindac and indomethacin also suggest that MRP 
family members may play a role in melphalan resistance in the RPMI-2650 
melphalan-selected variant (section 3.8). Sulindac and indomethacin are nonsteroidal 
antiinflammatory drugs (NSAIDs) which are among the most frequently used medical 
drugs. They are used primarily as analgesics, anti-inflammatories and anti-pyretics. 
Their main known mode of action is through inhibition of the cyclo-oxygenase- 
mediated production of prostaglandins, but this is not thought to be sufficient to 
explain their wide variety of actions. There is currently widespread interest in their 
potential roles as chemotherapy modulators. It has been reported that indomethacin 
may reverse MRP-mediated efflux of adriamycin and vincristine via inhibition of the 
MRP pump and inhibition of glutathione-S-transferase (Draper et al., 1997). The 
effect of combining a range of NSAIDs with a variety of chemotherapeutic drugs on 
cytotoxicity was examined in the human lung cancer cell lines DLKP, A-549, COR- 
L23R and in a human leukaemia line HL60/ADR. Sulindac and indomethacin 
significantly increased the cytotoxicity of the anthracyclines, as well as VP-16 and 
vincristine, but not cisplatin, cyclophosphamide, bleomycin and taxol (Duffy et al.,
1998). In the MRP 1-overexpressing HL60/ADR and COR-L23R cell lines, a 
significant increase in cytotoxicity was observed in the presence of sulindac and 
indomethacin. It was found that sulindac and indomethacin were potent inhibitors of 
[3H]-LTC4 transport into inside-out plasma membrane vesicles prepared from MRP- 
expressing cells, of adriamycin efflux from preloaded cells and of glutathione-S- 
transferase activity which agreed with the results of Draper et al. mentioned above 
(Duffy et al., 1998). Sulindac and indomethacin were believed to reverse MRP1- 
mediated efflux of drug by competitive inhibition of MRP1; whether these two 
compounds can inhibit cMOAT (MRP2)- and MRP3-mediated drug efflux is 
unknown. In section 3.8, the results showed that indomethacin is more cytotoxic than 
sulindac to the RPMI-2650, DLKP cell lines and their MDR variants. Treatment with 
sulindac or indomethacin resulted in increased cytotoxicity of melphalan in the 
RPMI-2650 melphalan-resistant variant, which again suggests the involvement of 
MRP1 in this variant.
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Cross resistance studies revealed that the RPMI-2650 melphalan-resistant variant was 
11-fold resistant to melphalan compared to its parental cell line and also cross 
resistant to cadmium chloride, adriamycin, vincristine, vinblastine and VP-16 (see 
section 3.2.4.2). Very low level of cross resistance to taxol, 5-FU and cisplatin was 
observed. Since Pgp (but not MRP) is related to taxol resistance, the slightly increased 
expression of Pgp in the RPMI-2650 melphalan-resistant variant might explain the 
low resistance to taxol in this variant. The RPMI-2650 melphalan-resistant variant 
showed extremely high resistance to cadmium chloride which is a substrate for 
MRP1, cMOAT and possibly MRP3. This variant also showed high resistance to 
adriamycin (which is substrate of MRP1, cMOAT, MRP3 and Pgp), to vinblastine 
(which is substrate of MRP1, cMOAT (MRP2) and Pgp) and to VP-16 (which is 
substrate of MRP1, MRP3 and Pgp). The cross resistance profile also strongly 
suggests the involvement of MRP 1, cMOAT and MRP3 in multidrug resistance in the 
RPMI-2650 melphalan-resistant variant.
Compared to the RPMI-2650 melphalan-resistant variant, the DLKP melphalan long 
term and pulse selected variants exhibited low level resistance to melphalan which 
probably relates more to the clinical situation. Cross resistance patterns of these 
variants showed high resistance to cadmium chloride and cisplatin (see section 3.2.4.3 
and 3.2.4.4). These variants were also resistant to adriamycin and VP-16. Resistance 
to vinblastine was observed in the DLKP long term melphalan-selected variant, but 
not in pulse selected variant, suggesting that very low level resistance to melphalan 
and/or very low level of MRP 1 overexpression might not be able to induce vinblastine 
resistance. No significant resistance to taxol was observed in these two variants, 
suggesting once again that Pgp was not involved in melphalan resistance in these 
variants. All these results suggest the involvement of MRP 1 and/or its homologue in 
melphalan resistance in the DLKP melphalan-selected variants.
Studies on the role played by LRP in melphalan resistance were based on the 
observation that LRP is widely expressed in untreated multiple myeloma and it is 
associated with a low probability of response and shorter survival in patients treated 
with conventional MP (melphalan combined with prednisone) regimen. It was found 
that LRP is an independent predictor for response and survival in patients treated with 
MP regimen (Raaijimakers et al., 1998). Also, it was reported that the melphalan-
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resistant variant 8226LR5 of the human myeloma cell line RPMI-8226 overexpressed 
LRP without any other MDR proteins (Raaijimakers et al., 1998). A mitoxantrone- 
selected, highly LRP-positive cell population of RPMI-8226 also showed cross 
resistance to melphalan (Raaijimarkers et al., 1998). It was hypothesised that vaults 
(LRP is the major protein of vaults) which localise in the nuclear membrane and 
nuclear pore complexes are involved in the nucleo-cytoplasmic exchange of 
melphalan which exerts its main cytotoxic effect in the cell nucleus. LRP was 
undetectable in both RPMI-2650 and its melphalan-resistant variant (see section
3.4.1.3), suggesting that LRP does not play a major role in drug resistance in this 
variant.
Some in vitro models of melphalan resistance have involved glutathione-mediated 
pathways, a finding observed in some rodent cell lines such as Chinese hamster 
L1210 leukaemia cell line (Ahmad et al., 1987) and human cancer cell lines, 
including ovarian (Green et al., 1984), myeloma (Gupta et al., 1989; Bellamy et al.,
1991) and prostate cells (Bailey et al., 1992).
Green et al. (1984) reported that they developed a human ovarian cancer cell line 
1847ME which was 4-fold resistant to melphalan compared to the parental cell line 
A1847. No detectable difference in melphalan uptake between the A1847 and 1847ME 
cell lines was noted. However, glutathione levels were found to be 2-fold greater in 
the 1847ME cells than in the A1847 cells. Similarly, murine L1210 cancer cell lines 
with acquired resistance to melphalan were shown to have elevated GSH levels 
(Suzukake et al., 1983). Several other independent studies using tumour models have 
also found an association between increased glutathione levels and resistance to 
melphalan and other alkylating agents (Ball et al., 1966; Calcutt et al., 1983; Somfai- 
Relle et al., 1984; Suzukake et al., 1983). Thus, GSH has been shown to play a crucial 
role in the resistance to melphalan in some cell lines.
In order to reverse GSH mediated resistance, buthionine sulfoximine (BSO), a 
specific inhibitor of y -g lu tam ylcyste ine  synthetase, has been used to deplete or lower 
GSH levels. Skapek et al. (1988) demonstrated that depletion of intracellular 
glutathione in the human medulloblastoma-derived cell line, TE-671, could
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significantly increase the activity of melphalan. Somfai-Relle et al. (1984) also 
demonstrated that L1210 leukaemia cells resistant to melphalan could be rendered 
sensitive by BSO-mediated reduction in cellular glutathione. Similar observations 
were seen with the melphalan-resistant human ovarian cancer cell line, 1847ME, which 
demonstrated an increased response to melphalan following depletion of glutathione 
(Green et al., 1984). Ozols et al. (1991) also demonstrated that the survival of mice 
inoculated i.p. with NIH:OVCAR-3 ovarian cancer cells (derived from a patient 
clinically refractory to alkylating agents) and treated with melphalan could be 
extended by pretreatment with BSO.
There are also examples in which the development of resistance to melphalan or other 
alkylating agents is associated with increased expression or activity of the enzyme 
glutathione S-transferase. Batist et al. (1986) demonstrated an increase in the total 
activity of GST in human breast cancer cells from 3.6nmol/min/mg protein in the 
parental line to 161nmol/min/mg protein in the resistant line. Bolton et al. (1991) 
reported that they purified GST isozymes from mouse liver and analysed the 
metabolic products of the reaction of melphalan with glutathione in the presence of 
GST isozymes. They found that only isozymes of the a  GST class catalysed the 
conjugation of melphalan with glutathione whereas p, or n isozyme appeared to have 
no effect. Thus, they suggested that increased levels of GST a  isozyme may represent 
a specific mechanism whereby cells can acquire resistance to melphalan. Hall et al.
(1994) also reported that a Chinese hamster ovary cell line, CHO-Chl, generated by 
exposure to chlorambucil and demonstrating a greater than 20-fold collateral 
resistance to melphalan showed increased expression of GST a. Their results 
suggested that overexpression of GST a  may be directly responsible for the 
development of resistance to bifunctional alkylating agents. In order to further define 
the function of human GST a, Leyland-Iones et al. (1991) transfected cDNA of GST 
a  into human MCF-7 breast cancer cells. However, the transfected cells failed to 
show any increased resistance to melphalan, adriamycin or cisplatin. Their results 
indicated that expression of human GST a  by itself in MCF-7 human breast cancer 
cell line does not confer resistance to the chemotherapeutic drugs.
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Elevated levels of GST n have also been shown in cultured cell lines resistant to 
melphalan (Robson et al., 1987). Ban et al. (1996) reported that they transfected GST 
7t antisense cDNA into the human colon cancer cell line M7609. They found that the 
sensitivity of the antisense transfectants to adriamycin, cisplatin, melphalan and 
etoposide was increased compared to those of the parental cells. They concluded that 
GST 7t was responsible for resistance to melphalan. However, Moscow et al. (1989) 
transfected a GST k experssion vector into MCF-7 cells and showed that the cells 
acquired resistance to etoposide, but there was no change in the cells' sensitivity to 
cisplatin and melphalan. Another group, Nakagawa et al. (1990) transfected a GST % 
expression vector into NIH-3T3 cells that had been transformed with H-ras and found 
that although resistance to adriamycin had increased, the cells did not acquire 
resistance to alkylating agents.
The results of GST activity assays in section 3.7 showed that the RPMI-2650 
melphalan-resistant variant had a slightly higher GST activity than the parental cells. 
No significant difference in GST % expression was observed by 
immunocytochemistry between the RPMI-2650 cell line and its melphalan-resistant 
variant. GST a  and were not detected in either of these cell lines. All the results 
obtained indicate that GST may play a minor role in drug resistance in the RPMI- 
2650 melphalan-resistant variant. Cellular glutathione content assays were not carried 
out for this study. In order to confirm the results, Western blotting of GST % and 
cellular glutathione content assay should be carried out. Grant (1993) reported that 
GST activity was decreased approximately 3-fold in the DLKP-C cell line 
(carboplatin-resistant variant) compared to the DLKP parental line. No significant 
difference was noted between the DLKP and DLKP-A (adriamycin-resistant variant) 
cells (Geraldine Grant, Ph.D. thesis, DCU, 1993).
Decreased influx and increased efflux which lead to decreased drug accumulation has 
also been associated with melphalan resistance. Evidence has shown that melphalan 
efflux occurs by a process different from the influx mechanism. Two leucine- 
preferring amino acid transporters have been identified as melphalan transporters and 
are designated system L and ASC. System L is a sodium-independent transporter and 
system ASC is a sodium dependent transporter (Begleiter et al., 1979; Vistica, 1979).
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Melphalan uptake studies in melphalan-resistant L1210 cells have demonstrated both 
a lower velocity of melphalan uptake and a lower affinity of the carrier for melphalan 
compared to the parental line. The results demonstrated an association between 
altered system L transport and melphalan resistance. Another melphalan-resistant cell 
line MelRMCF-7 was developed by Moscow et al. (1993) from the parental MCF-7 
cell line. MelRMCF-7 was found to be 30-fold resistant to melphalan. Monitoring the 
cellular uptake of melphalan (50|iM) over a 30 minutes period revealed a 4-fold 
decrease in the MelRMCF-7 cells compared with the parental cell line. Their results 
suggested that melphalan resistance was mediated by decreased capacity of system L 
amino acid transporter. Enhanced melphalan efflux has also been associated with 
melphalan resistance. Overexpression of MRP family members may be responsible 
for enhanced melphalan efflux.
Reduced DNA cross-linking is another mechanism of melphalan resistance. The 
relationship between DNA cross-linking and resistance to melphalan has been studied 
in the resistant variant, ZCR9, of the L1210 leukaemia cell line (Zwelling et al., 
1981). This cell line, selected with cisplatin, was found to be cross resistant to 
melphalan. In the resistant line, interstrand cross-linking by cisplatin or melphalan 
was reduced relative to the parental cell line. DNA-protein cross-linking by cisplatin 
was also reduced whereas DNA-protein cross-linking by melphalan was similar to 
that of the parental cells. These results suggest that DNA cross-linking correlates with 
tumour sensitivity to alkylating agent. Misonidazole (MISO), a 2-nitroimidazole 
compound in clinical trial as an oxygen-mimetic radiosensitiser of hypoxic tumour 
cells, has been shown to enhance the effectiveness of melphalan (Taylor et al., 1983). 
The study showed that enhanced efficiency of DNA cross-link formation can account 
for the sensitisation to melphalan following treatment with MISO. In a melphalan- 
resistant melanoma cell line MM253-12M, a 50% decrease in melphalan-DNA 
binding was observed (Parsons et al., 1981). The degree of cross-linking in the 
MM253-12M cells was also 50% less than that seen in the MM253 parental cells. 
Thus, the decrease in melphalan binding to DNA was almost sufficient to account for 
the decrease of cross-linking in the resistant cell line. In addition, increased DNA 
repair capacity of the cells may also contribute to melphalan resistance.
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Metallothioneins (MTs) play a role in heavy metal detoxification, regulation of 
intracellular levels of Cu and Zn, free-radical scavenging, protection from ionising 
radiation and also in the control of growth and differentiation (see section 1.5.4). MTs 
have been shown to be induced by melphalan. The role of metallothionein was proven 
when it was demonstrated that transfection of murine cells with the metallothionein 
cDNA conferred resistance to cisplatin as well as to melphalan (Kelley et al., 1988). 
Conflicting results, however, have been reported that murine C l27 cells, after being 
transfected with MT, showed no resistance to cisplatin (Schilder et al., 1990). 
Additionally, no significant difference in MT expression level was observed between 
untreated and cisplatin-treated ovarian cancer patients (Murphy et al., 1991). In this 
thesis, the results obtained by immunocytochemistry (section 3.4.1.6) show no 
significant difference in the metallothionein expression between the RPMI-2650 
parental cells and its melphalan-resistant variant. A possible explanation for these 
variable results is that the contribution of metallothionein to drug resistance may vary 
from tumour to tumour. Metallothioneins exist in all eukaryotic cells as well as in 
some prokaryotic cells. Consequently, all human cells will show positive 
immunostaining for metallothioneins. This would suggest that even minor difference 
in the level of MT expression between different cells may contribute to the resistance 
phenotype. Thus the results of immunocytochemistry may not be sensitive or precise 
enough to draw any conclusion. To determine the role of metallothionein in the 
RPMI-2650 melphalan-resistant variant, further studies need to be carried out 
including Western blotting and RT-PCR.
In the past 5 years, it has been found that cytokeratin expression may be related to 
resistance to a panel of chemotherapeutic drugs including melphalan. This finding 
was initiated by the observation that epithelial-derived untreated tumour cells are in 
some cases 10 to 2000 times more resistant to various chemotherapeutic agents than 
hematopoietic cell lines. Interest was then focused on cytokeratin because a major 
feature of epithelial cells is the expression of cytokeratins. Later it was reported that 
drug resistance in epithelial cells was due in part to cytokeratin 8 and 18. Bauman et 
al. (1994) compared the survival of mouse L fibroblasts lacking cytokeratins with that 
of L cells transfected with cytokeratin 8 and 18 (LK 8+18) in the presence of 
chemotherapeutic drugs. The expression of cytokeratin 8 and 18 conferred a MDR 
phenotype in cells exposed to mitoxantrone, adriamycin, methotrexate, melphalan and
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vincristine. LK 8+18 cells were 6.5 times more resistant to melphalan than the 
parental cells. Drug resistance could not be attributed to altered growth 
characteristics, altered drug accumulation or less DNA damage in the transfected 
cells. Anderson et al. (1996) obtained similar results after transfecting cytokeratin 8 
and 18 into murine NIH-3T3 cells. Since these studies, cytokeratin dependent drug 
resistance (C-MDR) has been established as a unique resistant mechanism in 
epithelial cells. C-MDR phenotype is defined as the ability of cytokeratin expression 
to alter cell survival by at least five-fold increase in the IC50. To date, cytokeratin 8 
and 18 has been related to drug resistance to adriamycin, mitoxantrone, bleomycin, 
mitomycin C and melphalan (Cress et al., 1996).
Bichat et al. (1997) reported that similar levels of cytokeratin 8 and 18 were 
expressed in the human breast cancer cell line MCF7 and its adriamycin-resistant 
variant MCF7R. However, cytokeratin 19 was expressed in the MCF7S cell line and 
not in the MCF7R variant, while vimentin was highly expressed in MCF7R and 
weakly expressed in MCF7S. This suggested that other cytokeratins and intermediate 
filament might be involved in multidrug resistance.
From the data listed above, it seems that the drug-cytokeratin interaction initiates a 
cascade of events for an improved cellular response to potentially lethal damage. To 
support this assumption, Anderson et al. (1996) reported that the cytokeratin-positive 
cell lines were protected from apoptosis while the cell lines without cytokeratins were 
susceptible to apoptosis in response to mitoxantrone exposure. The exact mechanisms 
underlying C-MDR need to be elucidated.
Although cytokeratin 18 and vimentin were expressed in the RPMI-2650 melphalan- 
resistant variant, no significant difference in cytokeratin 18 and vimentin expression 
was observed in the parental cell line and its variant. These results suggest that 
cytokeratin and vimentin do not play a major role in drug resistance in the RPMI- 
2650 melphlan-resistant variant.
Various mutant oncogenes have been shown to affect the ability of tumour cells to 
express drug resistance properties. Expression of mutated oncogenes also results in 
inappropriate cellular proliferation. There are three main methods whereby normal
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cellular genes (proto-oncogenes) are mutated to their oncogenic counterpart. The 
methods include: (1) deletion or point mutation in the coding sequence of gene 
resulting in a hyperactive protein produced in normal amounts. (2) gene amplification 
leading to the over-production of a normal protein (3) chromosomal rearrangement 
whereby a gene is under transcriptional regulation of an actively transcribed gene 
(Alberts et al., 1994). Oncogenes can be grouped into two main categories - those that 
increase the rate of cell division and those that influence cell death. The latter group 
can be sub-divided into genes that suppress or induce apoptosis. The balance of these 
genes in the cell determines the cell's ability to survive the attack of chemotherapy. 
The products of oncogenes are parts of a cascade of proteins leading from the plasma 
membrane through the cytoplasm and into the nucleus (Bishop, 1991). Three 
biochemical mechanisms are known whereby the genes exert their transforming 
capacities. These mechanisms include (a) phosphorylation of proteins on serine, 
threonine or tyrosine residues, (b) transmission of signals by GTPases, or (c) 
transcription from DNA (Bishop, 1991). Molecular signals at the plasma membrane 
are transmitted through to the nucleus via kinases in the cytoplasm as part of a signal 
transduction cascade. The primary cascade involved in signal transduction initiates 
signalling through the family of small nucleotide binding proteins, namely small G- 
proteins, to effector proteins that eventually transmit the signal to the nucleus. The 
initiating proteins in this event are the ras proteins which are members of the small G- 
proteins. It has been reported that spontaneous apoptosis can be suppressed by the 
expression of c-Ha-ras (Wyllie et al., 1987) which rapidly up-regulates the survival 
factors bcl-xL and bcl-2 (Kinoshita et al., 1995). C-myc is a member of the nuclear 
oncoproteins and acts as a transcription factor (as a heterodimeric partner to Max) to 
promote cell proliferation and play a role in cell cycle (Pardee, 1989). The Myc-Max 
heterodimer can activate several promoters, including that of p53 (D'Amico and 
McKenna, 1994). myc usually stimulates proliferation, but if growth is inhibited by 
other factors, myc-induced apoptosis will occur. Therefore it has a dual role to play in 
the cell. Transfection of c-myc oncogenes into NIH-3T3 mouse fibroblasts resulted in 
increased resistance to such drugs as cisplatin, melphalan, cyclophosphamide and 
adriamycin (Niimi et al., 1991). Transfection of c-Ha-ras into NIH-3T3 cells resulted 
in increased resistance to melphalan and cyclophosphamide (Niimi et al., 1991), In 
addition, cells that have an impaired ability to undergo apoptosis would be expected 
to be resistant to chemotherapeutic agents. The overexpression of the bcl-2 oncogenes
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has been shown to inhibit apoptosis in several cell types, and also to produce cells that 
are less sensitive to alkylating agents (Collin et al., 1992). Preliminary results of RT- 
PCR analysis (described in section 3.5.7) revealed the overexpression of c-myc in the 
RPMI-2650 melphalan-resistant variant compared to its parental cell line. c-Ha-ras 
was not detected in either of these cell lines. It is possible that c-myc might be 
involved in drug resistance in the melphalan-resistant variant. Increased levels of c- 
myc have been demonstrated in the DLKP-C cell line compared to DLKP parental 
line. However, decreased levels were found in the adriamycin-selected DLKP-A cell 
line. Slight alterations in c-Ha-ras level were observed between the DLKP, DLKP-C 
and DLKP-A cell lines (Roisin NicAmhlaoibh, Ph.D. thesis, DCU, 1997).
4.5 Drug resistance and cancer invasion
Almost all types of cancer are characterised by their ability to progress toward 
increased malignancy. In terms of their evolution, three aspects of cancer behaviour 
are critical: proliferation, invasiveness and metastasis, and resistance to
chemotherapy. For example, colon cancer can derive from in situ carcinoma which is 
proliferative and resistant to chemotherapy. It has to acquire the ability to invade 
tissue and metastasise to be a cancer. Another example, small cell lung cancer is 
sensitive to chemotherapy, but is proliferative, invasive and metastatic at diagnosis. 
The evolution of this tumour would be to acquire resistance to chemotherapy.
All these factors contribute to the slow pace of progress made in developing more 
effective cancer treatments. Unfortunately, studies of metastasis and drug resistance 
have generally proceeded along separate pathways of research. However, it is possible 
that drug resistance and cancer invasion/metastasis are linked to each other.
The evidence is growing that most malignant cancers arise as the end result of an 
accumulation of genetic mutations involving a number of oncogenes and recessive 
tumour suppressor genes. Many of these genes encode transcription factors which can 
act to regulate the expression of other genes. Some of these genes could affect the 
expression of drug resistance, and not just cell growth, differentiation, invasion and 
metastasis. Moreover, highly malignant cancers have a higher number of mutant
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oncogenes and tumour suppressor genes than their benign counterparts. Hence, highly 
metastatic cancers have a greater chance of acquiring a drug resistant phenotype.
For example, transfection of the ras oncogene into rat embryo fibroblast cells resulted 
in the development of a malignant and invasive phenotype characterised by the 
production of MMP-9. Marked pulmonary metastases were also observed following 
injection of the transfected cells into the rat tail vein (Pozzatti et al., 1986). Burt et al. 
(1988) demonstrated that transfection of v-H-ras into rat liver epithelial cells resulted 
in increased resistance to adriamycin and vinblastine. Transfection of c-H-ras into 
mouse fibroblasts NIH-3T3 resulted in increased resistance to cisplatin, melphalan 
and cyclophosphamide (Niimi et al, 1991; Isonishi et a l, 1991). These results 
suggested that ras could affect the phenotypes of both invasion and drug resistance. In 
some cases, co-transfection of two oncogenes, such as ras and c-myc, into cells was 
required for the acquisition of metastatic capacity (Lee et a l, 1985). c-myc, v-raf and 
c-erbB2 have also been reported to play a role in resistance to cisplatin (Sklar, 1988), 
adriamycin, vinblastine (Burt et a l, 1988) and taxol (Yu et a l, 1998). Similarly, 
tumours overexpressing the bcl-2 oncogene were also shown to express increased 
resistance to various chemotherapeutic drugs (Reed, 1994; Fisher et a l,  1993) since 
many drugs have their effect by inducing apoptosis and bcl-2 acts as an inhibitor of 
apoptosis. With respect to tumour suppressor genes, studies have demonstrated that 
the absence of the wild-type p53 suppressor gene renders cells more resistant to 
various DNA damaging chemotherapeutic drugs. This may be due to the failure of the 
cells to undergo drug-induced apoptosis (Lowe et al, 1993). The absence of p53 and 
Rb-1 has also been demonstrated to increase the ability of proliferation and invasion 
in tumour cells (Li et al., 1996; Valente et al., 1996).
A question that is often asked in relation to drug resistance is: why can oncogenes and 
tumour suppressor genes increase drug resistance in the cells? This question was 
partially answered by the finding that the promoter for the human mdr-1 gene was 
shown to be a target for the c-Ha-Ras-1 oncogene and the p53 tumour suppressor gene 
products. A mutant p53 specifically stimulated the mdr-1 promoter and wild-type p53 
exerted specific repression. These results suggested that the mdr-1 gene could be 
activated during tumour progression and may be associated with mutations in ras and 
p53 (Chin et a l,  1992). Observations from clinical work have been consistent with
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this statement. Benhattar (1996) carried out a study on seventeen tumours from 
patients treated with 5-FU for unresectable colorectal hepatic metastasis. The results 
obtained showed that colorectal tumours with mutated p53 had little or no response to 
chemotherapeutic treatment. This may be due to the significant correlation between 
mutant p53 and mdr-1 expression (de Kant el al., 1996). Moreover, elevated mdr-1 
gene expression was also found to accompany transfection of v-raf (Burt et al., 1988). 
Kerbel et al. (1988 and 1990) reported the so called "growth dominant" phenomenon 
which refers to the ability of the metastatic tumour cells to gradually displace their 
non-metastatic cellular counterpart at the primary tumour site so that primary tumours 
may become progressively overgrown by the metastatic clone. This indicates that 
metastatic cells have survival advantages compared to non-metastatic cells. It is well 
known that the pattern of gene expression in the metastatic cells can be very different 
from their non-metastatic precursors. A large family of diverse genes can be switched 
on including genes encoding proteases, adhesion molecules and growth factors. These 
genes could also include those which affect drug resistance. If so, then metastatically 
competent tumour cells would be more drug resistant than their benign counterparts. 
Hence primary tumours could evolve to become increasingly drug resistant in the 
absence of drug exposure and selection.
Genetic instability is recognised as an important aspect of development of tumour 
heterogeneity and malignancy. It was demonstrated that metastatic variants were 
generated more rapidly in the highly metastatic B16F10 mouse melanoma cell line 
than in the less metastatic B16F1 cell line (Hill et al., 1984). It was also observed that 
the highly metastatic B16F10 cell line generated variants resistant to methotrexate at 
higher rates than the B16F1 cell line. Thus it was concluded that the B16F10 cells 
possessed an increased ability to amplify DNA since resistance to methotrexate 
usually results from gene amplification. Hence, the higher rate of generation of drug- 
resistant variants corresponds to the higher rate of generation of metastatic variants 
(Cillo et al., 1987). Similar results were also obtained in the KHT fibrosarcoma cell 
line. It was observed that the highly metastatic KHT 35L1 cell line was more resistant 
to methotrexate than the KHT parental cell line. The likely reason for this increased 
resistance is that the KHT 35L1 cell line generates variants resistant to methotrexate 
at higher rate than the KHT parental cells (Cillo et al., 1989). The association between 
the rates of generation of drug-resistant and metastatic variants supports the
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hypothesis that the mechanism of gene amplification may be involved in the 
generation of both phenotypes. However, Yamashima and Heppner (1985) found no 
correlation between metastatic ability and the rate of spontaneous mutation in three 
murine mammary tumour cell lines. They also showed that reproducing the selection 
procedure for B16F19 melanoma cell line did not result in increased resistance of this 
cell line to methotrexate (Jang and Hill, 1991). This suggested that these two 
phenotypes do not necessarily arise in parallel.
In the case of P-glycoprotein overexpression related drug resistance, Greene et al. 
(1997) reported that highly metastatic subclones of the prostate cancer cells, PC-3M, 
expressed higher levels of bFGF, IL-8 , MMP-2, MMP-9 and mdr-1 mRNA than low 
metastatic subclones (Greene et al., 1997). Similar results were obtained with the CT- 
26 murine colon cancer where subcutaneous tumours were found to be sensitive to 
adriamycin while metastases growing in the liver or lung were not (Wilmann et al.,
1992). A direct correlation was observed between the increased resistance to 
adriamycin of CT-26 and expression levels of mdr-1. Once removed from the lung, 
the tumour cells reverted to a sensitive phenotype similar to the parental cells. This 
indicated that increased resistance to adriamycin in the CT-26 cells in lung metastases 
was not due to selection of resistant subpopulations. This conclution is supported by 
results obtained from an experiment that involved implantation of CT-26 cells from 
lung metastases into the subcutis of syngeneic mice. Adriamycin-sensitive tumours 
were produced in the mice. In parallel studies, adriamycin-sensitive CT-26 cells from 
subcutaneous tumours developed the resistant phenotype when they were inoculated 
intraveneously and grew in the lung (Wilmann et al., 1992). Moreover, in patients 
with colon carcinoma, high levels of Pgp expression were found on the invasive edge 
of the primary tumour and in lymph node, lung, and liver metastases (Weinstein et al., 
1991). Further investigations need to be carried out in order to identify organ-specific 
factors that can up-regulate expression of mdr-1 (or other resistant mechanisms).
The relationship between the metastatic potential of a tumour and its capability to 
escape treatments has not only been observed by the clinicians. The relationship 
between these two phenotypes has also been demonstrated by two types of 
experiments: (1) metastatic cells develop drug resistance more readily than non­
metastatic cells as the series of experiments carried out by Cillo et al. mentioned
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above. (2) Studies have demonstrated that at least in certain cases, tumour cells 
selected for resistance to chemotherapeutic drugs are more metastatic relative to non- 
resistant cells.
The adriamycin-resistant murine fibrosarcoma UV-2237M-ADMR cell line has been 
found to display more metastases than its parental UV-2237M cell line (Giavazzi et 
al., 1983). Similarly, the MCF-7/AdrR cell line, an adriamycin-resistant variant of 
human bresat cancer cell line, MCF-7, was found to be highly metastatic compared to 
its parental cell line. The analysis of expression of lysosomal cysteine proteases 
showed that alterations of cysteine protease inhibitor activities contribute to increased 
levels of cathepsin activities in MCF-7/AdrR cells (Scaddan and Dufresne, 1993). 
Lticke-Huhle (1994) reported that the methotrexate-resistant variant of rat 
adenocarcinoma BSP73ASML was metastatic in contrast to the BSP73AS parental 
cell line. BSP73ASML cells also underwent amplification of the dihydrofolate 
reductase (DHFR) gene which results in the development of methotrexate resistance 
at an accelerated rate in contrast to its parental cell line. The capacity for gene 
amplification in metastatic BSP73ASML cells was correlated with a deletion in the 
p53 gene and enhanced expression of the c-myc oncogene. Haga et al. (1997) 
developed a cadmium-resistant HT-1080 cd-R cell variant and found that it was 
significantly more invasive than the parental HT-1080 cells. The HT-1080 cd-R cells 
showed increased expression of MMP-9. A more metastatic spread to the lungs was 
observed in mice inoculated i.v. with B16/col/R cells, a Pgp-overexpressing 
colchicine-resistant variant of B16 melanoma cells. B16/col/R cells displayed higher 
motility and a higher capacity to grow in the kidney and spleen than the B16 cells 
(Staroselsky et al., 1996). Cisplatin resistance has also been correlated with enhanced 
metastasis. A variant of the fibrosarcoma cell line OR-32SK established from 
cisplatin-treated mice had a significantly higher level of metastasis to the lung 
compared to the parental cells, which may be related to the overproduction of MMP-9 
(Choi et al., 1999). Similar results were also obtained with a cisplatin-resistant cell 
line (Mitsumono et al., 1998). In this thesis, the RPMI-2650 melphalan-resistant 
variant and DLKP melphalan-resistant variants were found to be more invasive than 
their parental cells, confirming that drug treatment does affect invasive behaviour of 
the cells.
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In a study by Weinstein (1991), in all but 1 of the 95 cases of primary colon 
adenocarcinomas, invading carcinoma cells were present at the leading edge of the 
tumour. This subpopulation of invasive carcinoma cells expressed Pgp in 47 of the 95 
specimens. Cases were grouped on the basis of the presence (Group 1, 47 cases) or 
absence (Group 2, 48 cases) of Pgp+ invasive carcinoma cells. A significantly greater 
incidence of vessel invasion and lymph node metastases was noted in Group 1 cases. 
This finding indicated that Pgp+ invasive colon cancer cells may have an increased 
potential for dissemination. Bradley and Ling (1994) reported that strong expression 
of Pgp was associated with a highly vascular stroma in rat liver carcinoma models.
Cytokeratins have also been found to be correlated with drug resistance in epithelial 
cells (see section 4.4). In some cancers, particularly malignant melanoma and breast 
carcinoma, there is a strong indication that overexpression of keratin or vimentin 
leads to augmentation of motility and invasiveness in vitro (Hendrix et al., 1996). It 
has been reported in melanoma that the coexpression of vimentin and keratin 8 and 18 
is associated with metastatic behaviour (Hendrix et al., 1992). A375P, a human 
melanoma cell line of low invasive potential, expresses vimentin, but is keratin- 
negative. Co-transfection of A375P cells with cDNAs for both keratin 8 and 18 
resulted in a 30-fold increase in experimental lung metastases when mice were 
injected i.v. with the transfectants (Hendrix et al., 1992). In a study by Chu et al., 
(1991), the highly metastatic melanoma cell line, C8161, which endogenously 
expresses both vimentin and keratins 8 and 18, was genetically manipulated to 
produce disrupted keratins. A three- to four-fold decrease in the invasive and 
migratory ability was observed in the genetically manipulated cells compared to the 
parental cells. The keratin-positive human breast cancer MCF-7 cell line (of poor 
invasive ability) was transfected with vimentin cDNA, with a resultant increase in the 
invasiveness. Similarly, MDA-MB-231, a highly invasive and metastatic cell line, 
positive for both vimentin and keratin 8 and 18, was treated with antisense 
oligonucleotides to vimentin and resulted in a 70% reduction in the migration of this 
cell line (Hendrix et al., 1996).
Additional evidence linking the coexpression of vimentin and keratin expression with 
metastasis includes: (a) a non-metastatic rat pancreas adenocarcinoma expressed only 
vimentin whereas a metastatic variant contains a high amount of keratins in addition
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to vimentin (Ben-Ze'ev et al., 1986); (b) solid epithelial tumours contain keratin 
filaments exclusively. However, when these cells are present in ascitic or pleural 
fluid, they coexpress vimentin (Ramaekers et al., 1983); (c) cells from murine 
sarcoma ascites were found to coexpress keratins and vimentin, while cells from the 
solid tumour of the same sarcoma expressed only vimentin (Gunther et al., 1984) and 
(d) in rat ascites hepatoma, a spontaneously derived metastatic line contained both 
keratins and vimentin, but the poorly metastatic counterpart expressed only vimentin 
(Kinjo et al., 1984). Therefore, it is apparent that coexpression of keratin and 
vimentin is related to invasion and metastasis.
There have been several reports which indicate that cell lines selected in vitro for drug 
resistance usually manifest a non-tumorigenic phenotype in vivo or are strongly 
suppressed in their ability to form metastases (Ganapathi et al., 1987; Sircar et al., 
1987; Kawai et al., 1990). It is possible, however, that a different picture may emerge 
when drug resistant variants are selected in vivo. In fact, there is evidence to suggest 
that tumour cells selected for drug resistance in vivo are more malignant. An 
interesting example of this comes from studies initiated in the laboratory of Teicher et 
al. (1990). These investigators established variants resistant to alkylating agent from a 
murine mammary carcinoma cell line called EMT-6  by serial passage in Balb/C mice. 
The sublines selected expressed high levels of resistance to cyclophosphamide, 
cisplatin and carboplatin. Of considerable interest was the finding that the drug 
resistant sublines failed to express their resistance properties in vitro in monolayer cell 
cultures (Teicher et al., 1990). In subsequent studies, Teicher et al. (1993) found that 
the EMT-6  drug resistant variants were much more efficient at forming spontaneous 
lung metastases after subcutaneous injection of the cells than the drug-sensitive 
parental cell lines. These results suggested the new mechanism of drug resistance 
"only in vivo". In subsequent studies, it was found that if the EMT-6  drug-resistant 
variants were grown under more in v/vo-like conditions in tissue culture, i.e. as three- 
dimensional spheroids, they expressed their resistance properties in a manner similar 
to that observed in vivo (Kobayashi et al., 1993).
This form of acquired drug resistance is termed "multicellular drug resistance". It was 
shown that multicellular drug resistance can be induced in EMT-6  mammary tumour 
cells by a single transient exposure to agents such as cyclophosphamide or cisplatin
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(Graham et al., 1994). These experiments were undertaken to address why it usually 
takes a long time to isolate drug-resistant variants in cell culture under ideal selection 
conditions while drug resistance can develop in an accelerated fashion in the clinical 
setting (Cadman, 1989). Therefore studies were carried out to determine if drug 
resistance could be induced at a faster rate by exposure to drug in three-dimensional 
culture systems. The results indicated that this may indeed be the case (Graham el al., 
1994). EMT-6  tumour cells were selected with cyclophosphamide in monolayer 
versus three-dimentional culture conditions for 1 month. Resistance to 
cyclophosphamide was induced but could only be detected in the three-dimentional 
culture system (Graham et al., 1994). Jardillier et al. (1998) also reported that 
spheroids made from the human breast cancer cell line MCF-7 were more resistant to 
adriamycin than the same cells grown as monolayers. Two unidentified serine 
proteases were detected in media conditioned by spheroids of both MCF-7 and MCF- 
7 MDR variants but not in media conditioned by monolayers. All these results suggest 
that the nature of the inter-relationship of drug resistance and metastasis should 
probably be re-evaluated in the context of the multicellular drug resistance assays. 
However, it has also been reported that MDR variants could be established by pulse 
selecting sensitive parental cell lines growing as monolayers in flasks after four pulses 
(four-hour exposure of the cells to drug a week is one pulse) (NicAmhlaoibh et al., 
1999).
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Numerous studies have shown that dynamic interactions among integrins, ECM, 
proteases, cytoskeletal proteins and signalling molecules foster the invasive behaviour 
of the tumour cells. The experiments reported in this thesis include analysis of several 
proteins which may have an impact on invasion and metastasis. Increased expression 
of OC2P1, (X5P1, ot6Pi and 0 ^ 4  integrins, decreased expression of (X4P1, stronger 
adhesion to collagen type IV, laminin, fibronectin and matrigel, expression of MMP-2 
and MMP-9 and overexpression of c-myc might all contribute to the high 
invasiveness of the RPMI-2650 melphalan-resistant variant. Conversely, the 
overexpression of 0C4 integrin subunit, low attachment to collagen type IV, laminin, 
fibronectin, matrigel and non- detectable expression of MMPs might be related to the 
non-invasiveness of the RPMI-2650 parental cell line. The decreased expression of ot2 
integrin which might result in decreased attachment to collagen type IV, lack of 
cytokeratin 18, non-detectable expression of proteinases may contribute to the non- 
invasiveness of the taxol-resistant variant. The overexpression of 0,2 and Pi integrin 
subunits and the expression of MMP-2 and MMP-9 may contribute to the 
invasiveness of DLKP long term melphalan-selected variant. Overexpression of 
MMP-2 and MMP-9 was also observed in the invasive DLKP melphalan-pulse 
selected variant. More work needs to be carried out to further investigate the 
mechanisms underlying the relatively high invasiveness in these two DLKP low level 
melphalan-resistant variants.
In addition, recent experiments by Dr. Joanne Keenan in our laboratory have shown 
that glucose uptake in the RPMI-2650 melphalan-resistant variant was greater than in 
the taxol-resistant variant, while the lowest uptake was seen in the parental cells. 
Expression of glucose transporter GLUT1 has been associated with aggressive 
behaviour in some cancers. Overexpression of GLUT 1 was observed in the RPMI- 
2650 melphalan-resistant variant and to a lesser extent in the taxol-resistant variant. 
The RPMI-2650 parental cell lines expressed little or no level of GLUT1. All these 
results are consistent with the motility behaviour of the RPMI-2650 cell line and its
4.6 Mechanisms of invasion in RPMI-2650, DLKP and their MDR
variants
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MDR variants, i.e. more mobile cells use more glucose to supply their energy 
(personal communication with Dr. Joanne Keenan).
RPMI-2650 and DLKP are epithelial cell lines. The distinguishing features of 
epithelia are their polarised morphology, their attachment to an underlying basement 
membrane, the presence of specialised cell-cell contacts and their capacity for rapid 
self-renewal. Low levels of E-cadherin was found to be expressed in the RPMI-2650 
cell line which suggests that E-cadherin may play a minor role in cell-cell interactions 
in the RPMI-2650 cells. St Croix and Kerbel et al. (1997) reported that E-cadherin 
was capable of upregulating P27KIP1, a cyclin-dependent kinase inhibitor which 
causes growth arrest in the G1 phase of the cell cycle and resistance to apoptosis 
induced by anticancer agents. However, no E-cadherin was detected in the taxol- and 
melphalan-resistant variants, indicating that E-cadherin does not play a major role in 
mediating drug resistance of these cell lines.
Immonucytochemistry studies showed that the expression of ot2, as, a 6, P4 integrin 
subunits was increased in the RPMI-2650 melphalan-resistant variant whereas the 
expression of as and a 6 was slightly increased in the taxol-resistant variant. These 
studies also showed that high levels of Pi integrin subunit was expressed in the RPMI- 
2650 melphalan-resistant variant. The taxol-resistant variant was also found to 
express some Pi integrin subunits while the lowest level was observed in the parental 
cells. The results obtained from RT-PCR analysis were consistent with the 
immunocytochemistry results. Expression of a 2 and Pi integrin subunits was found to 
be increased in the DLKP long term melphalan-selected variant compared to DLKP 
parental cell line while no significant difference was noted in the pulse selected 
variant. Expression of the a 4 and p4 integrin subunits was undetected in DLKP 
parental cell line and its melphalan-resistant variants.
The expression of aiP i integrin was also studied in the RPMI-2650 cell line and its 
MDR variants, a ip i integrin is a dual receptor for collagen type IV and laminin. The 
results illustrated that only trace amount of aiP i integrin was observed in the RPMI- 
2650 parental cell line and its taxol- and melphalan-resistant variants.
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The expression of ot^Pi integrin varied greatly between the RPMI-2650 parental cell 
line and its MDR variants and also between DLKP and its MDR variants. OC2P1 
integrin was uniformly stained in the RPMI-2650 parental cells whereas it appeared to 
be concentrated on some particular clones in the taxol-resistant variants. CX2P1 was 
overexpressed in the melphalan-resistant variants. The expression of OC2P1 appeared to 
be restricted to certain clones of the DLKP parental cells while uniformly intense 
staining for 012P1 integrin was observed in the DLKP long term melphalan-selection 
variant. However, only weak staining was observed in the DLKP melphalan-pulse 
selected variant. Studies by Koukoulis et al. (1991) and Pignatelli et al. (1992) 
demonstrated that (X2P1 integrin expression was decreased in breast adenocarcinomas. 
Studies on other adenocarcinomas (colon, prostate, lung, pancreas and skin) have 
yielded similar findings regarding (X2P1 expression (Koretz et al., 1991; Stallmach et 
al., 1992; Hall et al., 1991). These results suggested that (X2P1 integrin may function 
as a tumour suppressor for epithelial malignancies. In contrast, expression of (X2P1 
integrin by malignant melanoma and rhabdomyosarcoma was markedly increased. 
These studies suggested that the function of the a 2Pi-integrin may be cell type- 
dependent. It was found that erbB2 may contribute to the inability of SP1 protein to 
bind to the promoter of the 012 integrin gene thereby reducing a 2-integrin gene 
expression. The modest expression of (X2P1 integrin in the RPMI-2650 and DLKP 
agrees with the report which states that OC2P1 expression is decreased in epithelial 
carcinomas. The mechanisms underlying the localisation of (X2P1 integrins in 
particular clones of the RPMI-2650 taxol-resistant variants and the DLKP cells are 
unknown. It appears that the RPMI-2650 melphalan-resistant variant utilises more 
0C2P1 to strongly adhere to collagen type IV compared to the parental cell line and the 
taxol-resistant variant. The DLKP long term melphalan-selected variant may also use 
more 012P1 integrin in the same manner.
(X3P1 integrin is a versatile integrin which can bind to collagen type IV, laminin and 
fibronectin. 013P1 was found to be expressed at similar level in the RPMI-2650 cell 
line and its MDR variants. Previous studies have shown that (X3P1 is a low-affinity 
receptor for type IV collagen (Kuhn and Eble, 1994). It was also demonstrated that 
binding to type IV collagen is initiated via the 0C2P1 or aiP i integrin and then 0 ,33 1
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integrin is recruited to focal contacts following cell adhesion (DiPersio et al., 1995). 
Most of the reports to date have indicated that reduced expression of a 3Pi integrin is 
likely to be involved in tumour metastasis although increases in a 3Pi expression has 
also been reported in cutaneous malignant melanoma (Natali et al., 1993).
0C4P1 integrin which recognises fibronectin and VCAM-1 (vascular cell adhesion 
molecule-1) may influence metastatic process at various stages. The detachment of 
tumour cells from the primary tumour and the invasion of the surrounding tissue 
represent the onset of tumour metastasis. It was reported that at the primary tumour 
site, expression of a 4 integrin inhibits the ability of melanoma cells to break loose. 
This could be achieved either by strengthening of homotypic adhesion to adjacent 
tumour cells or by down regulation of MMPs that are required for tumour cell 
migration through the extracellular matrix (Holzmann et al., 1998). Intense staining 
for 0C4P1 integrin was observed by immunocytochemistry in the RPMI-2650 cell line 
whereas OC4P1 was not detected in the RPMI-2650 MDR variants. This may explain 
the non-invasiveness of the RPMI-2650 cells by matrigel invasion assay. Qian et al.
(1994) also reported that matrigel invasion by a.4pi-positive cells of B16 melanoma 
cell lines was reduced. In contrast, VCAM-1 positive endothelial cells co-localise 
with tumour cells expressing a 4Pi integrin at later stages of metastasis, thus 
enhancing the metastatic capacity of the tumour cells. No ouPi integrin staining was 
observed in either the DLKP cell line or its melphalan-selected variants, indicating 
that this integrin may not be involved in either melphalan resistance or high 
invasiveness in these variants.
Damiano et al. (1999) reported that the drug-sensitive 8226 human myeloma cell 
clones which expressed both ouPi and as Pi integrins, were relatively more resistant to 
the apoptotic effects of adriamycin and melphalan. These results are not entirely 
consistent with the results obtained for the melphalan-resistant variants of RPMI-2650 
and DLKP. This indicates that either overexpression or underexpression of particular 
integrins in resistant cells may be cell-type specific.
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as Pi integrin is the major receptor for fibronectin. Forced expression of the 0 .5pi 
integrin in tumour cells has been shown to reduce tumorigenicity (Giancotti and 
Ruoslahti, 1990; V arner^ a/., 1995). Conversely, decreased asPi expression has been 
shown to increase the tumorigenicity of CHO cells (Schreiner et al., 1991). 0 .5Pi is the 
integrin that controls the assembly of fibronectin matrix. Consistent with the above 
observation, asPi integrin was modestly expressed in the RPMI-2650 parental cell 
line. No significant difference in the as pi integrin expression was seen between the 
RPMI-2650 and its taxol-resistant variant. However, the melphalan-resistant variant 
was found to express higher levels of 0C5P1. It seems that the melphalan-resistant 
variant utilises more as Pi integrins to enable the cells to attach strongly to fibronectin.
Nista et al. (1997) reported that the adriamycin-resistant MCF-7 variant expressed 
more a 4Pi and asPi integrins and was more adhesive to fibronectin than MCF-7 
parental cell line.
Both aePi and a 6p4 integrins are receptors for laminin. It was reported that inhibiting 
aePi function or its expression reduces the invasive and metastatic ability of several 
types of tumour cells (Lin et al., 1993; Rabinovitz et al., 1995; Shaw et al., 1996). It 
was also found that high aeP4 integrin expression was related to more advanced 
clinical stage of colon carcinoma and thyroid carcinoma (Falcioni et al., 1994, Serini 
et al., 1996). Expression of the a 6p4 integrin in RKO cells, a p4-deficient rectal 
carcinoma cell line, significantly increased the ability of these cells to invade matrigel 
(Chao et al., 1996). Expression of the a 6p4 integrin in MDA-MB-435 cells, a human 
breast carcinoma cell line that lacks p4 integrin sbunit also resulted in a dramatic 
increase in invasion (Rabinovitz and Mercurio, 1996). The results obtained in the 
RPMI-2650 melphalan-resistant variant were very consistent with the above 
observations. Higher levels of ac, integrin subunit were expressed in the melphalan- 
resistant variant than in the RPMI-2650 parental line and taxol-resistant variant. High 
levels of p4 integrin subunit were also expressed in the melphalan-resistant variant 
whereas no p4 was detected in the other two cell lines. The increase in a.c integrin 
subunit expression could be due to the increase in the p4 integrin subunit in the RPMI- 
2650 melphalan-resistant variant. Apart from that, the melphalan-resistant variant
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utilises more (X6P4 or ot6Pi to attach to laminin. The expression of 0 ^ 4  probably 
contributes to the high invasiveness of the RPMI-2650 melphlan-resistant variant.
Narita et al. (1998) investigated alterations in the expression of integrins in 
adriamycin-resistant MCF-7 (MCF-7/ADR) cells. Expression of a 6 integrin subunit 
was found to be increased whereas the expression of 012 was decreased in the MCF- 
7/ADR cells. MCF-7/ADR cells also showed increased attachment to laminin, but not 
to collagen or fibronectin. The migration activity of MCF-7/ADR cells was higher 
than that of the parental cells. A significant inhibitory effect on the migration of 
MCF-7/ADR cells was observed by the addition of antibodies to ot6 and Pi integrin 
subunits.
Duensing et al. (1996) studied alterations in Pi integrin family expression and 
adhesiveness to ECM proteins in the human renal carcinoma cell line Caki-1. They 
compared the results with the vinblastine-resistant sublines Caki-1 /VI and Caki- 
1/V10 cultured in the presence of lng/ml and lOng/ml vinblastine respectively. Their 
results indicated that otiPi and OC2P1 integrins were expressed in the Caki-1/V10 
subline whereas untreated and Caki-l/Vl cells did not express these integrins. oi6pi 
was found to be decreased in the vinblastine-resistant sublines. Attachment of both 
Caki-1/VI and Caki-1/V10 cells to collage type IV was significantly increased 
compared to the parental cells. Both Caki-l/Vl and Caki-1/V10 cells also exhibited 
increased adhesion to fibronectin. No studies with regard to invasiveness were carried
Overall, it seems that overexpression or underexpression of integrin subunits varies in 
different drug resistant variants. Therefore, each resistant variant should be analysed 
on an individual base.
The results of invasion assay with sulindac or indomethacin showed that neither 
sulindac nor indomethacin could affect the invasive behaviour of RPMI-2650 
melphalan-resistant variant, indicating that the inhibition of MRP 1-mediated transport 
of endogenous substances such as leukotrienes might not correlate with the 
invasiveness of the cells.
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4.7 Relationship between melphalan resistance and cell invasion in 
the HT-1080, NIH-3T3, A549, DLKP, DLKPC, COR-L23S and 
COR-L23R cell lines
Based on the observation that the RPMI-2650 melphalan-resistant variant was 
significantly more invasive than the taxol-resistant variant and its parental cell line, 
and also that the DLKP long term melphalan-selected variant was more invasive than 
the DLKP parental cell line, the following question was raised: is there any 
relationship between melphalan resistance and cell invasion? Since the melphalan- 
resistant variants of the RPMI-2650 and DLKP cell lines were found to overexpress 
MRP family members, another question that was raised was: is there any relationship 
between overexpression of MRP and cell invasion? Chemosensitivities to melphalan, 
expression of MRP and invasive behaviour (including secretion of MMPs) were thus 
studied in the HT-1080, NIH-3T3, A-549, DLKP, DLKPC, COR-L23S and COR- 
L23R cell lines.
HT-1080, a human fibrosarcoma cell line, is a highly invasive cell line which is 
widely used as positive control of invasion assay. The expression of MMP-2 and 
MMP-9 which was shown by gelatin zymograph probably plays an important role in 
the invasion behaviour of the HT-1080 cells. However, it was reported that HT-1080 
is Pgp-negative and MRP 1-negative (Vanhoefer et al., 1997) which could explain the 
sensitivity of the HT-1080 to melphalan.
In the case of NIH-3T3, a murine fibroblast cell line, low invasiveness was observed, 
although both MMP-2 and MMP-9 were expressed. This suggests that other factors 
such as high activity of TIMPs maybe contribute to the weak invasiveness of this cell 
line. NIH-3T3 is approximately 2-fold more resistant to melphalan than the HT-1080. 
Breuninger et al. (1995) reported that no MRP1 was expressed in this cell line. The 
results obtained for the HT-1080 and NIH-3T3 cells indicate that neither melphalan 
resistance nor the expression of MRP is necessarily related to cell invasion. The same 
conclusion could be drawn in the COR-L23S and COR-L23R cell lines. COR-L23S, a 
human large cell lung cancer cell line, does not express Pgp and only expresses very 
low level of MRP 1 COR-L23R, a MRP 1-overexpressing adriamycin-resistant variant
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of the COR-L23S, was found to be even more sensitive to melphalan than its parental 
cell line, COR-L23S. This indicates that although MRP1 overexpression is involved 
in melphalan resistance in some cell lines, it does not apply in all cases; it may also 
suggest that MRP1 may not play a major role in mediating melphalan resistance, and 
other MRP family members, such as MRP2 and MRP3, may play a role in melphalan 
resistance. COR-L23S was found to express MMP-2 and MMP-9 whereas 
nondetectable levels were observed in the COR-L23R cells. However, the COR-L23R 
cell line exhibited slightly more invasiveness than COR-L23S, indicating that 
proteinases other than MMP-2 and MMP-9 might be involved in its invasiveness.
In addition to melphalan-resistant variants of RPMI-2650 and DLKP, the human lung 
adenocarcinoma cell line, A-549, was found to overexpress MRPs 1-3. This cell line 
was also shown to be very resistant to melphalan and highly invasive. The cisplatin- 
resistant variant of DLKP, DLKP-C, was found to be cross resistant to melphalan and 
more invasive than the DLKP cells. Thus, it seems that melphalan-resistant cell lines 
(if this melphalan resistance is caused by the overexpression of MRP family 
members), with their resistance either intrinsic or acquired, are more invasive than 
melphalan-sensitive cell line. However, this does not mean that any highly invasive 
cell line, such as HT-1080, is resistant to melphalan.
Kiefer et al. (1990) reported that c-myc and c-Ha-ras were expressed in the A-549 cell 
line. C-Ha-ras and c-myc are believed to increase cell invasiveness (Ura, 1990). 
Giambernardi et al. (1998) also reported that overexpression of c-Ha-ras correlated 
with up-regulation of MMP-9. Expression of c-myc and c-Ha-ras was also reported to 
correlate with melphalan resistance (Niimi et al., 1991). All these results suggest that 
c-H-ras or c-myc might link melphalan resistance to cell invasion.
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4.8 Conclusions and future work
The establishment and characterisation of novel taxol- and melphalan-resistant 
variants of the RPMI-2650 cell line was the objective of the early work reported in 
this thesis. Investigation of the mechanisms underlying the high invasiveness of the 
RPMI-2650 and DLKP melphalan-resistant variants represented the objective of the 
later work of this project.
1. A 11X melphalan-resistant variant of the RPMI-2650 cell line was established. 
The cross resistance profile showed that it was resistant to cadmium chloride 
(54X), adriamycin (23X), vinblastine (24X), VP-16(26X), vincristine (6X) and 
cisplatin (2.6X), but displayed no significant resistance to taxol (1.7X) or 5-FU 
(1 IX).
2. Overexpression of MRP 1 and cMOAT (MRP2) was detected by Western blotting, 
RT-PCR and immunocytochemistry in RPMI-2650 melphalan-resistant variant.
3. High levels of mrp3 mRNA were expressed in the RPMI-2650 melphalan- 
resistant variant as demonstrated by RT-PCR. Expression of mrp4 and mrp5 was 
undetectable in this cell variant.
4. Expression of Pgp (MDR-1) was slightly increased in the RPMI-2650 melphalan- 
resistant variant compared to the RPMI-2650 parental cell line.
5. A low level of adriamycin accumulated in the nuclei of the RPMI-2650 
melphalan-resistant variant as detected by fluorescence microscopy. A significant 
increase in nuclear fluorescence was observed following treatment with verapamil 
or cyclosporin A in this variant.
6 . Both verapamil and cyclosporin A can reverse adriamycin toxicity in the RPMI- 
2650 melphalan-resistant variant as determined by toxicity assays. Verapamil 
appears to be more effective than cyclosporin A in this cell line. Sulindac and 
indomethacin can also reverse melphalan toxicity in this variant.
On the basis of these results, it was concluded that overexpression of MRP1, and 
possibly cMOAT (MRP2) and MRP3, plays an important role in drug resistance in the 
RPMI-2650 melphalan-resistant variant.
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7. Preliminary RT-PCR results demonstrated that c-myc expression was higher in the 
RPMI-2650 melphalan-resistant variant than in the parental cell line. C-Ha-ras 
was not detected in either of these cell lines.
It was concluded that c-myc may be involved in drug resistance in the RPMI-2650
melphalan-resistant variant.
Immunocytochemistry studies demonstrated that:
8 . Expression of LRP was undetectable in the RPMI-2650 melphalan-resistant 
variant.
9. Topoisomerase II a  was expressed at similar levels in the RPMI-2650 melphalan- 
resistant variant and the parental cell line.
10. Metallothionein was expressed at similar levels in the RPMI-2650 melphalan- 
resistant variant and the parental cell line.
11. GST activity in the RPMI-2650 melphalan-resistant variant was slightly higher 
than in the parental cell line as detected by GST activity assay.
On the basis of these results, it was concluded that LRP, topoisomerase II a,
metallothionein and GST might not play an important role in drug resistance in the
RPMI-2650 melphalan-resistant variant.
12. Cytokeratin 18, vimentin and tubulin in the RPMI-2650 melphalan-resistant 
variant were expressed at a similar level as in the RPMI-2650 parental cell line, 
indicating that these cytoskeletal proteins do not play a role in drug resistance in 
the RPMI-2650 melphalan-resistant variant.
13. The RPMI-2650 melphalan-resistant variant was shown to be highly invasive in 
vitro and the invasiveness was not affected by sulindac or indomethacin.
14. The RPMI-2650 melphalan-resistant variant exhibited higher adhesiveness to 
collagen type IV, laminin, fibronectin and matrigel.
15. Increased expression of (X2P1, otsPi, a.6pi, integrins, and decreased expression 
of a 4Pi integrin was observed in the RPMI-2650 melphalan-resistant variant.
16. The RPMI-2650 melphalan-resistant variant expressed MMP-2 and MMP-9 
whereas the parental cells did not, as detected by zymography.
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On the basis of these results, it was concluded that melphalan treatment can increase 
the invasiveness of RPMI-2650 cells by affecting its integrin and proteinase 
expression.
17. The RPMI-2650 melphalan-resistant variant showed high motility as detected by 
motility assay and videomicroscopy.
On the basis of this result, it was concluded that melphalan treatment can increase the 
motility of RPMI-2650 cells.
18. A 3.3X melphalan-resistant variant of the DLKP cell line was established by 
continual exposure to melphalan. It was cross resistant to cadmium chloride 
(9.8X), cisplatin (8 . IX), adriamycin (1.8X) and vinblastine (1.9X), but not 
significantly resistant to taxol (1,3X).
19. A 2. IX melphalan-resistant variant of the DLKP cell line was established by pulse 
selection with melphalan. It was cross resistant to cadmium chloride (7.3X), 
cisplatin (3.IX), adriamycin (1.5X), but not significantly resistant to taxol (1.2X) 
and vinblastine (1.2X).
20. Overexpression of MRP1 was detected in the DLKP long-term melphalan- 
selection and melphalan-pulse selected variants by Western blotting and RT-PCR.
21. Expression of MDR-1 (Pgp) was not detected in these two variants by either 
Western blotting or RT-PCR.
On the basis of these results, it was concluded that MRP1, but not Pgp, plays an 
important role in melphalan resistance in the DLKP long term and pulse selected 
melphalan variants.
22. The DLKP long-term melphalan-selection variant was found to be more invasive 
than the melphalan-pulse selected variant which in turn was more invasive than 
the parental cell line.
23. Zymography showed that the DLKP long-term melphalan-selection variant and 
the DLKP melphalan pulse-selected variant expressed MMP-2 and MMP-9. These 
proteinases were not detected in the DLKP parental cell line.
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24. Expression of Pi and 0C2 integrin subunits was increased in these two variants 
compared to the DLKP parental cell line. 0.4 and P4 integrin subunits were not 
detected in any of these cell lines.
On the basis of these results, it was concluded that melphalan treatment increased 
invasiveness of the DLKP cell line by affecting integrin and proteinase expression.
25. A 226X taxol-resistant variant of RPMI-2650 was established by continuous 
exposure to taxol. Studies showed that it was cross resistant to adriamycin (218X), 
vincristine (595X), vinblastine (94X) and VP-16 (20X), but not significantly 
resistant to melphalan (4.5X), 5-FU (3.6X), cadmium chloride (8.3X) and 
cisplatin ( 1.1X).
26. Overexpression of Pgp (MDR-1) was detected in the RPMI-2650 taxol-resistant 
variant by Western blotting, RT-PCR and immunocytochemistry.
27. Little or no MRP1 expression was observed in the RPMI-2650 taxol-resistant 
variant by Western blotting, RT-PCR and immunocytochemistry.
28. Significant levels of MRP2, MRP3, MRP4 and MRP5 were not detected in the 
RPMI-2650 taxol-resistant variant either by Western blotting or RT-PCR.
29. A low level of adriamycin accumulated in the nuclei of the RPMI-2650 taxol- 
resistant variants as detected by fluorescence microscopy. A significant increase 
in nuclear fluorescence was observed following treatment with cyclosporin A or 
verapamil in this variant.
30. Both cyclosporin A and verapamil could circumvent adriamycin toxicity in the 
RPMI-2650 taxol-resistant variant. Cyclosporin A was more effective than 
verapamil at circumventing resistance.
On the basis of these results, it was concluded that overexpression of Pgp plays an 
important role in drug resistance in the RPMI-2650 taxol-resistant variant.
31. c-myc was expressed at a higher level in the RPMI-2650 taxol-resistant variant 
than in the parental cell line as detected by RT-PCR. c-Ha-ras was not detected in 
either of these cell lines. It indicates that c-myc might be involved in drug resistance 
in the RPMI-2650 taxol-resistant variant.
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Immunocytochemistry studies demonstrated that:
32. No expression of LRP was detected in the RPMI-2650 taxol-resistant variant.
33. Topoisomerase II a  was expressed at a similar level in the RPMI-2650 taxol- 
resistant variant as in the parental cell line.
34. Metallothionein was expressed at a similar level in the RPMI-2650 taxol-resistant 
variant as in the parental cell line.
35. GST activity was slightly higher in the RPMI-2650 taxol-resistant variant than 
in the RPMI-2650 parental cell line as detected by GST activity assay.
On the basis of these results, it was concluded that LRP, topoisomerase II a, 
metallothionein and GST do not play a major role in drug resistance in the RPMI- 
2650 taxol-resistant variant.
36. As detected by immunofluorescence, tubulin content in the RPMI-2650 taxol- 
resistant variant was slightly less than the parental cell line. Expression of cytokeratin 
18 was significantly decreased in the taxol-resistant variant. Vimentin was expressed 
at similar levels in the taxol-resistant variant and the parental cell line. These results 
indicate that cytoskeleton proteins may be involved in drug resistance in the RPMI- 
2650 taxol-resistant variant.
37. RPMI-2650 taxol-resistant variant was non-invasive as detected by invasion 
assays.
38. RPMI-2650 taxol-resistant variant exhibited low adhesiveness to collagen type IV, 
laminin, fibronectin and matrigel.
39. Decreased expression of a 2 integrin subunit was observed in the RPMI-2650 
taxol-resistant variant compared to its parental line.
40. No proteinases were detected by gelatin zymography in the RPMI-2650 taxol- 
resistant variant.
On the basis of these results, it was concluded that taxol treatment did not affect the 
invasiveness of RPMI-2650 cells.
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41. RPMI-2650 taxol-resistant variant exhibited modest motility as detected by 
motility assays and videomicroscopy.
On the basis of this result, it was concluded that taxol treatment can slightly increase 
the motility of the RPMI-2650 cell line.
Two main questions have been raised from these studies. Firstly, is MRP 
overexpression always associated with melphalan resistance? If not, what determines 
the particular mechanisms underlying melphalan resistance in a particular cell line? A 
similar question could be asked for cisplatin, another alkylating agent, often appears 
to share the same resistance mechanisms as melphalan, which several papers report 
that MRP overexpression was not observed in some cisplatin-resistant cell lines. 
Analysis of expression of MRP family members in other melphalan-resistant variants 
needs to be carried out. Since DLKP-C, a carboplatin-selected, cisplatin-resistant 
variant of DLKP has been established in this centre, it would be interesting to further 
investigate the mechanisms of cisplatin resistance in this variant. A second question 
needs to be answered is: how much does MRP1, cMOAT (MRP2) and MRP3 
individually contribute to the melphalan resistance in the RPMI-2650 melphalan- 
resistant variant? Direct evidence may be obtained by knocking out each MRP 
member through genetic manipulation and rechecking the melphalan resistance in 
each MRP member-deficient cell line or by looking at properties of cell lines 
transfected with cDNAs of individual MRP family members.
In the DLKP long term melphalan-selected and melphalan-pulse selected variants, 
overexpression of MRP 1 may contribute to their melphalan resistance. It has been 
shown that the melphalan-resistant variants of RPMI-2650 and DLKP cells all exhibit 
significant resistance to cadmium chloride, indicating that cadmium chloride may 
share some resistance mechanisms with melphalan.
Attempts to co-select RPMI-2650 cells with taxol and melphalan always failed, 
suggesting that cells cannot survive the effects of these two drugs. This might have 
clinical significance in chemotherapy. Further work needs to be carried out to confirm 
the lethal effects of the combination of these drugs, and perhaps animal trials should 
be carried out to study the drug reaction and pharmacokinetics.
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Although interest in our laboratory have focused on the modulating effect of NSAIDs 
such as sulindac and indomethacin, the circumvention effect of these two drugs on 
melphalan cytotoxicity in the RPMI-2650 melphalan-resistant variant raises the 
following questions: are these two drugs the inhibitors of MRP 1 only, or can they also 
inhibit other members of MRP family? Also, are these two drugs always effective in 
reversing MRP 1-mediated drug resistance? If not, what limits their effects? Further 
work is required to establish the exact mechanisms by which NSAIDs exert their 
chemotherapy circumvention, e.g. are they substrates of MRP, or merely inhibitors?
It is concluded from the later work of this project that melphalan treatment can 
increase invasiveness of the RPMI-2650 and DLKP cells whereas taxol treatment 
cannot. This pointed out that chemotherapy can not only kill cancer cells, but can also 
result in induction or selection of cancer cells which are more malignant. The dogma 
that chemotherapy always plays an important role in cancer cure is not always true. 
From the work on the relationship between melphalan resistance and invasion 
phenotype in the HT-1080, NIH-3T3, A549, DLKP, DLKP-C, COR-L23S and COR- 
L23R cell lines in this study, there seems to be a trend that melphalan-resistant cell 
lines are generally more invasive than melphalan-sensitive cell lines. One question 
that needs to be answered is exactly what mechanisms link melphalan resistance to 
cell invasion, i.e. what events does melphalan treatment trigger to lead to increased 
cell invasion and metastasis? Another question is: How widely does melphalan 
treatment exert its effect on cell invasion? Is it on a few cell lines or tumours or on 
most cell lines or tumours? Intensive research, both scientifically and clinically, is 
required to answer these questions. Future work may start by finding out whether a 
common transcription factor exists to turn on two sets of genes, those responsible for 
melphalan resistance, e.g. MRP genes, and those responsible for increased cell 
invasion, e.g. MMP genes. Studies with the MRP gene promoter indicated that wild- 
type (wt) p53 markedly suppressed MRP promotor activity whereas mutant p53 had 
very little inhibitory effect. Wt p53 acts as a negative regulator of MRP gene 
transcription at least in part by diminishing the effect of a powerful transcription 
factor SP-1 (Wang and Beck, 1998). Binding sites for the transcription factors AP-1 
and SP-1 were also found in MMP-9 gene which suggested that AP-1 and SP-1 were 
responsible for the induction of expression of MMP-9 (Sato and Seiki, 1993; Baylis et 
al. 1995). Sato et al. (1993) also reported that v-src activates the expression of MMP-
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9 gene through the AP-1 site. All these results suggest that v-src, AP-1 or SP-1 may 
link MRP expression to cell invasion.
Moreover, it has been shown that the cisplatin-resistant variant, DLKP-C was more 
invasive than the DLKP parental cell line. Further studies are required to establish if a 
correlation exists between drug resistance and cell invasion in this cell line.
Finally, as discussed in section 4.5, an entirely different picture may emerge when 
drug resistant variants are selected in vivo. It would be of great interest to culture the 
MDR variants established in this study under more in v/'vo-like conditions such as 
three-dimensional spheroids to determine their drug resistance and cell invasion 
phenotypes.
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6. Appendices
6.1 Abbreviations
ADR Adriamycin
ATCC American Tissue Culture Collection
ATP Adenosine Triphosphate
BCA Bicinchoninic acid
BSO Buthionine sulfoximide
cdc Cell division cycle
CDK Cyclin Dependent Kinase
cDNA Complementry DNA
DEPC Diethyl Pyrocarbonate
DMEM Dulbeccos Modified Eagles Medium
DMSO Dimethyl Sulfoxide
DNA Deoxyribonucleic acid
DTT DiThiothretol
ECL Enhanced Chemiluminescence
EDTA Ethylene diamino tetra-acetic acid
EGF Epidermal Growth Factor
ELISA Enzyme-linked immunosorbant assay
FCS Foetal calf serum
FITC Fluorescein-isocyanate
5-FU 5-fluorouracil
GSH Glutathione
GST Glutathione- S -transferase
HC1 Hydrochloric acid
HEPES 4-(2-hydroxethyl)-piperazine ethane sulphonic acid
IC50 Inhibitory concentration 50%
Ig Immunoglobulin
IGF Insulin-like growth factor
KC1 Potassium chloride
kDa Kilodalton
LRP Lung resistance protein
MDR M ultidrug resistance
MEM M inimum Essential Medium
MgCl2 M agnesium chloride
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MMLV-RT Moloney murine leukemia virus-reverse transcriptase
mRNA M essenger RNA
MRP M ultidrug resistance associated protein
MT Metallothionein
MW Molecular weight
NaCl Sodium chloride
N aH C 03 Sodium bicarbonate
NaOH Sodium hydroxide
NCTCC National Cell & Tissue Culture Centre
NEAA Non essential amino acids
O D . Optical density
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PDGF Platelet derived growth factor
PgP P-glycoprotein
PKC Phosphokinase C
PMSF Phenylmethyl sulfonyl fluoride
psi Pounds per square inch
RNA Ribonucleic acid
RT-PCR Reverse transcriptase-polymerase chain reaction
rpm Revolutions per minute
SDS Sodium dodecyl sulfate
TBE Tris boric acid, EDTA buffer
TBS Tris buffered saline
TGF Transforming growth factor
Tris T ris(hydroxymethyl)aminomethane
TNF Tumour necrosis factor
UV Ultraviolet
VCR Vincristine
VEGF Vascular endothelial growth factor
VLB Vinblastine
VP 16 Etoposide
v/v Volume to volume ratio
w/v W eight to volume ratio
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6.2 Chemical structures of chemotherapeutic drugs
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6.4 Molecular weight of the chemotherapeutic drugs
Adriamycin 543.54
Vincristine 824.9
Vinblastine 811
VP-16 588.57
Taxol 853.92
M elphalan 305.20
Cisplatin 300.05
Cadmium Chloride 183.32
5-FU 130.1
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